<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="Issue 4, 2009" DOI="10.1002/14651858.CD004977" GROUP_ID="ARI" ID="572501083113262545" MERGED_FROM="" MODIFIED="2009-08-04 00:58:54 +0200" MODIFIED_BY="Liz Dooley" REVIEW_NO="A050" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-08-04 00:58:18 +0200" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2009-03-01 11:27:25 +1000" MODIFIED_BY="Liz Dooley">Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age</TITLE>
<CONTACT MODIFIED="2009-08-04 00:58:18 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="4789" ROLE="AUTHOR"><FIRST_NAME>Marilla</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Lucero</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><POSITION>Chief Science Research Specialist</POSITION><EMAIL_1>marilla.lucero@gmail.com</EMAIL_1><EMAIL_2>nonidulalia@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Research Institute for Tropical Medicine</ORGANISATION><ADDRESS_1>Alabang</ADDRESS_1><CITY>Muntinlupa City</CITY><ZIP>1781</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 8072634</PHONE_1><PHONE_2>+63 2 8072628 ext: 224</PHONE_2><FAX_1>+63 2 8072634</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-04 00:58:18 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="4789" ROLE="AUTHOR"><FIRST_NAME>Marilla</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Lucero</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><POSITION>Chief Science Research Specialist</POSITION><EMAIL_1>marilla.lucero@gmail.com</EMAIL_1><EMAIL_2>nonidulalia@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Research Institute for Tropical Medicine</ORGANISATION><ADDRESS_1>Alabang</ADDRESS_1><CITY>Muntinlupa City</CITY><ZIP>1781</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 8072634</PHONE_1><PHONE_2>+63 2 8072628 ext: 224</PHONE_2><FAX_1>+63 2 8072634</FAX_1></ADDRESS></PERSON><PERSON ID="C660FBBA82E26AA2004D27862255E9AD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vernoni</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Dulalia</LAST_NAME><POSITION>Physician Research Assistant</POSITION><EMAIL_1>ritmari@smartwifi.com.ph</EMAIL_1><EMAIL_2>nonidulalia@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Research Institute for Tropical Medicine</ORGANISATION><ADDRESS_1>Alabang</ADDRESS_1><CITY>Muntinlupa City</CITY><ZIP>1781</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 807 2634</PHONE_1><PHONE_2>+63 2 807 2628  ext 224</PHONE_2><FAX_1>+63 2 807 2634</FAX_1></ADDRESS></PERSON><PERSON ID="052E7BCF82E26AA2005274A34451A289" ROLE="AUTHOR"><FIRST_NAME>Leilani</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Nillos</LAST_NAME><POSITION>Physician Research Assistant</POSITION><EMAIL_1>leilanitn@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Research Institute for Tropical Medicine</ORGANISATION><ADDRESS_1>Alabang</ADDRESS_1><ADDRESS_2>Alabang</ADDRESS_2><CITY>Muntinlupa City</CITY><ZIP>1781</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+63 2 807 2634</PHONE_1><PHONE_2>+63 2 807 2628  ext 224</PHONE_2><FAX_1>+63 2 807 2634</FAX_1></ADDRESS></PERSON><PERSON ID="12362" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gail</FIRST_NAME><LAST_NAME>Williams</LAST_NAME><SUFFIX>MS, PhD</SUFFIX><EMAIL_1>Gail.Williams@sph.uq.edu</EMAIL_1><ADDRESS><DEPARTMENT>Australian Centre for International and Tropical Health and Nutrition</DEPARTMENT><ORGANISATION>School of Population Health, Queensland University</ORGANISATION><ADDRESS_1>Herston Road</ADDRESS_1><CITY>Herston</CITY><ZIP>4006</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 3365 5406</PHONE_1></ADDRESS></PERSON><PERSON ID="CF949CF682E26AA2004D27865763EC21" ROLE="AUTHOR"><FIRST_NAME>Rhea Angela</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Parreño</LAST_NAME><EMAIL_1>rhea.parreno@abbott.com</EMAIL_1><EMAIL_2>rhea.a.parreno@wmich.edu</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Research Institute for Tropical Medicine</ORGANISATION><ADDRESS_1>Alabang</ADDRESS_1><CITY>Muntinlupa City</CITY><ZIP>1781</ZIP><COUNTRY CODE="PH">Philippines</COUNTRY></ADDRESS></PERSON><PERSON ID="12312" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Nohynek</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>Hanna.Nohynek@ktl.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vaccines, Unit of Clinical Trials</DEPARTMENT><ORGANISATION>National Institute for Health and Welfare</ORGANISATION><ADDRESS_1>Mannerheimintie 166</ADDRESS_1><CITY>Helsinki</CITY><ZIP>00300</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 47448246</PHONE_1><FAX_1>+358 9 47448675</FAX_1></ADDRESS></PERSON><PERSON ID="12325" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ian</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Riley</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>i.riley@sph.uq.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Australian Centre for International and Tropical Health and Nutrition</DEPARTMENT><ORGANISATION>School of Population Health, Queensland University</ORGANISATION><ADDRESS_1>Herston Road</ADDRESS_1><CITY>Herston</CITY><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 3365 5529</PHONE_1><FAX_1>+61 7 3365 5550</FAX_1></ADDRESS></PERSON><PERSON ID="12305" ROLE="AUTHOR"><FIRST_NAME>Helena</FIRST_NAME><LAST_NAME>Makela</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>Pirjo.Makela@ktl.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vaccines, Unit of Clinical Trials</DEPARTMENT><ORGANISATION>National Institute for Health and Welfare</ORGANISATION><ADDRESS_1>Mannerheimintie 166</ADDRESS_1><CITY>Helsinki</CITY><ZIP>00300</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 4744235</PHONE_1><FAX_1>+358 9 4744675</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-03-16 08:22:40 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="9" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="3" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2009-06-01 23:24:23 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-06-01 23:24:23 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Two new trials were included - the Gambian trial (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>), and the Philippines trial (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-03-16 08:51:53 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="9" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Searches conducted. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-03-16 08:22:50 +1000" MODIFIED_BY="Liz Dooley">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-03-16 08:21:39 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Changes in authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-16 08:22:50 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="14" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-03-01 11:00:17 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="20" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-26 21:18:06 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Manpower and physical resources from the Research Institute for Tropical Medicine and the ARIVAC Project under New Tropical Medicine Foundation, Inc.</NAME>
<COUNTRY CODE="PH">Philippines</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-11-26 21:18:06 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-26 21:18:06 +1000" MODIFIED_BY="[Empty name]">
<NAME>PneumoAdip</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-04 08:55:56 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-06-25 16:30:20 +1000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2009-01-29 08:30:06 +1000" MODIFIED_BY="[Empty name]">Vaccines against overwhelming blood infection due to pneumococcus bacteria and lung infection (pneumonia) among children less than two years of age</TITLE>
<SUMMARY_BODY MODIFIED="2009-06-25 16:30:20 +1000" MODIFIED_BY="Liz Dooley">
<P>Pneumococcus is one of the major causes of overwhelming blood infection and lung infection (pneumonia) among young children. Pneumococci resistant to antibiotics are now being found in great numbers worldwide which may reduce the effectiveness of recommended antibiotic treatment. Preventive measures like vaccination are needed. This review found two trials from the US, two from Africa, one from the Philippines, and another from Finland that involved 113,044 children less than two years of age. In these studies, PCV was able to prevent overwhelming pneumococcal blood infection and pneumonia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-27 15:37:32 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-06-18 17:09:23 +1000" MODIFIED_BY="Clare Dooley">
<P>Pneumonia, caused by <I>Streptococcus pneumoniae</I>, is a major cause of morbidity and mortality among children in low-income countries. The effectiveness of pneumococcal conjugate vaccines (PCVs) against invasive pneumococcal disease (IPD), pneumonia, and mortality needs to be evaluated.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-03 15:08:18 +1000" MODIFIED_BY="[Empty name]">
<P>To update the 2004 review on the efficacy of PCVs in preventing vaccine-serotypes IPD (VT-IPD) , X-ray defined pneumonia among HIV-1 negative children, and other new outcomes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-06-25 16:16:47 +1000" MODIFIED_BY="Liz Dooley">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1990 to Week 4 February 2009); and EMBASE (1974 to March 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-27 15:37:32 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing PCV with placebo, or another vaccine, in children under two with IPD and clinical / radiographic pneumonia as outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-03 15:19:41 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently identified studies, extracted data, and evaluated their corresponding risks of bias. Differences were resolved by discussion. Meta-analysis used the inverse variance method.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-08 19:56:01 +1000" MODIFIED_BY="[Empty name]">
<P>We identified 11 publications from six RCTs conducted in Africa, US, Philippines and Finland where 57,015 children received PCV; while 56,029 received placebo or another vaccine. Seven publications provided high quality evidence on PCV efficacy against IPD and four provided moderate quality evidence against pneumonia. None of the five trials with all-cause mortality data were powered to investigate this outcome. Only two trials have data on all-cause admissions.</P>
<P>The main analysis for this review involved HIV-1 negative children and used the pooled results of random-effects model, intent-to-treat analysis (ITT).</P>
<P>Pooled vaccine efficacy (VE) for VT-IPD was 80% (95% confidence interval (CI) 58% to 90%, P &lt; 0.0001); all serotypes-IPD, 58% (95% CI 29% to 75%, P = 0.001); World Health Organization X-ray defined pneumonia was 27% (95% CI 15% to 36%, P &lt; 0.0001); clinical pneumonia, 6% (95% CI 2% to 9%, P = 0.0006); and all-cause mortality, 11% (95% CI -1% to 21%, P = 0.08). Analysis involving HIV-1 positive children had similar findings.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-03 15:22:03 +1000" MODIFIED_BY="[Empty name]">
<P>PCV is effective in preventing IPD, X-ray defined pneumonia, and clinical pneumonia among HIV-1 negative and HIV-1 positive children under two years. The impact was greater for VT-IPD than for all serotypes-IPD, and for X-ray defined pneumonia than for clinical pneumonia. An 11% reduction with a 95% CI of -1% to 21% and a P = 0.08 is compatible with reduction in all-cause mortality.  </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-04 08:55:56 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-07-02 18:14:12 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-06-25 16:32:07 +1000" MODIFIED_BY="Liz Dooley">
<P>
<I>Streptococcus pneumoniae</I> (<I>S. pneumoniae</I>) is one of the leading causes of invasive disease, bacterial pneumonia and meningitis among children in low-income countries (<LINK REF="REF-Berman-1985" TYPE="REFERENCE">Berman 1985</LINK>; <LINK REF="REF-Shann-1986" TYPE="REFERENCE">Shann 1986</LINK>; <LINK REF="REF-Tupasi-1990" TYPE="REFERENCE">Tupasi 1990</LINK>). It is also an important bacterial cause of acute otitis media (AOM) worldwide. According to the World Health Organization (WHO), pneumococcal pneumonia and meningitis are responsible for 800,000 to 1 million child deaths each year (<LINK REF="REF-GAVI-2004" TYPE="REFERENCE">GAVI 2004</LINK>; <LINK REF="REF-WHO-2003" TYPE="REFERENCE">WHO 2003</LINK>). All possible means (curative or preventive) to combat this affliction will help in the realisation of one of the Millennium Development Goals of the United Nations, which is to reduce child mortality (<LINK REF="REF-UNGA-2000" TYPE="REFERENCE">UNGA 2000</LINK>). These infections place a heavy burden on health services and are associated with frequent use of antibiotics.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-06-25 16:33:27 +1000" MODIFIED_BY="Liz Dooley">
<P>The successful WHO pneumonia control programme depends heavily on antibiotic treatment (<LINK REF="REF-Sazawal-1992" TYPE="REFERENCE">Sazawal 1992</LINK>). The emergence of antibiotic resistant strains of target bacteria like the pneumococcus (<LINK REF="REF-Crewe_x002d_Brown-1997" TYPE="REFERENCE">Crewe-Brown 1997</LINK>) may in the future affect the impact of the programme on pneumonia mortality. Thus, prevention of pneumococcal disease in children by vaccination is a logical approach to improving health outcomes.</P>
<P>A seven-valent pneumococcal conjugate vaccine (7PCV) manufactured by Wyeth Vaccines was licensed in the USA in 2000 for use among infants and toddlers to prevent invasive pneumococcal disease (IPD). Other countries have introduced this vaccine into their immunisation programmes; the schedule is different for each country but is usually given before the child is six months of age. Three doses are given with four to eight week intervals starting at six weeks or two months of age. Nine-valent PCV and 11-valent PCV have been studied in Africa and the Philippines, respectively, to determine their efficacy on IPD and pneumonia among children under two years of age.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-06-01 15:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>There are more than 90 pneumococcal serotypes but only a few commonly cause IPD. A 14-valent pneumococcal polysaccharide (PS) vaccine was licensed in 1977. It was replaced by a 23-valent PS vaccine in 1984. However, vaccines using capsular PS, which are T-cell independent antigens, are generally not immunogenic in children under two years of age. These children lack mature B-lymphocytes necessary for T-cell independent antibody-mediated immunity. A vaccine is effective in young children only if it can stimulate a T-cell dependent antibody response present soon after birth (<LINK REF="REF-Giebink-2001" TYPE="REFERENCE">Giebink 2001</LINK>). Covalent conjugation of a capsular PS to a protein carrier converts T-cell independent anti-PS antibody response to a T-cell dependent one. This leads to good antibody responses and subsequent immunity in children less than two years of age. This vaccine is capable of inducing memory in the immune system and is the vaccine used for children.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-07-02 18:14:12 +1000" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2004 (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>) where findings from only four trials were evaluated. This update now includes results from two more trials, <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>, and an unpublished study (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>) in which results were provided by O'Brien in a personal communication (<LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>). Moreover, in the 2004 review, the investigators from the USA (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>) employed the regular method of assessing pneumonia on chest radiography. This current review utilizes updated information of the radiology outcome from <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK> which Hansen re-analysed (<LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) using films re-read according to the WHO standardised guidelines used by all the other trials. Other outcomes were added such as all-cause admissions and all-cause mortality.</P>
<P>This current review makes use of the most recent version of Review Manager (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) which is now more rigorous in investigating individual trials as to the presence of bias (through the domain-based approach) and to the quality of the evidence presented in the publications.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-27 12:16:58 +1000" MODIFIED_BY="[Empty name]">
<P>The primary objective was to determine the efficacy of PCV in reducing the incidence of IPD due to vaccine serotypes (VT) and X-ray defined pneumonia according to WHO standardised guidelines (WHO X-ray pneumonia) among HIV-1 negative children who received PCV before 12 months of age, compared to a group of children with the same characteristics who received either placebo, or control vaccine.</P>
<P>The secondary objective was to determine the efficacy of PCV against other outcomes such as all serotypes-IPD, non-vaccine serotypes IPD (NVT), vaccine-related IPD (VRT), clinical pneumonia, all-cause admissions, and all-cause mortality in HIV-1 negative children less than 24 months of age.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-04 08:53:42 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-27 16:42:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-06-23 11:11:02 +1000" MODIFIED_BY="Clare Dooley">
<P>Randomised controlled trials (RCTs), including cluster-RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-06-23 11:11:11 +1000" MODIFIED_BY="Clare Dooley">
<P>Healthy infants who participated in trials with primary series immunisations (three doses) given before 12 months of age and followed up to 24 months of age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-01-29 07:11:09 +1000" MODIFIED_BY="[Empty name]">
<P>PCV (any valency) compared to placebo, or other vaccines.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-27 16:42:55 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Invasive disease caused by <I>S. pneumoniae</I>, including vaccine serotypes (VT), which are serotypes contained in the study vaccine; all serotypes combined; non-vaccine serotypes (NVT), serotypes that are not contained in the study vaccine; and vaccine-related serotypes (VRT).</LI>
<LI>Pneumonia: (i) X-ray defined pneumonia according to WHO standard guidelines; (ii) clinical pneumonia (of unspecified aetiology), with or without X-ray confirmation (clinical diagnosis only).</LI>
</OL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-27 16:42:55 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>IPD: vaccine serotypes IPD (VT-IPD).</LI>
<LI>X-ray defined pneumonia according to WHO standardised guidelines (WHO X-ray pneumonia).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-02 18:14:18 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>IPD: all serotypes, NVT, VRT.</LI>
<LI>Clinical pneumonia.</LI>
<LI>All-cause admissions.</LI>
<LI>All-cause mortality.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-27 16:43:05 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-06-25 16:39:19 +1000" MODIFIED_BY="Liz Dooley">
<P>In this updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1990 to week 4 February 2009); and EMBASE (1974 to March 2009). The MEDLINE search was not commenced until 1990 as relevant trials were published only after 1997.</P>
<P>We combined specific search terms with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). The search strategy was adapted for EMBASE (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We did not apply language or publication restrictions.</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1 exp Pneumonia/<BR/>2 pneumonia.mp.<BR/>3 exp Pneumococcal Infections/<BR/>4 pneumococc$.mp.<BR/>5 or/1-4<BR/>6 exp Pneumococcal Vaccines/<BR/>7 (pneumococc$ adj vaccin$).mp.<BR/>8 or/6-7<BR/>9 Child/<BR/>10 Infant/<BR/>11 (children or infant$1 or pediatric or paediatric).mp.<BR/>12 or/9-11<BR/>13 5 and 8 and 12</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-27 16:43:05 +1000" MODIFIED_BY="[Empty name]">
<P>The following sources were also searched to identify additional relevant studies:</P>
<OL>
<LI>Unpublished literature such as conference proceedings (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details); personal communication with authors of publications included or considered for inclusion; other pneumococcal conjugate vaccine trialists; and vaccine manufacturers to identify ongoing or future phase three trials;</LI>
<LI>Handsearching of relevant journals and phase two trial results to identify future countries, vaccine manufacturers, or principal investigators (PI) participating in PCV phase three trials;</LI>
<LI>Reference lists of all identified relevant studies; and</LI>
<LI>Published books pertaining to pneumococcal vaccines.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-04 08:53:42 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-07-28 14:44:51 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (VED, LTN) independently screened results of the literature search and selected eligible studies according to the criteria for considering studies in this review. Differences were resolved through discussion. To check if we missed any other trial, or outcomes of trials on pneumococcal vaccines, we consulted the book <I>Pneumococcal Vaccines</I>, which considered all pneumococcal conjugate vaccine trials that have been conducted to date, with particular emphasis on the years following the introduction of the conjugate vaccines (<LINK REF="REF-PneumoVac-2008" TYPE="REFERENCE">PneumoVac 2008</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-27 16:43:15 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (VED, LTN) independently extracted data from each of the studies using a data extraction form designed according to the Cochrane Collaboration&#8217;s checklist of items to consider in data collection (<LINK REF="REF-Higgins-2008b" TYPE="REFERENCE">Higgins 2008b</LINK>). For the included studies already considered in the 2004 publication of this review (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>), we simply added the items in the collaboration&#8217;s checklist that were previously not found in the earlier data extraction form. In particular, we extracted the type of conjugate vaccine (valency, serotypes contained, carrier protein); control information; method of enrolment; allocation of participants; study site; participants' information (ethnicity, age on enrolment, number allocated to either intervention or control); vaccination schedule (study/control and Expanded Program on Immunization (EPI)); outcome measures; results per outcome measure; and miscellaneous information including the key conclusions, and funding source. We also updated the information needed to assess individual studies of their risks of bias. Disagreements were resolved by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-07-27 16:43:21 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (VED, LTN) independently appraised the validity of included trials through assessment of their corresponding risks of bias. We used the Cochrane Collaboration&#8217;s two-part 'Risk of bias' tool, a domain-based evaluation in which critical assessments for each of the six domains were made separately for each study. The six domains consist of 1) sequence generation; 2) allocation concealment; 3) blinding of participants, personnel and outcome assessors; 4) incomplete outcome data; 5) selective outcome reporting; and 6) topic-specific, design-specific, or other threats to validity. Each domain includes one or more specific entries in a &#8216;Risk of bias&#8217; table. Within each entry, the first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of &#8216;Yes&#8217; indicates low risk of bias, &#8216;No&#8217; indicates high risk of bias, and &#8216;Unclear&#8217; indicates unclear or unknown risk of bias (<LINK REF="REF-Higgins-2008a" TYPE="REFERENCE">Higgins 2008a</LINK>). See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for details of the risk of bias assessment for each study.</P>
<P>Assessment information not found in the publication was obtained through personal communication with authors. Instead of asking directly about the six domains, we used open ended questions when asking trial authors for information about study design and conduct in order to avoid overly positive answers. Any disagreement was resolved through discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-08-04 08:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>The intention-to-treat (ITT) principle was used in the primary analysis since it aims to include all participants randomised into a trial regardless of the number of doses received subsequently and is often recommended as the least biased way to estimate intervention effects in randomised trials (<LINK REF="REF-Lewis-1993" TYPE="REFERENCE">Lewis 1993</LINK>; <LINK REF="REF-Newell-1992" TYPE="REFERENCE">Newell 1992</LINK>). The risk ratio (RR) was used to measure treatment effect. We determined RR by first obtaining the vaccine efficacy (VE) of the PCV as reported in the article. The VE and 95% confidence interval (CI) of each PCV on the outcome parameters were encoded into a pre-programed Microsoft (MS) Excel worksheet. The MS Excel file calculated RR and 95% CI from the VE as specified in the published article, logarithm of RR to the base e (logRR), and the standard error of this logarithm (SE (logRR)) for each outcome parameter.</P>
<P>In publications where VE was not presented, RR and 95% CI were calculated using PROC FREQ of SAS version 9.1. Due to the small number of IPD events in the Finnish (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>) and Philippines (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) trials, some cells contained zero events. We conducted analysis using continuity correction to take into account these cells with zero events. In fact we conducted analyses using three methods of continuity correction which included a) constant, b) "treatment arm", and c) empirical continuity corrections (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>).  In constant continuity correction, a factor which is often equal to 0.5 is added to both the treatment and control group cells. The "treatment arm" continuity correction requires adding a factor of the reciprocal of the size of the opposite treatment arm. The empirical continuity correction on the other hand, adopted an empirical approach where all the studies in the meta-analysis without a zero event are used to calculate a pooled effect measure. Using this estimate, a continuity correction can be calculated, which will produce effect measure estimates close to the pooled effect measure in the studies with zero events in both treatment and control arms. The calculated continuity correction factor may act as a "prior" and will be added to the observed events. These continuity correction methods were applied to VT-IPD, NVT-IPD, VRT-IPD and all-cause mortality outcomes where one or two studies have zero events in either treatment or control arms (<LINK REF="TBL-22" TYPE="TABLE">Table 22</LINK>). The three continuity correction methods gave almost similar results (<LINK REF="TBL-23" TYPE="TABLE">Table 23</LINK>). The main method that we present in the meta-analyses is the constant continuity correction. In the meta-analyses, we reported separately the outcomes from the two different PCV arms in the Finnish trial (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>). To avoid counting twice the children allocated to the control arm of this study, we halved the number of children and number of outcome events in the control arm.</P>
<P>In the South African trial, VE against several outcomes was calculated among all children (regardless of HIV status) and that of HIV-1 negative children. In the Gambian trial, what was published was the per-protocol VE among children &lt; 29 months old and further stratified among those three to 11 months, 12 to 23 and 24 to 29 months of age for IPD and X-ray defined pneumonia. Thus, we had to ask for ITT data from the Gambian investigators. We received the results for the stratified analysis of the same age-groups from which we calculated the ITT-VE for IPD, X-ray defined pneumonia and clinical pneumonia for children &lt; 24 months old. For generic inverse-variance method only the VE (95% CI) or RR (95% CI) was needed to calculate the pooled effect estimates. However, when total population was calculated, we had to use the population &lt; 29 months old since we did not have data for children &lt; 24 months old from Gambia. We also obtained from Hansen (<LINK REF="REF-Hansen-2007" TYPE="REFERENCE">Hansen 2007</LINK>) data on children younger than 24 months of age for the outcome of X-ray defined pneumonia. It must be emphasised that the results of individual RR and VE in this review will be different from the ones published in <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> and <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> since we obtained through personal communication the actual data for children younger than 24 months of age. Despite these differences, we have cited the main publications as the references, i.e. <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> for <LINK REF="REF-Cutts-2007" TYPE="REFERENCE">Cutts 2007</LINK> and <LINK REF="REF-Jaffar-2007" TYPE="REFERENCE">Jaffar 2007</LINK> and <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> for <LINK REF="REF-Hansen-2007" TYPE="REFERENCE">Hansen 2007</LINK>.<BR/>
<BR/>The pooled RR from each meta-analysis of relevant outcomes was later converted to VE (pooled) and is reported together with the pooled RR.<BR/>
<BR/>RevMan 5 includes the assessment of quality of trials through the use of the software Grade Profiler (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>). This software incorporates characteristics of each study entered in the software to come up with a summary of findings table. These characteristics include numbers of events for relevant outcomes, total numbers of participants studied, presence of limitations (in the form of bias), inconsistency, imprecision, and indirectness. The resultant pooled RR for each outcome after the meta-analysis, is used together with the number of events and participants, to come up with the absolute effect of the PCV against the outcomes studied.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-07-27 13:27:07 +1000" MODIFIED_BY="[Empty name]">
<P>The review involved RCTs whether individual-randomised or cluster-randomised. Only one trial (with two, separate offshoot publications: <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>, <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) used the cluster-randomised study design. Because of the inclusion of this trial with this study design, the pooled RR and 95% CI were calculated using the generic inverse variance method. This approach allows a cluster-randomised trial to be included in the meta-analysis of mostly individual randomised trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-27 13:28:47 +1000" MODIFIED_BY="[Empty name]">
<P>Data missing from the articles, like VE for certain outcomes and age groups were obtained from the authors through personal communication. However, not all trials studied all outcomes relevant for PCV efficacy. We could ask for missing data from the trial investigators only if the outcome had been studied. Meta-analysis was therefore done only for trials which had relevant outcomes. From reading the book <I>Pneumococcal Vaccines</I> (<LINK REF="REF-PneumoVac-2008" TYPE="REFERENCE">PneumoVac 2008</LINK>), we were able to obtain missing information on the effect of PCV against X-ray pneumonia from the American Indian trial. Although O&#8217;Brien presented orally in Alaska in 2002 the findings of the efficacy of PCV on X-ray defined pneumonia (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>), these did not appear in the printed abstract and it remains to be formally published in a journal. Through personal communication with Madhi, O&#8217;Brien gave the actual VE and 95% Cl for this outcome (<LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK>). However, the value for VE in this book was erroneous according to O'Brien (<LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>) and she gave us the correct value to use for VE (95% CI, P value) against per-protocol (PP) and ITT X-ray pneumonia (<LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-06-25 16:58:53 +1000" MODIFIED_BY="Liz Dooley">
<P>An initial qualitative comparison of all individually analysed publications was conducted to determine if pooling of results (meta-analysis) was reasonable. This took into account differences in study populations, interventions, outcome assessment, presence of bias, estimated effect size and sample size used, based on the primary outcome of the study.</P>
<P>To determine how variable the studies included in the analysis were (heterogeneity), the value of Chi<SUP>2</SUP> test for heterogeneity (P &lt; 0.05) and the I<SUP>2</SUP> statistic (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>) were sought. Although we chose &#8805; 34% as the threshold for interpreting the I<SUP>2</SUP> statistic, this threshold is arbitrary. Thresholds for the interpretation of I<SUP>2</SUP> can be misleading, since the importance of inconsistency depends on other factors. A rough guide to interpretation is as follows<B> </B>(<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>): 0% to 40%, might not be important; 30% to 60%, may represent moderate heterogeneity; 50% to 90%, may represent substantial heterogeneity; 75% to 100%, considerable heterogeneity. It is important to note that although the value 0% to 40% is interpreted as &#8220;might not be important&#8221;, the values overlap with that of moderate heterogeneity. Moreover, the importance of the observed value of I<SUP>2 </SUP>also depends on (i) magnitude and direction of effects and, (ii) strength of evidence for heterogeneity (for example, P value from the chi-squared test, or a confidence interval for I<SUP>2</SUP>).<B> </B>We looked for possible explanations of the heterogeneity by reviewing individual outcomes and their respective effect estimates. Possible explanations for heterogeneity include the presence of a) outliers, or studies which had results with a direction totally different from other studies and, b) studies with small number of events. Please see 'Additional Tables' <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-06-23 13:47:43 +1000" MODIFIED_BY="Clare Dooley">
<P>The authors of this review identified the relevant articles that should be included in the review of phase three trials determining the efficacy of a pneumococcal conjugate vaccine against the outcomes included in the objectives.</P>
<P>There were only six trials reviewed and these were too few to be able to assess reporting bias using a funnel plot. We initially assessed <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK> as having reporting bias since the investigators failed to publish the results of the X-ray defined pneumonia outcome, particularly since the results were different from the other trials. However, the results, although not published, were presented in a conference. Thus, we revised this assessment and only reported this as a time-lag bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-06-25 17:06:13 +1000" MODIFIED_BY="Liz Dooley">
<P>Random-effects model, which assumes trial heterogeneity, and fixed-effect model, which assumes trial homogeneity, were used in the calculation of pooled RR and 95% CI but conclusions were made based on the random-effects model. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects and is based on the inverse-variance approach that makes adjustment to the study weights according to the extent of variation, or heterogeneity, among the varying intervention effects. We used the inverse-variance approach since the American Indian trial is a cluster-randomised study. The random-effects method and the fixed-effect method will give identical results when there is no heterogeneity among the studies. Where there is heterogeneity, Cls for the average intervention effect will be wider if the random-effects method is used rather than a fixed-effect method, and corresponding claims of statistical significance will be more conservative. It is also possible that the central estimate of the intervention effect will change if there are relationships between observed intervention effects and sample sizes<B> </B>(<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>)<B>. </B>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-06-25 17:07:33 +1000" MODIFIED_BY="Liz Dooley">
<P>We performed subgroup analyses on children &lt; 24 months of age against HIV status; and on children &lt; 29 months of age against HIV status.</P>
<P>Since only the South African trial reported results for both HIV-1 negative and HIV-1 positive children, we decided to have as the main population for analysis the HIV-1 negative children. The other trials did not report HIV-1 status and children were presumed to be HIV-1 negative. Although the main population included only HIV-1 negative children, we conducted a sub-group analysis including the HIV-1 positive children from South Africa to determine whether there would be a change in the pooled RR against the outcomes. This subgroup of HIV-1 positive children in the South African study was included in the randomisation process. Thus, the results are actual randomised comparisons and not observational in nature.</P>
<P>The Gambian trial included children younger than 29 months of age. Since the original review objective only studied children younger than 24 months of age, we obtained from the author data for this population. Nonetheless, we also conducted an analysis of children younger than 29 months of age to determine if there would be differences in pooled VE compared to that of the group younger than 24 months of age.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-06-25 17:08:46 +1000" MODIFIED_BY="Liz Dooley">
<P>We had to make decisions about the validity and robustness of the pooled estimates that we obtained depending on the studies included in the meta-analysis. Thus, for some outcomes, we conducted sensitivity analysis by excluding some studies in the model when a study differed from others in terms of methods of collection of outcome data (only inpatient data collected, IPD data as primary outcome or not), and when studies had VE clearly different from the other studies (outliers).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-27 16:43:33 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-07-27 16:43:33 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-07-27 16:43:33 +1000" MODIFIED_BY="[Empty name]">
<P>From the series of searches conducted in four batches between 2005 and 2009, we obtained a combined number of hits as follows: MEDLINE 541; EMBASE 222; and CENTRAL 301 hits. All 1064 articles downloaded were entered into the reference management software EndNote and duplicates were discarded. A total of 624 references were left from which 263 duplicates of the references in this review's first publication in 2004 (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>) were likewise eliminated. With further removal of 312 non-PCV and non-RCT articles, the search yield was trimmed down to 49 articles which we considered potentially eligible for inclusion: 46 were eventually excluded for reasons stated in the 'Characteristics of excluded studies' table; three new publications were included from the electronic search (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>; <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>). A handsearched, unpublished study (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>), and a newly published study (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) were also included. A total of five publications were included in this update, giving a grand total of 11 publications in the 'Included studies' section. Of the 55 references in the 'Additional references' section, 16 are personal communications with authors through which additional information or data sets were obtained (<LINK REF="REF-Black-2003" TYPE="REFERENCE">Black 2003</LINK>; <LINK REF="REF-Black-2004" TYPE="REFERENCE">Black 2004</LINK>; <LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>; <LINK REF="REF-Cutts-2007" TYPE="REFERENCE">Cutts 2007</LINK>; <LINK REF="REF-Cutts-2008" TYPE="REFERENCE">Cutts 2008</LINK>; <LINK REF="REF-Hansen-2007" TYPE="REFERENCE">Hansen 2007</LINK>; <LINK REF="REF-Hansen-2008a" TYPE="REFERENCE">Hansen 2008a</LINK>; <LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>; <LINK REF="REF-Jaffar-2007" TYPE="REFERENCE">Jaffar 2007</LINK>; <LINK REF="REF-Klugman-2004" TYPE="REFERENCE">Klugman 2004</LINK>; <LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>; <LINK REF="REF-O_x0027_Brien-2009a" TYPE="REFERENCE">O'Brien 2009a</LINK>; <LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>; <LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>; <LINK REF="REF-Palmu-2003a" TYPE="REFERENCE">Palmu 2003a</LINK>; <LINK REF="REF-Palmu-2003b" TYPE="REFERENCE">Palmu 2003b</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-10 09:49:39 +1000" MODIFIED_BY="[Empty name]">
<P>There were ten publications from six adequately randomised clinical trials that met the eligibility criteria and were considered in this review: <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>, and <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> of the Northern California Kaiser Permanente (NCKP) trial; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> of the Finnish Otitis Media trial; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK> and <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK> of the South African trial; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK> of the American Indian trial; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> of the Gambian Trial; and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK> of the Philippines trial. There is one unpublished study from the American Indian trial for the outcome of X-ray pneumonia (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>). This was an oral presentation in the 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-3) in Alaska in 2002 that remains unpublished to this day, but the result of which was found in a section of a book <I>Pneumococcal Vaccines</I> (<LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK>). The results published in this book were later corrected in <LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK> and we have included these results in the evaluation of the effectiveness of PCV against X-ray pneumonia, bringing to 11 the total number of included studies considered in this review. Details of these publications are available in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All included publications are individual-randomised, double-blind, placebo-controlled trials, except for the American Indian trial, which is cluster-randomised. The authors of the trial discussed this particular design in a separate publication (<LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample size, setting, participants and interventions</HEADING>
<P>The participants in each trial were healthy infants &lt; 12 months of age who were eligible for vaccination with vaccines in their national immunisation programmes or EPI. Each one had their own exclusion criteria for not enrolling children into their trials. The important exclusion criteria that we gathered from the publications were: non-residence in trial area; low likelihood of receiving three doses of vaccine because of possible<I> </I>migration; children with sickle cell disease; known immunodeficiency; any serious chronic or progressive disease; a history of seizures or a history of either pneumococcal or meningococcal disease; previous receipt of diphtheria-pertussis-tetanus (DPT) or <I>Haemophilus influenzae</I> type b (Hib) vaccines; age younger than 40 days or older than 364 days; inclusion in a previous vaccine trial; hypersensitivity to any components of the vaccine; contraindications specified on the manufacturers&#8217; package inserts for any routine non study vaccines that the child would receive; any medical condition (for example, one that required frequent or long-term referrals to health-care facilities outside the trial area) which, in the opinion of the investigator, might interfere with the assessment of the study objectives; or a moderate or severe illness with or without fever until resolved.</P>
<P>In all six trials included in this review, children were enrolled for the first dose of the vaccine when they were approximately six weeks to less than seven months of age. Two trials were done in the US. One trial (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) involved 37,868 infants of diverse ethnic backgrounds (Asian, Afro-American, Hispanic, White, etc.) from Northern California, while the other trial (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) was done among 8292 American Indian and White Mountain Apache infants in Central Arizona. In both trials, three doses of a 7-valent CRM197 PCV were given before the child turned 12 months old. However, the American Indian trial, also enrolled children more than seven months old who were classified into two "catch-up" groups (seven to 11 months and 12 to 23 months). These in particular, were not analysed in this review.<BR/>
<BR/>In the three-arm trial conducted in Finland (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>), three doses of either heptavalent PCV CRM197, PCV OMP, or hepatitis B vaccine as control were given to 2497 children using the same immunisation schedule. Both the US and Finnish trials gave a booster dose of PCV starting at 12 months of age.<BR/>
<BR/>In a study conducted among infants in South Africa, three doses of either a 9-valent CRM197 PCV, or placebo were given to 39,836 children before they reached nine months of age. No booster dose was given. Moreover, this study involved both HIV-1 negative and HIV-1 positive infants. However, only HIV-1 negative infants were included in the analysis of the primary outcome in this review.<BR/>
<BR/>In the trial conducted in Eastern Gambia, three doses of either a 9-valent PCV, or placebo were given to 17,437 children before they turned 12 months old. No booster was given.<BR/>
<BR/>In the Philippines trial, three doses of an 11-valent PCV, or placebo were given to 12,191 children in the province of Bohol, Philippines before they reached nine months of age. As with the South African and Gambian trials, no booster was given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Three of these publications (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) are reports of three types of outcomes (IPD, clinical pneumonia and X-ray defined pneumonia, respectively) from one phase three trial. The data on X-ray defined pneumonia outcome, originally reported by <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK> in the 2004 publication of this review (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>), was superseded by that of <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>, which re-evaluated radiographs from the Northern California Kaiser Permanente trial using the standardised WHO criteria for interpretation of chest radiographs in children. However, <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK> remains the source of the clinical pneumonia outcome for this trial. Similarly, the publications of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK> are reports from the same three-arm Finnish Otitis Media trial. The difference between the two publications lies in the protein conjugate used for the PCV: Eskola reported on the PCV CRM197 arm compared to the control group, while Kilpi reported on the PCV OMP arm compared to the same control group utilised in <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>. Although the two publications reported AOM as their primary outcome, they considered four cases each of IPD in their safety reporting and for this reason they are included in this review.<BR/>
<BR/>The South African trial (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>) reported on IPD and X-ray defined pneumonia, with <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK> reporting later on the clinical pneumonia outcome. The American Indian trial (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) reported only IPD as an outcome, but an earlier, unpublished oral presentation in the ISPPD-3 in Alaska in 2002 (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>) reported an outcome on X-ray pneumonia. The Gambian trial (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>) and the Philippines trial (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) both reported on five outcomes, namely, X-ray defined pneumonia, clinical pneumonia, IPD, all-cause admissions, and all-cause mortality.<BR/>
<BR/>Overall, in terms of specific outcomes of IPD, seven publications reported on both VT-IPD and all serotypes-IPD (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>); six publications reported on NVT-IPD (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>); and four on VRT-IPD (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>). For all the other outcomes, five publications reported on X-ray pneumonia (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>); and only four on clinical pneumonia (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>). There were only two publications that had data on all-cause admissions (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>); and five with data on all-cause mortality (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>). It should be noted that although <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> reported ITT data on NVT-IPD and VRT-IPD, her population covered &lt; 29 months old children. The above publications compared populations covering only children &lt; 24 months of age. Please refer to the Data and Analyses Section comparisons 3 and 4 for details on Cutts' NVT-IPD and VRT-IPD on children &lt; 29 months.</P>
<P>Additional information on the included studies can be found in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>, <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>, <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>, <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>, <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>, <LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>, and <LINK REF="TBL-13" TYPE="TABLE">Table 13</LINK>.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-07-03 12:57:16 +1000" MODIFIED_BY="[Empty name]">
<P>Forty-six publications were initially considered for inclusion, despite having outcomes other than those specified in the inclusion criteria on account of possible cases of IPD and other outcomes. However, on closer scrutiny, they all turned out to have no IPD or X-ray pneumonia as outcomes, or they were not RCTs.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-27 14:17:16 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed the methodological quality of 11 publications (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>; <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>). The methodological quality of <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> and <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK> follows that of their parent trials <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, and <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, respectively. <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK> follows the same methodological assessment of <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>. In the case of <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, they share the same methodological assessment in that they belong to one Finnish trial that utilised the same control population, differing only in the protein conjugates used for the treatment arms, <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> having utilised the <I>S. pneumoniae </I>CRM197 while <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, the <I>S. pneumoniae </I>OMP. Details are available in the 'Risk of Bias' table in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.<BR/>
<BR/>Review Manager (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) automatically generates an individual 'Risk of bias' table and a corresponding risk of bias summary graph for all eleven included studies. To avoid making duplicates of assessment for publications arising from a single trial (i.e. <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> from the NCKP trial), we made a separate risk of bias summary graph for only six trials (instead of 11 publications) so that a true summary could be created (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2009-06-24 15:30:09 +1000" MODIFIED_BY="Clare Dooley">
<P>All included trials had adequate sequence generation having made use of a computer-generated random sequence. Five trials (Finnish, South African, American Indian, Philippines, and the Gambian Trial) stated explicitly in the published articles how the random sequence was generated. On further inquiry, the NCKP trial affirmed to have used a computer-generated random sequence as well (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>).</P>
<P>All trials had adequate allocation concealment. The Finnish trial used sequentially-labelled smaller envelopes in bigger envelopes prepared by an external consultant and a vaccinator who was not involved in any other activities (<LINK REF="REF-Palmu-2003a" TYPE="REFERENCE">Palmu 2003a</LINK>); the Gambian trial used sequentially-numbered, opaque, sealed envelopes; the Philippines, the NCKP (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>), and the American Indian trials used sequentially-labelled vaccine containers of identical appearance. The South African trial also used identical-looking vaccine and placebo containers, but used colour-codes instead of serial numbers (<LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>).</P>
<P>As all six trials had adequate generation of random sequence and concealment of allocation, all six trials were adequately randomised.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-06-01 22:25:26 +1000" MODIFIED_BY="[Empty name]">
<P>All included trials, except for the NCKP trial, indicated explicitly in the published articles that blinding was done on participants, staff, and outcome assessors. On verification with Black (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>), however, participants, staff and investigators were all blinded as well.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-06-26 09:37:17 +1000" MODIFIED_BY="Liz Dooley">
<P>Except for <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, all included publications adequately addressed the domain on incomplete data outcome. In <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, 45 out of 831 in the <I>S. pneumoniae </I>CRM group and 37 out of 831 in the hepatitis B control group were not accounted for. Similarly for <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, 30 out of 835 in the <I>S. pneumoniae </I>OMPC group and 37 out of 831 in the hepatitis B control group were not accounted for. In both publications, the reasons for these exclusions were not addressed even though the patients had been allocated to the interventions. The investigators chose to do per protocol analysis instead of ITT analysis and the reason they gave was that compliance was excellent, with more than 95% of children enrolled having had complete follow-up data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-06-03 16:25:04 +1000" MODIFIED_BY="[Empty name]">
<P>We did not encounter selective reporting in the trials that we reviewed.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-07-27 13:05:04 +1000" MODIFIED_BY="[Empty name]">
<P>Potential threats to validity were noted in two trials that stopped early for benefit, namely, the NCKP and the American Indian trials both of which tested Wyeth's 7PCV, because the vaccine was accepted for licensure during the course of the trial. Where early stopping for apparent benefit demonstrated at an interim evaluation used to be fairly acceptable in past years, studies have shown that this trend may introduce bias. Trials that were stopped early (whether or not as a result of a formal stopping rule) are more likely to show extreme intervention effects than those that continue to the end, particularly if they have very few events (<LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>). Alternatively, this might be the case when a study stops because early results show large, statistically significant, intervention effect, although it may also be the case if a study stops because of harm. If a study does not describe having a pre-specified sample size, or any formal stopping rules, or the attained sample size is much less than the intended size but no explanation is given, then the study may have stopped at a point chosen because of the observed results, and so the available results may be biased (<LINK REF="REF-Higgins-2008a" TYPE="REFERENCE">Higgins 2008a</LINK>). In the <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK> article itself, qualified in a personal communication<B> </B>(<LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>), the authors mentioned that despite the limitations of a cluster-randomised trial, only the mixing of the intervention and control groups was certain to have occurred to some degree in the trial. They had no trouble maintaining the masking<B> </B>
<U>(</U>
<LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>). On the other hand, we maintain that because of early termination of trial, the appropriate sample size was not attained. As written earlier, we had assessed that the American Indian trial (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>; <LINK REF="REF-O_x0027_Brien-2009a" TYPE="REFERENCE">O'Brien 2009a</LINK>) had time lag bias for late reporting of the X-ray defined pneumonia outcome.</P>
<SUBSECTION>
<HEADING LEVEL="4">Summarising risk of bias for an outcome within a study (across domains)</HEADING>
<P>All six trials reviewed showed a low risk of bias for three critical and important domains namely: sequence generation, allocation concealment, and blinding (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). However, based on the criteria set by RevMan 5, the Finnish trial would have been considered as having a high risk of bias in terms of incomplete data outcome (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The US trials of Black (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) and O'Brien (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>), were considered as having a high risk of bias for the early stopping of trial. The late reporting of results for X-ray defined pneumonia (results appearing five years after the trial ended) puts the American Indian trial at an added risk of time-lag bias.</P>
<P>Despite the biases mentioned, the authors of this review also considered other factors in their final judgment of risk of bias for particular outcomes. For example, the number of missing data for the IPD outcome in the Finnish trial was too few and was similar in both intervention and control groups. Moreover, the risk of IPD was very low for this particular study population that a few missing data would not impact on the effect estimate. The same is true for the USA trials. Even though it is true that the trials in the USA were stopped early for apparent benefit brought on by the intervention, the magnitude of the effect of the intervention against the IPD outcome was very large (RR &lt; 0.5) offsetting any bias that may have been introduced by early stopping. The results are shown in several tables: the 'Summary of Findings' table provides much clearer and more detailed information in the 'Additional Tables' section, particularly <LINK REF="TBL-18" TYPE="TABLE">Table 18</LINK> and <LINK REF="TBL-19" TYPE="TABLE">Table 19</LINK> generated from GradePro 2008. Tables 18 and 19 were created using GRADEPro software as a single table with 14 columns. However, duplicating the table into RevMan's Additional table section was not possible because RevMan 5 can only create tables with a maximum of 10 columns.</P>
<P>Thus, for the IPD outcome, we have judged the publications to have a low risk of bias. Not so for the pneumonia outcomes. Although for IPD, the authors considered <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> as having low risk of bias for reasons stated above, this is not true for the pneumonia outcomes (X-ray defined and clinical pneumonia). A high risk of bias was retained for the USA study of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> for the pneumonia outcome. The pooled RR from the analysis for X-ray defined pneumonia was not large, only 0.73 (VE of 27%), and although the result showed that the PCV reduced the incidence of X-ray defined pneumonia, there is a possibility that the results could still be affected by small changes in the numbers analysed, if for example, the study had not been prematurely terminated, and more events could have been collected. Overall, for the pneumonia outcomes, there is a high risk of bias for both <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> and <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK> (early stopping of trial) and presence of time lag bias (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>). For all-cause mortality, despite having data from five publications, these were not powered to detect VE against this outcome. The Gambian trial originally had all-cause mortality as the primary outcome but this was changed during the course of the study to X-ray defined pneumonia. Still, among the five publications with mortality data, it is possible that the Gambian trial may have come close to having power to detect a difference of impact between groups for this outcome. The other four did not attempt to have mortality as an outcome but reported whatever data they had in the publications emanating from their respective trials.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-07-27 14:31:54 +1000" MODIFIED_BY="[Empty name]">
<P>A total of 113,044 children were randomised. The trial from South Africa reported the results of the efficacy of PCV among HIV-1 negative and positive infants (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>). The rest of the trials did not indicate the HIV-1 status of participating infants and for this review, they were presumed to be HIV-1 negative. The principal analysis involved HIV-1 negative infants. However, we also conducted subgroup analysis combining the results for HIV-1 negative and HIV-1 positive infants from South Africa and pooled this with the results from other publications.</P>
<SUBSECTION>
<HEADING LEVEL="3">Results from analyses using data from HIV-1 negative infants from the South African study and children &lt;24 months of age from the Gambian study pooled with the other studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(A) Risk ratio and vaccine efficacy for vaccine serotypes IPD (VT-IPD); ITT analysis</HEADING>
<P>Seven publications (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) had data for VT-IPD. Using the ITT population, we conducted analysis using the generic inverse variance method and random-effects model, to obtain a pooled RR. The pooled RR was 0.20 (95% CI 0.10 to 0.42, P &lt; 0.0001). Thus, the pooled VE for VT-IPD was 80% (95% CI 58% to 90%). The I<SUP>2</SUP> was 34% (P = 0.17), representing some heterogeneity but which might not be important (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). Refer to <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for more details.<BR/>Despite the low I<SUP>2</SUP> of 34% we conducted a sensitivity analysis that took into account exclusion of publications according to the presence of characteristics peculiar to an individual or group of studies (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> &#8211; Summary of analysis to explore heterogeneity):<BR/>a) Outlying study, i.e., having an effect or estimate with a different direction compared to the other publications (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>). With the exclusion of just one study (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) that had an RR of 2.99 (95% CI 0.31 to 28.73) and the only one with a different direction of effect from the other publications, the I<SUP>2</SUP> decreased considerably to 0% (P = 0.64) with a pooled RR of 0.18 (95% CI 0.11 to 0.30).<BR/>b) Small number of outcome events (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>). With the exclusion of these publications from the model, the I<SUP>2</SUP> decreased to 11% with a P = 0.34 with a RR of 0.17 (95% CI 0.09 to 0.31, P &lt; 0.00001). The heterogeneity was thus explained by the presence of an outlier. Despite this, the point estimate remained high even after the sensitivity analysis using the above exclusion models. It must be noted that the authors have judged all the publications included in this review to have a low risk of bias for the IPD outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(B) Risk ratio and vaccine efficacy for all serotypes-IPD; ITT analysis</HEADING>
<P>From the same seven publications in (A) above and using the same methods of analysis (generic inverse and random-effects), the pooled RR for all serotypes-IPD was 0.42 (95% CI 0.25 to 0.71, P = 0.001). The pooled VE was 58% (95% CI 29% to 75%). The I<SUP>2</SUP> was 49% and P = 0.07. See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<P>Sensitivity analysis excluding <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>, <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK> did not explain the heterogeneity although the effect estimate improved to 0.39 (95% CI 0.20 to 0.75, P = 0.005, I<SUP>2</SUP> = 72%, P = 0.01). Upon examination of individual effect estimates, <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> had the highest VE (or lowest RR). Upon exclusion of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, the heterogeneity disappeared with an I<SUP>2</SUP> of 0%, P = 0.96 but still with high pooled RR of 0.56 (95% CI 0.41 to 0.77).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(C) Risk ratio and vaccine efficacy for non-vaccine serotypes IPD (NVT-IPD); ITT analysis</HEADING>
<P>Only six out of the seven publications in (A) had data on NVT-IPD (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>). Using the same method of analysis as (A) (generic inverse and random-effects), the pooled RR was 0.92 (95% CI 0.39 to 2.17). The pooled VE for NVT-IPD was 8% (95% CI -117% to 61%; P = 0.84). There was no heterogeneity (I<SUP>2</SUP> 0%, P = 0.93). See <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(D) Risk ratio and vaccine efficacy for vaccine-related serotypes IPD (VRT-IPD); ITT analysis</HEADING>
<P>Four publications provided information on VRT-IPD (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>). Using the generic inverse and random-effects model, the pooled RR was 0.89 (95% CI 0.24 to 3.36, P = 0.87) giving a pooled VE of 11% (95% CI -236% to 76%) for VRT-IPD. There was no statistical heterogeneity (I<SUP>2</SUP> 0%, P = 0.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(E) Risk ratio and vaccine efficacy for WHO X-ray defined pneumonia; ITT analysis</HEADING>
<P>From four publications with results of analysis on the effect of PCV on WHO X-ray defined pneumonia (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>), and from <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK> in which results were provided by O'Brien in a personal communication (<LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>), the pooled RR was 0.81 (95% CI 0.66 to 1.00, P = 0.05, random-effects model) giving a VE of 19% (95% CI 0% to 44%) for X-ray defined pneumonia. Heterogeneity was present with I<SUP>2</SUP> = 77%, and P = 0.001. The outlier was the American Indian trial with a VE of &#8211;11.0% (95% CI -39.3% to 11.5%). The PCV did not decrease the incidence of X-ray defined pneumonia in this trial. See <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>.</P>
<P>In exploring heterogeneity, sensitivity analysis was done taking out <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>. The pooled estimate decreased with a RR of 0.73 (95% CI 0.64 to 0.85, P &lt; 0.0001, I<SUP>2</SUP> 41%, P = 0.16, random-effects model) giving a VE of 27% (95% CI 15% to 36%) for X-ray defined pneumonia. I<SUP>2</SUP> decreased but heterogeneity was still present although not significant. The RR was also not large (i.e., not &lt; 0.5) even if significant. See <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>.</P>
<P>Because there were only four publications left in the model, we did not want to do sensitivity analysis excluding one more study. But we needed to know whether the other publication with a bias (<LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) would remove heterogeneity if excluded together with <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>. Its exclusion only increased the I<SUP>2</SUP> to 61%. Upon closer look at individual estimates of the publications left in the model (four including <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> which was re-included), the study of <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> was the one which had the highest estimate. With exclusion of <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> and <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>, the heterogeneity disappeared (I<SUP>2</SUP> = 0%) and with a pooled RR of 0.80 (95% CI 0.69 to 0.93) which was still significant. If only <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> were excluded, heterogeneity remained (I<SUP>2</SUP> = 49%) and the pooled RR was 0.88 (95% CI 0.73 to 1.05).</P>
<P>Thus for X-ray defined pneumonia, the final model excluded the study of O'Brien in which the quality was doubtful because of the limitations previously mentioned (early stopping of trial and time lag bias). The final result for this outcome would therefore be: RR of 0.73 (95% CI 0.64 to 0.85, P &lt; 0.0001, I<SUP>2</SUP> 41%, P = 0.16) giving a VE of 27% (95% CI 15% to 36%). Please see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(F) Risk ratio and vaccine efficacy for clinical pneumonia; ITT analysis</HEADING>
<P>Four publications (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>) which had data on clinical pneumonia showed a pooled RR of 0.94 (95% CI 0.91 to 0.98, P = 0.0006, random-effects model). The pooled VE was 6% (95% CI 2% to 9%). There was no statistical heterogeneity (I<SUP>2</SUP> 0%, P = 0.43). See <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(G) Risk ratio and vaccine efficacy for all-cause admissions; ITT analysis</HEADING>
<P>From the data on all-cause admissions for the two publications (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>), the pooled RR was 0.95 (95% CI 0.83 to 1.10) for random-effects model. The pooled VE was 5% (95% CI -10% to 17%, P = 0.50) for random-effects model. There was statistical heterogeneity (I<SUP>2</SUP> 87%, P = 0.006). However, the results are not valid because there were only two publications reviewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(H) Risk ratio and vaccine efficacy for all-cause mortality; ITT analysis</HEADING>
<P>From five articles (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>;<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) with data on all-cause mortality, the pooled RR was 0.89 (95% CI 0.79 to 1.01, P = 0.08, random-effects models) with VE of 11% (95% CI -1% to 21%). There was no statistical heterogeneity (I<SUP>2</SUP> 0%, P = 0.98). See <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>. Despite the absence of heterogeneity, we still conducted analysis excluding the four other publications which had mortality data results but not as primary or secondary outcomes (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>;<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>). The exclusion of one, two, three or even four publications did not change the pooled RR significantly (range of 0.88 to 0.89).</P>
<P>Please refer to <LINK REF="TBL-14" TYPE="TABLE">Table 14</LINK> for additional information.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Results from analyses using data from all the infants in the South African study (HIV-1 negative plus HIV-1 positive infants) and children &lt; 24 months of age from the Gambian study pooled with data from the other studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(A) Risk ratio and vaccine efficacy for VT-IPD, all serotypes-IPD, NVT-IPD, and VRT-IPD; ITT analyses</HEADING>
<P>With the inclusion of HIV-1 positive infants into the ITT analyses for VT-IPD, the pooled RR (random-effects model) was 0.23 (95% CI 0.12 to 0.42) and a pooled VE of 77% (95% CI 58% to 88%).<BR/>For All serotypes-IPD, the pooled RR was 0.42 (95% CI 0.27 to 0.66, P = 0.0002), I<SUP>2</SUP> = 48%, P = 0.07 with a VE of 58% (95% CI 34% to 73%).</P>
<P>The results for VT-IPD and all serotypes-IPD were similar to that involving only HIV-1 negative children.</P>
<P>The results for NVT-IPD showed a RR of 1.06 (95% CI 0.55 to 2.04, random-effects model) and a decrease in VE to -6% (95% CI -104% to 45%). There was no statistical heterogeneity (I<SUP>2</SUP> = 0%, P = 0.95).</P>
<P>For VRT-IPD, the result showed that the pooled RR was 0.60 (95% CI 0.29 to 1.25, P = 0.17, random-effects model) and VE was 40% (95% CI -25% to 71%). There was no statistical heterogeneity (I<SUP>2</SUP> = 0%, P = 0.73).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(B) Risk ratio and vaccine efficacy for WHO X-ray defined pneumonia; ITT analysis</HEADING>
<P>The pooled RR was 0.75 (95% CI 0.64 to 0.88, random-effects model, P = 0.0004). The pooled VE was 25% (95% CI 12% to 36%). The I<SUP>2</SUP> was 61% (P = 0.05). The results were similar to that in HIV-1 negative children. This was also true when sensitivity analysis was done.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(C) Risk ratio and vaccine efficacy for clinical pneumonia; ITT analysis</HEADING>
<P>The pooled RR for clinical pneumonia was 0.94 (95% CI 0.91 to 0.97; P = 0.0006). The VE was 6 % (95% CI 3% to 9%). I<SUP>2</SUP> was 18%, P = 0.30 (random-effects model). The results were similar to that in HIV-1 negative children.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(D) Risk ratio and vaccine efficacy for all-cause admissions; ITT analysis</HEADING>
<P>The pooled RR for all-cause admissions was 0.95 (95% CI 0.83 to 1.10, P = 0.50). The VE was 5% (95% CI -10% to 17%). There was heterogeneity with an I<SUP>2</SUP> of 87%, P = 0.006.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(E) Risk ratio and vaccine efficacy for all-cause mortality; ITT analysis</HEADING>
<P>The pooled RR was 0.91 (95% CI 0.81 to 1.01, P = 0.07, random-effects model) with a VE of 9% (95% CI -0.01% to 19%). There was no statistical heterogeneity (I<SUP>2</SUP> 0%, P = 0.97).</P>
<P>Refer to <LINK REF="TBL-15" TYPE="TABLE">Table 15</LINK> for additional information.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Results from analyses using data from HIV-1 negative infants from the South African study and children &lt; 29 months of age from the Gambian study pooled with the other studies</HEADING>
<P>The results of the analyses were almost similar to the results of analyses that included only HIV-1 negative infants from the South African study and children &lt; 24 months of age from the Gambian study pooled with data from the other trials. An important difference between the subgroup of &lt; 24 month-old children from that of the subgroup &lt; 29 months old children was that for all-cause mortality, the results were similar but the results had become statistically significant, with a pooled RR of 0.87 (95% CI 0.77 to 0.98).</P>
<P>For additional information, please see <LINK REF="TBL-16" TYPE="TABLE">Table 16</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Results from analyses using data from all the infants in the South African study (HIV-1 negative plus HIV-1 positive infants) and children &lt; 29 months of age from the Gambian study pooled with data from the other studies</HEADING>
<P>The results of the analyses were almost similar to the results of analyses that included HIV-1 negative plus HIV-1 positive infants from the South African study and children &lt; 24 months of age from the Gambian study pooled with data from the other trials. As in HIV-1 negative infants, the results in &lt; 29 month-old children for all-cause mortality were similar but this time, the results had become statistically significant RR of 0.89 [95% CI 0.80 to 0.98].</P>
<P>Refer to <LINK REF="TBL-17" TYPE="TABLE">Table 17</LINK> for additional information.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-04 08:55:56 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-08-04 08:55:56 +1000" MODIFIED_BY="[Empty name]">
<P>This review included 11 publications arising from six trials. Seven publications provided high quality evidence for the outcome IPD. Evidence for the pneumonia outcomes from four publications was of moderate quality because of the presence of high risk of bias for the US trial of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> due to early stopping for benefit.</P>
<P>The PCV used by <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>; <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>; and <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK> had CRM197 as the protein conjugate. Kilpi utilised OMP while Lucero had diphtheria / tetanus proteins as conjugate. Safety of the vaccine was not included in this review although three phase 3 trials (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>; <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) showed the PCV to have an acceptable safety profile. There were some concerns on safety in the <LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK> study, which showed an increase in the incidence of general seizures and asthma in those vaccinated with the PCV, and in the Philippines trial (diphtheria / tetanus conjugate) which showed an increase in the occurrence of respiratory events during the first week after the first dose of the vaccine. In general, the 7PCV CRM197 (Prevnar, Wyeth Lederle) has been found to be safe and tolerable in children under two years of age and has been incorporated into the national immunisation programmes of several countries.</P>
<P>For this review, the conclusions are focused on the prevention of the outcomes studied in the context of the baseline risk among children younger than two years of age as derived from the studies reviewed to understand the absolute benefit that can be expected from the use of the PCV. For countries or populations where there is a baseline rate of 0.2% (rate for VT-IPD from the control group, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>), considered as medium risk among children younger than two years of age, PCV prevents about two VT-IPD cases per 1000 children but this is increased to 4/1000 if VT-IPD baseline risk is high at 0.5% (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). PCV prevents two all serotypes-IPD cases per 1000 children, and 5/1000, in medium-risk (control event rate of 0.4%, <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) and high-risk (control event rate of 0.8%, <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) populations, respectively. There was no reduction in the incidence of NVT-IPD and VRT-IPD with the use of PCV. However, we did not conduct a meta-analysis for individual serotypes. In some studies, there was some cross protection observed for certain VRT like 6A (<LINK REF="REF-Klugman-2008b" TYPE="REFERENCE">Klugman 2008b</LINK>).</P>
<P>For X-ray defined pneumonia, the number of cases PCV prevented was one case per 1000 in areas with low baseline risk (control event rate of 0.3%, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>) but prevents five cases per 1000 children in medium-risk populations (control event rate of 1.7%, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>), and 17/1000 children in high baseline-risk (control event rate of 6.3%, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>) populations. PCV prevents four clinical pneumonia cases per 1000 children in low baseline-risk populations (control event rate of 5.9%, <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>), 8/1000 in medium baseline-risk populations (control event rate of 12.6%, <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>), and 19/1000 in high baseline-risk populations (control event rate of 31.5%, <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
<P>The five publications with mortality data were not powered to assess the impact of PCV against all-cause mortality but the Gambia trial probably came close to having power to detect a difference between groups since mortality was their original primary outcome. But we must further clarify that the meta-analysis we did for the Gambia data included children &lt; 24 months of age, ITT population, as obtained through personal communication (<LINK REF="REF-Cutts-2007" TYPE="REFERENCE">Cutts 2007</LINK>), not children &lt; 29 months of age Per Protocol population as published by Cutts (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>). We received from the author ITT data for children &lt; 29 months of age stratified in three groups: 3 to 11, 12 to 23, and 24 to 29 months old. From this information, we calculated the ITT mortality data for &lt; 24 months old. Thus, the values included in the forest plot contain the VE for ITT in children &lt; 24 months of age (<LINK REF="REF-Cutts-2007" TYPE="REFERENCE">Cutts 2007</LINK>), with a model including the Finnish, SA, and Philippines publications. All these data are contained in the 'Additional Tables' with the relevant headings. The pooled estimate result did not present with heterogeneity. But a sensitivity analysis was still done using models with or without exclusion of the Finnish and Philippines data. With exclusion of the two Finnish studies, very little change was seen in the pooled VE. Although we assessed the quality of evidence for all-cause mortality to be weak, we have considered the ITT-VE of 11% with a 95% Cl of -1% to 21% to be compatible with reduction in all-cause mortality and is clinically important. This assessment also took into account the results of sub-group analysis including HIV-1 negative children &lt; 29 months of age where the ITT-VE reached statistical significance (VE 13% (95% CI 2% to 23%)). Even the results of analysis for HIV-1 negative and HIV-1 positive &lt; 29 months old children was significant.</P>
<P>Regarding all-cause admissions, there were only two publications from which to evaluate this outcome. Thus, there is no strong evidence at this point in time to indicate whether or not PCV has an impact on all-cause admissions.</P>
<SUBSECTION>
<HEADING LEVEL="3">Difference between the 2004 review and the 2009 update</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">General changes (methods)</HEADING>
<OL>
<LI>Use of Review Manager version 5 (RevMan 5) in 2009 (RevMan version 4 in 2004). The latest version of RevMan (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) contains many modifications on how to assess studies and how to present results.     </LI>
<LI>Assessment of the quality of publications (or trials from which the publications came from): There was a more stringent assessment of the publications included in the review using the new assessment criteria in the <I>Cochrane Handbook of Systematic Reviews of Interventions </I>in RevMan 5 not available in 2004. Publications regarded as having valid results in 2004, may have changed and now be considered as invalid due to certain criteria on how the trial was conducted.</LI>
<LI>Addition of a 'Summary of Findings' table: This is a summary of the findings with the addition of absolute effects of the intervention per outcome assessed including the quality of evidence presented using the software Grade Profiler (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>).</LI>
<LI>Addition of new publications: <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>; <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; <LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>; and <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>.</LI>
<LI>Addition of new findings from revisions of definition of outcomes, particularly that of the radiology-defined outcome with all definitions for this outcome fulfilling the criteria for WHO standardised definition of the presence of pneumonia on chest x-ray (for example, general radiologist X-ray readings of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> to the publication of <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK> article displaying the results of readings from readers conforming to the WHO definitions of X-ray pneumonia.)</LI>
<LI>Addition of all-cause mortality and all-cause admissions as outcomes.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Specific Changes</HEADING>
<P>
<LINK REF="TBL-20" TYPE="TABLE">Table 20</LINK> and <LINK REF="TBL-21" TYPE="TABLE">Table 21</LINK>
<B> </B>in the 'Additional Tables' section show a summary of the differences between the 2004 review and this 2009 update with regards the VE and 95% CI for the outcomes studied. In the 2004 review, empty cells for VE, 95% CI, effect P value, I<SUP>2</SUP> statistic, and heterogeneity P value for particular outcomes, meant that data were not available at that time or the results of only one study was available. Below are some important changes for IPD and pneumonia:</P>
<SUBSECTION>
<HEADING LEVEL="5">Changes from 2004 and 2009 (only ITT, random-effects model results for IPD)</HEADING>
<OL>
<LI>VT-IPD: There was a decrease of VE from 88% (in 2004) to 80% (in 2009) when the results of <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>; and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>; were added. However the pooled VE was still significant in the 2009 update, although heterogeneity appeared.</LI>
<LI>All serotypes-IPD: There was a decrease of VE from 68% to 58%, but pooled estimates of efficacy were still significant.</LI>
<LI>NVT-IPD and VRT-IPD: There was an increase in VE but it was not significant.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Changes from 2004 and 2009 (only ITT, random-effects model results for X-ray defined and clinical pneumonia)</HEADING>
<OL>
<LI>There was an increase in VE for X-ray defined pneumonia from 22% (in 2004) to 27% (in 2009) with the addition of <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>. Although <LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK> had contributed, this publication was excluded after sensitivity analysis showed that it was an outlier. The results remained significant.</LI>
<LI>VE for clinical pneumonia decreased by 1% with the addition of <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> and <LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>. Nevertheless, the VE attained significance in 2009.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-07-02 18:14:45 +1000" MODIFIED_BY="[Empty name]">
<P>Because phase 3 studies of the efficacy of an intervention are expensive, assessment of the impact of PCV against relevant outcomes at this point in time are limited only to the six trials which have been conducted since the late 1990s starting with the study in the US (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>) up to the publication of the Philippines trial (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>). Despite the paucity of studies, the review has provided sufficient evidence to address the IPD and pneumonia outcome objectives of this review but not the objective of studying the outcomes of all-cause mortality and all-cause admissions.</P>
<P>How applicable is the evidence of the impact of PCV against the outcomes studied in this review? The trials have been conducted in both high-income and low-income country settings where population characteristics are quite dissimilar, particularly in the context of incidence of IPD and pneumonia, socio-demographic factors like nutritional status, crowding, and environmental pollution that may put children younger than two years of age at greater risk of acquiring lower respiratory tract infections. Accessibility to health care facilities will also differ. Despite these differences, the direction of effect of the vaccine has been consistent. The Grade Profiler (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>) software incorporated in the Review Manager (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) software has made it possible to present the results not only of the pooled VE but also the absolute effect. Moreover, the software has also calculated the possible absolute effect in areas with low, medium, or high baseline rates for the relevant outcomes given the pooled vaccine efficacy for these endpoints. We believe that the evidence presented in this review can be applied to various settings.</P>
<P>How do the results of this review fit into the context of current immunisation guidelines or practices? The US was the first country to introduce the PCV into their national immunisation programme as a result of the study of <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, and mainly for prevention of IPD. Other high-income countries have also introduced the PCV and based on the burden of IPD, some countries have instituted their own schedule of vaccination. Some 31 low-income countries have expressed their interest to Global Alliance for Vaccines and Immunisation (GAVI) about including a PCV into their EPI programmes (<LINK REF="REF-Prevent-Pneumo-2008" TYPE="REFERENCE">Prevent Pneumo 2008</LINK>). Rwanda is the first GAVI-eligible country to include into their EPI a PCV, 7PCV being the only PCV available in the market so far (<LINK REF="REF-Rwanda-2009" TYPE="REFERENCE">Rwanda 2009</LINK>). The WHO on the other hand, has recommended that the PCV be introduced into low-income countries where mortality among children aged younger than five years is &gt; 50/1000 live births, or where &gt; 50,000 children die annually (<LINK REF="REF-WER-2007" TYPE="REFERENCE">WER 2007</LINK>). The results of this review are in line with the WHO position on the use of PCV in low-income countries. Ultimately, the decision to include the PCV into national programmes depends on the availability of estimates on disease burden, costs incurred and averted by vaccination, country-specific health care priorities in relation to available resources, and political will.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-08 17:55:48 +1000" MODIFIED_BY="[Empty name]">
<P>The evidence that has come out of this review is robust enough to make a conclusion regarding the effect of the PCV in reducing the incidence of VT-IPD and all serotypes-IPD in HIV-1 negative and HIV-1 positive children. The review included six randomised trials with more than 100,000 children participating. All trials were randomised, controlled, double-blind trials which were low-risk for bias in terms of sequence generation, allocation concealment, and blinding - domains which are crucial to avoid selection bias, performance bias, attrition bias, and detection bias. The analysis used a generic inverse method to allow comparability of one cluster-randomised trial (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>, <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>) with the rest of the included trials, all of which were individual randomised. Also, despite the presence of incomplete data reporting for the Finnish trial, and early stopping in the NCKP and American Indian trials making them high risk for bias, these were judged by the authors to have insufficient influence or impact on the calculated pooled effect estimate for IPD. The quality of evidence was rated high based on criteria of study design, no limitation, which affects validity of results, consistent results, and presence of direct evidence, absence of imprecision and, strong association of the effect of PCV against IPD. If the quality of the evidence is high, further research is unlikely to change our confidence in the estimate of effect at this point (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>).</P>
<P>The quality of evidence on the effect of PCV against X-ray defined and clinical pneumonia on the other hand was rated as moderate. This means that although the four publications reviewed for the pneumonia outcomes were randomised trials, and therefore of high quality, the NCKP trial from which two publications came out (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>) had serious limitations due to the presence of bias in the form of early stopping due to intervention benefits. In the context of the outcome X-ray defined pneumonia, the quality could not be upgraded because the magnitude of the effect was not large (RR was 0.73) which is not &gt; 5 or &lt; 0.2 (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>). For clinical pneumonia, the RR was similarly not large at 0.94 but with a narrow 95% CI of 0.91 to 0.98, estimates which could either become narrower or wider with the upper limit increasing to as high as 1 or &gt; 1 rendering an effect inconclusive of a real reduction of the incidence of clinical pneumonia. When the quality of evidence is assessed as moderate, this means that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>). Despite this reservation of the quality of evidence for the outcomes of X-ray defined and clinical pneumonia, we have to mention that the effect estimates of individual studies were very similar even if the risk of disease varied in the study sites. Most importantly, the direction of effect was consistent in four out of five trials studied for the pneumonia outcomes.</P>
<P>Other factors must be considered in assessing the validity of results. It must be emphasised that since the pneumonia outcome is not etiology-specific, only a portion of these pneumonias would be caused by vaccine-type pneumococcus. The more specific the outcome, that is, outcome as near as possible to making an aetiology of pneumococcal disease, the more robust would be the results. This can be shown by the disparity of point estimates between the more specific X-ray defined pneumonia, relative to that of non-specific clinical pneumonia. The disparity is all the more apparent by the difference in point estimates between the most specific outcome of IPD and X-ray defined or clinical pneumonia (RR = 0.20 versus RR = 0.73, and RR = 0.94, respectively).</P>
<P>Overall, the review authors have judged that the results from the meta-analysis of these six trials are valid for the outcomes of IPD and pneumonia</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-06-02 00:31:23 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors have made sure that all the relevant publications were identified and that relevant data were obtained. All the methods for searching for studies, selection of studies, data collection and analyses were appropriately conducted so as not to introduce bias. Investigation of heterogeneity was done. It is of course really not possible to determine the extent of bias or even the true risk of bias in a given study. However, we have followed as explicitly as possible, the guidelines regarding identification of risks of bias through the tools available in <LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>. We have judged that there were no potential biases in conducting the review as far as these processes were followed. We have made our own judgments regarding the quality of the trials involved based on other factors but these have also been made according to criteria set by <LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-06-24 17:40:28 +1000" MODIFIED_BY="Clare Dooley">
<P>A meta-analysis (<LINK REF="REF-Klugman-2008b" TYPE="REFERENCE">Klugman 2008b</LINK>) on the effect of PCV against IPD (including individual serotypes) was done but the follow-up time was longer than in this review, particularly with the South African population which extended to 6.2 years. Moreover, <LINK REF="REF-Klugman-2008b" TYPE="REFERENCE">Klugman 2008b</LINK> included all child participants in his study regardless of age of vaccination. Nevertheless, the findings of <LINK REF="REF-Klugman-2008b" TYPE="REFERENCE">Klugman 2008b</LINK> are in agreement with the findings of this updated review. Madhi (<LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK>) has written an excellent review (narrative, not systematic) on the factors relating to the varied PCV efficacy against X-ray defined pneumonia as a result of different methods of outcome event identification, health care practices, and availability or accessibility of health care in the different sites where the trials have been conducted. There is agreement that the PCV can reduce the incidence of X-ray defined pneumonia in children younger than two years of age.</P>
<P>After the introduction of the PCV in the US in 2000, many studies have reported on the indirect effects of the PCV in this country, corroborating the results of this review. A reduction in the IPD incidence in adults has been reported (<LINK REF="REF-Whitney-2003" TYPE="REFERENCE">Whitney 2003</LINK>). A number of studies on the reduction of pneumonia hospitalisations in the US (<LINK REF="REF-Grijalva-2007" TYPE="REFERENCE">Grijalva 2007;</LINK> <LINK REF="REF-MMWR-2009" TYPE="REFERENCE">MMWR 2009</LINK>) have been reported.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-28 14:52:28 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-06-24 17:41:46 +1000" MODIFIED_BY="Clare Dooley">
<P>The PCV is efficacious in preventing invasive disease due to vaccine serotypes. The evidence so far for the outcomes of X-ray defined and clinical pneumonia favour the conclusion that PCV reduces the incidence of X-ray defined pneumonia. The impact is considerably lower for clinical pneumonia relative to that of X-ray defined pneumonia but is still significant. Policy makers should look into existing data on burden of pneumonia disease or risk of disease in children under two years of age, serotype-specific disease, drug resistance in the local setting, and the cost of the vaccine to make informed decisions on the inclusion of the vaccine into national immunisation programmes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-28 14:52:28 +1000" MODIFIED_BY="[Empty name]">
<P>In countries where IPD burden identified by blood culture is thought to be low, more effort should be made to use tools that would improve the identification of pneumococcus so as to clarify the role of this organism in causing high morbidity and mortality. A GSK phase 3 trial on 10 PCV currently underway still aims to determine by blood culture the efficacy of this candidate vaccine against IPD caused by <I>S. pneumoniae</I> or <I>Haemophilus influenzae</I> (<I>H. influenzae)</I>, as well as its impact on the occurrence of hospital-diagnosed pneumonia cases, tympanostomy tube placement and outpatient antimicrobial prescriptions (started 11 May 2009, <LINK REF="REF-GSK-2009" TYPE="REFERENCE">GSK 2009</LINK>). Studies are needed to identify outcomes or combination of clinical or laboratory outcomes other than blood cultures that would improve specificity of the diagnosis of pneumococcal infection for future phase 3 studies. But because phase 3 trials are quite expensive such that this GSK trial may very well be the last phase 3 trial on PCV, other correlates of pneumococcal infection may need to be explored. Trials ought to have adequate sample size to investigate an outcome. Where PCV trials are concerned, trialists and/or pharmaceutical companies have to discuss the consequences of decisions to stop clinical trials for apparent intervention benefits as the validity of study results may be compromised by unnecessarily putting the trial at high risk for bias. Replacement IPD has been reported in the US (<LINK REF="REF-Hicks-2007" TYPE="REFERENCE">Hicks 2007</LINK>; <LINK REF="REF-Singleton-2007" TYPE="REFERENCE">Singleton 2007</LINK>). There has been an increased identification of NVT-IPD. Monitoring of this phenomenon should continue to re-evaluate the current vaccine being used in national immunisation programmes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-06-25 16:15:16 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>This work was performed under a collaborative arrangement with the PneumoADIP at Johns Hopkins Bloomberg School of Public Health and was funded in full by the GAVI Alliance.</LI>
<LI>Ms. Elizabeth Dooley, for providing the authors the impetus to complete this update, and for providing solutions to our countless queries.</LI>
<LI>Ms. Nancy Santesso of the GRADE working team for having given us her time, expertise and patience in answering our queries regarding absolute effect calculations in the GradePro software.</LI>
<LI>Ms. Sarah Thorning for updating our electronic searches.</LI>
<LI>Dr Kenneth John Lim, for helping us with the use of EndNote.</LI>
<LI>All the authors with whom we communicated through email and who gave us their time, talent, and data in the format we required.</LI>
<LI>Vicky Debold, Kate O&#8217;Brien, Robert Ware, and Peter Morris for commenting on the draft of this updated review.</LI>
</OL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-06-02 00:40:26 +1000" MODIFIED_BY="[Empty name]">
<P>The Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP) provided funding for the update of this review.</P>
<P>The authors collaborated with the ARIVAC consortium composed of scientists from the National Public Health Institute of Finland, the University of Queensland, University of Colorado, and sanofi-pasteur, the pharmaceutical company which developed the 11-valent PCV used in the phase three RCT in the Philippines. The primary author of this review was the principal investigator of the trial (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>) included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-27 15:08:42 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Marilla G. Lucero (MGL), MD, MSc, PhD, guarantor of the review; conceived, designed and coordinated the review; primarily responsible for writing of review, data management, analysis and interpretation of data;</LI>
<LI>Vernoni E. Dulalia (VED), MD, conducted the electronic and manual search of journal articles, screening search results with the main author, screening retrieved papers against eligibility criteria, reviewed materials together with a co-author and encoded/exported relevant materials into the review, performed data extraction, appraised the methodological quality of included studies using Cochrane's new 'risk of bias' tool, wrote to authors of included studies for additional information, entered data into RevMan, assisted in writing the review, incorporated recommendations and revisions made by peer reviewers; proofread and copy edited the final review;</LI>
<LI>Leilani T. Nillos (LTN), conducted the statistical analysis of data, entered data into RevMan, reviewed materials together with a co-author and encoded relevant materials into the review, appraised the quality of evaluated studies and performed data extraction of these studies; incorporated recommendations and revisions made by peer reviewers, proofread and copy edited the final review;</LI>
<LI>Gail Williams (GW), PhD, provided comments on the proposal and review in its preliminary stages of development; helped extensively in statistical analysis particularly in the clarification of the calculation of standard errors to be entered in Revman;</LI>
<LI>Rhea Angela N. Parreño (RAP), provided assistance in statistical analysis in the first publication in 2004: reviewed materials together with the main author and encoded relevant materials into the review; appraised the quality of evaluated studies and performed data extraction of these studies; incorporation of recommendations and revisions made by peer reviewers; proofread and copy edited the final document;</LI>
<LI>Hanna Nohynek (HN), MD, PhD, provided comments on the proposal and review; also provided majority of reference materials, helped contact authors of major articles included in this review;</LI>
<LI>Ian Riley (IR), provided general advice on the proposal and gave comments to the review;</LI>
<LI>Helena Makela (HM), MD, PhD, provided general advice on the proposal and gave comments to the review.</LI>
</OL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-05-29 16:56:40 +1000" MODIFIED_BY="[Empty name]">
<P>The major difference between the protocol and this updated review is the use of the latest version of RevMan which is RevMan 5.01. As such, the method by which the presence of risk of bias and quality of the evidence provided by the studies included in the review is vastly different than what was stated in the protocol or even in the 2004 version of this review (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-06-26 10:14:02 +1000" MODIFIED_BY="Liz Dooley">
<P>The title has changed from<B> </B>
<I>Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age</I> to <I>Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children under two years of age. </I>The reason for this is the change in terminology for the diagnosis of pneumonia using radiography. It used to be just the presence of consolidation. However, the WHO standardised the definition of X-ray defined pneumonia which did not only include consolidation. Moreover, all the pneumococcal trialists, including the main author of this review, used the WHO standardised definitions in reading chest radiographs. Thus, the title change reflects the change in terminology. </P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-28 14:51:38 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-06-25 12:48:11 +1000" MODIFIED_BY="Clare Dooley">
<INCLUDED_STUDIES MODIFIED="2009-06-25 12:40:08 +1000" MODIFIED_BY="Clare Dooley">
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2000" MODIFIED="2009-02-03 15:41:01 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-03 15:41:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J, et al</AU>
<TI>Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>3</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2002a" MODIFIED="2009-02-03 15:41:08 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2002a" YEAR="2002">
<REFERENCE MODIFIED="2009-02-03 15:41:08 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger&lt;/p&gt;" NOTES_MODIFIED="2009-02-03 15:41:08 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Ling S, Hansen J, Fireman B, Spring D, et al</AU>
<TI>Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>9</NO>
<PG>810-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cutts-2005" MODIFIED="2009-06-25 12:40:08 +1000" MODIFIED_BY="Clare Dooley" NAME="Cutts 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-25 12:40:08 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, et al</AU>
<TI>Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9465</NO>
<PG>1139&#8211;46</PG>
<IDENTIFIERS MODIFIED="2009-06-25 12:40:08 +1000" MODIFIED_BY="Clare Dooley"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eskola-2001" MODIFIED="2009-02-03 15:41:21 +1000" MODIFIED_BY="[Empty name]" NAME="Eskola 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-03 15:41:21 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eskola J, Kilpi T, Palmu A,  Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH, Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001 Feb 8;344(6):403-409,.&lt;/p&gt;" NOTES_MODIFIED="2009-02-03 15:41:21 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al</AU>
<TI>Efficacy of a pneumococcal conjugate vaccine against acute otitis media</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>6</NO>
<PG>403-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2006" MODIFIED="2009-04-27 13:34:07 +1000" MODIFIED_BY="Liz Dooley" NAME="Hansen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-27 13:34:07 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al</AU>
<TI>Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>9</NO>
<PG>779-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilpi-2003" MODIFIED="2009-02-03 15:41:30 +1000" MODIFIED_BY="[Empty name]" NAME="Kilpi 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 15:41:30 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clinical Infectious Diseases 2003 Nov 1; 37(9):1155-64.&lt;/p&gt;" NOTES_MODIFIED="2009-02-03 15:41:30 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al</AU>
<TI>Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>9</NO>
<PG>1155-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klugman-2003" MODIFIED="2009-03-01 11:49:45 +1000" MODIFIED_BY="Liz Dooley" NAME="Klugman 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-01 11:49:45 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-03-01 11:49:45 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N for the Vaccine Trialists Group</AU>
<TI>A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>14</NO>
<PG>1341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucero-2009" MODIFIED="2009-06-01 21:44:02 +1000" MODIFIED_BY="[Empty name]" NAME="Lucero 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-06-01 21:44:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lucero M, Nohynek H, Williams G, Tallo V, Simoes E, Lupisan S, et al</AU>
<TI>Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than two years of age in the Philippines: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>June 2009</YR>
<VL>28</VL>
<NO>6</NO>
<PG>455-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madhi-2005a" MODIFIED="2009-01-30 18:18:27 +1000" MODIFIED_BY="[Empty name]" NAME="Madhi 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-01-30 18:18:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madhi SA, Kuwanda L, Cutland C, Klugman KP</AU>
<TI>The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>10</NO>
<PG>1511-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2002" MODIFIED="2009-04-27 13:30:05 +1000" MODIFIED_BY="Liz Dooley" NAME="O'Brien 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-27 13:30:05 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>OBrien KL, David A, Benson J, Moenne  K, Reid R, Moulton L, et al</AU>
<TI>The effect of conjugate pneumococcal vaccine on pneumonia and otitis media among Navajo and White Mountain Apache children</TI>
<SO>3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) Book of Abstracts</SO>
<YR>2002</YR>
<PG>110-11</PG>
<CY>Anchorage Alaska, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-2003" MODIFIED="2009-04-27 13:35:30 +1000" MODIFIED_BY="Liz Dooley" NAME="O'Brien 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-27 13:35:30 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Efficacy and safety of seven valent conjugate pneumococcal vaccine in american indian children : group randomised trial. The Lancet 2003&lt;/p&gt;" NOTES_MODIFIED="2009-04-27 13:35:30 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien K, Moulton L, Reid R, Weatherholtz R, Oski J, Brown L, et al</AU>
<TI>Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9381</NO>
<PG>355-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12907008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-06-25 12:48:11 +1000" MODIFIED_BY="Clare Dooley">
<STUDY DATA_SOURCE="PUB" ID="STD-Adam-2001" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Adam 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="No original title" NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adam D, Scholz H</AU>
<TI>Value of pneumococcal vaccination in infants and young children</TI>
<SO>Klinische Padiatrie</SO>
<YR>2001</YR>
<VL>213</VL>
<NO>3</NO>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2004a" MODIFIED="2009-06-25 12:39:34 +1000" MODIFIED_BY="Clare Dooley" NAME="Black 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-06-25 12:39:34 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al</AU>
<TI>Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>6</NO>
<PG>485-9</PG>
<IDENTIFIERS MODIFIED="2009-06-25 12:39:34 +1000" MODIFIED_BY="Clare Dooley"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2004b" MODIFIED="2009-06-25 12:40:50 +1000" MODIFIED_BY="Clare Dooley" NAME="Black 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-06-25 12:40:50 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Shinefield H, Cohen R, Floret D, Gaudelus J, Olivier C, et al</AU>
<TI>Clinical effectiveness of seven-valent pneumococcal conjugate vaccine (Prevenar) against invasive pneumococcal diseases: prospects for children in France</TI>
<SO>Archives de Pediatrie</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>7</NO>
<PG>843-53</PG>
<IDENTIFIERS MODIFIED="2009-06-25 12:39:13 +1000" MODIFIED_BY="Clare Dooley"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-2000" MODIFIED="2009-02-03 15:48:13 +1000" MODIFIED_BY="[Empty name]" NAME="Blum 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-03 15:48:13 +1000" MODIFIED_BY="[Empty name]" NOTES="Blum MD, Dagan R, Mendelman PM, Pinsk V, Giordani M, Li S, Bohidar N, McNeely TB. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000;18(22):2359-67." NOTES_MODIFIED="2009-02-03 15:48:13 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum MD, Dagan R, Mendelman PM, Pinsk V, Giordani M, Li S, et al</AU>
<TI>A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>22</NO>
<PG>2359-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogaert-2005" MODIFIED="2009-03-01 11:50:54 +1000" MODIFIED_BY="Liz Dooley" NAME="Bogaert 2005" YEAR="2005 Apr 8">
<REFERENCE MODIFIED="2009-03-01 11:50:54 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogaert D, Veenhoven RH, Ramdin R, Luijendijk IH, Rijkers GT, Sanders EA, et al</AU>
<TI>Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media</TI>
<SO>Vaccine</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>20</NO>
<PG>2607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-2005" MODIFIED="2009-03-01 11:51:06 +1000" MODIFIED_BY="Liz Dooley" NAME="Brouwer 2005" YEAR="2005 Feb">
<REFERENCE MODIFIED="2009-03-01 11:51:06 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer CN, Maille AR, Rovers MM, Veenhoven RH, Grobbee DE, Sanders EA, et al</AU>
<TI>Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>2</NO>
<PG>273-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choo-2000" MODIFIED="2009-02-03 15:48:57 +1000" MODIFIED_BY="[Empty name]" NAME="Choo 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-03 15:48:57 +1000" MODIFIED_BY="[Empty name]" NOTES="Choo S, Seymour L, Morris R, Quataert S, Lockhart S, Cartwright K, Finn A. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a hemophilus influenzae type b conjugate vaccine in United Kingdom infants. Pediatric Infectious Disease Journal 2000;19(9):854-62." NOTES_MODIFIED="2009-02-03 15:48:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choo S, Seymour L, Morris R, Quataert S, Lockhart S, Cartwright K, et al</AU>
<TI>Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a hemophilus influenzae type b conjugate vaccine in United Kingdom infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>9</NO>
<PG>854-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagan-2001" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatric Infectious Disease Journal 2001 Oct; 20(10):951-958." NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D</AU>
<TI>Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>10</NO>
<PG>951-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagan-2002" MODIFIED="2009-02-03 15:48:35 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-03 15:48:35 +1000" MODIFIED_BY="[Empty name]" NOTES="Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. Journal of Infectious Diseases 2002 Apr 1; 185(7):927-936." NOTES_MODIFIED="2009-02-03 15:48:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al</AU>
<TI>Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>185</VL>
<NO>7</NO>
<PG>927-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagan-2003" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Dagan 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Givon-Lavi N, Zamir O, Fraser D</AU>
<TI>Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>6</NO>
<PG>532-40</PG>
<IDENTIFIERS MODIFIED="2008-12-17 19:48:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="2003261596"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dagan-2005" MODIFIED="2009-03-01 11:51:26 +1000" MODIFIED_BY="Liz Dooley" NAME="Dagan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-01 11:51:26 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Sibe GR, Kohberger R</AU>
<TI>Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>3</NO>
<PG>367-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Aristegui-Fernan-2005" MODIFIED="2009-04-27 13:32:08 +1000" MODIFIED_BY="Liz Dooley" NAME="De Aristegui Fernan 2005" YEAR="2005 Mar 14">
<REFERENCE MODIFIED="2009-04-27 13:32:08 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Aristegui Fernandez J, Cos Arregui B, Zurimendi Carril A, Alday Esteban MV, Alzua Ruiz J, De la Fuente Jausoro E, et al</AU>
<TI>Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months</TI>
<SO>Vaccine</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16</NO>
<PG>1917-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Einarsdottir-2005" MODIFIED="2009-06-25 12:45:09 +1000" MODIFIED_BY="Clare Dooley" NAME="Einarsdottir 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-25 12:45:09 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Einarsdottir HM, Erlendsdottir H, Kristinsson KG, Gottfredsson M</AU>
<TI>Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>9</NO>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekstrom-2005" MODIFIED="2009-03-01 11:52:24 +1000" MODIFIED_BY="Liz Dooley" NAME="Ekstrom 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-01 11:52:24 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekstrom N, Ahman H, Verho J, Jokinen J, Vakevainen M, Kilpi T, et al</AU>
<TI>Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial</TI>
<SO>Infection and Immunity</SO>
<YR>2005</YR>
<VL>73</VL>
<NO>1</NO>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esposito-2005" MODIFIED="2009-01-30 18:27:48 +1000" MODIFIED_BY="[Empty name]" NAME="Esposito 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-30 18:27:48 +1000" MODIFIED_BY="[Empty name]" NOTES="120.Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine. 2005;23(14):1703-8." NOTES_MODIFIED="2009-01-30 18:27:48 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, et al</AU>
<TI>Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants</TI>
<SO>Vaccine</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>14</NO>
<PG>1703-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finn-2002" MODIFIED="2009-03-01 11:53:00 +1000" MODIFIED_BY="Liz Dooley" NAME="Finn 2002" YEAR="2002 May 5-8">
<REFERENCE MODIFIED="2009-03-01 11:53:00 +1000" MODIFIED_BY="Liz Dooley" NOTES="Finn A, Arnaoutakis K, Race G, Burkinshaw R, Shaw L, Zhang Q. Mucosal anticapsular polysaccharide responses at 3 years of age after pneumococcal immunization in infancy and their relation to pneumococcal carriage. 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Anchorage Alaska, USA 2002 May 5-8;" NOTES_MODIFIED="2009-03-01 11:53:00 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Finn A, Arnaoutakis K, Race G, Burkinshaw R, Shaw L, Zhang Q</AU>
<TI>Mucosal anticapsular polysaccharide responses at 3 years of age after pneumococcal immunization in infancy and their relation to pneumococcal carriage</TI>
<SO>3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) (May 5-8)</SO>
<YR>2002</YR>
<CY>Anchorage Alaska, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fireman-2003" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Fireman 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media [erratum appears in Pediatr Infect Dis J. 2003 Feb;22(2):163]. Pediatric Infectious Disease Journal 2003 Jan; 22(1):10-16." NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P</AU>
<TI>Impact of the pneumococcal conjugate vaccine on otitis media. Erratum appears in Pediatric Infectious Disease Journal 2003;22(2):163</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>1</NO>
<PG>10-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frazao-2005" MODIFIED="2009-03-01 11:53:16 +1000" MODIFIED_BY="Liz Dooley" NAME="Frazao 2005" YEAR="2005 Mar">
<REFERENCE MODIFIED="2009-03-01 11:53:16 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao N, Brito-Avo A, Simas C, Saldanha J, Mato R, Nunes S, et al</AU>
<TI>Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>3</NO>
<PG>243-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaffar-2005" MODIFIED="2009-03-01 11:47:46 +1000" MODIFIED_BY="Liz Dooley" NAME="Ghaffar 2005" YEAR="2005 Jul">
<REFERENCE MODIFIED="2009-03-01 11:47:46 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghaffar F</AU>
<TI>The safety of 7-valent pneumococcal conjugate vaccine</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>4</NO>
<PG>631-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Givon_x002d_Lavi-2003" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Givon-Lavi 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Givon-Lavi N, Fraser D, Dagan R</AU>
<TI>Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>6</NO>
<PG>524-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldblatt-2006" MODIFIED="2009-03-01 11:48:22 +1000" MODIFIED_BY="Liz Dooley" NAME="Goldblatt 2006" YEAR="2006 April 2006">
<REFERENCE MODIFIED="2009-03-01 11:48:22 +1000" MODIFIED_BY="Liz Dooley" NOTES="139.Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatric Infectious Disease Journal. 2006 April 2006;25(4):312-9." NOTES_MODIFIED="2009-03-01 11:48:22 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al</AU>
<TI>Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>4</NO>
<PG>312-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanna-2006" MODIFIED="2009-06-25 12:48:11 +1000" MODIFIED_BY="Clare Dooley" NAME="Hanna 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-25 12:48:11 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanna JN, Humphreys JL, and Murphy DM</AU>
<TI>Invasive pneumococcal disease in Indigenous people in north Queensland, 1999-2004</TI>
<SO>Medical Journal of Australia</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>1</NO>
<PG>118-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jokinen-2004" MODIFIED="2009-03-01 11:53:49 +1000" MODIFIED_BY="Liz Dooley" NAME="Jokinen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-01 11:53:49 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH</AU>
<TI>Concentration of anti-pneumococcal antibodies as a serological correlate of protection: an application to acute otitis media</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>190</VL>
<NO>3</NO>
<PG>545-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kayhty-2005" MODIFIED="2009-04-27 13:32:43 +1000" MODIFIED_BY="Liz Dooley" NAME="Kayhty 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-27 13:32:43 +1000" MODIFIED_BY="Liz Dooley" NOTES="182.Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatric Infectious Disease Journal. 2005;24(2):108-14." NOTES_MODIFIED="2009-04-27 13:32:43 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L</AU>
<TI>Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>108-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madhi-2004" MODIFIED="2009-01-30 18:26:31 +1000" MODIFIED_BY="[Empty name]" NAME="Madhi 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 18:26:31 +1000" MODIFIED_BY="[Empty name]" NOTES="226.Madhi SA, Klugman KP, Group VT. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature-Medicine. 2004;10(8):811-3." NOTES_MODIFIED="2009-01-30 18:26:31 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madhi SA, Klugman KP, Group VT</AU>
<TI>A role for Streptococcus pneumoniae in virus-associated pneumonia</TI>
<SO>Nature-Medicine</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>8</NO>
<PG>811-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madhi-2005b" MODIFIED="2009-04-27 13:36:49 +1000" MODIFIED_BY="Liz Dooley" NAME="Madhi 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-04-27 13:36:49 +1000" MODIFIED_BY="Liz Dooley" NOTES="225.Madhi SA, Heera JR, Kuwanda L, Klugman KP. Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS medicine. 2005;2(2):e38." NOTES_MODIFIED="2009-04-27 13:36:49 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madhi SA, Heera JR, Kuwanda L, Klugman KP</AU>
<TI>Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia</TI>
<SO>PLoS Medicine</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>2</NO>
<PG>e38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moulton-2006" MODIFIED="2009-03-01 11:54:11 +1000" MODIFIED_BY="Liz Dooley" NAME="Moulton 2006" YEAR="2006 1 Aug 2006">
<REFERENCE MODIFIED="2009-03-01 11:54:11 +1000" MODIFIED_BY="Liz Dooley" NOTES="265.Moulton LH, O'Brien KL, Reid R, Weatherholtz R, Santosham M, Siber GR. Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study. Journal of Biopharmaceutical Statistics. 2006 1 Aug 2006;16(4 ):453-62." NOTES_MODIFIED="2009-03-01 11:54:11 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moulton LH, O'Brien KL, Reid R, Weatherholtz R, Santosham M, Siber GR</AU>
<TI>Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study</TI>
<SO>Journal of Biopharmaceutical Statistics</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>4</NO>
<PG>453-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmu-2002" MODIFIED="2009-03-01 11:54:25 +1000" MODIFIED_BY="Liz Dooley" NAME="Palmu 2002" YEAR="2002 May 5-8">
<REFERENCE MODIFIED="2009-03-01 11:54:25 +1000" MODIFIED_BY="Liz Dooley" NOTES="Palmu A, Verho J, Makela PH, Kilpi TM. Long-term efficacy of the seven-valent PncCRM vaccine on otitis media. 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Anchorage Alaska, USA. 2002 May 5-8." NOTES_MODIFIED="2009-03-01 11:54:25 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Palmu A, Verho J, Makela PH, Kilpi TM</AU>
<TI>Long-term efficacy of the seven-valent PncCRM vaccine on otitis media</TI>
<SO>3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) (May 5-8)</SO>
<YR>2002</YR>
<CY>Anchorage Alaska, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmu-2004" MODIFIED="2009-03-01 11:54:42 +1000" MODIFIED_BY="Liz Dooley" NAME="Palmu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-01 11:54:42 +1000" MODIFIED_BY="Liz Dooley" NOTES="301.Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. The Pediatric infectious disease journal. 2004;23(8):732-8." NOTES_MODIFIED="2009-03-01 11:54:42 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM</AU>
<TI>The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>8</NO>
<PG>732-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plotkin-2000" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Plotkin 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Plotkin SA. Development of a nonavalent pneumococcal conjugate vaccine. Medecine Therapeutique Pediatrie 2000; 3(SPEC. ISS 2.):17-18." NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plotkin SA</AU>
<TI>Development of a nonavalent pneumococcal conjugate vaccine</TI>
<SO>Medecine Therapeutique Pediatrie</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Spec. Iss. 2</NO>
<PG>17-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prymula-2006" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Prymula 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al</AU>
<TI>Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9512</NO>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinert-2003" MODIFIED="2009-02-03 15:49:50 +1000" MODIFIED_BY="[Empty name]" NAME="Reinert 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 15:49:50 +1000" MODIFIED_BY="[Empty name]" NOTES="Reinert P, Guy M, Girier B, Szelechowski B, Baudoin B, Deberdt P, et al. [The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule]. [French]. Archives de Pediatrie 2003 Dec;10(12):1048-55. No original title" NOTES_MODIFIED="2009-02-03 15:49:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reinert P, Guy M, Girier B, Szelechowski B, Baudoin B, Deberdt P, et al</AU>
<TI>The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule</TI>
<SO>Archives de Pediatrie</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>12</NO>
<PG>1048-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenfeld-2005" MODIFIED="2009-04-27 13:33:17 +1000" MODIFIED_BY="Liz Dooley" NAME="Rosenfeld 2005" YEAR="Jan 2005">
<REFERENCE MODIFIED="2009-04-27 13:33:17 +1000" MODIFIED_BY="Liz Dooley" NOTES="354.Rosenfeld RM, Lous J, Bluestone CD, Marchisio P, Casselbrant ML, Paradise JL, et al. Recent advances in otitis media. Annals of Otology, Rhinology, &amp;amp; Laryngology - Supplement. Jan 2005;194:114-39." NOTES_MODIFIED="2009-04-27 13:33:17 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld RM, Lous J, Bluestone CD, Marchisio P, Casselbrant ML, Paradise JL, et al</AU>
<TI>Recent advances in otitis media</TI>
<SO>Annals of Otology, Rhinology, &amp; Laryngology</SO>
<YR>2005</YR>
<VL>194</VL>
<PG>114-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheifele-2006" MODIFIED="2009-03-01 11:55:42 +1000" MODIFIED_BY="Liz Dooley" NAME="Scheifele 2006" YEAR="2006 15 Mar 2006">
<REFERENCE MODIFIED="2009-03-01 11:55:42 +1000" MODIFIED_BY="Liz Dooley" NOTES="365.Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine. 2006 15 Mar 2006;24(12 ):2057-64." NOTES_MODIFIED="2009-03-01 11:55:42 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D</AU>
<TI>Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>12</NO>
<PG>2057-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitt-2003" MODIFIED="2009-03-01 11:55:50 +1000" MODIFIED_BY="Liz Dooley" NAME="Schmitt 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-01 11:55:50 +1000" MODIFIED_BY="Liz Dooley" NOTES="Schmitt HJ, Faber J, Lorenz I, Schmole-Thoma B, Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003; 21(25-26): 3653-3662" NOTES_MODIFIED="2009-03-01 11:55:50 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt HJ, Faber J, Lorenz I, Schmole-Thoma B, Ahlers N</AU>
<TI>The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>25-6</NO>
<PG>3653-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-1999" MODIFIED="2009-03-01 11:56:00 +1000" MODIFIED_BY="Liz Dooley" NAME="Shinefield 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-03-01 11:56:00 +1000" MODIFIED_BY="Liz Dooley" NOTES="Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso PR, Siber G, Kohberger R, Madore DV, Malinowski FJ, Kimura A, Le C, Landaw I, Aguilar J, Hansen J. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatric Infectious Disease Journal 1999 Sep; 18(9):757-763." NOTES_MODIFIED="2009-03-01 11:56:00 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al</AU>
<TI>Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>9</NO>
<PG>757-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinefield-2002a" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Shinefield 2002a" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatric Infectious Disease Journal 2002 Mar; 21(3):182-186." NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E</AU>
<TI>Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>3</NO>
<PG>182-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Straetemans-2003" MODIFIED="2009-01-30 12:34:22 +1000" MODIFIED_BY="[Empty name]" NAME="Straetemans 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Straetemans M, Palmu A, Auranen K, Zielhuis GA, Kilpi T. The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age. International Journal of Pediatric Otorhinolaryngology 2003; 67(11): 1235-1242" NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Straetemans M, Palmu A, Auranen K, Zielhuis GA, Kilpi T</AU>
<TI>The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2003</YR>
<VL>67</VL>
<NO>11</NO>
<PG>1235-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tichmann_x002d_Schumann-2005" MODIFIED="2009-04-27 13:37:20 +1000" MODIFIED_BY="Liz Dooley" NAME="Tichmann-Schumann 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-27 13:37:20 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al</AU>
<TI>Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>1</NO>
<PG>70-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kempen-2006" MODIFIED="2009-03-01 11:56:25 +1000" MODIFIED_BY="Liz Dooley" NAME="Van Kempen 2006" YEAR="2006 Feb">
<REFERENCE MODIFIED="2009-03-01 11:56:25 +1000" MODIFIED_BY="Liz Dooley" NOTES="425.Van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative? International Journal of Pediatric Otorhinolaryngology. 2006 Feb;70(2):275-85." NOTES_MODIFIED="2009-03-01 11:56:25 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al</AU>
<TI>Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2006</YR>
<VL>70</VL>
<NO>2</NO>
<PG>275-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veenhoven-2002a" MODIFIED="2009-03-01 11:56:43 +1000" MODIFIED_BY="Liz Dooley" NAME="Veenhoven 2002a" YEAR="2002 May 5-8">
<REFERENCE MODIFIED="2009-03-01 11:56:43 +1000" MODIFIED_BY="Liz Dooley" NOTES="Veenhoven RH, Schilder AGM, Bogaert D, Brouwer CNM, Kiezebrink HH, Uiterwaal CSPM, Hermans PWM, De Groot R, Zegers BJM, Kuis W, Ridgkers GT, Sanders EAM. Prevention of acute otitis media by pneumococcal conjugate vaccine combined with 23-valent polysaccharide vaccine in children with recurrent acute otitis media (Dutch OMAVAX- study). 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Anchorage Alaska, USA 2002 May 5-8;" NOTES_MODIFIED="2009-03-01 11:56:43 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Veenhoven RH, Schilder AGM, Bogaert D, Brouwer CNM, Kiezebrink HH, Uiterwaal CSPM, et al</AU>
<TI>Prevention of acute otitis media by pneumococcal conjugate vaccine combined with 23-valent polysaccharide vaccine in children with recurrent acute otitis media (Dutch OMAVAX- study)</TI>
<SO>3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) (May 5-8)</SO>
<YR>2002</YR>
<CY>Anchorage Alaska, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veenhoven-2003a" MODIFIED="2009-02-03 15:50:46 +1000" MODIFIED_BY="[Empty name]" NAME="Veenhoven 2003a" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 15:50:46 +1000" MODIFIED_BY="[Empty name]" NOTES="Comment in: Lancet. 2003 Jun 28; 361(9376): 2170-1; PMID: 12842365" NOTES_MODIFIED="2009-02-03 15:50:46 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al</AU>
<TI>Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9376</NO>
<PG>2189-95</PG>
<IDENTIFIERS MODIFIED="2008-12-17 19:48:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="200326195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veenhoven-2003b" MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NAME="Veenhoven 2003b" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 19:48:05 +1000" MODIFIED_BY="[Empty name]" NOTES="Veenhoven RH, Bogaert D, Schilder AGM, Uiterwaal CSPM, Rijkers GT, Hermans PWM, et al. Clinical ineffectiveness of combined vaccination with 7-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in children with recurrent acute otitis media; a randomised double-blind study. Nederlands Tijdschrift voor Geneeskunde 2003; 147(45): 2220-2226" NOTES_MODIFIED="2008-12-17 19:48:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veenhoven RH, Bogaert D, Schilder AGM, Uiterwaal CSPM, Rijkers GT, Hermans PWM, et al</AU>
<TI>Clinical ineffectiveness of combined vaccination with 7-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in children with recurrent acute otitis media: a randomised double-blind study</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2003</YR>
<VL>147</VL>
<NO>45</NO>
<PG>2220-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veenhoven-2004" MODIFIED="2009-03-01 11:57:12 +1000" MODIFIED_BY="Liz Dooley" NAME="Veenhoven 2004" YEAR="2004 Oct 1">
<REFERENCE MODIFIED="2009-03-01 11:57:12 +1000" MODIFIED_BY="Liz Dooley" NOTES="428.Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clinical Infectious Diseases. 2004 Oct 1;39(7):911-9." NOTES_MODIFIED="2009-03-01 11:57:12 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al</AU>
<TI>Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>7</NO>
<PG>911-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeh-2003" MODIFIED="2009-02-03 15:51:09 +1000" MODIFIED_BY="[Empty name]" NAME="Yeh 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 15:51:09 +1000" MODIFIED_BY="[Empty name]" NOTES="Yeh SH, Zangwill KM, Lee H, Chang SJ, Wong VI, Greenberg DP, et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 2003 Jun 2;21(19-20):2627-31." NOTES_MODIFIED="2009-02-03 15:51:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeh SH, Zangwill KM, Lee H, Chang SJ, Wong VI, Greenberg DP, et al</AU>
<TI>Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>19-20</NO>
<PG>2627-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zangwill-2003" MODIFIED="2009-02-03 15:51:16 +1000" MODIFIED_BY="[Empty name]" NAME="Zangwill 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 15:51:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zangwill KM, Greenberg DP, Chiu CY, Mendelman P, Wong VK, Chang SJ, et al</AU>
<TI>Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>17-18</NO>
<PG>1894-900</PG>
<IDENTIFIERS MODIFIED="2008-12-17 19:48:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="2003156541"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-09-01 19:01:09 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-07-28 14:51:38 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-07-28 14:51:38 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Berman-1985" MODIFIED="2009-01-08 15:19:44 +1000" MODIFIED_BY="[Empty name]" NAME="Berman 1985" TYPE="JOURNAL_ARTICLE">
<AU>Berman S, McIntosh K</AU>
<TI>Selective primary health care: strategies for control of disease in the developing world. XXI. Acute respiratory infections [review]</TI>
<SO>Review of Infectious Diseases</SO>
<YR>1985</YR>
<VL>7</VL>
<NO>5</NO>
<PG>674-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-1999" MODIFIED="2009-03-01 11:57:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Black 1999" TYPE="JOURNAL_ARTICLE">
<AU>Black S</AU>
<TI>The clinical impact of pneumococcal conjugate vaccines</TI>
<SO>American Journal of Managed Care</SO>
<YR>1999</YR>
<VL>Suppl 5</VL>
<NO>17</NO>
<PG>1010-7</PG>
<IDENTIFIERS MODIFIED="2009-01-08 15:19:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="2000000365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Black-2002b" MODIFIED="2009-03-01 11:58:02 +1000" MODIFIED_BY="Liz Dooley" NAME="Black 2002b" NOTES="Black SB, Shinefield H, Fireman B, Hansen J, Ling S, Kaiser Permanente Vaccine Study Group, Austrian R, Siber G, Hackell J. Efficacy against pneumonia of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,868 infants and children: Expanded data analysis including duration of protection. 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Anchorage Alaska, USA 2002 May 5-8;" NOTES_MODIFIED="2009-03-01 11:58:02 +1000" NOTES_MODIFIED_BY="Liz Dooley" TYPE="CONFERENCE_PROC">
<AU>Black SB, Shinefield H, Fireman B, Hansen J, Ling S, Kaiser Permanente Vaccine Study Group, et al</AU>
<TI>Efficacy against pneumonia of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,868 infants and children: expanded data analysis including duration of protection</TI>
<SO>3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) (May 5-8)</SO>
<YR>2002</YR>
<CY>Anchorage Alaska, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2002c" MODIFIED="2009-03-01 11:58:17 +1000" MODIFIED_BY="Liz Dooley" NAME="Black 2002c" NOTES="Black S, Shinefield H, Ling S, Fireman B, Hansen J, Lee J, The Kaiser Permanente Study Group, Siber G, Hackell J. Efficacy against pneumonia of heptavalent conjugate pneumococcal vaccine (PCV) in 37,868 infants and children. 3rd World Congress of Pediatric Infectious Diseases (WSPID), Santiago, Chile 2002 Nov 19-23;" NOTES_MODIFIED="2009-03-01 11:58:17 +1000" NOTES_MODIFIED_BY="Liz Dooley" TYPE="CONFERENCE_PROC">
<AU>Black S, Shinefield H, Ling S, Fireman B, Hansen J, Lee J, et al</AU>
<TI>Efficacy against pneumonia of heptavalent conjugate pneumococcal vaccine (PCV) in 37,868 infants and children</TI>
<SO>3rd World Congress of Pediatric Infectious Diseases (WSPID) (November 19-23)</SO>
<YR>2002</YR>
<CY>Santiago, Chile</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2003" MODIFIED="2009-02-03 15:03:10 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2003" TYPE="CORRESPONDENCE">
<AU>Black S</AU>
<SO>Personnal communication</SO>
<YR>20 November 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2004" MODIFIED="2009-02-03 15:03:39 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2004" TYPE="CORRESPONDENCE">
<AU>Black S</AU>
<SO>Personnal communication</SO>
<YR>9 July 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2008" MODIFIED="2009-02-03 15:02:20 +1000" MODIFIED_BY="[Empty name]" NAME="Black 2008" TYPE="CORRESPONDENCE">
<AU>Black S</AU>
<SO>Personal communication</SO>
<YR>10 September 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crewe_x002d_Brown-1997" MODIFIED="2009-02-03 15:52:09 +1000" MODIFIED_BY="[Empty name]" NAME="Crewe-Brown 1997" TYPE="JOURNAL_ARTICLE">
<AU>Crewe-Brown HH, Karstaedt AS, Saunders GL, Khoosal M, Jones N, Wasas A, et al</AU>
<TI>Streptococcus pneumoniae blood culture isolates from patients with and without human immunodefieciency virus infection: alterations in penicillin susceptibilities and in serogroups of serotypes</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>5</NO>
<PG>1165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cutts-2007" MODIFIED="2009-01-30 08:07:16 +1000" MODIFIED_BY="[Empty name]" NAME="Cutts 2007" TYPE="CORRESPONDENCE">
<AU>Cutts F</AU>
<SO>Personal communication</SO>
<YR>28 Feb 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cutts-2008" MODIFIED="2009-01-30 08:07:33 +1000" MODIFIED_BY="[Empty name]" NAME="Cutts 2008" TYPE="CORRESPONDENCE">
<AU>Cutts F</AU>
<SO>Personal communication</SO>
<YR>24 November 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2009-03-01 11:59:37 +1000" MODIFIED_BY="Liz Dooley" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (Updated September 2008) (Available from www.cochrane-handbook.org)</SO>
<YR>2008</YR>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GAVI-2004" MODIFIED="2009-04-27 13:38:43 +1000" MODIFIED_BY="Liz Dooley" NAME="GAVI 2004" TYPE="OTHER">
<AU>Global Alliance on Vaccine and Immunization</AU>
<TI>Annual deaths in 2002 from vaccine-preventable diseases. WHO Estimates (Jan 2004)</TI>
<SO>http://www.vaccinealliance.org/home/General_Informatio/Immunization_informa/Diseases_Vaccines/vaccine_preventable_deaths.php (Accessed 16 July 2004)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giebink-2001" MODIFIED="2009-03-01 12:00:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Giebink 2001" TYPE="JOURNAL_ARTICLE">
<AU>Giebink GS</AU>
<TI>The prevention of pneumococcal disease in children</TI>
<SO>New England Journal of Medicine</SO>
<YR>18</YR>
<VL>345</VL>
<NO>16</NO>
<PG>1177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEPro-2008" MODIFIED="2009-03-16 08:45:51 +1000" MODIFIED_BY="Liz Dooley" NAME="GRADEPro 2008" TYPE="COMPUTER_PROGRAM">
<AU>GRADE Working Group 2004-2007</AU>
<TI>GRADEProfiler</TI>
<YR>June 2008</YR>
<EN>3.2</EN>
<PB>www.gradeworkinggroup.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grijalva-2007" MODIFIED="2009-01-30 12:24:03 +1000" MODIFIED_BY="[Empty name]" NAME="Grijalva 2007" TYPE="JOURNAL_ARTICLE">
<AU>Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR</AU>
<TI>Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time series analysis</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9568</NO>
<PG>1179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GSK-2009" MODIFIED="2009-05-29 23:46:59 +1000" MODIFIED_BY="[Empty name]" NAME="GSK 2009" TYPE="OTHER">
<AU>Glaxo Smith Kline</AU>
<TI>Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease. (FinIP)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00861380?term=pneumococcal+finland&amp;rank=8 (Accessed 18 May 2009)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2007" MODIFIED="2009-01-30 08:13:03 +1000" MODIFIED_BY="[Empty name]" NAME="Hansen 2007" TYPE="CORRESPONDENCE">
<AU>Hansen J</AU>
<SO>Personal communication</SO>
<YR>21 April 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2008a" MODIFIED="2009-03-01 12:00:47 +1000" MODIFIED_BY="Liz Dooley" NAME="Hansen 2008a" TYPE="CORRESPONDENCE">
<AU>Hansen J</AU>
<SO>Personal communication</SO>
<YR>5 November 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2008b" MODIFIED="2009-01-30 08:12:34 +1000" MODIFIED_BY="[Empty name]" NAME="Hansen 2008b" TYPE="CORRESPONDENCE">
<AU>Hansen J</AU>
<SO>Personal communication</SO>
<YR>20 November 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hicks-2007" MODIFIED="2009-01-30 12:27:11 +1000" MODIFIED_BY="[Empty name]" NAME="Hicks 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al</AU>
<TI>Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>9</NO>
<PG>1346-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008a" MODIFIED="2009-07-28 14:51:09 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008a" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (Updated September 2008) (Available from www.cochrane-handbook.org)</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008b" MODIFIED="2009-07-28 14:51:38 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008b" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data</TI>
<SO>Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). (Available from www.cochrane-handbook.org)</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISRCTN46147225" MODIFIED="2009-03-01 12:02:13 +1000" MODIFIED_BY="Liz Dooley" NAME="ISRCTN46147225" TYPE="OTHER">
<AU>ISRCTN46147225</AU>
<TI>Phase III, double-blind, randomised, placebo-controlled trial to evaluate efficacy against radiological pneumonia and invasive pneumococcal disease in Gambian infants</TI>
<SO>controlled-trials.com/ISRCTN46147225 (Accessed 5 November 2008)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISRCTN62323832" MODIFIED="2009-03-01 12:02:39 +1000" MODIFIED_BY="Liz Dooley" NAME="ISRCTN62323832" TYPE="OTHER">
<AU>ISRCTN62323832</AU>
<TI>Effectiveness of an 11-valent (types 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, AND 23F) conjugate vaccine against pneumonia in Philippine children: a double-blind, placebo-controlled, randomised, multicentre, effectiveness study</TI>
<SO>controlled-trials.com/ISRCTN62323832 (Accessed 5 November 2008)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaffar-2007" MODIFIED="2009-01-30 08:14:11 +1000" MODIFIED_BY="[Empty name]" NAME="Jaffar 2007" TYPE="CORRESPONDENCE">
<AU>Jaffar S</AU>
<SO>Personal communication</SO>
<YR>14 January 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klugman-2004" MODIFIED="2009-02-03 15:05:09 +1000" MODIFIED_BY="[Empty name]" NAME="Klugman 2004" TYPE="CORRESPONDENCE">
<AU>Klugman K</AU>
<SO>Personnal communication</SO>
<YR>18 March 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klugman-2008a" MODIFIED="2009-01-30 08:14:41 +1000" MODIFIED_BY="[Empty name]" NAME="Klugman 2008a" TYPE="CORRESPONDENCE">
<AU>Klugman K</AU>
<SO>Personal communication</SO>
<YR>22 November 2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klugman-2008b" MODIFIED="2009-06-25 12:57:49 +1000" MODIFIED_BY="Clare Dooley" NAME="Klugman 2008b" TYPE="BOOK_SECTION">
<AU>Klugman KP, Cutts F, Adegbola RA, Black S, Madhi SA, O'Brien KL, et al</AU>
<TI>Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease</TI>
<SO>Pneumococcal Vaccines: the impact of conjugate vaccine</SO>
<YR>2008</YR>
<PG>317-26</PG>
<PB>American Society for Microbiology</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-06-25 12:58:09 +1000" MODIFIED_BY="Clare Dooley" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews ofInterventions. Version 5.0.1 (Updated September 2008) (Available from www.cochrane-handbook.org)</SO>
<YR>2008</YR>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-1993" MODIFIED="2009-06-25 16:51:08 +1000" MODIFIED_BY="Liz Dooley" NAME="Lewis 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lewis JA, Machin D</AU>
<TI>Intention to treat--who should use ITT?</TI>
<SO>British Journal of Cancer</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>4</NO>
<PG>647-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madhi-2008" MODIFIED="2009-01-08 15:19:44 +1000" MODIFIED_BY="[Empty name]" NAME="Madhi 2008" TYPE="BOOK_SECTION">
<AU>Madhi S, Klugman KP</AU>
<TI>Efficacy and safety of conjugate pneumococcal vaccine in the prevention of pneumonia</TI>
<SO>Pneumococcal Vaccines: The impact of conjugate vaccines</SO>
<YR>2008</YR>
<PG>327-37</PG>
<ED>Siber GR, Klugman KP, Makela PH</ED>
<PB>ASM Press</PB>
<CY>Washington, D.C.</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-2009" MODIFIED="2009-03-01 12:04:32 +1000" MODIFIED_BY="Liz Dooley" NAME="MMWR 2009" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine - United States, 1997-2006</TI>
<SO>www.cdc.gov/mmwr/PDF/wk/mm5801.pdf (Accessed 22 January 2009)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2005" MODIFIED="2009-06-25 13:03:25 +1000" MODIFIED_BY="Clare Dooley" NAME="Montori 2005" TYPE="JOURNAL_ARTICLE">
<AU>Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al</AU>
<TI>Randomized trials stopped early for benefit: a systematic review</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>17</NO>
<PG>2203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moulton-2001" MODIFIED="2009-06-25 13:04:27 +1000" MODIFIED_BY="Clare Dooley" NAME="Moulton 2001" NOTES="Moulton 2001. Moulton LH, O'Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, Hackell J, Siber G, Santosham M. Design of a group-randomized Streptococcus pneumoniae vaccine trial. Controlled Clinical Trials 2001; 22: 438-452" NOTES_MODIFIED="2009-06-25 13:04:27 +1000" NOTES_MODIFIED_BY="Clare Dooley" TYPE="JOURNAL_ARTICLE">
<AU>Moulton LH, O'Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, et al</AU>
<TI>Design of a group-randomized Streptococcus pneumoniae vaccine trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>4</NO>
<PG>438-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-1992" MODIFIED="2009-06-25 16:51:38 +1000" MODIFIED_BY="Liz Dooley" NAME="Newell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newell DJ</AU>
<TI>Intention-to-treat analysis: implications for quantitative and qualitative research</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2001" MODIFIED="2009-03-01 12:15:04 +1000" MODIFIED_BY="Liz Dooley" NAME="O'Brien 2001" TYPE="CONFERENCE_PROC">
<AU>O'Brien KL, Moulton L, Reid R, Weatherholtz R, Hackell J, Kohberger R, et al</AU>
<TI>Invasive disease efficacy of a 7-valent pneumococcal conjugate vaccine among Navajo and White Mountain Apache (N/WMA) children</TI>
<SO>19th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) (March 26-8)</SO>
<YR>2001</YR>
<CY>Istanbul, Turkey</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2008" MODIFIED="2009-03-01 12:15:14 +1000" MODIFIED_BY="Liz Dooley" NAME="O'Brien 2008" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien KL, David AB, Chandran A, Moulton LH, Reid R, Weatherholtz R, et al</AU>
<TI>Randomized controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>1</NO>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2009a" MODIFIED="2009-05-29 12:18:01 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2009a" TYPE="CORRESPONDENCE">
<AU>O'Brien KL</AU>
<SO>Personal communication</SO>
<YR>6 January 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2009b" MODIFIED="2009-06-03 16:52:29 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2009b" TYPE="CORRESPONDENCE">
<AU>O'Brien KL</AU>
<SO>Pre-publication Peer Reviewer Commentary</SO>
<YR>12 May 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2009c" MODIFIED="2009-06-01 16:55:00 +1000" MODIFIED_BY="[Empty name]" NAME="O'Brien 2009c" TYPE="CORRESPONDENCE">
<AU>O'Brien KL</AU>
<SO>Personal Communication</SO>
<YR>29 May 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmu-2003a" MODIFIED="2009-02-03 15:23:21 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2003a" TYPE="CORRESPONDENCE">
<AU>Palmu A</AU>
<SO>Personnal communication</SO>
<YR>7 November 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmu-2003b" MODIFIED="2009-02-03 15:23:48 +1000" MODIFIED_BY="[Empty name]" NAME="Palmu 2003b" TYPE="CORRESPONDENCE">
<AU>Palmu A</AU>
<SO>Personnal communication</SO>
<YR>10 November 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PneumoVac-2008" MODIFIED="2009-01-30 08:22:16 +1000" MODIFIED_BY="[Empty name]" NAME="PneumoVac 2008" TYPE="BOOK">
<AU>Siber GR, Klugman KP, Makela PH, editors</AU>
<SO>Pneumococcal Vaccines: the impact of conjugate vaccine</SO>
<YR>2008</YR>
<PB>American Society for Microbiology</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prevent-Pneumo-2008" MODIFIED="2009-04-27 13:39:38 +1000" MODIFIED_BY="Liz Dooley" NAME="Prevent Pneumo 2008" TYPE="OTHER">
<AU>PneumoAdip</AU>
<TI>Vaccine Introduction: Countries Continue to Express Interest in Introducing Pneumococcal Vaccines</TI>
<SO>www.preventpneumo.org/vaccine (Accessed 15 October 2008)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-03-01 12:16:00 +1000" MODIFIED_BY="Liz Dooley" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rwanda-2009" MODIFIED="2009-05-29 17:43:45 +1000" MODIFIED_BY="[Empty name]" NAME="Rwanda 2009" TYPE="OTHER">
<AU>PneumoAdip</AU>
<TI>Rwanda Becomes First Developing Nation to Introduce Vaccine for World&#8217;s Leading Infectious Child Killer</TI>
<SO>www.preventpneumo.org/news/releases/upload/Press-Release_Rwanda_Introduces_PCV.pdf (Accessed 15 May 2009)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sazawal-1992" MODIFIED="2009-01-08 15:19:44 +1000" MODIFIED_BY="[Empty name]" NAME="Sazawal 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sazawal S, Black RE</AU>
<TI>Meta-analysis of intervention trials on case-management of pneumonia in community settings</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8818</NO>
<PG>528-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shann-1986" MODIFIED="2009-01-08 15:19:44 +1000" MODIFIED_BY="[Empty name]" NAME="Shann 1986" TYPE="JOURNAL_ARTICLE">
<AU>Shann F</AU>
<TI>Etiology of severe pneumonia in children in developing countries</TI>
<SO>Pediatric Infectious Diseases</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>2</NO>
<PG>247-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singleton-2007" MODIFIED="2009-03-01 12:16:13 +1000" MODIFIED_BY="Liz Dooley" NAME="Singleton 2007" TYPE="JOURNAL_ARTICLE">
<AU>Singleton RJ, Hennessy TW, Vulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al</AU>
<TI>Invasive pneumococcal disease caused by non-vaccine serotypes among Alaskan native children with high levels of 7-valent pneumococcal vaccine coverage</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>16</NO>
<PG>1784-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2009-06-25 13:06:52 +1000" MODIFIED_BY="Clare Dooley" NAME="Sweeting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1351-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tupasi-1990" MODIFIED="2009-03-01 12:16:21 +1000" MODIFIED_BY="Liz Dooley" NAME="Tupasi 1990" TYPE="JOURNAL_ARTICLE">
<AU>Tupasi TE, Lucero MG, Magdangal DM, Mangubat NV, Sunico ME, Torres CU, et al</AU>
<TI>Etiology of acute lower respiratory tract in children from Alabang, Metro Manila</TI>
<SO>Review of Infectious Diseases</SO>
<YR>1990</YR>
<VL>Suppl 12</VL>
<NO>8</NO>
<PG>929-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNGA-2000" MODIFIED="2009-03-01 12:16:46 +1000" MODIFIED_BY="Liz Dooley" NAME="UNGA 2000" TYPE="OTHER">
<AU>United Nations General Assembly</AU>
<TI>United Nations Millenium Declaration</TI>
<SO>http://www.un.org/millennium/declaration/ares552e.htm (Accessed September 18, 2000)</SO>
<YR>2000</YR>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2009-01-08 15:19:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="A/RES/55/2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WER-2007" MODIFIED="2009-01-30 08:24:59 +1000" MODIFIED_BY="[Empty name]" NAME="WER 2007" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO position paper on vaccines</TI>
<SO>Weekly Epidemiological Report</SO>
<YR>March 2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitney-2003" MODIFIED="2009-02-03 15:42:00 +1000" MODIFIED_BY="[Empty name]" NAME="Whitney 2003" NOTES="Whitney 2003. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett MM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson Delois, Facklam RR, Jorgensen JH, and Schuchat A for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. New England Journal of Medicine 2003 November; 348(18): 1737-1746." NOTES_MODIFIED="2009-02-03 15:42:00 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett MM, Lynfield R, et al</AU>
<TI>Decline in Invasive Pneumococcal Disease after the introduction of Protein-polysachharide Conjugate Vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>18</NO>
<PG>1737-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2003" MODIFIED="2009-01-30 08:24:44 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2003" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Pneumococcal Vaccines</TI>
<SO>Weekly Epidemiological Record</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>110-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-03-01 12:17:44 +1000" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Lucero-2004" MODIFIED="2009-03-01 12:17:44 +1000" MODIFIED_BY="Liz Dooley" NAME="Lucero 2004" TYPE="COCHRANE_REVIEW">
<AU>Lucero MG, Dulalia VE, Parreño RAN, Lim-Quianzon DM, Nohynek H, Makela H, Williams G</AU>
<TI>Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004977"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-03-01 12:17:44 +1000" MODIFIED_BY="Liz Dooley"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-28 14:53:54 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-28 14:53:54 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Conflict of Interest" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-03 18:38:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2000">
<CHAR_METHODS MODIFIED="2009-06-25 09:36:21 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> Randomised controlled, double-blind</P>
<P>
<B>Duration of the study: </B>October 1995 - April 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 17:05:04 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> 23 medical centres within Northern California Kaiser Permanente (NCKP)</P>
<P>
<B>Participants:</B> 37,868 healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal (7PCV) conjugate or the meningococcus type C CRM<SUB>197</SUB> conjugate (MnCC) vaccine at 2, 4, 6 and 12 to 15 months of age; 18,927 children were allocated to the 7PCV while 18,941 to MnCC.</P>
<P>
<B>Country: </B>Northern California, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 17:06:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent pneumococcal conjugate vaccine containing 2 &#956;g each of saccharides of serotypes 4, 9V, 14, 18C, 19F and 23F and 4 &#956;g of 6B coupled to the protein carrier CRM<SUB>197</SUB> (a noncatalytic <B>c</B>ross-<B>r</B>eacting <B>m</B>utant of diphtheria toxin)</P>
<P>
<B>Control:</B> Meningococcus type C CRM<SUB>197 </SUB>conjugate vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 20:02:17 +1000" MODIFIED_BY="[Empty name]">
<P>Pneumococcal invasive disease, acute otitis media (AOM), safety, immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-03-07 11:52:54 +1000" MODIFIED_BY="Liz Dooley">
<P>Wyeth Lederle vaccines and Pediatrics</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:33:35 +1000" MODIFIED_BY="[Empty name]">
<P>This is an industry-initiated study (Wyeth) <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-07-03 18:38:02 +1000" MODIFIED_BY="[Empty name]">
<P>A preliminary report of this study was published earlier and is listed in the 'Additional References' section as <LINK REF="REF-Black-1999" TYPE="REFERENCE">Black 1999</LINK>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 17:13:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2002a">
<CHAR_METHODS MODIFIED="2009-06-25 09:43:41 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> Randomised controlled, double-blind</P>
<P>
<B>Duration of the study</B>: October 1995 - April 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 17:13:38 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> 23 medical centres within Northern California Kaiser Permanente (NCKP)</P>
<P>
<B>Participants:</B> 37,868 healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal (7PCV) conjugate or the meningococcus type C CRM<SUB>197</SUB> (MnCC) conjugate vaccine at 2, 4, 6 and 12 to 15 months of age; 18,927 children were allocated to the 7PCV while 18,941 to MnCC.</P>
<P>
<B>Country: </B>Northern California, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 17:13:59 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent pneumococcal conjugate vaccine containing 2 &#956;g each of saccharides of serotypes 4, 9V, 14, 18C, 19F and 23F and 4 &#956;g of 6B coupled to the protein carrier CRM197 (a nontoxic mutant of diphtheria toxin)</P>
<P>
<B>Control:</B> Meningococcus Type C CRM<SUB>197</SUB> conjugate vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 20:02:41 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical pneumonia, radiograph-confirmed pneumonia</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-03-07 11:54:24 +1000" MODIFIED_BY="Liz Dooley">
<P>Wyeth Lederle vaccines and Pediatrics</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:33:22 +1000" MODIFIED_BY="[Empty name]">
<P>This is an industry-initiated study (Wyeth) <LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>
</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-06-25 09:44:58 +1000" MODIFIED_BY="Clare Dooley">
<P>This study was presented earlier at the May 2002 ISPPD in Anchorage, Alaska, and the abstract is listed in the 'Additional References' section as <LINK REF="REF-Black-2002b" TYPE="REFERENCE">Black 2002b</LINK>, and later in November at the WSPID 2002, the abstract of which, is listed in the 'Additional References' section as <LINK REF="REF-Black-2002c" TYPE="REFERENCE">Black 2002c</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 18:44:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cutts-2005">
<CHAR_METHODS MODIFIED="2009-06-25 09:49:15 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design: </B>Randomised, placebo-controlled, double-blind</P>
<P>
<B>Duration of the study:</B> August 2000 - April 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-01 12:06:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Mother-child-health clinics at 15 fixed facilities including Bansang Hospital in Central River Division and Basses health centre in Upper River Division and at about 110 outreach sites</P>
<P>
<B>Participants:</B> 17, 437 children age 6-51 weeks randomly allocated three doses of either pneumococcal conjugate vaccine or placebo, with intervals of at least 25 days between doses; 8718 were allocated to 9PCV while 8719 to placebo.</P>
<P>
<B>Country: </B>The Gambia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 18:40:42 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 9-valent pneumococcal conjugate vaccine containing 2 &#956;g of type 1, 4, 5, 9V, 14, 19F, and 23F polysaccharides, 4 &#956;g of type 6B polysaccharide, and 2 &#956;g of type 18C oligosaccharide linked to the diphtheria toxoid protein CRM<SUB>197</SUB>
</P>
<P>
<B>Control: </B>placebo</P>
<P>
<B>Mode of administration:</B> Intramuscular injection into the child's right thigh</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-02 18:14:48 +1000" MODIFIED_BY="[Empty name]">
<P>Radiological pneumonia, clinical pneumonia, invasive pneumococcal disease, all-cause admissions, all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-07-03 18:44:30 +1000" MODIFIED_BY="[Empty name]">
<P>National Institute of Allergy and Infectious Diseases at the USA National Institutes of Health; WHO; Children&#8217;s Vaccine Program at Program for Appropriate Technology in Health (PATH); US Agency for International Development (USAID); Wyeth Vaccines for donating the study vaccines and Prevenar for placebo recipients</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:34:48 +1000" MODIFIED_BY="[Empty name]">
<P>S K Obaro has received honoraria from Wyeth Vaccines for consultancies in the past three years. Since her involvement in the trial, A Leach has become an employee of Glaxo-SmithKline Biologicals, who are developing a pneumococcal conjugate vaccine, and own shares in Glaxo SmithKline <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>.</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:03:04 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 18:47:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eskola-2001">
<CHAR_METHODS MODIFIED="2009-06-25 09:53:02 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> a three-arm, randomised, double-blind</P>
<P>
<B>Duration of the study:</B> December 1995 - March 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-25 09:53:23 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Setting: </B>Eight study clinics, each with a specially trained study nurse and a study physician, established in the communities of Tampere, Kangasala, and Nokia, Finland</P>
<P>
<B>Participants:</B> 2,497 children receiving either the 7PCV-CRM197, 7PCV-OMP, or hepatitis B vaccine as a control at 2, 4, 6, and 12 months of age; 831 were allocated to 7PCV-CRM197, 835 to 7PCV-OMP, while 831 to Hep B vaccine as control.</P>
<P>
<B>Country: </B>Finland</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 18:47:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent containing 2 &#956;g each of capsular polysaccharides of pneumococcal serotypes 4, 9V, 14, 19F, and 23F, 4 &#956;g of serotype 6B polysaccharide, and 2 &#956;g of serotype 18C oligosaccharide, each conjugated individually to the CRM<SUB>197 </SUB>protein</P>
<P>
<B>Control: </B>Hepatitis B vaccine containing 5 &#956;g of recombinant hepatitis B surface protein</P>
<P>
<B>Mode of administration:</B> Intramuscular<BR/>
</P>
<P>
<B>Frequency:</B> Age of approximately 2 months (6 to 13 weeks), 4 months (14 to 21 weeks), 6 months (22 to 29 weeks), and 12 months (11 to 14 months). An interval of 6 to 11 weeks was required between the first and second vaccinations and between the second and third vaccinations</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Acute otitis media (AOM) and pneumococcal invasive disease</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-03-07 11:56:38 +1000" MODIFIED_BY="Liz Dooley">
<P>Merck, Pasteur Merrieux-Connaught, and Wyeth Lederle Vaccines and Pediatrics</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:35:26 +1000" MODIFIED_BY="[Empty name]">
<P>Dr Eskola has served as Consultant to Wyeth Lederle Vaccines (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:03:30 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 17:16:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-2006">
<CHAR_METHODS MODIFIED="2009-06-25 09:55:32 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design: </B>Randomised controlled, double-blind</P>
<P>
<B>Duration of the study: </B>October 1995 - April 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 17:15:59 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> 23 medical centres within Northern California Kaiser Permanente (NCKP)</P>
<P>
<B>Participants:</B> 37,868 healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal (7PCV) conjugate or the meningococcus type C CRM<SUB>197</SUB> (MnCC) conjugate vaccine at 2, 4, 6 and 12 to 15 months of age; 18,927 children were allocated to the 7PCV while 18,941 to MnCC.</P>
<P>
<B>Country: </B>Northern California, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 17:16:09 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent pneumococcal conjugate vaccine containing 2 &#956;g each of saccharides of serotypes 4, 9V, 14, 18C, 19F and 23F and 4 &#956;g of 6B coupled to the protein carrier CRM197 (a nontoxic mutant of diphtheria toxin)</P>
<P>
<B>Control: </B>Meningococcus Type C CRM<SUB>197</SUB> conjugate vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 20:03:49 +1000" MODIFIED_BY="[Empty name]">
<P>Radiograph-confirmed pneumonia</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-11-26 20:49:52 +1000" MODIFIED_BY="[Empty name]">
<P>Wyeth Lederle vaccines and Pediatrics</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:36:32 +1000" MODIFIED_BY="[Empty name]">
<P>This is an industry-initiated study (Wyeth) (<LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-06-25 09:56:13 +1000" MODIFIED_BY="Clare Dooley">
<P>An earlier report (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>) of this study was published earlier but did not use the WHO standardised criteria for reading chest radiographs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 17:18:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kilpi-2003">
<CHAR_METHODS MODIFIED="2009-06-25 09:59:23 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> Randomised, double-blind</P>
<P>
<B>Duration of the study:</B> December 1995 - March 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 17:18:42 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Eight study clinics, each with a specially trained study nurse and a study physician, established in the communities of Tampere, Kangasala, and Nokia, Finland</P>
<P>
<B>Participants:</B> 2,497 children receiving either the 7PCV-CRM197, 7PCV-OMPC, or hepatitis B vaccine as a control at 2, 4, 6, and 12 months of age; 831 were allocated to 7PCV-CRM197, 835 to 7PCV-OMPC, while 831 to Hep B vaccine as control.</P>
<P>
<B>Country: </B>Finland</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 17:18:19 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment: </B>7-valent containing 1 &#956;g of capsular polysaccharides of pneumococcal serotypes 4 and 14, 1.5 &#956;g of type 9V, 2 &#956;g of types 18C and 19F, 3 &#956;g of type 23F, and 5 &#956;g of type 6B, each individually conjugated to the outer membrane protein complex (OMPC) of <I>Neisseria meningitidis</I> serogroup B</P>
<P>
<B>Control: </B>Hepatitis B vaccine containing 5 &#956;g of recombinant hepatitis B surface protein</P>
<P>
<B>Mode of administration:</B> Intramuscular<BR/>
</P>
<P>
<B>Frequency: </B>Age of approximately 2 months (6 to 13 weeks), 4 months (14 to 21 weeks), 6 months (22 to 29 weeks), and 12 months (11 to 14 months). An interval of 6 to 11 weeks was required between the first and second vaccinations and between the second and third vaccinations</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Acute otitis media (AOM) and pneumococcal invasive disease</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-03-07 12:00:18 +1000" MODIFIED_BY="Liz Dooley">
<P>Aventis Pasteur, Merck, and Wyeth-Lederle Vaccines</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:38:01 +1000" MODIFIED_BY="[Empty name]">
<P>Dr Kilpi has served as Consultant to Wyeth Lederle Vaccines (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:04:17 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-06-25 11:50:45 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Klugman-2003">
<CHAR_METHODS MODIFIED="2009-06-25 10:00:58 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> Randomised, double-blind</P>
<P>
<B>Duration of the study:</B> March 2, 1998 - November 15, 2001</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-25 11:50:45 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Setting:</B> 21 vaccination centres in Soweto</P>
<P>
<B>Participants: </B>39,836 children receiving either the 9PCV or placebo as a control at 6, 10 and 14 weeks of age; 19,922 were allocated to 9PCV while 19,914 to placebo. Excluding the HIV-1 positive children, only 18, 633 children were allocated to the 9PCV, and 18,626 to the placebo, for a combined total of 37,259<B> </B>HIV-1 negative children considered in this review.</P>
<P>
<B>Country: </B>South Africa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-01 12:01:22 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 9-valent containing 2 &#956;g of capsular polysaccharide (serotypes 1, 4, 5, 9V, 14, 19F, and 23F), 4 &#956;g of serotype 6B, and 2 &#956;g of oligosaccharide 18C</P>
<P>
<B>Control: </B>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 20:04:42 +1000" MODIFIED_BY="[Empty name]">
<P>Invasive pneumococcal disease, radiologically confirmed pneumonia, antibiotic-resistant first episodes of invasive pneumococcal disease, safety</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-11-26 20:57:33 +1000" MODIFIED_BY="[Empty name]">
<P>Wyeth Lederle Vaccines and Pediatrics; WHO</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>S A Madhi was the recipient of research grant awards and salary support from Wyeth Vaccines and Pediatrics during the conduct of the study. C Cutland received salary support from Wyeth Vaccines and Pediatrics during the conduct of the study. K P Klugman has received research grant awards from Wyeth vaccines and Pediatrics, is a member of the Wyeth&#8217;s Speakers Bureau, and is a Consultant for Wyeth Vaccines and Pediatrics (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:04:42 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 18:53:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucero-2009">
<CHAR_METHODS MODIFIED="2009-06-25 10:03:18 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design: </B>Randomised, double-blind, placebo-controlled</P>
<P>
<B>Duration of the study:</B> July 5, 2000 - December 31, 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 17:20:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Six municipalities (Tagbilaran City, Dauis, Panglao, Baclayon, Cortes, and Balilihan) in Bohol Province</P>
<P>
<B>Participants: </B>12,191 children six weeks to younger than six months of age randomly allocated to receive three doses of either an 11-valent pneumococcal conjugate vaccine (11PCV) or a saline placebo, with a minimum interval of four weeks between doses; 6,097 were allocated to 11PCV while 6,094 to placebo.</P>
<P>
<B>Country: </B>Philippines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 18:53:43 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B>11-valent pneumococcal conjugate vaccine containing one &#956;g of <I>Streptococcus pneumoniae</I> capsular polysaccharide conjugated to tetanus toxoid for types 1, 4, 5, 7F, 9V, 19F and 23F, and 3 &#956;g of polysaccharide of types 3, 14 and 18C conjugated to diphtheria toxoid, and 10 &#956;g of polysaccharide of type 6B conjugated to diphtheria toxoid</P>
<P>
<B>Control:</B> Placebo<BR/>
</P>
<P>
<B>Mode of administration:</B> Intramuscularly into the antero-lateral aspect of the right thigh<BR/>
</P>
<P>
<B>Frequency: </B>Three doses of the study vaccines and DTwP//PRP-T, HepB, and OPV vaccines were given following the Philippines' Expanded Programme on Immunisation schedule (<I>i.e</I>. officially 6, 10, and 14 weeks of age) starting at six weeks to younger than six months of age</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-02 18:14:50 +1000" MODIFIED_BY="[Empty name]">
<P>Radiologically defined pneumonia, clinical pneumonia, invasive pneumococcal disease, all-cause admissions, all-cause mortality, safety, immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-06-25 10:04:53 +1000" MODIFIED_BY="Clare Dooley">
<P>European Commission DG Research INCO programme, Academy of Finland, Finnish Ministry of Foreign Affairs, Finnish Physicians for Social Responsibility, GAVI ADIP Pneumo, Sanofi Pasteur for the study vaccines, Research Institute for Tropical Medicine of the Philippines, National Public Health Institute Finland, University of Queensland, University of Colorado, National Health and Medical Research Council of Australia and PATH</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-11-26 21:02:11 +1000" MODIFIED_BY="[Empty name]">
<P>None</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:05:11 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 17:38:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madhi-2005a">
<CHAR_METHODS MODIFIED="2009-06-25 10:05:38 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design: </B>Randomised, double-blind</P>
<P>
<B>Duration of the study:</B> March 2, 1998 - November 15, 2001</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-25 10:06:17 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Setting:</B> 21 vaccination centres in Soweto</P>
<P>
<B>Participants: </B>39,836 children receiving either the 9PCV or placebo as a control at 6, 10 and 14 weeks of age; 19,922 were allocated to 9PCV while 19,914 to placebo. Excluding the HIV-1 positive children, only 18, 633 children were allocated to the 9PCV, and 18, 626 to the placebo, for a combined total of 37,259<B> </B>HIV-1 negative children considered in this review.</P>
<P>
<B>Country: </B>South Africa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-01 12:02:20 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment: </B>9-valent containing 2 &#956;g of capsular polysaccharide (serotypes 1, 4, 5, 9V, 14, 19F, and 23F), 4 &#956;g of serotype 6B, and 2 &#956;g of oligosaccharide 18C</P>
<P>
<B>Control: </B>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-05 15:52:14 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical pneumonia</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-11-26 21:05:48 +1000" MODIFIED_BY="[Empty name]">
<P>Wyeth Lederle Vaccines and Pediatrics; WHO</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-07-03 17:38:07 +1000" MODIFIED_BY="[Empty name]">
<P>S A Madhi was the recipient of research grant awards and salary support from Wyeth vaccines and Pediatrics during the conduct of the study. C Cutland received salary support from Wyeth Vaccines and Pediatrics during the conduct of the study. K P Klugman has received research grant awards from Wyeth vaccines and Pediatrics, is a member of the Wyeth&#8217;s speakers bureau, and is a Consultant for Wyeth Vaccines and Pediatrics (<LINK REF="STD-Madhi-2005a" TYPE="STUDY">Madhi 2005a</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2008-11-26 20:05:33 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-27 15:22:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2002">
<CHAR_METHODS MODIFIED="2009-06-25 10:10:10 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design:</B> Cluster randomised</P>
<P>
<B>Duration of the study:</B> April 30, 1997 - May 31, 2000</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 18:25:35 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Navajo or White Mountain Apache Indian Reservation</P>
<P>
<B>Participants: </B>8091 children aged between six weeks and 24 months from the Navajo and White Mountain Apache tribes, who resided on or adjacent to the Navajo or White Mountain Apache Indian reservations; 4165 were allocated to the PnCRM7 while 3926 to MnCC. Excluding the catch-up groups of 7 to 11 months and 12 to 23 months, however, the primary efficacy group considered in this review involved only 2974 children allocated to PnCRM7, and 2818 allocated to MnCC control vaccine for a combined total of 5792</P>
<P>
<B>Country: </B>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-08 18:58:31 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent pneumococcal conjugate vaccine containing 2 &#956;g each of serotypes 4, 9V, 14, 19F, and 23F polysaccharides; 2 &#956;g of serotype 18C oligosaccharide; 4 &#956;g of serotype 6B polysaccharide, all independently conjugated to the protein carrier CRM<SUB>197 </SUB>protein; and 0·5 mg of aluminium phosphate as an adjuvant (PnCRM7)</P>
<P>
<B>Control: </B>
<I>Neisseria meningitidis</I> group-C protein conjugate vaccine containing 10 &#956;g of group-C oligosaccharides coupled to CRM<SUB>197</SUB> by reductive amination, and 0·5 mg of aluminium phosphate as an adjuvant (MnCC)</P>
<P>
<B>Frequency:</B> Three doses at 2, 4, 6 months and a booster dose at 12-15 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-02 11:53:06 +1000" MODIFIED_BY="[Empty name]">
<P>Invasive pneumococcal disease, safety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-01-02 11:53:06 +1000" MODIFIED_BY="[Empty name]">
<P>USA National Institutes of Health, Wyeth Lederle Vaccines, USAID, WHO, CDC</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:40:23 +1000" MODIFIED_BY="[Empty name]">
<P>A J Parkinson, J G Hackell, I Chang, G R Siber own stocks in Wyeth Vaccines or its parent company. J Hackell, I Chang, R Kohberger and G Siber are employed by Wyeth vaccines. M Santosham and K L O'Brien have received consultations, honoraria, or travel grants from Wyeth Vaccines (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-07-27 15:22:37 +1000" MODIFIED_BY="[Empty name]">
<P>This is an abstract presented orally in the ISPPD-3 in Anchorage, Alaska in May 2002. The results for the outcomes on X-ray pneumonia and clinical pneumonia were presented orally but not printed in the abstract. The outcome on X-ray pneumonia has been cited erroneously in <LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK> and corrected in <LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>. According to <LINK REF="REF-O_x0027_Brien-2009a" TYPE="REFERENCE">O'Brien 2009a</LINK>, the pneumonia outcomes will be formally published soon</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-03 18:26:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2003">
<CHAR_METHODS MODIFIED="2009-06-25 11:57:32 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>Design: </B>Cluster randomised</P>
<P>
<B>Duration of the study: </B>April 30, 1997 - May 31, 2000</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 18:26:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Navajo or White Mountain Apache Indian Reservation</P>
<P>
<B>Participants: </B>8091 children aged between six weeks and 24 months from the Navajo and White Mountain Apache tribes, who resided on or adjacent to the Navajo or White Mountain Apache Indian reservations; 4165 were allocated to the PnCRM7 while 3926 to MnCC. Excluding the catch-up groups of 7 to 11 months and 12 to 23 months, however, the primary efficacy group considered in this review involved only 2974 children allocated to PnCRM7, and 2818 allocated to MnCC control vaccine for a combined total of 5792</P>
<P>
<B>Country: </B>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 18:23:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment:</B> 7-valent pneumococcal conjugate vaccine containing 2 &#956;g each of serotypes 4, 9V, 14, 19F, and 23F polysaccharides; 2 &#956;g of serotype 18C oligosaccharide; 4 &#956;g of serotype 6B polysaccharide, all independently conjugated to the protein carrier CRM<SUB>197 </SUB>protein; and 0·5 mg of aluminium phosphate as an adjuvant (PnCRM7)</P>
<P>
<B>Control: </B>
<I>Neisseria meningitidis</I> group-C protein conjugate vaccine containing 10 &#956;g of group-C oligosaccharides coupled to CRM<SUB>197</SUB> by reductive amination, and 0·5 mg of aluminium phosphate as an adjuvant (MnCC)</P>
<P>
<B>Frequency:</B> Three doses at 2, 4, 6 months and a booster dose at 12-15 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-26 20:06:03 +1000" MODIFIED_BY="[Empty name]">
<P>Invasive pneumococcal disease, safety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-11-26 21:11:31 +1000" MODIFIED_BY="[Empty name]">
<P>USA National Institutes of Health, Wyeth Lederle Vaccines, USAID, WHO, CDC</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-29 23:40:47 +1000" MODIFIED_BY="[Empty name]">
<P>A J Parkinson, J G Hackell, I Chang, G R Siber own stocks in Wyeth Vaccines or its parent company. J Hackell, I Chang, R Kohberger and G Siber are employed by Wyeth vaccines. M Santosham and K L O&#8217;Brien have received consultations, honoraria, or travel grants from Wyeth Vaccines (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-07-03 18:26:34 +1000" MODIFIED_BY="[Empty name]">
<P>A hand searched source of this same study is listed in the 'Additional References' section as <LINK REF="REF-O_x0027_Brien-2001" TYPE="REFERENCE">O'Brien 2001</LINK>. The study was first presented in ESPID 2001</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AOM: acute otitis media<BR/>CRM<SUB>197</SUB>: <B>C</B>ross-<B>R</B>eacting <B>M</B>utant of diphtheria toxin<BR/>DSMB: Data and Safety Monitoring Board<BR/>DTwP//PRP-T: Haemophilus Influenzae type b (Hib) vaccine reconstituted with diphtheria-tetanus-whole cell pertussis (DTwP) vaccine<BR/>ESPID: European Society for Pediatric Infectious Diseases<BR/>ISPPD: International Symposium on Pneumococci and Pneumococcal Diseases<BR/>MnCC: Meningococcus type C CRM<SUB>197</SUB> conjugate vaccine<BR/>OMP or OMPC: outer membrane protein complex <BR/>OPV: Oral Polio Vaccine<BR/>PATH: Program for Appropriate Technology in Health<BR/>PnCRM7: seven-valent polysaccharide protein conjugate pneumococcal vaccine<BR/>PCV: pneumococcal conjugate vaccine<BR/>USAID: United States Agency for International Development</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-10 09:56:26 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-06-01 16:52:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adam-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-01 16:52:33 +1000" MODIFIED_BY="[Empty name]">
<P>Article in German</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:15:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:15:05 +1000" MODIFIED_BY="[Empty name]">
<P>Post-licensure surveillance study; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:10:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:10:17 +1000" MODIFIED_BY="[Empty name]">
<P>Article in French</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 19:50:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blum-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 19:50:58 +1000" MODIFIED_BY="[Empty name]">
<P>Subjects are toddlers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:15:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogaert-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:15:24 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective study; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:15:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brouwer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:15:33 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are QOL and FHS; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:15:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choo-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:15:40 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are immunogenicity and reactogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 19:51:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 19:51:49 +1000" MODIFIED_BY="[Empty name]">
<P>Subjects comprised of 12 to 35 months old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 19:52:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 19:52:15 +1000" MODIFIED_BY="[Empty name]">
<P>Subjects comprised of toddlers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 19:52:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 19:52:35 +1000" MODIFIED_BY="[Empty name]">
<P>Subjects comprised of 12 to 35 months old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:11:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dagan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:11:34 +1000" MODIFIED_BY="[Empty name]">
<P>Subjects comprised of 12 to 35 months old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:15:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Aristegui-Fernan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:15:55 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are safety and immunogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:12:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Einarsdottir-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:12:14 +1000" MODIFIED_BY="[Empty name]">
<P>Population based study of recurrent IPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:12:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ekstrom-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:12:37 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are antibody kinetics and avidity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:16:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Esposito-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:16:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are immunogenicity, safety and tolerability</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-07 12:13:54 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Finn-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-07 12:13:54 +1000" MODIFIED_BY="Liz Dooley">
<P>Subjects comprised of children two to four years old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:16:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fireman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:16:46 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is efficacy against acute otitis media (AOM)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:16:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frazao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:16:53 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is nasopharyngeal carriage; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:13:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghaffar-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:13:17 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Givon_x002d_Lavi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:03 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is herd immunity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldblatt-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:07 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is immunogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:13:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanna-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:13:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:13:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jokinen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:13:58 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is anti-pneumococcal antibodies; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kayhty-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are immunogenicity and tolerability</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madhi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is the role of the pneumococcus in viral pneumonias</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madhi-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:27 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is antibody response</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:17:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moulton-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:17:58 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is indirect effects of PCV</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palmu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:03 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is efficacy against AOM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palmu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:09 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is tympanostomy tube placement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-01 16:52:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plotkin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-01 16:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Article in French</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:07:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prymula-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:07:26 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is AOM; no IPD case reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reinert-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:19 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are safety and immunogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenfeld-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is otitis media</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scheifele-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:28 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is compatibility of PCV with co-administered vaccines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitt-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:35 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are safety, reactogenicity and immunogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 19:59:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shinefield-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 19:59:52 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome was immunogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shinefield-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are efficacy, immunogenicity, and safety in low birth weight and preterm infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Straetemans-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:51 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is effectiveness against AOM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:18:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tichmann_x002d_Schumann-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:18:55 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are immunogenicity and reactogenicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-07 12:15:09 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Van-Kempen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-07 12:15:09 +1000" MODIFIED_BY="Liz Dooley">
<P>Outcome is recurrent AOM on one to seven year old children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:19:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veenhoven-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:19:17 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is efficacy against AOM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:05:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veenhoven-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:05:28 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome was AOM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-07 12:15:20 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Veenhoven-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-07 12:15:20 +1000" MODIFIED_BY="Liz Dooley">
<P>Outcome is effectiveness of PCV plus PPV against AOM in children one to six years old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:19:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veenhoven-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:19:29 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is nasopharyngeal carriage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:19:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeh-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:19:35 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome is nasopharyngeal carriage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-17 20:19:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zangwill-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-17 20:19:40 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes are immunogenicity and safety</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AOM: acute otitis media<BR/>ESPID: European Society of Paediatric Infectious Diseases<BR/>PCV: pneumococcal conjugate vaccine<BR/>PPV: pneumococcal polysaccharide vaccine<BR/>OM: otitis media<BR/>RCT: randomised, controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-09-01 19:01:09 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-07-28 14:53:41 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-27 15:36:52 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:36:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal conjugate vaccine . . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 5, left column).</P>
<P>&#8220;The two vaccines were identical in appearance. Multiple lots of both the pneumococcal and meningococcal conjugate vaccines were used in this study&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D. Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product. (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:35:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal conjugate vaccine . . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 5, left column).</P>
<P>&#8220;The two vaccines were identical in appearance. Multiple lots of both the pneumococcal and meningococcal conjugate vaccines were used in this study&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D.  Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product. (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:34:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> An independent statistician randomly assigned vial codes 0-9 to vaccine or placebo in a 1/1 ratio and study numbers to codes 0-9, using a blocked design with block sizes of 10, with a Proc Plan procedure in SAS (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1140, paragraph 3, left column)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:33:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>
<B>Quote: </B>Six letters corresponding to the three treatment options were randomly allocated to consecutive subject identification numbers using an allocation ratio of 1:1:1 and a block size of 12 (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1157, paragraph 2, right col)</P>
<P>
<B>Comment:</B> Done. Used a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:33:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Healthy infants were randomised 1:1 to receive either the heptavalent pneumococcal conjugate vaccine . . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 5, left column).</P>
<P>&#8220;The two vaccines were identical in appearance. Multiple lots of both the pneumococcal and meningococcal conjugate vaccines were used in this study&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D. Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product. (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:32:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>
<B>Quote: </B>Six letters corresponding to the three treatment options were randomly allocated to consecutive subject identification numbers using an allocation ratio of 1:1:1 and a block size of 12 (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1157, paragraph 2, right column)</P>
<P>
<B>Comment:</B> Done. Used a computer random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-25 10:02:00 +1000" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>
<B>Quote: </B>We evaluated the efficacy of a 9-valent pneumococcal conjugate vaccine in randomised blocks of 10 (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1341, par 1)</P>
<P>
<B>Comment: </B>probably done (computer generated random sequence) although procedure was not expounded any further</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 17:35:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>
<B>Quote:</B>  A list containing random permutations of the letters A-F was generated by sanofi pasteur using the SAS software; three of the letters were allocated to the 11-PCV and three to the placebo (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:31:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>
<B>Quote: </B>We evaluated the efficacy of a 9-valent pneumococcal conjugate vaccine in randomised blocks of 10 (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1,341, paragraph 1)</P>
<P>
<B>Comment: </B>probably done (computer generated random sequence) although procedure was not expounded any further.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:30:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>
<B>Quote: </B>A blocking scheme with three blocks of four units and 13 blocks of two units was used to ensure that randomisation units covered roughly the same geographical area and included about the same number of children (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 1, right column)</P>
<P>We decided to assign six labels to the vaccine (B, F, H, M, T, U), with the three labels for the 7PCV and three for the MnCC. The grouping of these codes is known only to a statistician (Chang I.) employed by the manufacturer who has no other responsibilities with respect to the trial other than handling treatment allocation and randomisation issues (<LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>, page 445, paragraph 6)</P>
<P>
<B>Comment:</B> The random sequence containing the six letter codes were computer generated by a statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:29:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>
<B>Quote: </B>A blocking scheme with three blocks of four units and 13 blocks of two units was used to ensure that randomisation units covered roughly the same geographical area and included about the same number of children (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 1, right column)</P>
<P>We decided to assign six labels to the vaccine (B, F, H, M, T, U), with the three labels for the 7PCV and three for the MnCC. The grouping of these codes is known only to a statistician (Chang I.) employed by the manufacturer who has no other responsibilities with respect to the trial other than handling treatment allocation and randomisation issues (<LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>, page 445, paragraph 6)</P>
<P>
<B>Comment:</B> The random sequence containing the six letter codes were computer generated by a statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-28 14:53:41 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:36:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;The two vaccines were identical in appearance&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>Patients were randomised in blocks of ten using enrolment sheets which had random allocations in blocks of ten. The sheets were rub-off sheets so that the next allocation could not be seen until the patient consented and then the next spot on the allocation sheet was rubbed off to reveal their assignment. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D.  Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product.  Once a child was enrolled and consented the study nurse at the site would take the next subject identification number on the list, assign it to the patient, and would then remove a label that obscured the treatment assignment. The assignment was kept in a casebook at the site so that further dosing could be done properly (i.e. if they were assigned a B at randomisation they would continue to get B for doses 2-4). The assignment was not known to other study staff, paediatricians, investigator, parents, etc.  After the study was over, subject assignments were unblinded (although a study advisory committee had the authority to unblind an individual subject or the entire study at any time if safety issues warranted it). (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:35:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;The two vaccines were identical in appearance&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>Patients were randomised in blocks of ten using enrolment sheets which had random allocations in blocks of ten. The sheets were rub-off sheets so that the next allocation could not be seen until the patient consented and then the next spot on the allocation sheet was rubbed off to reveal their assignment. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D. Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product. Once a child was enrolled and consented the study nurse at the site would take the next subject identification number on the list, assign it to the patient, and would then remove a label that obscured the treatment assignment. The assignment was kept in a casebook at the site so that further dosing could be done properly (i.e. if they were assigned a B at randomisation they would continue to get B for doses 2-4). The assignment was not known to other study staff, paediatricians, investigator, parents, etc. After the study was over, subject assignments were unblinded (although a study advisory committee had the authority to unblind an individual subject or the entire study at any time if safety issues warranted it). (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:34:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> Independent contractors labelled vaccine and placebo vials, prepared study stickers detailing the unique study identity number with window stickers showing vial code and dose number (1, 2, 3), and sealed these in opaque envelopes. Only the DSMB and the safety monitor had access to the code before data were locked;</P>
<P>After a child was enrolled, staff opened the next envelope, attached the study sticker to the health card, and at every vaccination peeled off the window sticker to put it on the case report form. After the third dose of vaccine or placebo, no record was present of the randomisation assignment on the health card (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1140, paragraph 3 and 4, left column).</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-25 09:54:59 +1000" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>
<B>Quote:</B> Randomisation envelopes containing four smaller envelopes (for each vaccination) with a letter A to F (two letters for <I>S. pneumoniae </I>CRM, <I>S. pneumoniae </I>OMPC, and the control) were assigned to each child at enrolment. The envelopes were prepared by an external consultant. The envelopes were distributed to the study clinics and assigned in a given order within the original blocks of 12. The vaccinator (not involved in any other study activities) checked one small envelope before each vaccination from the envelope assigned to each specific child, took the vaccine from the corresponding box, destroyed the letter code, and vaccinated the child. The vaccine was drawn into the syringe out of sight of anyone else (<LINK REF="REF-Palmu-2003a" TYPE="REFERENCE">Palmu 2003a</LINK>)</P>
<P>
<B>Comment:</B> Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:33:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;The two vaccines were identical in appearance&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 6, left column).</P>
<P>Patients were randomised in blocks of ten using enrolment sheets which had random allocations in blocks of ten. The sheets were rub-off sheets so that the next allocation could not be seen until the patient consented and then the next spot on the allocation sheet was rubbed off to reveal their assignment. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>A statistician (a staff member at Northern California Kaiser Permanente's division of research) generated a randomisation list that contained sequential subject identification numbers and a group A, B, C or D. Two of these groups were pneumococcal vaccine and two were meningococcal vaccine - which codes were which was only known to the statistician who prepared the randomisation and the individuals at the manufacturer who were responsible for the labelling of the product. Once a child was enrolled and consented the study nurse at the site would take the next subject identification number on the list, assign it to the patient, and would then remove a label that obscured the treatment assignment. The assignment was kept in a casebook at the site so that further dosing could be done properly (i.e. if they were assigned a B at randomisation they would continue to get B for doses 2-4). The assignment was not known to other study staff, paediatricians, investigator, parents, etc. After the study was over, subject assignments were unblinded (although a study advisory committee had the authority to unblind an individual subject or the entire study at any time if safety issues warranted it). (<LINK REF="REF-Hansen-2008b" TYPE="REFERENCE">Hansen 2008b</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-25 10:00:27 +1000" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> Randomisation envelopes containing four smaller envelopes (for each vaccination) with a letter A to F (two letters for <I>S. pneumoniae </I>CRM, <I>S. pneumoniae </I>OMPC, and the control) were assigned to each child at enrolment. The envelopes were prepared by an external consultant. The envelopes were distributed to the study clinics and assigned in a given order within the original blocks of 12. The vaccinator (not involved in any other study activities) checked one small envelope before each vaccination from the envelope assigned to each specific child, took the vaccine from the corresponding box, destroyed the letter code, and vaccinated the child. The vaccine was drawn into the syringe out of sight of anyone else (<LINK REF="REF-Palmu-2003a" TYPE="REFERENCE">Palmu 2003a</LINK>)</P>
<P>
<B>Comment:</B> Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 14:53:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> Doses of vaccine and placebo were made up in a blinded fashion, appeared identical, and were colour-coded with the use of 10 colours at 21 vaccination centres in Soweto, in randomised blocks of 10 (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1342, paragraph 3, left column)</P>
<P>There was a colour code using ten colours which was kept by the pharmacist in the US who did the coding. Even the safety committee were kept blinded to the colour code. The colour codes were kept from the doctors and nurses and anyone who had access to the children who were evaluated for disease. Unblinding was done by a separate statistical contractor who got the code from the US pharmacist after the study was completed. The patients in the primary analysis were identified to the Chair of the safety committee prior to the final analysis  and the investigators remain blinded to the colour codes to this day (<LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>)</P>
<P>
<B>Comment: </B>Instead of serially numbering the identical-looking vaccine and placebo containers, the study colour coded them. The correspondence of the colour codes with the vaccine or placebo was kept confidential from the staff, parents participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 17:34:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>
<B>Quote:</B>  Both the 11-PCV and placebo were contained in pre-filled, ready-to-use glass syringes labelled serially with vaccine letter codes and looked identical. The correspondence between the letters and the  vaccine/placebo was unknown to researchers and subjects (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:31:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>
<B>Quote:</B> Doses of vaccine and placebo were made up in a blinded fashion, appeared identical, and were colour-coded with the use of 10 colours at 21 vaccination centres in Soweto, in randomised blocks of 10 (Klugman 2003, page 1342, paragraph 3, left column)</P>
<P>There was a colour code using ten colours which was kept by the pharmacist in the US who did the coding. Even the safety committee were kept blinded to the colour code. The colour codes were kept from the doctors and nurses and anyone who had access to the children who were evaluated for disease. Unblinding was done by a separate statistical contractor who got the code from the US pharmacist after the study was completed. The patients in the primary analysis were identified to the Chair of the safety committee prior to the final analysis  and the investigators remain blinded to the colour codes to this day (<LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>)</P>
<P>
<B>Comment: </B>Instead of serially numbering the identical-looking vaccine and placebo containers, the study colour coded them. The correspondence of the colour codes with the vaccine or placebo was kept confidential from the staff, parents participants and investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:30:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>
<B>Quote:</B>  Vaccine was provided in single-use vials, which were labelled with one of six lettered codes; three letters encoded the intervention vaccine, and three the control vaccine (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 2, right column)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:29:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>
<B>Quote:</B>  Vaccine was provided in single-use vials, which were labelled with one of six lettered codes; three letters encoded the intervention vaccine, and three the control vaccine (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 2, right column)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-07-28 14:53:31 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:36:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;This study was a . . . double-blind trial. . .&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 4, left column).</P>
<P>&#8220;blinded follow-up and per protocol vaccination of the two groups were continued until April 20, 1999&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column).</P>
<P>The investigator and the study personnel were blinded in that they did not know which letter codes A, B, C, or D went with placebo and which colours went with pneumococcal conjugate vaccine (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P> <B>Comment</B>: Done.  Mention of blinded follow-up until the end of the trial also implies blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:53:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;This study was a . . . double-blind trial. . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 188, paragraph 4, left column).</P>
<P>&#8220;. . . blinded follow-up and per protocol vaccination of the two groups were continued until April 20, 1999&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column).</P>
<P>The investigator and the study personnel were blinded in that they did not know which letter codes A, B, C, or D went with placebo and which colours went with pneumococcal conjugate vaccine (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>
<B>Comment</B>: Done.  Mention of blinded follow-up until the end of the trial also implies blinding of outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:34:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;We undertook a randomised, double-blind, placebo-controlled trial (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1139, paragraph 2, left column).</P>
<P>&#8220;Pneumococcal vaccine and placebo lyophilised powders were identical in appearance (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1140, paragraph 4, left column) </P>
<P>&#8220;. . .and data were audited before locking and unmasking&#8221; (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1141, paragraph 3, right column).</P>
<P>
<B>Comment:</B> No explicit mention of who was blinded, but most probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:33:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>
<B>Quote:</B> the patients, care providers, and outcome assessors were all blinded (<LINK REF="REF-Palmu-2003b" TYPE="REFERENCE">Palmu 2003b</LINK>)</P>
<P>Blinding was ensured by destruction of the letter code and by use of vaccinators who were not otherwise involved in the trial follow-up (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1158, paragraph 1, left column)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:32:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;This study was a . . . double-blind trial. . . &#8221;(<LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>, page 188, paragraph 4, left column)</P>
<P>&#8220;. . . blinded follow-up and per protocol vaccination of the two groups were continued until April 20, 1999&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column)</P>
<P>The investigator and the study personnel were blinded in that they did not know which letter codes A, B, C, or D went with placebo and which colours went with pneumococcal conjugate vaccine (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>
<B>Comment</B>: Done.  Mention of blinded follow-up until the end of the trial also implies blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:32:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> Blinding was ensured by destruction of the letter code and by use of vaccinators who were not otherwise involved in the trial follow-up (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1158, paragraph 1, left column)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-25 10:03:01 +1000" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>
<B>Quote:</B>  double-blind randomised trial and assigned to receive the 9-valent pneumococcal vaccine or a placebo made up in a blinded fashion, appeared identical  (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1342); vaccine and placebo containers appeared identical</P>
<P>
<B>Comment:</B>  Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-03 17:34:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>
<B>Quote:</B>  Both the 11-PCV and placebo were contained in pre-filled, ready-to-use glass syringes and looked identical. The correspondence between the letters and the  vaccine / placebo was unknown to researchers and subjects (<LINK REF="STD-Lucero-2009" TYPE="STUDY">Lucero 2009</LINK>)</P>
<P>
<B>Comment: </B>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-25 10:09:49 +1000" MODIFIED_BY="Clare Dooley" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>
<B>Quote:</B> double-blind randomised trial and assigned to receive the 9-valent pneumococcal vaccine or a placebo made up in a blinded fashion, appeared identical  (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1342); vaccine and placebo containers appeared identical</P>
<P>
<B>Comment:</B>  Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:30:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>
<B>Quote:</B>  &#8220;Vaccine codes and randomisation units were concealed from study staff and participants&#8221; (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 2, right column)</P>
<P>&#8220;Field staff were blinded as to serotype of the invasive disease cases, and thus did not know which ones would be likely to be prevented by an effective vaccine&#8221; (<LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>, page 446, paragraph 1)</P>
<P>
<B>Comment:</B> Blinding of the care providers, participants and outcome assessors were explicitly mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-27 15:29:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>
<B>Quote:</B>  &#8220;Vaccine codes and randomisation units were concealed from study staff and participants&#8221; (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 356, paragraph 2, right column)</P>
<P>&#8220;Field staff were blinded as to serotype of the invasive disease cases, and thus did not know which ones would be likely to be prevented by an effective vaccine&#8221; (<LINK REF="REF-Moulton-2001" TYPE="REFERENCE">Moulton 2001</LINK>, page 446, paragraph 1)</P>
<P>
<B>Comment:</B> Blinding of the care providers, participants and outcome assessors were explicitly mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-27 15:36:23 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:36:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>
<B>Quote: </B>&#8220;. . .an intent-to-treat analysis included all invasive disease caused by any pneumococcal serotype occurring after randomisation regardless of whether the child completed the three-dose primary series . . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 189, paragraph 2, left column)</P>
<P>Patients were excluded from follow up only if they left the health plan or died. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>
<B>Comment</B>: Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:35:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>
<B>Quote: </B>&#8220;. . .an intent-to-treat analysis included all invasive disease caused by any pneumococcal serotype occurring after randomisation regardless of whether the child completed the three-dose primary series . . . &#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 189, paragraph 2, left column)</P>
<P>Patients were excluded from follow up only if they left the health plan or died. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>
<B>Comment</B>: Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:33:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> We did per protocol and intention-to-treat analyses (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1141, paragraph 6, left column).</P>
<P>
<B>Comment: </B>
</P>
<P>Probably done.<B> </B>The trial profile gave the number of subjects excluded and the reasons why they were excluded. The 917 deaths and 115 withdrawals &#8220;were not shown as losses to follow-up because they contributed person-time to the estimation of rates of every endpoint.&#8221; (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1141, right column)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-07 11:57:39 +1000" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>45/831 missing in the <I>S. pneumoniae </I>CRM group, and 37/831 missing in the Hep B control group (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1157, Figure 1).  These exclusions, including the reasons they were excluded were not addressed in the discussion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:32:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>
<B>Quote: </B>&#8220;. . .an intent-to-treat analysis included all invasive disease caused by any pneumococcal serotype occurring after randomisation regardless of whether the child completed the three-dose primary series . . . &#8221; (<LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>, page 189, paragraph 2, left column)</P>
<P>Patients were excluded from follow up only if they left the health plan or died (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
<P>
<B>Comment</B>: Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:32:07 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> Because compliance was excellent, the difference between the per protocol and intent to treat data sets is negligible, and we therefore only report the efficacy and the immunogenicity results of the per protocol analysis (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1158, paragraph 4, left column)</P>
<P>
<B>Comment: </B>30/835 missing in the <I>S. pneumoniae </I>OMPC group and 37/831 missing in the Hep B control group (<LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>, page 1157, Figure 1). These exclusions, including the reasons they were excluded were not addressed in the discussion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:31:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> The results presented are for analyses conducted according to the intention to treat principle and include all cases of invasive pneumococcal disease and pneumonia (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1343, paragraph 3, left column)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-07 12:05:30 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>Although the primary analysis performed was per protocol, intention-to-treat analysis was also performed on all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-27 15:30:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>
<B>Quote:</B> The results presented are for analyses conducted according to the intention to treat principle and include all cases of invasive pneumococcal disease and pneumonia (<LINK REF="STD-Klugman-2003" TYPE="STUDY">Klugman 2003</LINK>, page 1343, paragraph 3, left column)</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-07 12:08:51 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>Per protocol and intention-to-treat analyses were done for all of the three enrolment groups and for the three enrolment groups together</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-07 12:11:27 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>Per protocol and intention-to-treat analyses were done for all of the three enrolment groups and for the three enrolment groups together</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-07-27 15:33:52 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 19:21:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 19:21:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way. (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:33:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> The pre-specified primary outcome was originally all-cause child mortality, but because of practical constraints on the sample size, we changed it to radiologically-confirmed pneumonia in February 2002 (<LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK>, page 1141, paragraph 3, right column) although this was still reported as part of the tertiary endpoints.</P>
<P>
<B>Comment:</B> The change in the level of the original pre-specified outcome (from primary to tertiary) does not introduce bias in that this was still reported adequately in the published paper.</P>
<P>All other pre-specified outcomes of interest as stated in the protocol were reported (<LINK REF="REF-ISRCTN46147225" TYPE="REFERENCE">ISRCTN46147225</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-07 11:57:45 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 19:22:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way (<LINK REF="REF-Black-2008" TYPE="REFERENCE">Black 2008</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-07 12:01:27 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 19:25:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way (<LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-07 12:05:41 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way (<LINK REF="REF-ISRCTN62323832" TYPE="REFERENCE">ISRCTN62323832</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 19:27:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>All the pre-specified outcomes that are of interest in the review were reported in the pre-specified way (<LINK REF="REF-Klugman-2008a" TYPE="REFERENCE">Klugman 2008a</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:30:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>
<B>Quote:</B> "The efficacy of <I>S. pneumoniae </I>CRM7 to prevent primary endpoint consolidation will be presented [orally]. The efficacy of <I>S. pneumoniae </I>CRM7 to prevent clinically diagnosed otitis media episodes and culture-confirmed spontaneously draining otitis media episodes will be presented [orally]" (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>, page 111, paragraph 1, left column)</P>
<P>
<B>Comment:</B> The actual results were supposedly presented orally during the ISPPD-3 but were not actually printed in the abstract. The efficacy of <I>S. pneumoniae </I>CRM7 on AOM was published in <LINK REF="REF-O_x0027_Brien-2008" TYPE="REFERENCE">O'Brien 2008</LINK> but the efficacy of <I>S. pneumoniae </I>CRM7 on pneumonia remain unpublished. The VE for X-ray pneumonia was cited in a table in a section of a book (<LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK>) on pneumococcal vaccines. In an email, nevertheless, the author admits to having every intention of formally publishing the pneumonia outcomes very soon (<LINK REF="REF-O_x0027_Brien-2009a" TYPE="REFERENCE">O'Brien 2009a</LINK>). Thus, the review authors judge this to be only a time-lag bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:28:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>
<B>Quote:</B> "The efficacy of <I>S. pneumoniae </I>CRM7 to prevent primary endpoint consolidation will be presented [orally]. The efficacy of <I>S. pneumoniae </I>CRM7 to prevent clinically diagnosed otitis media episodes and culture-confirmed spontaneously draining otitis media episodes will be presented [orally]" (<LINK REF="STD-O_x0027_Brien-2002" TYPE="STUDY">O'Brien 2002</LINK>, page 111, paragraph 1, left column)</P>
<P>
<B>Comment:</B> The actual results were supposedly presented orally during the ISPPD-3 but were not actually printed in the abstract. The efficacy of <I>S. pneumoniae </I>CRM7 on AOM was published in <LINK REF="REF-O_x0027_Brien-2008" TYPE="REFERENCE">O'Brien 2008</LINK> but the efficacy of <I>S. pneumoniae </I>CRM7 on pneumonia remain unpublished. The VE for X-ray pneumonia was cited in a table in a section of a book (<LINK REF="REF-Madhi-2008" TYPE="REFERENCE">Madhi 2008</LINK>) on pneumococcal vaccines. In an email, nevertheless, the author admits to having every intention of formally publishing the pneumonia outcomes very soon (<LINK REF="REF-O_x0027_Brien-2009a" TYPE="REFERENCE">O'Brien 2009a</LINK>). Thus, the review authors judge this to be only a time-lag bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-07-27 15:36:17 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:36:17 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Black-2000">
<DESCRIPTION>
<P>Trial stopped early &#8220;because of the high level of efficacy demonstrated at an interim evaluation&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:35:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Black-2002a">
<DESCRIPTION>
<P>Trial stopped early &#8220;because of the high level of efficacy demonstrated at an interim evaluation&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-05 15:40:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cutts-2005">
<DESCRIPTION>
<P>No other topic-specific, design specific, or other potential threats to validity were noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-02 11:47:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eskola-2001">
<DESCRIPTION>
<P>No other potential sources of bias noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:32:34 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hansen-2006">
<DESCRIPTION>
<P>Trial stopped early &#8220;because of the high level of efficacy demonstrated at an interim evaluation&#8221; (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK>, page 190, paragraph 4, left column); no mention of sample size calculation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-02 11:50:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kilpi-2003">
<DESCRIPTION>
<P>No other potential sources of bias noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-05 15:49:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klugman-2003">
<DESCRIPTION>
<P>No other potential sources of bias noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-05 15:51:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucero-2009">
<DESCRIPTION>
<P>No other topic-specific, design-specific threats to validity were identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-05 15:52:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madhi-2005a">
<DESCRIPTION>
<P>No other potential sources of bias noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:29:58 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Brien-2002">
<DESCRIPTION>
<P>
<B>Quote: </B>"The end of the study was determined by advice from the data safety and monitoring board on the basis of their unblinded assessment of the cases accrued, at the time PnCRM7 became licensed and recommended for use in the USA." (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 357, left column, paragraph 2)</P>
<P>Mixing of the intervention and control groups was certain to have occurred to some degree in the trial. (<LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>)</P>
<P>
<B>Comment:</B> Early stopping for apparent benefit - resulted in failure to attain pre-specified sample size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:28:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Brien-2003">
<DESCRIPTION>
<P>
<B>Quote: </B>"The end of the study was determined by advice from the data safety and monitoring board on the basis of their unblinded assessment of the cases accrued, at the time PnCRM7 became licensed and recommended for use in the USA." (<LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>, page 357, left column, paragraph 2)</P>
<P>Mixing of the intervention and control groups was certain to have occurred to some degree in the trial. (<LINK REF="REF-O_x0027_Brien-2009b" TYPE="REFERENCE">O'Brien 2009b</LINK>)</P>
<P>
<B>Comment:</B> Early stopping for apparent benefit - resulted in failure to attain pre-specified sample size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-06-02 00:44:39 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-06-02 00:44:39 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-01-28 17:07:15 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>11 PCV for preventing vaccine-type invasive pneumococcal disease and X</B>-<B>ray defined pneumonia in children less than two years of age</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Children under two years of age<BR/>
</P>
<P>
<B>Intervention: </B>11PCV</P>
<P>
<B>Comparison: </B>Placebo or other vaccines</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Placebo or other vaccines</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>11PCV </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>VT-IPD, ITT (random)</B>
<BR/>(follow-up: mean 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>RR 0.20 </B>
<BR/>(0.10 to 0.42)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>113,044<BR/>(7)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>++++<BR/>high<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>2 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>0 per 1000<BR/>(0 to 1)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>5 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>1 per 1000<BR/>(1 to 2)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>All serotypes-IPD, ITT (random)</B>
<BR/>(follow-up: mean 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>RR 0.42 </B>
<BR/>(0.25 to 0.71)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>113,044<BR/>(7)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>++++<BR/>high<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>4 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>2 per 1000<BR/>(1 to 3)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>8 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>3 per 1000<BR/>(2 to 6)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>
<B>X</B>-<B>ray defined pneumonia, ITT (random)</B>
<BR/>(follow-up: mean 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>
<B>RR 0.73 </B>
<BR/>(0.64 to 0.85)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>104,755<BR/>(4)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>6</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>3 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>2 per 1000<BR/>(2 to 3)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>17 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>12 per 1000<BR/>(11 to 14)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>63 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>46 per 1000<BR/>(40 to 54)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>
<B>Clinical pneumonia, ITT (random)</B>
<BR/>(follow-up: mean 24 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>
<B>RR 0.94 </B>
<BR/>(0.91 to 0.98)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>104,755<BR/>(4)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>6</SUP>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>59 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>55 per 1000<BR/>(54 to 58)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>126 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>118 per 1000<BR/>(115 to 123)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>315 per 1000<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>296 per 1000<BR/>(287 to 309)<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (for example, the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; [other abbreviations, for example, RR, OR, etc]; GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1</SUP>No data on total population obtained for <LINK REF="STD-Cutts-2005" TYPE="STUDY">Cutts 2005</LINK> &lt;24 months old children; Used data on children &lt;29 months for denominator<BR/>
<SUP>2</SUP> Corresponding intervention risk (per 1000 people) = 1000 x ACR x RR where ACR = Assumed Control Risk, RR = Risk Ratio or Relative Risk, Assumed risk was calculated from low, medium, and high control group risk from the included studies<BR/>
<SUP>3</SUP> Incomplete accounting of patients and outcome events for the Finnish trial (<LINK REF="STD-Eskola-2001" TYPE="STUDY">Eskola 2001</LINK> and <LINK REF="STD-Kilpi-2003" TYPE="STUDY">Kilpi 2003</LINK>) and early stopping for the US trials (<LINK REF="STD-Black-2000" TYPE="STUDY">Black 2000</LINK> and <LINK REF="STD-O_x0027_Brien-2003" TYPE="STUDY">O'Brien 2003</LINK>)<BR/>
<SUP>4</SUP> Total number of events for VT-IPD (142) and all serotypes-IPD (233) is less than 300 (criteria from the <LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>) which should further downgrade the quality of evidence for imprecision. However, the event rates (0.1 for VT-IPD and 0.2 for all serotypes) were considered low. Therefore the quality of evidence was not downgraded.<BR/>
<SUP>5</SUP> Since the effect was large (RR &lt; 0.5) with RR of 0.20 for VT-IPD and 0.42 for all serotypes-IPD, the &#8220;serious&#8221; limitation was removed and the evidence was upgraded to high.<BR/>
<SUP>6</SUP> Early stopping for the NCKP trial (<LINK REF="STD-Black-2002a" TYPE="STUDY">Black 2002a</LINK>; <LINK REF="STD-Hansen-2006" TYPE="STUDY">Hansen 2006</LINK>); effect was not large therefore quality of evidence was not increased.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-08 19:57:00 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-06-02 00:45:29 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-06-02 00:45:29 +1000" MODIFIED_BY="[Empty name]">Sensitivity analysis to explore heterogeneity for VT-IPD, ITT (Random)</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH ROWSPAN="2">
<P>
<B>Study</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>log RR</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>SE</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Weight</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Point estimate RR (95% CI)</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Reasons for exclusion</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P/>
<P>
<B>Outlier</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Small number of events</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Eskola 2001</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-1.7904</P>
<P/>
</TD>
<TD>
<P/>
<P>1.6323</P>
<P/>
</TD>
<TD>
<P/>
<P>4.70%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.17 [0.01, 4.09]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TH>
<P/>
<P> </P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Kilpi 2003</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-1.7952</P>
<P/>
</TD>
<TD>
<P/>
<P>1.6311</P>
<P/>
</TD>
<TD>
<P/>
<P>4.70%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.17 [0.01, 4.06]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TH>
<P/>
<P> </P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Lucero 2009</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>1.0953</P>
<P/>
</TD>
<TD>
<P/>
<P>1.1545</P>
<P/>
</TD>
<TD>
<P/>
<P>8.50%</P>
<P/>
</TD>
<TD>
<P/>
<P>2.99 [0.31, 28.73]</P>
<P/>
</TD>
<TH>
<P/>
<P> </P>
<P/>
</TH>
<TH>
<P/>
<P> </P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Klugman 2003</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-1.772</P>
<P/>
</TD>
<TD>
<P/>
<P>0.7684</P>
<P/>
</TD>
<TD>
<P/>
<P>15.50%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.17 [0.04, 0.77]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>O'Brien 2003</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-1.7487</P>
<P/>
</TD>
<TD>
<P/>
<P>0.7662</P>
<P/>
</TD>
<TD>
<P/>
<P>15.60%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.17 [0.04, 0.78]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Black 2000</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-2.7969</P>
<P/>
</TD>
<TD>
<P/>
<P>0.6658</P>
<P/>
</TD>
<TD>
<P/>
<P>18.60%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.06 [0.02, 0.22]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Cutts 2005</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-1.4159</P>
<P/>
</TD>
<TD>
<P/>
<P>0.3525</P>
<P/>
</TD>
<TD>
<P/>
<P>32.50%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.24 [0.12, 0.48]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Total RR (95% CI)</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.20 [0.10, 0.42]</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.18 [0.11, 0.30]</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.17 [0.09, 0.31]</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Note: Shaded cells represent excluded studies</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.30; Chi² = 9.07, df = 6 (P = 0.17); I² = 34%</P>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.00; Chi² = 3.37, df = 5 (P = 0.64); I² = 0%</P>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.04; Chi² = 3.37, df = 3 (P = 0.34); I² = 11%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 4.31 (P &lt; 0.0001)</P>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 6.58 (P &lt; 0.00001)</P>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 5.90 (P &lt; 0.00001)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-07-08 18:16:20 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-06-02 00:46:02 +1000" MODIFIED_BY="[Empty name]">Sensitivity analysis to explore heterogeneity for WHO X-ray defined pneumonia, ITT (Random)</TITLE>
<TABLE COLS="8" ROWS="10">
<TR>
<TH ROWSPAN="2">
<P>
<B>Study</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>log RR</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>SE</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Weight</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Point estimate RR</B>
</P>
<P>
<B>(95% CI)</B>
</P>
</TH>
<TH COLSPAN="3">
<P>
<B>Reasons for exclusion</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P/>
<P>
<B>Outlier</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Presence of bias</B>
</P>
<P/>
</TH>
<TH>
<P/>
<P>
<B>Highest estimate or presence of bias</B>
</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Cutts 2005</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-0.4368</P>
<P/>
</TD>
<TD>
<P/>
<P>0.0666</P>
<P/>
</TD>
<TD>
<P/>
<P>24.80%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.65 [0.57, 0.74]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TH>
<P/>
<P> </P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Hansen 2006</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-0.3299</P>
<P/>
</TD>
<TD>
<P/>
<P>0.2149</P>
<P/>
</TD>
<TD>
<P/>
<P>12.90%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.72 [0.47, 1.10]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TH>
<P/>
<P> </P>
<P/>
</TH>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Klugman 2003</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-0.2231</P>
<P/>
</TD>
<TD>
<P/>
<P>0.1047</P>
<P/>
</TD>
<TD>
<P/>
<P>21.70%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.80 [0.65, 0.98]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Lucero 2009</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>-0.1744</P>
<P/>
</TD>
<TD>
<P/>
<P>0.1247</P>
<P/>
</TD>
<TD>
<P/>
<P>19.90%</P>
<P/>
</TD>
<TD>
<P/>
<P>0.84 [0.66, 1.07]</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<B>O'Brien 2002 <SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD>
<P>0.1044</P>
</TD>
<TD>
<P>0.1157</P>
</TD>
<TD>
<P>20.7%</P>
</TD>
<TD>
<P>1.11 [0.88, 1.39]</P>
</TD>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
<P> </P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>
<B>Total RR (95% CI)</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.81 [0.66, 1.00]</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.73 [0.64, 0.85]</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.74 [0.62, 0.88]</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P>
<B>0.80 [0.69, 0.93]</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>
<SUP>1</SUP> Aside from being an outlier, the parent trial also has bias (early stopping of trial)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.04; Chi² = 17.61, df = 4 (P = 0.001); I² = 77%</P>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.01; Chi² = 5.12, df = 3 (P = 0.16); I² = 41%</P>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.01; Chi² = 5.12, df = 2 (P = 0.08); I² = 61%</P>
<P/>
</TD>
<TD>
<P/>
<P>Heterogeneity: Tau² = 0.00; Chi² = 0.40, df = 2 (P = 0.82); I² = 0%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Note: Shaded cells represent excluded studies</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 2.00 (P = 0.05)</P>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 4.23 (P &lt; 0.0001)</P>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 3.36 (P = 0.0008)</P>
<P/>
</TD>
<TD>
<P/>
<P>Test for overall effect: Z = 2.91 (P = 0.004)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-05-29 19:57:19 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-05-29 19:55:55 +1000" MODIFIED_BY="[Empty name]">Assumed risk for VT-IPD, ITT</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Number of events</B>
</P>
</TH>
<TH>
<P>
<B>Control event rate or Control Group Risk (CGR)</B>
</P>
</TH>
<TH>
<P>
<B>Range of assumed risk of disease in the population</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0.0%</P>
</TD>
<TD ROWSPAN="7">
<P>
<B>Low control risk</B> 0.0% to 0.1%</P>
<P>
<B>Medium control risk</B> 0.2% to 0.4%<BR/>
</P>
<P>
<B>High control risk</B> <U>&gt;</U> 0.5%</P>
</TD>
</TR>
<TR>
<TD>
<P>Klugman 2003</P>
</TD>
<TD>
<P>18,626</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0.1%</P>
</TD>
</TR>
<TR>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P/>
<P>415.5</P>
<P/>
</TD>
<TD>
<P/>
<P>1</P>
<P/>
</TD>
<TD>
<P/>
<P>0.2%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P/>
<P>415.5</P>
<P/>
</TD>
<TD>
<P/>
<P>1</P>
<P/>
</TD>
<TD>
<P/>
<P>0.2%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P/>
<P>18,941</P>
<P/>
</TD>
<TD>
<P/>
<P>49</P>
<P/>
</TD>
<TD>
<P/>
<P>0.3%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P/>
<P>2818</P>
<P/>
</TD>
<TD>
<P/>
<P>11</P>
<P/>
</TD>
<TD>
<P/>
<P>0.4%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cutts 2005</P>
</TD>
<TD>
<P/>
<P>8719</P>
<P/>
</TD>
<TD>
<P/>
<P>41</P>
<P/>
</TD>
<TD>
<P/>
<P>0.5%</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-07-02 18:01:09 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-07-02 18:01:09 +1000" MODIFIED_BY="[Empty name]">Assumed risk for all serotypes-IPD, ITT</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Number of events</B>
</P>
</TH>
<TH>
<P>
<B>Control event rate or Control Group Risk (CGR)</B>
</P>
</TH>
<TH>
<P>
<B>Range of assumed risk of disease in the population</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Lucero 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>6094</P>
<P/>
</TD>
<TD>
<P/>
<P>3</P>
<P/>
</TD>
<TD>
<P/>
<P>0.0%</P>
<P/>
</TD>
<TD ROWSPAN="7">
<P/>
<P/>
<P/>
<P/>
<P>
<B>Low control risk</B>  0.0% to 0.3%</P>
<P>
<B>Medium control risk </B> 0.4% to 0.7%</P>
<P>
<B>High control risk </B>
<U>&gt;</U> 0.8%</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Klugman 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>18,626</P>
<P/>
</TD>
<TD>
<P/>
<P>19</P>
<P/>
</TD>
<TD>
<P/>
<P>0.1%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Black 2000</P>
<P/>
</TD>
<TD>
<P/>
<P>18,941</P>
<P/>
</TD>
<TD>
<P/>
<P>55</P>
<P/>
</TD>
<TD>
<P/>
<P>0.3%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Kilpi 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>415.5</P>
<P/>
</TD>
<TD>
<P/>
<P>1.5</P>
<P/>
</TD>
<TD>
<P/>
<P>0.4%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Eskola 2001</P>
<P/>
</TD>
<TD>
<P/>
<P>415.5</P>
<P/>
</TD>
<TD>
<P/>
<P>1.5</P>
<P/>
</TD>
<TD>
<P/>
<P>0.4%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>O'Brien 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>2818</P>
<P/>
</TD>
<TD>
<P/>
<P>18</P>
<P/>
</TD>
<TD>
<P/>
<P>0.6%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Cutts 2005</P>
<P/>
</TD>
<TD>
<P/>
<P>8719</P>
<P/>
</TD>
<TD>
<P/>
<P>66</P>
<P/>
</TD>
<TD>
<P/>
<P>0.8%</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-05-29 19:57:48 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-05-29 19:55:37 +1000" MODIFIED_BY="[Empty name]">Assumed risk for X-ray defined pneumonia, ITT</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Number of events</B>
</P>
</TH>
<TH>
<P>
<B>Control event rate or Control Group Risk (CGR)</B>
</P>
</TH>
<TH>
<P>
<B>Range of assumed risk of disease in the population</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Hansen 2006</P>
<P/>
</TD>
<TD>
<P/>
<P>18,942</P>
<P/>
</TD>
<TD>
<P/>
<P>51</P>
<P/>
</TD>
<TD>
<P/>
<P>0.3%</P>
<P/>
</TD>
<TD ROWSPAN="4">
<P/>
<P/>
<P/>
<P/>
<P>
<B>Low control risk </B>0.0% to 1.6%</P>
<P>
<B>Medium control risk  </B>1.7% to 6.2%</P>
<P>
<B>High control risk </B>
<U>&gt;</U> 6.3%</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Klugman 2003</P>
<P/>
</TD>
<TD>
<P/>
<P>18,626</P>
<P/>
</TD>
<TD>
<P/>
<P>212</P>
<P/>
</TD>
<TD>
<P/>
<P>1.1%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Lucero 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>6094</P>
<P/>
</TD>
<TD>
<P/>
<P>141</P>
<P/>
</TD>
<TD>
<P/>
<P>2.3%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Cutts 2005</P>
<P/>
</TD>
<TD>
<P/>
<P>8719</P>
<P/>
</TD>
<TD>
<P/>
<P>551</P>
<P/>
</TD>
<TD>
<P/>
<P>6.3%</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2009-05-29 19:58:11 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-03-07 12:22:33 +1000" MODIFIED_BY="Liz Dooley">Assumed risk for clinical pneumonia, ITT</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Number of events</B>
</P>
</TH>
<TH>
<P>
<B>Control event rate or Control Group Risk (CGR)</B>
</P>
</TH>
<TH>
<P>
<B>Range of assumed risk of disease in the population</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
<P>Madhi 2005a</P>
<P/>
</TD>
<TD>
<P/>
<P>18,626</P>
<P/>
</TD>
<TD>
<P/>
<P>1106</P>
<P/>
</TD>
<TD>
<P/>
<P>5.9%</P>
<P/>
</TD>
<TD ROWSPAN="4">
<P/>
<P/>
<P/>
<P/>
<P>
<B>Low control risk  </B>0.0% to 12.5%</P>
<P>
<B>Medium control risk  </B>12.6% to 30%</P>
<P>
<B>High control risk  </B>
<U>&gt;</U> 31.5%</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Black 2002a</P>
<P/>
</TD>
<TD>
<P/>
<P>18,942</P>
<P/>
</TD>
<TD>
<P/>
<P>1429</P>
<P/>
</TD>
<TD>
<P/>
<P>7.5%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Lucero 2009</P>
<P/>
</TD>
<TD>
<P/>
<P>6094</P>
<P/>
</TD>
<TD>
<P/>
<P>1080</P>
<P/>
</TD>
<TD>
<P/>
<P>17.7%</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Cutts 2005</P>
<P/>
</TD>
<TD>
<P/>
<P>8719</P>
<P/>
</TD>
<TD>
<P/>
<P>2746</P>
<P/>
</TD>
<TD>
<P/>
<P>31.5%</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2009-06-02 00:47:31 +1000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE>Characteristics of studies with invasive disease outcome</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Age at enrolment</P>
</TH>
<TH>
<P>Follow up</P>
</TH>
<TH>
<P>Age at completion of primary series</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>PCV serotypes</P>
</TH>
</TR>
<TR>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>2-4 months</P>
</TD>
<TD>
<P>Earliest of the following dates: onset of first invasive disease, death, end of trial</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Northern California Kaiser Permanente (NCKP)</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Cutts 2005</P>
</TD>
<TD>
<P>6-51 weeks</P>
</TD>
<TD>
<P>Earliest of the following dates: first episode of the relevant endpoint, withdrawal, death, age 30 months, end of follow-up on April 30, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>The Gambia</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>6-13 weeks</P>
</TD>
<TD>
<P>24 months of age</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Finland</P>
</TD>
<TD>
<P>1246.5</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>6-13 weeks</P>
</TD>
<TD>
<P>24 months of age</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Finland</P>
</TD>
<TD>
<P>1250.5</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Klugman 2003 (HIV-1 negative children only)</P>
</TD>
<TD>
<P>28-84 days old</P>
</TD>
<TD>
<P>60-1354 days after enrolment</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Soweto, South Africa</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6 weeks - &lt; 6 months</P>
</TD>
<TD>
<P>earliest of the following dates: 24 months of age, end of follow-up on December 31, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Philippines</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>6 weeks-7 months of age</P>
</TD>
<TD>
<P>First 24 months of life</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>American Indian and Apache Indian Reservations</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2009-06-02 00:48:04 +1000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2009-05-29 19:59:21 +1000" MODIFIED_BY="[Empty name]">Characteristics of studies with WHO X-ray defined pneumonia</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Age at enrolment</P>
</TH>
<TH>
<P>Follow up</P>
</TH>
<TH>
<P>Age at completion of primary series</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>PCV serotypes</P>
</TH>
</TR>
<TR>
<TD>
<P>Hansen 2006</P>
</TD>
<TD>
<P>2 months</P>
</TD>
<TD>
<P>Earliest of the following dates: onset of first invasive disease, death, end of trial</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Northern California Kaiser Permanente (NCKP)</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Cutts 2005</P>
</TD>
<TD>
<P>6-51 weeks</P>
</TD>
<TD>
<P>Earliest of the following dates: first episode of the relevant endpoint, withdrawal, death, age 30 months, end of follow-up on April 30, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>The Gambia</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Klugman 2003</P>
<P>(HIV-1 negative children only)</P>
</TD>
<TD>
<P>28-84 days</P>
</TD>
<TD>
<P>60-1354 days after enrolment</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Soweto, South Africa</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6 weeks- &lt; 6 months</P>
</TD>
<TD>
<P>Earliest of the following dates: 24 months of age, end of follow-up on December 31, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Philippines</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 2002</P>
</TD>
<TD>
<P>6 weeks-7 months of age</P>
</TD>
<TD>
<P>First 24 months of life</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>American Indian and Apache Indian Reservations</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2009-06-02 00:48:16 +1000" MODIFIED_BY="[Empty name]" NO="9">
<TITLE>Characteristics of studies with clinical pneumonia as outcome</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Age at enrolment</P>
</TH>
<TH>
<P>Follow up</P>
</TH>
<TH>
<P>Age at completion of primary series</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>No. of participants</P>
</TH>
<TH>
<P>PCV serotypes</P>
</TH>
</TR>
<TR>
<TD>
<P>Black 2002a</P>
</TD>
<TD>
<P>2 months</P>
</TD>
<TD>
<P>Earliest of the following dates: onset of first invasive disease, death, end of trial</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Northern California Kaiser Permanente (NCKP)</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>4, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Cutts 2005</P>
</TD>
<TD>
<P>6-51 weeks</P>
</TD>
<TD>
<P>Earliest of the following dates: first episode of the relevant endpoint, withdrawal, death, age 30 months, end of follow-up on April 30, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>The Gambia</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6 weeks- &lt; 6 months</P>
</TD>
<TD>
<P>Earliest of the following dates: 24 months of age, end of follow-up on December 31, 2004</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Philippines</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
<TR>
<TD>
<P>Madhi 2005a (HIV-1 negative children only)</P>
</TD>
<TD>
<P>28-84 days old</P>
</TD>
<TD>
<P>60-1354 days after enrolment</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Soweto, South Africa</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2009-07-02 18:13:31 +1000" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2009-05-29 19:59:56 +1000" MODIFIED_BY="[Empty name]">Vaccine and control group's events (invasive disease and WHO X-ray defined pneumonia)</TITLE>
<TABLE COLS="8" ROWS="84">
<TR>
<TH>
<P>
<B>Outcome</B>
</P>
</TH>
<TH>
<P>
<B>Study</B>
</P>
</TH>
<TH>
<P>
<B>Vaccine denominator</B>
</P>
</TH>
<TH>
<P>
<B>Vaccine events</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Control events</B>
</P>
</TH>
<TH>
<P>
<B>VE (95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>RR (95% CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>18,927</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>18,941</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>89.1 (73.7 to 95.8)</P>
</TD>
<TD>
<P>0.109 (0.042 to 0.263)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>41 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>74 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>45 (19 to 62)</P>
</TD>
<TD>
<P>0.55 (0.38 to 0.81)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>14,094 (person-time)</P>
</TD>
<TD>
<P>38 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>13,956 (person-time)</P>
</TD>
<TD>
<P>66 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>42.99 (15.08 to 61.72)</P>
</TD>
<TD>
<P>0.5701 (0.3828 to 0.8492)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>66.67 (-317.43 to 97.34)</P>
</TD>
<TD>
<P>0.3333 (0.0266 to 4.1743)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>66.83 (-315.43 to 97.35)</P>
</TD>
<TD>
<P>0.3317 (0.0265 to 4.1543)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>50 (23 to 68)</P>
</TD>
<TD>
<P>0.50 (0.32 to 0.77)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>Not all children had serum taken for HIV testing (personal communication with Klugman).</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>42 (-28 to 75)</P>
</TD>
<TD>
<P>0.58 (0.25 to 1.28)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (from Madhi 2005a)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>1288 (from Madhi 2005a)</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>53 (21 to 73)</P>
</TD>
<TD>
<P>0.47 (0.27 to 0.79)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>0.4 (-393 to 79.9)</P>
</TD>
<TD>
<P>0.996 (0.201 to 4.93)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>4951 (person-years)</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>4742 (person-years)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>52.1 (-6.6 to 78.5)</P>
</TD>
<TD>
<P>0.479 (0.215 to 1.066)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2974 (number of children)</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>2818 (number of children)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>13,549 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>3 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>13,569 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>42 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>92.87 (77.01 to 97.79)</P>
</TD>
<TD>
<P>0.0713 (0.0221 to 0.2299)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>50 (21 to 69)</P>
</TD>
<TD>
<P>0.50 (0.31 to 0.79)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>10,717 (person-time)</P>
</TD>
<TD>
<P>27 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>10,554 (person-time)</P>
</TD>
<TD>
<P>51 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>47.86 (16.94 to 67.27)</P>
</TD>
<TD>
<P>0.5214 (0.3273 to 0.8306)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33.7 (-297 to 88.9)</P>
</TD>
<TD>
<P>0.663 (0.111 to 3.97)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>2879 (person-years)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>2674 (person-years)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>61.3 (-9.7 to 86.35)</P>
</TD>
<TD>
<P>0.3870 (0.1365 to 1.0970)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2472 (number of children)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>2283 (number of children)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>18,927</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>18,941</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>93.9 (79.6 to 98.5)</P>
</TD>
<TD>
<P>0.061 (0.015 to 0.204)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>13 (not in published article, personal communication with Dr Cutts)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>45 (not in published article, personal communication with Dr Cutts)</P>
</TD>
<TD>
<P>71 (46 to 86)</P>
</TD>
<TD>
<P>0.29 (0.14 to 0.54)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>14,167 (person-time)</P>
</TD>
<TD>
<P>10 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>14,095 (person-time)</P>
</TD>
<TD>
<P>41 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>75.73 (51.58 to 87.84)</P>
</TD>
<TD>
<P>0.2427 (0.1216 to 0.4842)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>75 (-643.66 to 99.16)</P>
</TD>
<TD>
<P>0.25 (0.0084 to 7.4366)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>75.12 (-640.1 to 99.16)</P>
</TD>
<TD>
<P>0.2488 (0.0084 to 7.4010)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>72 (46 to 87)</P>
</TD>
<TD>
<P>0.28 (0.13 to 0.54)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>83 (39 to 97)</P>
</TD>
<TD>
<P>0.17 (0.03 to 0.61)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (Madhi 2005a)</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>1288 (Madhi 2005a)</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>65 (24 to 86)</P>
</TD>
<TD>
<P>0.35 (0.14 to 0.76)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-199 (-2772 to 68.9)</P>
</TD>
<TD>
<P>2.99 (0.311 to 28.72)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>4951 (person-years)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>4742 (person-years)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>82.6 (21.4 to 96.1)</P>
</TD>
<TD>
<P>0.174 (0.039 to 0.786)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2974 (number of children)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2818 (number of children)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>13,549 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>13,569 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>97.4 (82.7 to 99.9)</P>
</TD>
<TD>
<P>0.026 (0.001 to 0.173)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>77 (51 to 90)</P>
</TD>
<TD>
<P>0.23 (0.10 to 0.49)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>10,476 (person-time)</P>
</TD>
<TD>
<P>6 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>10,733 (person time)</P>
</TD>
<TD>
<P>34 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>81.92 (56.95 to 92.41)</P>
</TD>
<TD>
<P>0.1808 (0.0759 to 0.4305)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>18,245 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>18,268 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>17,356 (Madhi 2005a)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>17,350 (Madhi 2005a)</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>85 (32 to 98)</P>
</TD>
<TD>
<P>0.15 (0.02 to 0.68)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1201 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>1200 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>65 (24 to 86)</P>
</TD>
<TD>
<P>0.35 (0.14 to 0.76)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-99 (-2095 to 82.0)</P>
</TD>
<TD>
<P>1.99 (0.18 to 21.95)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>2879 (person-years)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2674 (person-years)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>76.8 (-9.4 to 95.1)</P>
</TD>
<TD>
<P>0.232 (0.049 to 1.094)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2472 (number of children)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2283 (number of children)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>18,927</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>18,941</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33.28 (-299.23 to 88.85)</P>
</TD>
<TD>
<P>0.6672 (0.1115 to 3.9923)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>28 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>29 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>3.7 (-68 to 45)</P>
</TD>
<TD>
<P>0.963 (0.55 to 1.68)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>0 (-2874 to 96.64)</P>
</TD>
<TD>
<P>1 (0.0336 to 29.7466)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>0.48 (-2860.42 to 96.65)</P>
</TD>
<TD>
<P>0.9952 (0.0335 to 29.6042)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>-44 (-283 to 43)</P>
</TD>
<TD>
<P>1.44 (0.57 to 3.83)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-300 (-19599 to 60)</P>
</TD>
<TD>
<P>4 (0.4 to 196.99)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (from Madhi 2005a)</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>1288 (from Madhi 2005a)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>-13 (-235 to 62)</P>
</TD>
<TD>
<P>1.13 (0.38 to 3.35)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>50.21 (-1383.83 to 98.33)</P>
</TD>
<TD>
<P>0.4979 (0.0167 to 14.8383)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>4951 (person-years)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>4742 (person-years)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>4.22 (-230.63 to 72.25)</P>
</TD>
<TD>
<P>0.9578 (0.2775 to 3.3063)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2974 (number of children)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>2818 (number of children)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>13,549 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>13,569 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33.38 (-298.07 to 88.88)</P>
</TD>
<TD>
<P>0.6652 (0.1112 to 3.9807)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>-65 (-327 to 32)</P>
</TD>
<TD>
<P>1.65 (0.68 to 4.27)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>50.24 (-1383.01 to 98.33)</P>
</TD>
<TD>
<P>0.4976 (0.0167 to 14.8301)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>2879 (person-years)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2674 (person-years)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>7.12 (-558.89 to 86.91)</P>
</TD>
<TD>
<P>92.88 (0.1309 to 6.5889)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2472 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2283 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>18,927</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>18,941</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>66.64 (-220.66 to 96.53)</P>
</TD>
<TD>
<P>0.3336 (0.0347 to 3.2066)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>10 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>16 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>38 (-46 to 75)</P>
</TD>
<TD>
<P>0.62 (0.25 to 1.46)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>41 (-36 to 75)</P>
</TD>
<TD>
<P>0.59 (0.25 to 1.36)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-300 (-19599 to 60)</P>
</TD>
<TD>
<P>4 (0.4 to 196.99)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (Madhi 2005a)</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1288 (Madhi 2005a)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>63 (-1 to 88)</P>
</TD>
<TD>
<P>0.37 (0.12 to 1.01)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>50.21 (-1383 to 98.33)</P>
</TD>
<TD>
<P>0.4979 (0.0167 to 14.8383)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>4951 (person-years)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>4742 (person-years)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-91.56 (-2011.83 to 82.62)</P>
</TD>
<TD>
<P>1.9156 (0.1738 to 21.1183)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2974 (number of children)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2818 (number of children)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP</P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>46 (-59 to 84)</P>
</TD>
<TD>
<P>0.54 (0.16 to 1.59)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>50.24 (-1383.01 to 98.33)</P>
</TD>
<TD>
<P>0.4976 (0.0167 to 14.8301)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>2879 (person-years)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2674 (person-years)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>7.12 (-1384.17 to 94.19)</P>
</TD>
<TD>
<P>0.9288 (0.0581 to 14.8417)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2472 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>2283 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray pneumonia, ITT</P>
</TD>
<TD>
<P>Hansen 2006</P>
</TD>
<TD>
<P>8396 (person-years, not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>38 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8382 (person-years, not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>51(not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>28.1 (-9.6 to 52.8)</P>
</TD>
<TD>
<P>0.719 (0.472 to 1.096)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>388 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>590 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>35 (26 to 43)</P>
</TD>
<TD>
<P>0.65 (0.57 to 0.74)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>13,728 (person-time)</P>
</TD>
<TD>
<P>361(not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>13,537 (person-time)</P>
</TD>
<TD>
<P>551 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>35.39 (26.38 to 43.3)</P>
</TD>
<TD>
<P>0.6461 (0.567 to 0.7362)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>356</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>428</P>
</TD>
<TD>
<P>17 (4 to 28)</P>
</TD>
<TD>
<P>0.83 (0.72 to 0.96)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>169</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>212</P>
</TD>
<TD>
<P>20 (2 to 35)</P>
</TD>
<TD>
<P>0.80 (0.65 to 0.98)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (Madhi 2005a)</P>
</TD>
<TD>
<P>182</P>
</TD>
<TD>
<P>1288 (Madhi 2005a)</P>
</TD>
<TD>
<P>209</P>
</TD>
<TD>
<P>13 (-7 to 29)</P>
</TD>
<TD>
<P>0.87 (0.71 to 1.07)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>141</P>
</TD>
<TD>
<P>16 (-7.3 to 34.2)</P>
</TD>
<TD>
<P>0.84 (0.658 to 1.073)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2002</P>
</TD>
<TD>
<P>4058 (person-years)</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>3866 (person-years)</P>
</TD>
<TD>
<P>139</P>
</TD>
<TD>
<P>-11.0 (-39.3 to 11.5)</P>
</TD>
<TD>
<P>1.11 (0.885 to 1.393)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2974 (number of children)</P>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>2818 (number of children)</P>
</TD>
<TD>
<P>139</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>X-ray pneumonia, PP</P>
</TD>
<TD>
<P>Hansen 2006</P>
</TD>
<TD>
<P>5634 (person-years, not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>28 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>5594 (person-years, not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>45 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>41.0 (5.2 to 63.3)</P>
</TD>
<TD>
<P>0.59 (0.367 to 0.948)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>333</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>513</P>
</TD>
<TD>
<P>37 (27 to 45)</P>
</TD>
<TD>
<P>0.63 (0.55 to 0.73)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>10,620 (person-time)</P>
</TD>
<TD>
<P>305 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>10,382 (person-time)</P>
</TD>
<TD>
<P>473 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>36.96 (27.39 to 45.27)</P>
</TD>
<TD>
<P>0.6304 (0.5473 to 0.7261)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>18,245 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>18,268 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>17,356 (Madhi 2005a)</P>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>17,350 (Madhi 2005a)</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>25 (4 to 41)</P>
</TD>
<TD>
<P>0.75 (0.59 to 0.96)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1201 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>1200 (Madhi 2005a)</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
<TD>
<P>not specified</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>22.9 (-1.1 to 41.2)</P>
</TD>
<TD>
<P>0.771 (0.5888 to 1.011)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2002</P>
</TD>
<TD>
<P>2350 (person-years)</P>
</TD>
<TD>
<P>147</P>
</TD>
<TD>
<P>2176 (person-years)</P>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>-8.0 (-37.0 to 14.9)</P>
</TD>
<TD>
<P>1.08 (0.851 to 1.37)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2472 (number of children)</P>
</TD>
<TD>
<P>147</P>
</TD>
<TD>
<P>2283 (number of children)</P>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2009-07-02 18:15:09 +1000" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2009-07-02 18:15:02 +1000" MODIFIED_BY="[Empty name]">Vaccine and control group's events (clinical pneumonia, all-cause admissions and all-cause mortality)</TITLE>
<TABLE COLS="8" ROWS="34">
<TR>
<TH>
<P>
<B>Outcome</B>
</P>
</TH>
<TH>
<P>
<B>Study</B>
</P>
</TH>
<TH>
<P>
<B>Vaccine denominator</B>
</P>
</TH>
<TH>
<P>
<B>Vaccine events</B>
</P>
</TH>
<TH>
<P>
<B>Control denominator</B>
</P>
</TH>
<TH>
<P>
<B>Control events</B>
</P>
</TH>
<TH>
<P>
<B>VE (95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>RR (95% CI)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT</P>
</TD>
<TD>
<P>Black 2002a</P>
</TD>
<TD>
<P>30,301 (person-years)</P>
</TD>
<TD>
<P>43.8 (cases per 1000 person years)</P>
</TD>
<TD>
<P>30,327 (person-years)</P>
</TD>
<TD>
<P>47.1 (cases per 1000 person years)</P>
</TD>
<TD>
<P>6.9 (-0.3 to 13.6)</P>
</TD>
<TD>
<P>0.931 (0.864 to 1.003)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>18,926 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>18,942 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>2808 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>2943 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>6 (1 to 11)</P>
</TD>
<TD>
<P>0.94 (0.89 to 0.99)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>11,695 (person-time)</P>
</TD>
<TD>
<P>2603 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>11,527 (person-time)</P>
</TD>
<TD>
<P>2746 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>6.57 (2.07 to 10.86)</P>
</TD>
<TD>
<P>0.9343 (0.8914 to 0.9793)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>1093</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1080</P>
</TD>
<TD>
<P>-0.8 (-9.6 to 7.4)</P>
</TD>
<TD>
<P>1.008 (0.926 to 1.096)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>1493</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>1646</P>
</TD>
<TD>
<P>9 (3 to 15)</P>
</TD>
<TD>
<P>0.91 (0.85 to 0.97)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (HIV-negative)</P>
</TD>
<TD>
<P>18,633</P>
</TD>
<TD>
<P>1033</P>
</TD>
<TD>
<P>18,626</P>
</TD>
<TD>
<P>1106</P>
</TD>
<TD>
<P>7 (-1 to 14)</P>
</TD>
<TD>
<P>0.93 (0.86 to 1.01)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (HIV-positive)</P>
</TD>
<TD>
<P>1289</P>
</TD>
<TD>
<P>412</P>
</TD>
<TD>
<P>1288</P>
</TD>
<TD>
<P>487</P>
</TD>
<TD>
<P>15 (6 to 24)</P>
</TD>
<TD>
<P>0.85 (0.76 to 0.94)</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP</P>
</TD>
<TD>
<P>Black 2002a</P>
</TD>
<TD>
<P>17,645 (person-years)</P>
</TD>
<TD>
<P>53.6 (cases per 1000 person years)</P>
</TD>
<TD>
<P>17,695 (person-years)</P>
</TD>
<TD>
<P>56.8 (cases per 1000 person years)</P>
</TD>
<TD>
<P>5.5 (-3.3 to 13.5)</P>
</TD>
<TD>
<P>0.945 (0.865 to 1.033)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>16,901 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>16,865 (number of children)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>2172</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>2284</P>
</TD>
<TD>
<P>7 (1 to 12)</P>
</TD>
<TD>
<P>0.93 (0.88 to 0.99)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>8007 (person-time)</P>
</TD>
<TD>
<P>2000 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>7865 (person-time)</P>
</TD>
<TD>
<P>2120 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>7.33 (2.33 to 12.08)</P>
</TD>
<TD>
<P>0.9267 (0.8792 to 0.9767)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>934</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>930</P>
</TD>
<TD>
<P>0.1 (-9.4 to 8.7)</P>
</TD>
<TD>
<P>0.999 (0.913 to 1.094)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (all children)</P>
</TD>
<TD>
<P>18,245</P>
</TD>
<TD>
<P>858</P>
</TD>
<TD>
<P>18,268</P>
</TD>
<TD>
<P>970</P>
</TD>
<TD>
<P>11 (3 to 19)</P>
</TD>
<TD>
<P>0.89 (0.81 to 0.97)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (HIV-negative)</P>
</TD>
<TD>
<P>17,356</P>
</TD>
<TD>
<P>650</P>
</TD>
<TD>
<P>17,350</P>
</TD>
<TD>
<P>717</P>
</TD>
<TD>
<P>9 (-1 to 18)</P>
</TD>
<TD>
<P>0.91 (0.82 to 1.01)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Madhi 2005a (HIV-positive)</P>
</TD>
<TD>
<P>1201</P>
</TD>
<TD>
<P>186</P>
</TD>
<TD>
<P>1200</P>
</TD>
<TD>
<P>228</P>
</TD>
<TD>
<P>18 (3 to 31)</P>
</TD>
<TD>
<P>0.82 (0.69 to 0.97)</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT</P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>1313 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>1485 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>13 (6 to 19)</P>
</TD>
<TD>
<P>0.87 (0.81 to 0.94)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>12,996 (person-time)</P>
</TD>
<TD>
<P>1215 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>12,827 (person-time)</P>
</TD>
<TD>
<P>1353 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>11.37 (4.61 to 17.65)</P>
</TD>
<TD>
<P>0.8863 (0.8235 to 0.9539)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>1538</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>1506</P>
</TD>
<TD>
<P>2.4 (-9.23 to 4)</P>
</TD>
<TD>
<P>1.024 (0.96 to 1.0923)</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP</P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>1065</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>1216</P>
</TD>
<TD>
<P>15 (7 to 21)</P>
</TD>
<TD>
<P>0.85 (0.79 to 0.93)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>9949 (person-time)</P>
</TD>
<TD>
<P>964 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>9718 (person-time)</P>
</TD>
<TD>
<P>1081 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>12.89 (5.43 to 19.77)</P>
</TD>
<TD>
<P>0.8711 (0.8023 to 0.9457)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>1396</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>1387</P>
</TD>
<TD>
<P>-0.78 (-7.76 to 5.75)</P>
</TD>
<TD>
<P>1.0078 (0.9425 to 1.0776)</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT</P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8718</P>
</TD>
<TD>
<P>426 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>8719</P>
</TD>
<TD>
<P>491 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>14 (2 to 24)</P>
</TD>
<TD>
<P>0.86 (0.76 to 0.98)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>14,006 (person-time)</P>
</TD>
<TD>
<P>376 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>13,962 (person-time)</P>
</TD>
<TD>
<P>424 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>11.6 (-1.36 to 22.91)</P>
</TD>
<TD>
<P>0.884 (0.7709 to 1.0136)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0 (-2874.66 to 96.64)</P>
</TD>
<TD>
<P>1 (0.0336 to 29.7466)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0.48 (-2860.42 to 96.65)</P>
</TD>
<TD>
<P>0.9952 (0.0335 to 29.6042)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (all children)</P>
</TD>
<TD>
<P>19,922</P>
</TD>
<TD>
<P>229</P>
</TD>
<TD>
<P>19,914</P>
</TD>
<TD>
<P>242</P>
</TD>
<TD>
<P>5.41 (-13.2 to 20.96)</P>
</TD>
<TD>
<P>0.9459 (0.7904 to 1.132)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative)</P>
</TD>
<TD>
<P>18,633 (Madhi 2005a)</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>18,626 (Madhi 2005a)</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>0.04 (-58.59 to 36.99)</P>
</TD>
<TD>
<P>0.9996 (0.6301 to 1.5859)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Klugman 2003 (HIV-positive)</P>
</TD>
<TD>
<P>1289 (Madhi 2005a)</P>
</TD>
<TD>
<P>166</P>
</TD>
<TD>
<P>1288 (Madhi 2005a)</P>
</TD>
<TD>
<P>176</P>
</TD>
<TD>
<P>5.75 (-14.82 to 22.65)</P>
</TD>
<TD>
<P>0.9425 (0.7735 to 1.1482)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>6094</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>12.14 (-43.45 to 46.18)</P>
</TD>
<TD>
<P>0.8786 (0.5382 to 1.4345)</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP</P>
</TD>
<TD>
<P>Cutts 2005 (all children)</P>
</TD>
<TD>
<P>8189</P>
</TD>
<TD>
<P>330</P>
</TD>
<TD>
<P>8151</P>
</TD>
<TD>
<P>389</P>
</TD>
<TD>
<P>16 (3 to 28)</P>
</TD>
<TD>
<P>0.84 (0.72 to 0.97)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Cutts 2005 (younger than 24 months children)</P>
</TD>
<TD>
<P>10,823 (person-time)</P>
</TD>
<TD>
<P>281 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>10,708 (person-time)</P>
</TD>
<TD>
<P>324 (not in published article, personal communication with the author)</P>
</TD>
<TD>
<P>14.19 (-0.45 to 26.7)</P>
</TD>
<TD>
<P>0.8581 (0.733 to 1.0045)</P>
</TD>
</TR>
<TR>
<TD>
<P> </P>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>6018</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>12.62 (-43.78 to 46.9)</P>
</TD>
<TD>
<P>0.8738 (0.531 to 1.4378)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" MODIFIED="2009-07-02 18:18:21 +1000" MODIFIED_BY="[Empty name]" NO="12">
<TITLE>Invasive pneumococcal disease events rates</TITLE>
<TABLE COLS="7" ROWS="32">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study</P>
</TH>
<TH>
<P>All children</P>
</TH>
<TH>
<P>All events</P>
</TH>
<TH>
<P>Vaccine events rate</P>
</TH>
<TH>
<P>Control events rate</P>
</TH>
<TH>
<P>All events rate</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>(randomized)</P>
</TD>
<TD>
<P>(vaccine+control events)</P>
</TD>
<TD>
<P>(per 100,000 children)</P>
</TD>
<TD>
<P>(per 100,000 children)</P>
</TD>
<TD>
<P>(per 100,000 children)</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>290</P>
</TD>
<TD>
<P>161</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (&lt;29 months old children)</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>470</P>
</TD>
<TD>
<P>849</P>
</TD>
<TD>
<P>660</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>1246.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>361</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>1250.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>361</P>
</TD>
<TD>
<P>200</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative children)</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>81</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>49</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>303</P>
</TD>
<TD>
<P>639</P>
</TD>
<TD>
<P>466</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All studies</P>
</TD>
<TD>
<P>113,044</P>
</TD>
<TD>
<P>244</P>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>307</P>
</TD>
<TD>
<P>216</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>259</P>
</TD>
<TD>
<P>137</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (&lt;29 months old children)</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>516</P>
</TD>
<TD>
<P>333</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>1246.5</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>241</P>
</TD>
<TD>
<P>80</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>1250.5</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>241</P>
</TD>
<TD>
<P>80</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative children)</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>54</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>390</P>
</TD>
<TD>
<P>224</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All studies</P>
</TD>
<TD>
<P>113,044</P>
</TD>
<TD>
<P>149</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>223</P>
</TD>
<TD>
<P>132</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (&lt;29 months old children)</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>321</P>
</TD>
<TD>
<P>333</P>
</TD>
<TD>
<P>327</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>1246.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>1250.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative children)</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>168</P>
</TD>
<TD>
<P>177</P>
</TD>
<TD>
<P>173</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All studies</P>
</TD>
<TD>
<P>113,044</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>72</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT</P>
</TD>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>37,868</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cutts 2005 (&lt;29 months old children)</P>
</TD>
<TD>
<P>17,437</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>184</P>
</TD>
<TD>
<P>149</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Klugman 2003 (HIV-negative children)</P>
</TD>
<TD>
<P>37,259</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>12,191</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>5792</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All children</P>
</TD>
<TD>
<P>110,547</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>35</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-13" MODIFIED="2009-06-01 19:37:41 +1000" MODIFIED_BY="[Empty name]" NO="13">
<TITLE MODIFIED="2009-03-01 12:37:58 +1000" MODIFIED_BY="Liz Dooley">Proportion of IPD caused by vaccine type <I>S. pneumoniae</I>
</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Vaccine group (%)</P>
</TH>
<TH>
<P>Control group (%)</P>
</TH>
</TR>
<TR>
<TD>
<P>Black 2000</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
<TR>
<TD>
<P>Cutts 2005 (&lt;29 months old children)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>Eskola 2001</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>Kilpi 2003</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>Klugman 2003 (HIV-negative children)</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
<TR>
<TD>
<P>Lucero 2009</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Brien 2003</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-14" MODIFIED="2009-07-08 19:00:07 +1000" MODIFIED_BY="[Empty name]" NO="14">
<TITLE MODIFIED="2009-07-08 19:00:07 +1000" MODIFIED_BY="[Empty name]">Summary results (Children &lt; 24 months and/or HIV-1 negative children)</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Heterogeneity P-value</P>
</TH>
<TH>
<P>I<SUP>2</SUP>
</P>
</TH>
<TH>
<P>Effect P-value</P>
</TH>
<TH>
<P>RR [95% CI]</P>
</TH>
<TH>
<P>VE [95% CI]</P>
</TH>
<TH>
<P>Included studies</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.20 [0.10, 0.42]</P>
</TD>
<TD>
<P>80 [58, 90]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.42 [0.25, 0.71]</P>
</TD>
<TD>
<P>58 [29, 75]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.93</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.84</P>
</TD>
<TD>
<P>0.92 [0.39, 2.17]</P>
</TD>
<TD>
<P>8 [-117, 61]</P>
</TD>
<TD>
<P>Black 2000; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0.89 [0.24, 3.36]</P>
</TD>
<TD>
<P>11 [-236, 76]</P>
</TD>
<TD>
<P>Black 2000; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.16</P>
</TD>
<TD>
<P>41%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.73 [0.64, 0.85]</P>
</TD>
<TD>
<P>27 [15, 36]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.43</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009;Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>0.95 [0.83, 1.10]</P>
</TD>
<TD>
<P>5 [-10, 17]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0.89 [0.79, 1.01]</P>
</TD>
<TD>
<P>11 [-1, 21]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.20 [0.12, 0.34]</P>
</TD>
<TD>
<P>80 [66, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.47 [0.35, 0.64]</P>
</TD>
<TD>
<P>53 [36, 65]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.93</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.84</P>
</TD>
<TD>
<P>0.92 [0.39, 2.17]</P>
</TD>
<TD>
<P>8 [-117, 61]</P>
</TD>
<TD>
<P>Black 2000; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0.89 [0.24, 3.36]</P>
</TD>
<TD>
<P>11 [-236, 76]</P>
</TD>
<TD>
<P>Black 2000; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.16</P>
</TD>
<TD>
<P>41%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.71 [0.65, 0.78]</P>
</TD>
<TD>
<P>29 [22, 35]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.43</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009;Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0.96 [0.91, 1.01]</P>
</TD>
<TD>
<P>4 [-1, 9]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0.89 [0.79, 1.01]</P>
</TD>
<TD>
<P>11 [-1, 21]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P = 0.0005</P>
</TD>
<TD>
<P>0.20 [0.08, 0.49]</P>
</TD>
<TD>
<P>80 [51, 92]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.31 [0.12, 0.79]</P>
</TD>
<TD>
<P>69 [21, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>Black 2000; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.42</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.67 [0.60, 0.75]</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009;Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.38</P>
</TD>
<TD>
<P>0.94 [0.81, 1.08]</P>
</TD>
<TD>
<P>6 [-8, 19]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0.86 [0.74, 1.00]</P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.19 [0.10, 0.37]</P>
</TD>
<TD>
<P>81 [63, 90]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.41 [0.27, 0.60]</P>
</TD>
<TD>
<P>59 [40, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>Black 2000; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.42</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.67 [0.60, 0.75]</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009;Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>0.94 [0.89, 1.00]</P>
</TD>
<TD>
<P>6 [0, 11]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0.86 [0.74, 1.00]</P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-15" MODIFIED="2009-07-08 19:00:11 +1000" MODIFIED_BY="[Empty name]" NO="15">
<TITLE MODIFIED="2009-07-08 19:00:11 +1000" MODIFIED_BY="[Empty name]">Summary results (Children &lt; 24 months and/or HIV-1 negative and HIV-1 positive children)</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Heterogeneity P-value</P>
</TH>
<TH>
<P>I<SUP>2</SUP>
</P>
</TH>
<TH>
<P>Effect P-value</P>
</TH>
<TH>
<P>RR [95% CI]</P>
</TH>
<TH>
<P>VE [95% CI]</P>
</TH>
<TH>
<P>Included Studies</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.15</P>
</TD>
<TD>
<P>36%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.23 [0.12, 0.42]</P>
</TD>
<TD>
<P>77 [58, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P>P = 0.0002</P>
</TD>
<TD>
<P>0.42 [0.27, 0.66]</P>
</TD>
<TD>
<P>58 [34, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>1.06 [0.55, 2.04]</P>
</TD>
<TD>
<P>-6 [104, 45]</P>
</TD>
<TD>
<P>Black 2000; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.73</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>0.60 [0.29, 1.25]</P>
</TD>
<TD>
<P>40 [-25, 71]</P>
</TD>
<TD>
<P>Black 2000; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>P = 0.0004</P>
</TD>
<TD>
<P>0.75 [0.64, 0.88]</P>
</TD>
<TD>
<P>25 [12, 36]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>0.94 [0.91, 0.97]</P>
</TD>
<TD>
<P>6 [3, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>0.95 [0.83, 1.10]</P>
</TD>
<TD>
<P>5 [-10, 17]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.97</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>0.91 [0.81, 1.01]</P>
</TD>
<TD>
<P>9 [-1, 19]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.15</P>
</TD>
<TD>
<P>36%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.23 [0.15, 0.35]</P>
</TD>
<TD>
<P>77 [65, 85]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.47 [0.36, 0.61]</P>
</TD>
<TD>
<P>53 [39, 64]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>1.06 [0.55, 2.04]</P>
</TD>
<TD>
<P>-6 [-104, 45]</P>
</TD>
<TD>
<P>Black 2000; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.73</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>0.60 [0.29, 1.25]</P>
</TD>
<TD>
<P>40 [-25, 71]</P>
</TD>
<TD>
<P>Black 2000; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.74 [0.68, 0.81]</P>
</TD>
<TD>
<P>26 [19, 32]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.94 [0.91, 0.97]</P>
</TD>
<TD>
<P>6 [3, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0.96 [0.91, 1.01]</P>
</TD>
<TD>
<P>4 [-1, 9]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.97</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>0.91 [0.81, 1.01]</P>
</TD>
<TD>
<P>9 [-1, 19]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.11</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.22 [0.07, 0.71]</P>
</TD>
<TD>
<P>78 [29, 93]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.31 [0.12, 0.79]</P>
</TD>
<TD>
<P>69 [21, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>Black 2000; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.40</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.65 [0.58, 0.74]</P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.34</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.94 [0.90, 0.97]</P>
</TD>
<TD>
<P>6 [3, 10]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.38</P>
</TD>
<TD>
<P>0.94 [0.81, 1.08]</P>
</TD>
<TD>
<P>6 [-8, 19]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0.86 [0.74, 1.00]</P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.11</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.20 [0.10, 0.40]</P>
</TD>
<TD>
<P>80 [60, 90]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.41 [0.27, 0.60]</P>
</TD>
<TD>
<P>59 [40, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>Black 2000; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.40</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.65 [0.58, 0.74]</P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.34</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>P = 0.0004</P>
</TD>
<TD>
<P>0.94 [0.90, 0.97]</P>
</TD>
<TD>
<P>6 [3, 10]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>0.94 [0.89, 1.00]</P>
</TD>
<TD>
<P>6 [0, 11]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0.86 [0.74, 1.00]</P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-16" MODIFIED="2009-07-08 18:59:20 +1000" MODIFIED_BY="[Empty name]" NO="16">
<TITLE MODIFIED="2009-07-08 18:59:20 +1000" MODIFIED_BY="[Empty name]">Summary results (Pooled with Cutts 2005 children &lt; 29 months and/or HIV-1 negative children)</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Heterogeneity P-value</P>
</TH>
<TH>
<P>I<SUP>2</SUP>
</P>
</TH>
<TH>
<P>Effect P-value</P>
</TH>
<TH>
<P>RR [95% CI]</P>
</TH>
<TH>
<P>VE [95% CI]</P>
</TH>
<TH>
<P>Included Studies</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.14</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.21 [0.10, 0.46]</P>
</TD>
<TD>
<P>79 [54, 90]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P>P = 0.0009</P>
</TD>
<TD>
<P>0.42 [0.25, 0.70]</P>
</TD>
<TD>
<P>58 [30, 75]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.97</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.83</P>
</TD>
<TD>
<P>0.95 [0.59, 1.52]</P>
</TD>
<TD>
<P>5 [-52, 41]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.33</P>
</TD>
<TD>
<P>0.69 [0.33, 1.45]</P>
</TD>
<TD>
<P>31 [-45, 67]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.18</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.73 [0.64, 0.84]</P>
</TD>
<TD>
<P>27 [16, 36]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.46</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>0.95 [0.91, 0.98]</P>
</TD>
<TD>
<P>5 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>P = 0.48</P>
</TD>
<TD>
<P>0.94 [0.80, 1.11]</P>
</TD>
<TD>
<P>6 [-11, 20]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.96</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.87 [0.77, 0.98]</P>
</TD>
<TD>
<P>13 [2, 23]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.14</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.22 [0.14, 0.37]</P>
</TD>
<TD>
<P>78 [63, 86]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.47 [0.35, 0.62]</P>
</TD>
<TD>
<P>53 [38, 65]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.97</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.83</P>
</TD>
<TD>
<P>0.95 [0.59, 1.52]</P>
</TD>
<TD>
<P>5 [-52, 41]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.33</P>
</TD>
<TD>
<P>0.69 [0.33, 1.45]</P>
</TD>
<TD>
<P>31 [-45, 67]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.18</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.71 [0.65, 0.79]</P>
</TD>
<TD>
<P>29 [21, 35]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.46</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>0.95 [0.91, 0.98]</P>
</TD>
<TD>
<P>5 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>0.95 [0.90, 1.00]</P>
</TD>
<TD>
<P>5 [0, 10]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.96</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.87 [0.77, 0.98]</P>
</TD>
<TD>
<P>13 [2, 23]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P = 0.0008</P>
</TD>
<TD>
<P>0.22 [0.09, 0.53]</P>
</TD>
<TD>
<P>78 [47, 91]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>68%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.31 [0.13, 0.76]</P>
</TD>
<TD>
<P>69 [24, 87]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.67</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>1.20 [0.58, 2.50]</P>
</TD>
<TD>
<P>-20 [-150, 42]</P>
</TD>
<TD>
<P> </P>
<P>Black 2000; Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.89</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.25</P>
</TD>
<TD>
<P>0.55 [0.20, 1.51]</P>
</TD>
<TD>
<P>45 [-51, 80]</P>
</TD>
<TD>
<P> </P>
<P>Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.41</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.67 [0.60, 0.75]</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.53</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.004</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>P = 0.37</P>
</TD>
<TD>
<P>0.93 [0.78, 1.09]</P>
</TD>
<TD>
<P>7 [-9, 22]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P>P = 0.88</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.84 [0.73, 0.97]</P>
</TD>
<TD>
<P>16 [3, 27]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.22 [0.12, 0.41]</P>
</TD>
<TD>
<P>78 [59, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>68%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.39 [0.27, 0.58]</P>
</TD>
<TD>
<P>61 [42, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.67</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>1.20 [0.58, 2.50]</P>
</TD>
<TD>
<P>-20 [-150, 42]</P>
</TD>
<TD>
<P> </P>
<P>Black 2000; Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.89</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.25</P>
</TD>
<TD>
<P>0.55 [0.20, 1.51]</P>
</TD>
<TD>
<P>45 [-51, 80]</P>
</TD>
<TD>
<P> </P>
<P>Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.41</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.67 [0.60, 0.75]</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.53</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.004</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.93 [0.88, 0.99]</P>
</TD>
<TD>
<P>7 [1, 12]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.88</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.84 [0.73, 0.97]</P>
</TD>
<TD>
<P>16 [3, 27]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-17" MODIFIED="2009-07-08 19:57:00 +1000" MODIFIED_BY="[Empty name]" NO="17">
<TITLE MODIFIED="2009-07-08 18:59:54 +1000" MODIFIED_BY="[Empty name]">Summary results (Pooled with Cutts 2005 children &lt; 29 months and/or HIV-1 negative and HIV-1 positive children)</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Heterogeneity P-value</P>
</TH>
<TH>
<P>I<SUP>2</SUP>
</P>
</TH>
<TH>
<P>Effect P-value</P>
</TH>
<TH>
<P>RR [95% CI]</P>
</TH>
<TH>
<P>VE [95% CI]</P>
</TH>
<TH>
<P>Included Studies</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.14</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.24 [0.12, 0.45]</P>
</TD>
<TD>
<P>76 [55, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>47%</P>
</TD>
<TD>
<P>P = 0.0001</P>
</TD>
<TD>
<P>0.42 [0.27, 0.65]</P>
</TD>
<TD>
<P>58 [35, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.99</P>
</TD>
<TD>
<P>1.00 [0.66, 1.53]</P>
</TD>
<TD>
<P>0 [-53, 34]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.09</P>
</TD>
<TD>
<P>0.61 [0.35, 1.07]</P>
</TD>
<TD>
<P>39 [-7, 65]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.06</P>
</TD>
<TD>
<P>59%</P>
</TD>
<TD>
<P>P = 0.0003</P>
</TD>
<TD>
<P>0.75 [0.64, 0.88]</P>
</TD>
<TD>
<P>25 [12, 36]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P>17%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.94 [0.91, 0.98]</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>P = 0.48</P>
</TD>
<TD>
<P>0.94 [0.80, 1.11]</P>
</TD>
<TD>
<P>6 [-11, 20]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P>P = 0.92</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.89 [0.80, 0.98]</P>
</TD>
<TD>
<P>11 [2, 20]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.14</P>
</TD>
<TD>
<P>38%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.25 [0.16, 0.38]</P>
</TD>
<TD>
<P>75 [62, 84]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>47%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.47 [0.36, 0.60]</P>
</TD>
<TD>
<P>53 [40, 64]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.99</P>
</TD>
<TD>
<P>1.00 [0.66, 1.53]</P>
</TD>
<TD>
<P>0 [-53, 34]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.09</P>
</TD>
<TD>
<P>0.61 [0.35, 1.07]</P>
</TD>
<TD>
<P>39 [-7, 65]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Klugman 2003; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.06</P>
</TD>
<TD>
<P>59%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.74 [0.68, 0.81]</P>
</TD>
<TD>
<P>26 [19, 32]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Klugman 2003; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P>17%</P>
</TD>
<TD>
<P>P = 0.0003</P>
</TD>
<TD>
<P>0.94 [0.91, 0.97]</P>
</TD>
<TD>
<P>6 [3, 9]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>90%</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>0.95 [0.90, 1.00]</P>
</TD>
<TD>
<P>5 [0, 10]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P>P = 0.92</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.89 [0.80, 0.98]</P>
</TD>
<TD>
<P>11 [2, 20]</P>
</TD>
<TD>
<P>Cutts 2005; Eskola 2001; Kilpi 2003; Klugman 2003; Lucero 2009 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.12</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.24 [0.08, 0.75]</P>
</TD>
<TD>
<P>76 [25, 92]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>68%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.31 [0.13, 0.76]</P>
</TD>
<TD>
<P>69 [24,87]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.67</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>1.20 [0.58, 2.50]</P>
</TD>
<TD>
<P>-20 [-150, 42]</P>
</TD>
<TD>
<P> </P>
<P>Black 2000; Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD>
<P>P = 0.89</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.25</P>
</TD>
<TD>
<P>0.55 [0.20, 1.51]</P>
</TD>
<TD>
<P>45 [-51, 80]</P>
</TD>
<TD>
<P> </P>
<P>Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.39</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.65 [0.58, 0.74]</P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P>P = 0.35</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>0.94 [0.90, 0.98]</P>
</TD>
<TD>
<P>6 [2, 10]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>P = 0.37</P>
</TD>
<TD>
<P>0.93 [0.78, 1.09]</P>
</TD>
<TD>
<P>7 [-9, 22]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P>P = 0.88</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.84 [0.73, 0.97]</P>
</TD>
<TD>
<P>16 [3, 27]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.12</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>0.23 [0.12, 0.45]</P>
</TD>
<TD>
<P>77 [55, 88]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>68%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.39 [0.27, 0.58]</P>
</TD>
<TD>
<P>61 [42, 73]</P>
</TD>
<TD>
<P>Black 2000; Cutts 2005;  Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, Non vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.67</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>1.20 [0.58, 2.50]</P>
</TD>
<TD>
<P>-20 [-150, 42]</P>
</TD>
<TD>
<P> </P>
<P>Black 2000; Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.89</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.25</P>
</TD>
<TD>
<P>0.55 [0.20, 1.51]</P>
</TD>
<TD>
<P>45 [-51, 80]</P>
</TD>
<TD>
<P> </P>
<P>Cutts 2005; Lucero 2009; O'Brien 2003 </P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.39</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0.65 [0.58, 0.74]</P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>Cutts 2005; Hansen 2006; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.35</P>
</TD>
<TD>
<P>8%</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0.94 [0.90, 0.97]</P>
</TD>
<TD>
<P>6 [3, 10]</P>
</TD>
<TD>
<P>Black 2002a; Cutts 2005; Lucero 2009; Madhi 2005a</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.002</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>0.93 [0.88, 0.99]</P>
</TD>
<TD>
<P>7 [1, 12]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P>P = 0.88</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>0.84 [0.73, 0.97]</P>
</TD>
<TD>
<P>16 [3, 27]</P>
</TD>
<TD>
<P>Cutts 2005; Lucero 2009</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-18" MODIFIED="2009-07-02 18:32:08 +1000" MODIFIED_BY="[Empty name]" NO="18">
<TITLE MODIFIED="2009-05-29 20:09:48 +1000" MODIFIED_BY="[Empty name]">Quality assessment of the studies reviewed using GRADEPRO criteria</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TH>
<P>No of studies</P>
</TH>
<TH>
<P>Design</P>
</TH>
<TH>
<P>Limitations</P>
</TH>
<TH>
<P>Inconsistency</P>
</TH>
<TH>
<P>Indirectness</P>
</TH>
<TH>
<P>Imprecision</P>
</TH>
<TH>
<P>Other factors considered</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>IPD, vaccine serotypes, ITT (Random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>Randomized controlled trial</P>
</TD>
<TD ALIGN="LEFT">
<P>Serious<SUP>1</SUP>
</P>
</TD>
<TD>
<P>No serious inconsistency</P>
</TD>
<TD>
<P>No serious indirectness</P>
</TD>
<TD>
<P>No serious imprecision<SUP>2</SUP>
</P>
</TD>
<TD>
<P>strong association<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>IPD, all serotypes, ITT (Random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>Randomized controlled trial</P>
</TD>
<TD>
<P>Serious<SUP>1</SUP>
</P>
</TD>
<TD>
<P>No serious inconsistency</P>
</TD>
<TD>
<P>No serious indirectness</P>
</TD>
<TD>
<P>No serious imprecision<SUP>2</SUP>
</P>
</TD>
<TD>
<P>strong association<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>X-ray defined pneumonia, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>Randomized controlled trial</P>
</TD>
<TD>
<P>Serious<SUP>4a,5</SUP>
</P>
</TD>
<TD>
<P>No serious inconsistency</P>
</TD>
<TD>
<P>No serious indirectness</P>
</TD>
<TD>
<P>No serious imprecision</P>
</TD>
<TD>
<P>None (see <SUP>4b</SUP>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Clinical pneumonia, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>Randomized controlled trial</P>
</TD>
<TD>
<P>Serious<SUP>4a</SUP>
</P>
</TD>
<TD>
<P>No serious inconsistency</P>
</TD>
<TD>
<P>No serious indirectness</P>
</TD>
<TD>
<P>No serious imprecision</P>
</TD>
<TD>
<P>None (see <SUP>4b</SUP>)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Incomplete accounting of patients and outcome events for the Finnish trial (Eskola 2001; Kilpi 2003) and early stopping for the US trials (Black 2000; O'Brien 2003)</P>
<P>
<SUP>2 </SUP>Total number of events for VT (142) and all serotypes (233) IPD are less than 300 (criteria from the <LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>) which should further downgrade the quality of evidence for imprecision. However, the event rates (0.1% for VT IPD and 0.2% for all serotypes) were considered low. Therefore the quality of evidence was not downgraded</P>
<P>
<SUP>3</SUP> Since the effect was large (RR &lt; 0.5) with RR of 0.20 for VT-IPD and 0.42 for all serotype IPD, the "serious" limitation was removed and the evidence was upgraded to high</P>
<P>
<SUP>4a</SUP> Early stopping for the NCKP trial (Black 2002a; Hansen 2006); <SUP>4b</SUP> effect was not large therefore quality of evidence was not increased</P>
<P>
<SUP>5 </SUP>Excludes O'Brien 2002 since results are invalid for X-ray pneumonia</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-19" MODIFIED="2009-07-02 18:32:44 +1000" MODIFIED_BY="[Empty name]" NO="19">
<TITLE MODIFIED="2009-05-29 20:12:24 +1000" MODIFIED_BY="[Empty name]">Summary of Findings with absolute effects using GRADEPRO software</TITLE>
<TABLE COLS="7" ROWS="16">
<TR>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Number of events/Number of patients (rate in %)</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Effect</P>
</TH>
<TH ROWSPAN="2">
<P>Absolute effect<SUP>4</SUP> in areas with varying risks of outcome (low, medium, high)</P>
</TH>
<TH ROWSPAN="2">
<P>Quality of evidence</P>
</TH>
<TH ROWSPAN="2">
<P>Importance of outcome</P>
</TH>
</TR>
<TR>
<TH>
<P>11PCV</P>
</TH>
<TH>
<P>Placebo or other vaccines<SUP>1</SUP>
</P>
</TH>
<TH>
<P>Risk ratio (95% CI)</P>
</TH>
<TH>
<P>Absolute effect (95% CI)</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>IPD, vaccine serotypes, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>21/57,015 (0%)<SUP>2,3</SUP>
</P>
</TD>
<TD>
<P>121/56,029 (0.2%)<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>RR 0.20 (0.1 to 0.42)</P>
</TD>
<TD ROWSPAN="2">
<P>2 (1 to 2) fewer per 1000</P>
</TD>
<TD>
<P>2 fewer per 1,000<SUP>6</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;</P>
<P>HIGH</P>
</TD>
<TD ROWSPAN="2">
<P>CRITICAL</P>
</TD>
</TR>
<TR>
<TD>
<P>0.5%</P>
</TD>
<TD>
<P>4 fewer per 1,000<SUP>7</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>IPD, all serotypes, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>69/57,015 (0.1%)<SUP>2,3</SUP>
</P>
</TD>
<TD>
<P>164/56,029 (0.4%)<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>RR 0.42 (0.25 to 0.71)</P>
</TD>
<TD ROWSPAN="2">
<P>2 (1 to 2) fewer per 1000</P>
</TD>
<TD>
<P>2 fewer per 1,000<SUP>6</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;</P>
<P>HIGH</P>
</TD>
<TD ROWSPAN="2">
<P>IMPORTANT</P>
</TD>
</TR>
<TR>
<TD>
<P>0.8%</P>
</TD>
<TD>
<P>5 fewer per 1,000<SUP>7</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>X-ray defined pneumonia, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>687/52,374 (1.3%)<SUP>2,3</SUP>
</P>
</TD>
<TD>
<P>955/52,381 (0.3%)<SUP>7,8</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>RR 0.73 (0.64 to 0.85)</P>
</TD>
<TD ROWSPAN="3">
<P>5 (3 to 6) fewer per 1000</P>
</TD>
<TD>
<P>1 fewer per 1,000<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>&#8853;&#8853;&#8853;O</P>
<P>MODERATE</P>
</TD>
<TD ROWSPAN="3">
<P>CRITICAL</P>
</TD>
</TR>
<TR>
<TD>
<P>1.7%</P>
</TD>
<TD>
<P>5 fewer per 1,000<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>6.3%</P>
</TD>
<TD>
<P>17 fewer per 1,000<SUP>7</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Clinical pneumonia, ITT (random) (follow-up mean 24 months)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>6057/52,374 (11.6%)<SUP>2,3</SUP>
</P>
</TD>
<TD>
<P>6361/52,381 (5.9%)<SUP>2,3</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>RR 0.94 (0.91 to 0.98)</P>
</TD>
<TD ROWSPAN="3">
<P>7 (2 to 11) fewer per 1000</P>
</TD>
<TD>
<P>4 fewer per 1,000<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>&#8853;&#8853;&#8853;O</P>
<P>MODERATE</P>
</TD>
<TD ROWSPAN="3">
<P>IMPORTANT</P>
</TD>
</TR>
<TR>
<TD>
<P>12.6%</P>
</TD>
<TD>
<P>8 fewer per 1,000<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>31.5%</P>
</TD>
<TD>
<P>19 fewer per 1,000<SUP>7</SUP>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of relevant outcome in control populations: VT-IPD and all serotype IPD (Medium and High); X-ray and clinical pneumonia (Low, Medium, and High)</P>
<P>
<SUP>2</SUP> Denominators from Cutts still used the numbers from children younger than 29 months of age because we could not obtain data from the authors (Cutts 2005)</P>
<P>
<SUP>3</SUP> Corresponding intervention risk (per 1000 people) = 1000 x ACR x RR where ACR = Assumed Control Risk, RR = Risk Ratio or Relative Risk; Assumed risk was calculated from low, medium, and high control group risk from the included studies</P>
<P>
<SUP>4 </SUP>Absolute effect (per 1000 people) = 1000 x | CER x (1-RR)| where CER = Control Event Rate (CER = number of people with event in control groups / total number of people in control groups) RR = Risk Ratio</P>
<P>
<SUP>5 </SUP>Absolute effect in populations with Low risk of relevant outcome</P>
<P>
<SUP>6 </SUP>Absolute effect in populations with Medium risk of relevant outcome</P>
<P>
<SUP>7</SUP> Absolute effect in populations with High risk of relevant outcome</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-20" MODIFIED="2009-07-08 19:00:22 +1000" MODIFIED_BY="[Empty name]" NO="20">
<TITLE MODIFIED="2009-07-08 19:00:22 +1000" MODIFIED_BY="[Empty name]">Comparison of results between 2004 Review and 2009 Update (Children &lt; 24 months and/or HIV-1 negative children)</TITLE>
<TABLE COLS="10" ROWS="39">
<TR>
<TH ROWSPAN="2">
<P>
<B>Outcome</B>
</P>
</TH>
<TH>
<P>
<B>2004 Results</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Effect P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>I<SUP>2</SUP>
</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Heterogeneity</B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH>
<P>
<B>2009 Update</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Effect </B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>I<SUP>2</SUP>
</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Heterogeneity</B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Difference (%)</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>VE [95% CI]</B>
</P>
</TH>
<TH>
<P>
<B>VE [95% CI]</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Invasive pneumococcal disease (IPD)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>88 [73, 94]</P>
</TD>
<TD>
<P> </P>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.77</P>
</TD>
<TD>
<P>80 [58, 90]</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P> </P>
<P>34%</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>-9.09%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>68 [31, 85]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.003</P>
</TD>
<TD>
<P>51.1%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.09</P>
</TD>
<TD>
<P>58 [29, 75]</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>-14.71%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>1 [-143, 60]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.99</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.91</P>
</TD>
<TD>
<P>8 [-117, 61]</P>
</TD>
<TD>
<P>P = 0.84</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.93</P>
</TD>
<TD>
<P>700.00%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>-9 [-369, 74]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.90</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.38</P>
</TD>
<TD>
<P>11 [-236, 76]</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>222.22%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>88 [73, 94]</P>
</TD>
<TD>
<P> </P>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.77</P>
</TD>
<TD>
<P>80 [66, 88]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>-9.09%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>66 [46, 79]</P>
</TD>
<TD>
<P> </P>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>51.1%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.09</P>
</TD>
<TD>
<P>53 [36, 65]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>49%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>-19.70%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>1 [-143, 60]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.99</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.91</P>
</TD>
<TD>
<P>8 [-117, 61]</P>
</TD>
<TD>
<P>P = 0.84</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.93</P>
</TD>
<TD>
<P>700.00%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>-9 [-369, 74]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.90</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.38</P>
</TD>
<TD>
<P>11 [-236, 76]</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>222.22%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P>86 [60, 95]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.0003</P>
</TD>
<TD>
<P>25%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.36</P>
</TD>
<TD>
<P>80 [51, 92]</P>
</TD>
<TD>
<P>P = 0.0005</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>-6.98%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>69 [21, 88]</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P>86 [61, 95]</P>
</TD>
<TD>
<P> P = 0.0002</P>
</TD>
<TD>
<P>25%</P>
</TD>
<TD>
<P> P = 0.36</P>
</TD>
<TD>
<P>81 [63, 90]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>P = 0.19</P>
</TD>
<TD>
<P>-5.81%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>59 [40, 73]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>X-ray defined pneumonia</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>22 [11, 31]</P>
</TD>
<TD>
<P> P = 0.0002</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.80</P>
</TD>
<TD>
<P>27 [15, 36]</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>41%</P>
</TD>
<TD>
<P>P = 0.16</P>
</TD>
<TD>
<P>22.73%</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>22 [11, 31]</P>
</TD>
<TD>
<P> P = 0.0002</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.80</P>
</TD>
<TD>
<P>29 [22, 35]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>41%</P>
</TD>
<TD>
<P>P = 0.16</P>
</TD>
<TD>
<P>31.82%</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P>24 [11, 35]</P>
</TD>
<TD>
<P> P = 0.0007</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.90</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.42</P>
</TD>
<TD>
<P>37.50%</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>24 [11, 35]</P>
</TD>
<TD>
<P>P =0.0007</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.90</P>
</TD>
<TD>
<P>33 [25, 40]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.42</P>
</TD>
<TD>
<P>37.50%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Clinical pneumonia</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>7 [0, 14]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.06</P>
</TD>
<TD>
<P>N/A*</P>
</TD>
<TD>
<P> N/A*</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.43</P>
</TD>
<TD>
<P>-14.29%</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>7 [0, 14]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.06</P>
</TD>
<TD>
<P>N/A*</P>
</TD>
<TD>
<P> N/A*</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.43</P>
</TD>
<TD>
<P>-14.29%</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P>6 [-3, 14]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.21</P>
</TD>
<TD>
<P>N/A*</P>
</TD>
<TD>
<P> N/A*</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>0.00%</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P>6 [-3, 14]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.21</P>
</TD>
<TD>
<P>N/A*</P>
</TD>
<TD>
<P> N/A*</P>
</TD>
<TD>
<P>6 [2, 9]</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>0.00%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>All-cause admissions</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>5 [-10, 17]</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>4 [-1, 9]</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [-8, 19]</P>
</TD>
<TD>
<P>P = 0.38</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [0, 11]</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>All-cause mortality</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>11 [-1, 21]</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>11 [-1, 21]</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Include one study (Black 2000)</P>
<P>Empty cells for particular outcomes in the 2004 review means that data were not available at that time or the results of only one study was available</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-21" MODIFIED="2009-07-08 19:00:26 +1000" MODIFIED_BY="[Empty name]" NO="21">
<TITLE MODIFIED="2009-07-08 19:00:26 +1000" MODIFIED_BY="[Empty name]">Comparison of results between 2004 Review and 2009 Update (Children &lt; 24 months and/or HIV-1 negative plus HIV-1 positive children)</TITLE>
<TABLE COLS="10" ROWS="39">
<TR>
<TH ROWSPAN="2">
<P>
<B>Outcome</B>
</P>
</TH>
<TH>
<P>
<B>2004 Results</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Effect P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>I<SUP>2</SUP>
</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Hetero</B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH>
<P>
<B>2009 Update</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Effect </B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>I<SUP>2</SUP>
</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Hetero</B>
</P>
<P>
<B>P-value</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Difference (%)</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>VE [95% CI]</B>
</P>
</TH>
<TH>
<P>
<B>VE [95% CI]</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Invasive pneumococcal disease (IPD)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>81 [65, 89]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P> 2.4%</P>
</TD>
<TD>
<P>P =0.39</P>
</TD>
<TD>
<P>77 [58, 88]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>36%</P>
</TD>
<TD>
<P>P = 0.15</P>
</TD>
<TD>
<P>-4.94%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Random)</P>
</TD>
<TD>
<P>67 [36, 84]</P>
</TD>
<TD>
<P>P =0.001</P>
</TD>
<TD>
<P> 54.7%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>58 [34, 73]</P>
</TD>
<TD>
<P> </P>
<P>P = 0.0002</P>
<P> </P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P> </P>
<P>P = 0.07</P>
<P> </P>
</TD>
<TD>
<P>-13.43%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD>
<P>-12 [-118, 43]</P>
</TD>
<TD>
<P>P = 0.75</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.96</P>
</TD>
<TD>
<P>-6 [104, 45]</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>50.00%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD>
<P>38 [-32, 71]</P>
</TD>
<TD>
<P>P = 0.22</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.56</P>
</TD>
<TD>
<P>40 [-25, 71]</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.73</P>
</TD>
<TD>
<P>5.26%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>80 [66, 89]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>2.4% </P>
</TD>
<TD>
<P>P = 0.39</P>
</TD>
<TD>
<P>77 [65, 85]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>36%</P>
</TD>
<TD>
<P>P = 0.15</P>
</TD>
<TD>
<P>-3.75%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>61 [44, 72]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>54.7% </P>
</TD>
<TD>
<P>P =0.07</P>
</TD>
<TD>
<P>53 [39, 64]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>48%</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>-13.11%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>-12 [-118, 43]</P>
</TD>
<TD>
<P>P = 0.75</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.96</P>
</TD>
<TD>
<P>-6 [-104, 45]</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>50.00%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT (Fixed)</P>
</TD>
<TD>
<P>38 [-32, 71]</P>
</TD>
<TD>
<P>P = 0.22</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.56</P>
</TD>
<TD>
<P>40 [-25, 71]</P>
</TD>
<TD>
<P>P = 0.17</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.73</P>
</TD>
<TD>
<P>5.26%</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>78 [29, 93]</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>P = 0.11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>69 [21, 88]</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>80 [60, 90]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>50%</P>
</TD>
<TD>
<P>P = 0.11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, all serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>59 [40, 73]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>32 [-132, 80]</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.87</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>40 [-387, 93]</P>
</TD>
<TD>
<P>P = 0.63</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>X-ray defined pneumonia</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Random)</P>
</TD>
<TD>
<P>19 [10, 28]</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.53</P>
</TD>
<TD>
<P>25 [12, 36]</P>
</TD>
<TD>
<P>P = 0.0004</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>31.58%</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P>19 [10, 28]</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P> 0%</P>
</TD>
<TD>
<P>P = 0.53</P>
</TD>
<TD>
<P>26 [19, 32]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>36.84%</P>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.40</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>X-ray defined pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>35 [26, 42]</P>
</TD>
<TD>
<P>P &lt; 0.00001</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.40</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Clinical pneumonia</B> </P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [3, 9]</P>
</TD>
<TD>
<P>P = 0.0006</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, ITT (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [3, 9]</P>
</TD>
<TD>
<P>P &lt; 0.0001</P>
</TD>
<TD>
<P>18%</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [3, 10]</P>
</TD>
<TD>
<P>P = 0.001</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>P = 0.34</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Clinical pneumonia, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [3, 10]</P>
</TD>
<TD>
<P>P = 0.0004</P>
</TD>
<TD>
<P>11%</P>
</TD>
<TD>
<P>P = 0.34</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>All-cause admissions</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>5 [-10, 17]</P>
</TD>
<TD>
<P>P = 0.50</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, ITT (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>4 [-1, 9]</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>P = 0.006</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [-8, 19]</P>
</TD>
<TD>
<P>P = 0.38</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause admissions, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>6 [0, 11]</P>
</TD>
<TD>
<P>P = 0.04</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>P = 0.010</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>All-cause mortality</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>11 [-1, 21]</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.98</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>9 [-1, 19]</P>
</TD>
<TD>
<P>P = 0.07</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.97</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Random)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, PP (Fixed)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>14 [0, 26]</P>
</TD>
<TD>
<P>P = 0.05</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Empty cells for particular outcomes in the 2004 review means that data were not available at that time or the results of only one study was available</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-22" MODIFIED="2009-07-08 17:54:50 +1000" MODIFIED_BY="[Empty name]" NO="22">
<TITLE MODIFIED="2009-05-29 20:17:24 +1000" MODIFIED_BY="[Empty name]">Results from analysis using three types of continuity corrections by outcome for publications with zero events in either treatment or control arms</TITLE>
<TABLE COLS="9" ROWS="18">
<TR>
<TH ROWSPAN="2">
<P>Outcome</P>
</TH>
<TH ROWSPAN="2">
<P>Study</P>
</TH>
<TH ROWSPAN="2">
<P>Group</P>
</TH>
<TH ROWSPAN="2">
<P>Event</P>
</TH>
<TH ROWSPAN="2">
<P>No Event</P>
</TH>
<TH ROWSPAN="2">
<P>Total</P>
</TH>
<TH>
<P>Constant (0.5)</P>
</TH>
<TH>
<P>Treatment Arm</P>
</TH>
<TH>
<P>Empirical</P>
</TH>
</TR>
<TR>
<TH>
<P>RR (95% CI)</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>IPD, vaccine serotypes, ITT (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Eskola 2001</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD ROWSPAN="2">
<P>0.17 (0.01, 4.09)</P>
</TD>
<TD ROWSPAN="2">
<P>0.10 (0, 4.14)</P>
</TD>
<TD ROWSPAN="2">
<P>0.03 (0, 15.25)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>414.5</P>
</TD>
<TD>
<P>415.5</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Kilpi 2003</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD ROWSPAN="2">
<P>0.17 (0.01, 4.07)</P>
</TD>
<TD ROWSPAN="2">
<P>0.10 (0, 4.12)</P>
</TD>
<TD ROWSPAN="2">
<P>0.03 (0, 15.17)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>414.5</P>
</TD>
<TD>
<P>415.5</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>IPD, non-vaccine serotypes, ITT (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Lucero 2009</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.18)</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.18)</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.18)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>6093</P>
</TD>
<TD>
<P>6094</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>IPD, non-vaccine serotypes, PP (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Lucero 2009</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.19)</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.19)</P>
</TD>
<TD ROWSPAN="2">
<P>0.28 (0.01, 8.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>6017</P>
</TD>
<TD>
<P>6018</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>IPD, vaccine-related serotypes, ITT (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Lucero 2009</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD>
<P>6097</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.18)</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.18)</P>
</TD>
<TD ROWSPAN="2">
<P>0.35 (0.01, 8.27)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>6093</P>
</TD>
<TD>
<P>6094</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>IPD, vaccine-related serotypes, PP (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Lucero 2009</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD>
<P>6013</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.19)</P>
</TD>
<TD ROWSPAN="2">
<P>0.33 (0.01, 8.19)</P>
</TD>
<TD ROWSPAN="2">
<P>0.32 (0.01, 8.11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>6017</P>
</TD>
<TD>
<P>6018</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>All-cause mortality, ITT (Random)</P>
</TD>
<TD ROWSPAN="2">
<P>Eskola 2001</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>830</P>
</TD>
<TD>
<P>831</P>
</TD>
<TD ROWSPAN="2">
<P>1.50 (0.06, 36.79)</P>
</TD>
<TD ROWSPAN="2">
<P>0.99 (0.05, 18.71)</P>
</TD>
<TD ROWSPAN="2">
<P>0.95 (0.05, 17.52)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>415.5</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Kilpi 2003</P>
</TD>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>834</P>
</TD>
<TD>
<P>835</P>
</TD>
<TD ROWSPAN="2">
<P>1.49 (0.06, 36.61)</P>
</TD>
<TD ROWSPAN="2">
<P>0.99 (0.05, 18.62)</P>
</TD>
<TD ROWSPAN="2">
<P>0.95 (0.05, 17.44)</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>415.5</P>
</TD>
<TD>
<P>415.5</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-23" MODIFIED="2009-07-02 18:34:45 +1000" MODIFIED_BY="[Empty name]" NO="23">
<TITLE MODIFIED="2009-05-29 20:20:30 +1000" MODIFIED_BY="[Empty name]">Comparison of results of pooled estimates (RR) using the three types of continuity correction</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Constant (0.5)</P>
</TH>
<TH>
<P>Treatment Arm</P>
</TH>
<TH>
<P>Emprical</P>
</TH>
</TR>
<TR>
<TD>
<P>IPD, vaccine serotypes, ITT</P>
</TD>
<TD>
<P>0.20 [0.10, 0.42]</P>
</TD>
<TD>
<P>0.20 [0.09, 0.42]</P>
</TD>
<TD>
<P>0.21 [0.09, 0.52]*</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, ITT</P>
</TD>
<TD>
<P>0.92 [0.39, 2.17]</P>
</TD>
<TD>
<P>0.92 [0.39, 2.17]</P>
</TD>
<TD>
<P>0.92 [0.39, 2.17]</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, non-vaccine serotypes, PP</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>0.68 [0.20, 2.32]</P>
</TD>
<TD>
<P>0.68 [0.20, 2.31]</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, ITT</P>
</TD>
<TD>
<P>0.89 [0.24, 3.36]</P>
</TD>
<TD>
<P>0.89 [0.24, 3.36]</P>
</TD>
<TD>
<P>0.90 [0.24, 3.36]</P>
</TD>
</TR>
<TR>
<TD>
<P>IPD, vaccine-related serotypes, PP</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>0.60 [0.07, 4.87]</P>
</TD>
<TD>
<P>0.59 [0.07, 4.85]</P>
</TD>
</TR>
<TR>
<TD>
<P>All-cause mortality, ITT</P>
</TD>
<TD>
<P>0.89 [0.79, 1.01]</P>
</TD>
<TD>
<P>0.89 [0.79, 1.01]</P>
</TD>
<TD>
<P>0.89 [0.79, 1.01]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Without Kilpi 2003 and Eskola 2001</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-08 18:15:20 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-08 18:15:20 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Children &lt; 24 months and/or HIV-1 negative children</NAME>
<IV_OUTCOME CHI2="9.069656900002478" CI_END="0.4177694169205877" CI_START="0.09715013355533955" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.20146055358102097" ESTIMABLE="YES" I2="33.84534755666049" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.379063355999505" LOG_CI_START="-1.0125565980255251" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6958099770125151" MODIFIED="2009-07-03 12:30:35 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16969842502227295" P_Q="1.0" P_Z="1.665854236201061E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.3017777465987638" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="4.305531312904384">
<NAME>IPD, vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 15:31:17 +1000" MODIFIED_BY="[Empty name]" ORDER="3042" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="18.58504525282257"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 12:28:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3045" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="4.674501200675634">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 12:30:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3040" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="4.668329722793442">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7664669694602914" CI_START="0.03770221904235076" EFFECT_SIZE="0.16999266328673915" ESTIMABLE="YES" ESTIMATE="-1.7719999999999998" LOG_CI_END="-0.11550655612626679" LOG_CI_START="-1.4236330877388574" LOG_EFFECT_SIZE="-0.7695698219325622" MODIFIED="2009-05-27 15:33:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3041" SE="0.7684000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="15.519903630911129"/>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 15:33:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3039" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="15.578853549958891"/>
<IV_DATA CI_END="0.4843184202762225" CI_START="0.12162809344053996" EFFECT_SIZE="0.24270707875200323" ESTIMABLE="YES" ESTIMATE="-1.4159" LOG_CI_END="-0.31486901294357755" LOG_CI_START="-0.9149661009100509" LOG_EFFECT_SIZE="-0.6149175569268143" MODIFIED="2009-07-03 12:30:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3044" SE="0.3525" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="32.502361799500704">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 18:46:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3043" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="8.471004843337623"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.776359576364682" CI_END="0.7133134716049705" CI_START="0.2479534215243955" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.42055738717076074" ESTIMABLE="YES" I2="49.050468770993675" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.1467195738365252" LOG_CI_START="-0.6056298944754634" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.37617473415599434" MODIFIED="2009-07-03 12:31:00 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06714807370976028" P_Q="1.0" P_Z="0.0013125765884217486" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2101884835166026" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.00000000000001" Z="3.2132157316190013">
<NAME>IPD, all serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-29 20:51:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3037" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="16.819669886563364"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 12:30:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3034" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.8796573451859806">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 12:30:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3038" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.87858914829377">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 15:36:40 +1000" MODIFIED_BY="[Empty name]" ORDER="3032" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="19.305109525564063"/>
<IV_DATA CI_END="0.8492180263380804" CI_START="0.38275480981497956" EFFECT_SIZE="0.5701247970071853" ESTIMABLE="YES" ESTIMATE="-0.5619" LOG_CI_END="-0.07098079564585699" LOG_CI_START="-0.41707934311701733" LOG_EFFECT_SIZE="-0.24403006938143712" MODIFIED="2009-07-03 12:31:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3035" SE="0.20329999999999998" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="28.890789573837992">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.3123520639622117" CI_START="0.25634758642305827" EFFECT_SIZE="0.5800157619703381" ESTIMABLE="YES" ESTIMATE="-0.5447" LOG_CI_END="0.11805035861060773" LOG_CI_START="-0.5911707671960101" LOG_EFFECT_SIZE="-0.23656020429270125" MODIFIED="2009-05-27 15:37:07 +1000" MODIFIED_BY="[Empty name]" ORDER="3033" SE="0.41659999999999997" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.93604191851733"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-06-01 23:31:08 +1000" MODIFIED_BY="[Empty name]" ORDER="3036" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="8.29014260203751"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.3829195869170088" CI_END="2.1725969307098896" CI_START="0.38591886849240764" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.9156670514928656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3369791616607953" LOG_CI_START="-0.41350398721816717" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03826241277868596" MODIFIED="2009-07-03 12:31:23 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9261725430128892" P_Q="1.0" P_Z="0.8415959733565882" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48297" TOTAL_2="47311" WEIGHT="100.0" Z="0.19985245803280366">
<NAME>IPD, non-vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 15:37:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3050" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="7.29296152134779"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 15:38:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3051" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="23.324150311729632"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 15:38:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3047" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="48.63909814150943"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 12:31:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3046" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="6.4887896492346036">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 12:31:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3048" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="6.4850418284508775">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 15:39:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3049" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="7.769958547727675"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.3793558380094493" CI_END="3.355408248146125" CI_START="0.23764749775303254" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.8929750131508795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5257453677630577" LOG_CI_START="-0.6240667541349346" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04916069318593838" MODIFIED="2009-07-02 18:40:11 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4974892723319755" P_Q="1.0" P_Z="0.8668994324297268" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46631" TOTAL_2="46479" WEIGHT="100.0" Z="0.16759814279990878">
<NAME>IPD, vaccine-related serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 15:40:29 +1000" MODIFIED_BY="[Empty name]" ORDER="3055" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="34.2188857281767"/>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 15:40:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3052" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.238561304595844"/>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 15:40:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3053" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="17.118897736984703"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 15:40:40 +1000" MODIFIED_BY="[Empty name]" ORDER="3054" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="30.423655230242755"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="17.609494128622362" CI_END="0.9956185918588822" CI_START="0.6568409257675055" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8086798115372538" ESTIMABLE="YES" I2="77.28498064292248" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.0019070021133323024" LOG_CI_START="-0.18253979547255764" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09222339879294501" MODIFIED="2009-07-08 18:15:20 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0014709054614273631" P_Q="1.0" P_Z="0.04535489997190804" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04098189219037392" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="2.0013480033670237">
<NAME>X-ray defined pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7361904731975046" CI_START="0.567035367095218" EFFECT_SIZE="0.6461006386171966" ESTIMABLE="YES" ESTIMATE="-0.4368" LOG_CI_END="-0.133009806917231" LOG_CI_START="-0.2463898524734498" LOG_EFFECT_SIZE="-0.18969982969534038" MODIFIED="2009-07-08 18:15:19 +1000" MODIFIED_BY="[Empty name]" ORDER="3057" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="24.788236579449176">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-07-08 18:15:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3059" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="12.916110011595404">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.982267336595287" CI_START="0.6516105384595232" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.007770297338020087" LOG_CI_START="-0.1860119004872109" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2009-05-27 15:42:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3058" SE="0.1047" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="21.673705061824155"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 15:42:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3056" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="19.91471917506037"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-07-08 18:15:20 +1000" MODIFIED_BY="[Empty name]" ORDER="1079" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="20.707229172070903"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.7818007563116818" CI_END="0.9752549459359832" CI_START="0.9132479348527345" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9437423193493825" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.01088183851705938" LOG_CI_START="-0.039411301194420545" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.025146569855739972" MODIFIED="2009-07-03 12:31:55 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4265046966482998" P_Q="1.0" P_Z="5.500461327124723E-4" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.455120890943441">
<NAME>Clinical pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0077886986967415" CI_START="0.8581653148818031" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.0033694838856330425" LOG_CI_START="-0.06642904265798516" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-27 16:15:01 +1000" MODIFIED_BY="[Empty name]" ORDER="3062" SE="0.040999999999999995" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="16.706853912892132"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 16:15:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3396" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="19.34694678844295"/>
<IV_DATA CI_END="0.9792572876694232" CI_START="0.891331260414753" EFFECT_SIZE="0.9342604735772135" ESTIMABLE="YES" ESTIMATE="-0.068" LOG_CI_END="-0.009103187732264605" LOG_CI_START="-0.04996086180657764" LOG_EFFECT_SIZE="-0.029532024769421125" MODIFIED="2009-07-03 12:31:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3063" SE="0.024" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="48.75732886731193">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 16:15:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3060" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="15.188870431352987"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.675281316602188" CI_END="1.0978345601285273" CI_START="0.8272269849315297" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9529734377876196" ESTIMABLE="YES" I2="86.97116159329656" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.040536898368407966" LOG_CI_START="-0.08237530691973292" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.020919204275662427" MODIFIED="2009-07-03 12:32:03 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.005598248499378178" P_Q="1.0" P_Z="0.5046716726265177" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.009067335000000001" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="0.6671572911643245">
<NAME>All-cause admissions, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9538953108787704" CI_START="0.823494301353758" EFFECT_SIZE="0.8862998096562691" ESTIMABLE="YES" ESTIMATE="-0.1207" LOG_CI_END="-0.02049928609516539" LOG_CI_START="-0.08433940183627958" LOG_EFFECT_SIZE="-0.052419343965722495" MODIFIED="2009-07-03 12:32:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3065" SE="0.0375" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="49.770254793931905">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 16:16:17 +1000" MODIFIED_BY="[Empty name]" ORDER="3064" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="50.229745206068095"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4556362794746429" CI_END="1.0137976297055973" CI_START="0.7871454250905536" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8933119086805057" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.00595127149284461" LOG_CI_START="-0.1039450243374506" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04899687642230297" MODIFIED="2009-07-03 12:32:30 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9776735966997816" P_Q="1.0" P_Z="0.08051840078424807" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.00000000000001" Z="1.7476860783546153">
<NAME>All-cause mortality, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 16:16:48 +1000" MODIFIED_BY="[Empty name]" ORDER="3066" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.640883358096529"/>
<IV_DATA CI_END="1.0135970971511672" CI_START="0.7709702548524879" EFFECT_SIZE="0.8839984232499385" ESTIMABLE="YES" ESTIMATE="-0.1233" LOG_CI_END="0.005865358097725951" LOG_CI_START="-0.11296237733506795" LOG_EFFECT_SIZE="-0.05354850961867098" MODIFIED="2009-07-03 12:32:17 +1000" MODIFIED_BY="[Empty name]" ORDER="3069" SE="0.0698" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="85.53236240699927">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.585930844210166" CI_START="0.630040284267446" EFFECT_SIZE="0.9996000799893344" ESTIMABLE="YES" ESTIMATE="-4.0E-4" LOG_CI_END="0.20028424563433728" LOG_CI_START="-0.20063168121985994" LOG_EFFECT_SIZE="-1.7371779276129093E-4" MODIFIED="2009-05-27 16:17:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3068" SE="0.23550000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="7.513797556653579"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 12:32:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3070" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.15647833912531534">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 12:32:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3067" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.15647833912531534">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.069656900002478" CI_END="0.33628467220379465" CI_START="0.12305016391987635" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.20342046120884402" ESTIMABLE="YES" I2="33.84534755666049" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.47329292730034145" LOG_CI_START="-0.9099178034203388" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6916053653603401" MODIFIED="2009-07-03 13:01:31 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.16969842502227295" P_Q="1.0" P_Z="5.329224782258555E-10" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="99.99999999999999" Z="6.209090144687017">
<NAME>IPD, vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 16:18:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3002" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="14.838997895694154"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 12:32:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3001" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="2.4724697079611286">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:01:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3003" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="2.4688357276210304">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7664669694602914" CI_START="0.03770221904235076" EFFECT_SIZE="0.16999266328673915" ESTIMABLE="YES" ESTIMATE="-1.7719999999999998" LOG_CI_END="-0.11550655612626679" LOG_CI_START="-1.4236330877388574" LOG_EFFECT_SIZE="-0.7695698219325622" MODIFIED="2009-05-27 16:18:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3004" SE="0.7684000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="11.140827311724044"/>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 16:18:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3006" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="11.204896765568954"/>
<IV_DATA CI_END="0.4843184202762225" CI_START="0.12162809344053996" EFFECT_SIZE="0.24270707875200323" ESTIMABLE="YES" ESTIMATE="-1.4159" LOG_CI_END="-0.31486901294357755" LOG_CI_START="-0.9149661009100509" LOG_EFFECT_SIZE="-0.6149175569268143" MODIFIED="2009-07-03 13:01:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3005" SE="0.3525" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="52.93877801030547">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 16:18:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3000" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.935194581125219"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.77635957636468" CI_END="0.6350961904630033" CI_START="0.34976731063139216" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.47131293906542293" ESTIMABLE="YES" I2="49.050468770993675" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.1971604923087264" LOG_CI_START="-0.4562207822667248" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.3266906372877256" MODIFIED="2009-07-03 13:01:46 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.06714807370976017" P_Q="1.0" P_Z="7.682478694719533E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="99.99999999999999" Z="4.943265394122679">
<NAME>IPD, all serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 16:19:45 +1000" MODIFIED_BY="[Empty name]" ORDER="2993" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.438427624126426"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:01:38 +1000" MODIFIED_BY="[Empty name]" ORDER="2995" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.392625059031138">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:01:42 +1000" MODIFIED_BY="[Empty name]" ORDER="2994" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.392193170350518">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 16:19:45 +1000" MODIFIED_BY="[Empty name]" ORDER="2998" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="13.931422896607433"/>
<IV_DATA CI_END="0.8492180263380804" CI_START="0.38275480981497956" EFFECT_SIZE="0.5701247970071853" ESTIMABLE="YES" ESTIMATE="-0.5619" LOG_CI_END="-0.07098079564585699" LOG_CI_START="-0.41707934311701733" LOG_EFFECT_SIZE="-0.24403006938143712" MODIFIED="2009-07-03 13:01:46 +1000" MODIFIED_BY="[Empty name]" ORDER="2997" SE="0.20329999999999998" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="56.02761572673202">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.3123520639622117" CI_START="0.25634758642305827" EFFECT_SIZE="0.5800157619703381" ESTIMABLE="YES" ESTIMATE="-0.5447" LOG_CI_END="0.11805035861060773" LOG_CI_START="-0.5911707671960101" LOG_EFFECT_SIZE="-0.23656020429270125" MODIFIED="2009-05-27 16:19:45 +1000" MODIFIED_BY="[Empty name]" ORDER="2999" SE="0.41659999999999997" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="13.342535511762524"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 16:19:45 +1000" MODIFIED_BY="[Empty name]" ORDER="2996" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.475180011389931"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.3829195869170086" CI_END="2.1725969307098896" CI_START="0.38591886849240764" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.9156670514928656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.3369791616607953" LOG_CI_START="-0.41350398721816717" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03826241277868596" MODIFIED="2009-07-03 13:01:57 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9261725430128892" P_Q="1.0" P_Z="0.8415959733565882" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48297" TOTAL_2="47311" WEIGHT="100.0" Z="0.19985245803280366">
<NAME>IPD, non-vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 16:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3007" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="7.29296152134779"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 16:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3009" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="23.324150311729632"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 16:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3010" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="48.63909814150943"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:01:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3008" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="6.4887896492346036">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:01:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3011" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="6.4850418284508775">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 16:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3012" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="7.769958547727675"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.3793558380094493" CI_END="3.355408248146125" CI_START="0.23764749775303265" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.8929750131508795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.5257453677630577" LOG_CI_START="-0.6240667541349344" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04916069318593838" MODIFIED="2009-07-02 18:45:04 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.4974892723319755" P_Q="1.0" P_Z="0.8668994324297269" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46631" TOTAL_2="46479" WEIGHT="100.0" Z="0.16759814279990876">
<NAME>IPD, vaccine-related serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 16:21:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3016" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="17.1188977369847"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 16:21:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3015" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="34.218885728176694"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 16:21:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3014" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="30.42365523024275"/>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 16:21:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3013" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.23856130459584"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="17.60949412862236" CI_END="0.8341397620730222" CI_START="0.6971379922040692" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7625683700162017" ESTIMABLE="YES" I2="77.28498064292248" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.07876117620666011" LOG_CI_START="-0.15668124870091038" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11772121245378525" MODIFIED="2009-07-03 13:02:07 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.00147090546142703" P_Q="1.0" P_Z="3.176525409431141E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.00000000000001" Z="5.922205389191149">
<NAME>X-ray defined pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7361904731975046" CI_START="0.567035367095218" EFFECT_SIZE="0.6461006386171966" ESTIMABLE="YES" ESTIMATE="-0.4368" LOG_CI_END="-0.133009806917231" LOG_CI_START="-0.2463898524734498" LOG_EFFECT_SIZE="-0.18969982969534038" MODIFIED="2009-07-03 13:02:07 +1000" MODIFIED_BY="[Empty name]" ORDER="3017" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="47.23081520102007">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:14:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3020" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="4.536292696507507">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.982267336595287" CI_START="0.6516105384595232" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.007770297338020087" LOG_CI_START="-0.1860119004872109" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2009-05-27 16:29:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3018" SE="0.1047" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="19.110873444118464"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 16:29:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3019" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="13.472276666761196"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:08:24 +1000" MODIFIED_BY="[Empty name]" ORDER="1080" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="15.649741991592764"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.7818007563116818" CI_END="0.9752549459359832" CI_START="0.9132479348527345" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9437423193493825" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.01088183851705938" LOG_CI_START="-0.039411301194420545" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.025146569855739972" MODIFIED="2009-07-03 13:02:16 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4265046966482998" P_Q="1.0" P_Z="5.500461327124723E-4" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.455120890943441">
<NAME>Clinical pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0077886986967415" CI_START="0.8581653148818031" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.0033694838856330425" LOG_CI_START="-0.06642904265798516" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-27 16:46:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3022" SE="0.040999999999999995" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="16.706853912892132"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 16:46:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3395" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="19.34694678844295"/>
<IV_DATA CI_END="0.9792572876694232" CI_START="0.891331260414753" EFFECT_SIZE="0.9342604735772135" ESTIMABLE="YES" ESTIMATE="-0.068" LOG_CI_END="-0.009103187732264605" LOG_CI_START="-0.04996086180657764" LOG_EFFECT_SIZE="-0.029532024769421125" MODIFIED="2009-07-03 13:02:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3021" SE="0.024" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="48.75732886731193">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 16:46:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3023" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="15.188870431352987"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.675281316602188" CI_END="1.005106007312859" CI_START="0.9075556115131225" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9550861726055585" ESTIMABLE="YES" I2="86.97116159329656" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.0022118686849893223" LOG_CI_START="-0.04212675358297887" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.019957442448994785" MODIFIED="2009-07-03 13:02:26 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.005598248499378178" P_Q="1.0" P_Z="0.07766210938107829" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="1.764415149715616">
<NAME>All-cause admissions, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9538953108787704" CI_START="0.823494301353758" EFFECT_SIZE="0.8862998096562691" ESTIMABLE="YES" ESTIMATE="-0.1207" LOG_CI_END="-0.02049928609516539" LOG_CI_START="-0.08433940183627958" LOG_EFFECT_SIZE="-0.052419343965722495" MODIFIED="2009-07-03 13:02:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3025" SE="0.0375" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="48.236640912286646">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 16:47:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3026" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="51.763359087713354"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4556362794746429" CI_END="1.0137976297055973" CI_START="0.7871454250905536" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8933119086805057" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.00595127149284461" LOG_CI_START="-0.1039450243374506" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04899687642230297" MODIFIED="2009-07-03 13:02:42 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9776735966997816" P_Q="1.0" P_Z="0.08051840078424807" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.00000000000001" Z="1.7476860783546153">
<NAME>All-cause mortality, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 16:47:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3028" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.640883358096529"/>
<IV_DATA CI_END="1.0135970971511672" CI_START="0.7709702548524879" EFFECT_SIZE="0.8839984232499385" ESTIMABLE="YES" ESTIMATE="-0.1233" LOG_CI_END="0.005865358097725951" LOG_CI_START="-0.11296237733506795" LOG_EFFECT_SIZE="-0.05354850961867098" MODIFIED="2009-07-03 13:02:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3030" SE="0.0698" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="85.53236240699927">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.585930844210166" CI_START="0.630040284267446" EFFECT_SIZE="0.9996000799893344" ESTIMABLE="YES" ESTIMATE="-4.0E-4" LOG_CI_END="0.20028424563433728" LOG_CI_START="-0.20063168121985994" LOG_EFFECT_SIZE="-1.7371779276129093E-4" MODIFIED="2009-05-27 16:47:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3031" SE="0.23550000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="7.513797556653579"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:02:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3029" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.15647833912531534">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:02:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3027" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.15647833912531534">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.1045992644470255" CI_END="0.49325187220266337" CI_START="0.08040982978601383" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.19915395824700247" ESTIMABLE="YES" I2="34.47563342452532" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.3069312576505454" LOG_CI_START="-1.0946908572107792" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.7008110574306623" MODIFIED="2009-07-03 13:02:50 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.19147188649683478" P_Q="1.0" P_Z="4.879820444037713E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.36220180036777333" TOTALS="YES" TOTAL_1="47579" TOTAL_2="47371" WEIGHT="100.0" Z="3.487268027703683">
<NAME>IPD, vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 16:48:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3101" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="10.24326522269184"/>
<IV_DATA CI_END="0.8746631838195954" CI_START="0.025725216007809762" EFFECT_SIZE="0.15000299776283707" ESTIMABLE="YES" ESTIMATE="-1.8971" LOG_CI_END="-0.05815915334257466" LOG_CI_START="-1.5896409698947433" LOG_EFFECT_SIZE="-0.823900061618659" MODIFIED="2009-05-27 16:48:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3100" SE="0.8996" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="18.277929885662864"/>
<IV_DATA CI_END="0.43053616828498253" CI_START="0.07591992929760324" EFFECT_SIZE="0.18079346076740963" ESTIMABLE="YES" ESTIMATE="-1.7104" LOG_CI_END="-0.36599035866610513" LOG_CI_START="-1.1196442050285387" LOG_EFFECT_SIZE="-0.7428172818473219" MODIFIED="2009-07-03 13:02:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3098" SE="0.44270000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="38.36051070409829">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 16:48:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3102" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="21.62983771687481"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 16:48:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3099" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="11.488456470672206"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.88145013195652" CI_END="0.7861637321185019" CI_START="0.12470534689078916" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3131115151616038" ESTIMABLE="YES" I2="69.64008359159727" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.10448699524515417" LOG_CI_START="-0.9041149252272921" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5043009602362231" MODIFIED="2009-07-03 13:02:56 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.01960123606390296" P_Q="1.0" P_Z="0.01342922268950649" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5750784528622507" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="2.472179078222149">
<NAME>IPD, all serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 16:49:09 +1000" MODIFIED_BY="[Empty name]" ORDER="1041" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="23.66986242185094"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 16:49:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3095" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="25.723339149121703"/>
<IV_DATA CI_END="0.8306784044596943" CI_START="0.3272969413134059" EFFECT_SIZE="0.521419697551558" ESTIMABLE="YES" ESTIMATE="-0.6512" LOG_CI_END="-0.0805670799475478" LOG_CI_START="-0.48505805328324736" LOG_EFFECT_SIZE="-0.2828125666153976" MODIFIED="2009-07-03 13:02:56 +1000" MODIFIED_BY="[Empty name]" ORDER="3096" SE="0.2376" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="34.934586443769426">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 16:49:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3097" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="15.67221198525794"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.28795226665982154" CI_END="2.322357750826509" CI_START="0.2019643278037138" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.684860147815173" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.3659291220529434" LOG_CI_START="-0.694725331573632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16439810476034425" MODIFIED="2009-07-02 18:49:22 +1000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.8659084250996915" P_Q="1.0" P_Z="0.5434683888985625" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22034" TOTAL_2="21870" WEIGHT="100.0" Z="0.6075765077970616">
<NAME>IPD, non-vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 16:50:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3104" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="14.561638936598035"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 16:50:45 +1000" MODIFIED_BY="[Empty name]" ORDER="1042" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="46.59796412996252"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 16:50:45 +1000" MODIFIED_BY="[Empty name]" ORDER="3103" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="38.84039693343944"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.22472616261143383" CI_END="4.865741064929072" CI_START="0.0737056216968501" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.5988593075226357" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.6871489938129258" LOG_CI_START="-1.1324993862412167" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22267519621414542" MODIFIED="2009-07-03 10:48:48 +1000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.635462195530701" P_Q="1.0" P_Z="0.6314464349583269" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8485" TOTAL_2="8301" WEIGHT="99.99999999999999" Z="0.47969197743261693">
<NAME>IPD, vaccine-related serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 16:51:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3106" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="42.85853964080626"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 16:51:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3105" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="57.14146035919372"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.508379380654517" CI_END="0.940727671066982" CI_START="0.6097634228952891" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7573779272741691" ESTIMABLE="YES" I2="74.20749195115974" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-0.02653608121695549" LOG_CI_START="-0.21483863066131398" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12068735593913471" MODIFIED="2009-07-03 13:03:12 +1000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.003755051902279094" P_Q="1.0" P_Z="0.011992316132078885" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.042552008732479794" TOTALS="YES" TOTAL_1="39664" TOTAL_2="39396" WEIGHT="100.0" Z="2.5123703500357153">
<NAME>X-ray defined pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:15:11 +1000" MODIFIED_BY="[Empty name]" ORDER="3110" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="12.093717330927914">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7260861576753392" CI_START="0.5473245073001173" EFFECT_SIZE="0.6304004667725829" ESTIMABLE="YES" ESTIMATE="-0.46140000000000003" LOG_CI_END="-0.13901184268436928" LOG_CI_START="-0.26175510521595147" LOG_EFFECT_SIZE="-0.20038347395016035" MODIFIED="2009-07-03 13:03:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3108" SE="0.0721" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="25.62184618636752">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9566932487621087" CI_START="0.5879416757645449" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.019227290776280433" LOG_CI_START="-0.23066575411085066" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2009-05-27 16:51:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3107" SE="0.1242" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="21.102164555577186"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 16:51:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3109" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="19.835858117453306"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 15:11:14 +1000" MODIFIED_BY="[Empty name]" ORDER="537" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="21.346413809674075"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.4104885083727905" CI_END="0.9760932595105632" CI_START="0.9052104893180535" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9399839663853904" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-0.010508686271932936" LOG_CI_START="-0.04325042220896191" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02687955424044742" MODIFIED="2009-07-03 13:03:22 +1000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.49168537611556207" P_Q="1.0" P_Z="0.0012904644661638428" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="99.99999999999999" Z="3.2180919382583206">
<NAME>Clinical pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0100199508526517" CI_START="0.8199023067119334" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="0.004329952455553735" LOG_CI_START="-0.08623789174250697" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 16:52:01 +1000" MODIFIED_BY="[Empty name]" ORDER="3112" SE="0.053200000000000004" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="13.0693907461007"/>
<IV_DATA CI_END="0.9767027067465047" CI_START="0.8793018534006116" EFFECT_SIZE="0.9267235295726528" ESTIMABLE="YES" ESTIMATE="-0.0761" LOG_CI_END="-0.010237608714679334" LOG_CI_START="-0.055862011430995576" LOG_EFFECT_SIZE="-0.03304981007283749" MODIFIED="2009-07-03 13:03:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3111" SE="0.0268" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="51.50021227618072">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 16:52:01 +1000" MODIFIED_BY="[Empty name]" ORDER="3398" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="18.025287616646466"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 16:52:01 +1000" MODIFIED_BY="[Empty name]" ORDER="3114" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="17.405109361072103"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.650487778898627" CI_END="1.0818933798552024" CI_START="0.8131645164294696" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9379537872721663" ESTIMABLE="YES" I2="84.96350894481897" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.03418446333791012" LOG_CI_START="-0.08982158066742262" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02781855866475625" MODIFIED="2009-07-03 13:03:32 +1000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.009912907854337516" P_Q="1.0" P_Z="0.3792026636340208" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.009018235000000001" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="0.8793663812449681">
<NAME>All-cause admissions, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9456549629732606" CI_START="0.8024205026909985" EFFECT_SIZE="0.8710986917457983" ESTIMABLE="YES" ESTIMATE="-0.138" LOG_CI_END="-0.0242672938419463" LOG_CI_START="-0.09559798316335125" LOG_EFFECT_SIZE="-0.05993263850264875" MODIFIED="2009-07-03 13:03:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3115" SE="0.04190000000000001" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="49.24818015789159">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 16:52:13 +1000" MODIFIED_BY="[Empty name]" ORDER="3116" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="50.75181984210842"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.004599041390249462" CI_END="0.9989043381149315" CI_START="0.7396199751715565" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8595403432971169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="-4.7610078111165027E-4" LOG_CI_START="-0.13099136821373636" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06573373449742403" MODIFIED="2009-07-03 13:03:38 +1000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9459319218956488" P_Q="1.0" P_Z="0.048351810088496795" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="1.97426331368899">
<NAME>All-cause mortality, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0045916136575244" CI_START="0.7330208708144181" EFFECT_SIZE="0.8581297218113938" ESTIMABLE="YES" ESTIMATE="-0.153" LOG_CI_END="0.0019895483432768716" LOG_CI_START="-0.134883659805672" LOG_EFFECT_SIZE="-0.06644705573119752" MODIFIED="2009-07-03 13:03:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3117" SE="0.08039999999999999" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="90.92550917456886">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 16:52:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3118" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.074490825431132"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.1045992644470255" CI_END="0.3703046352405962" CI_START="0.10152022911108352" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.19389020452442032" ESTIMABLE="YES" I2="34.47563342452532" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="-0.43144085169127017" LOG_CI_START="-0.993447410795473" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.7124441312433716" MODIFIED="2009-07-03 13:03:44 +1000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.19147188649683478" P_Q="1.0" P_Z="6.722557625959203E-7" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47579" TOTAL_2="47371" WEIGHT="100.0" Z="4.969211891262048">
<NAME>Invasive Disease, Vaccine Serotype PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 16:53:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3077" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="6.306243218051282"/>
<IV_DATA CI_END="0.8746631838195954" CI_START="0.025725216007809762" EFFECT_SIZE="0.15000299776283707" ESTIMABLE="YES" ESTIMATE="-1.8971" LOG_CI_END="-0.05815915334257466" LOG_CI_START="-1.5896409698947433" LOG_EFFECT_SIZE="-0.823900061618659" MODIFIED="2009-05-27 16:53:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3078" SE="0.8996" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="13.466634681700654"/>
<IV_DATA CI_END="0.43053616828498253" CI_START="0.07591992929760324" EFFECT_SIZE="0.18079346076740963" ESTIMABLE="YES" ESTIMATE="-1.7104" LOG_CI_END="-0.36599035866610513" LOG_CI_START="-1.1196442050285387" LOG_EFFECT_SIZE="-0.7428172818473219" MODIFIED="2009-07-03 13:03:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3074" SE="0.44270000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="55.60821164839233">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 16:53:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3076" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="17.361156842466006"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 16:53:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3075" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="7.257753609389736"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.881450131956521" CI_END="0.5991644207893846" CI_START="0.27465254799104893" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.40566246416865526" ESTIMABLE="YES" I2="69.64008359159729" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="-0.22245398354892357" LOG_CI_START="-0.5612163676117847" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.39183517558035413" MODIFIED="2009-07-03 13:03:50 +1000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.01960123606390296" P_Q="1.0" P_Z="5.786326014403486E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.00000000000001" Z="4.534050226018687">
<NAME>IPD, all serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 16:53:21 +1000" MODIFIED_BY="[Empty name]" ORDER="1043" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="11.091486270510755"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 16:53:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3073" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.011854555669114"/>
<IV_DATA CI_END="0.8306784044596943" CI_START="0.3272969413134059" EFFECT_SIZE="0.521419697551558" ESTIMABLE="YES" ESTIMATE="-0.6512" LOG_CI_END="-0.0805670799475478" LOG_CI_START="-0.48505805328324736" LOG_EFFECT_SIZE="-0.2828125666153976" MODIFIED="2009-07-03 13:03:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3072" SE="0.2376" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="70.14111939331464">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 16:53:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3071" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="4.755539780505497"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.28795226665982154" CI_END="2.322357750826509" CI_START="0.2019643278037138" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.684860147815173" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.3659291220529434" LOG_CI_START="-0.694725331573632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16439810476034425" MODIFIED="2009-07-02 18:49:30 +1000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.8659084250996915" P_Q="1.0" P_Z="0.5434683888985625" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22034" TOTAL_2="21870" WEIGHT="100.0" Z="0.6075765077970616">
<NAME>IPD, non-vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 16:53:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3080" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="14.561638936598035"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 16:53:41 +1000" MODIFIED_BY="[Empty name]" ORDER="1044" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="46.59796412996252"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 16:53:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3079" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="38.84039693343944"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.22472616261143383" CI_END="4.865741064929072" CI_START="0.0737056216968501" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.5988593075226357" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.6871489938129258" LOG_CI_START="-1.1324993862412167" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22267519621414542" MODIFIED="2009-07-03 10:49:00 +1000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.635462195530701" P_Q="1.0" P_Z="0.6314464349583269" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8485" TOTAL_2="8301" WEIGHT="99.99999999999999" Z="0.47969197743261693">
<NAME>IPD, vaccine-related serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 16:53:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3081" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="42.85853964080626"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 16:53:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3082" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="57.14146035919372"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.508379380654517" CI_END="0.8042836713361072" CI_START="0.6601971207558468" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.728687699969637" ESTIMABLE="YES" I2="74.20749195115974" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="-0.09459074830679619" LOG_CI_START="-0.1803263740417183" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.13745856117425728" MODIFIED="2009-07-03 13:04:04 +1000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.003755051902279094" P_Q="1.0" P_Z="3.2836481857906936E-10" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39664" TOTAL_2="39396" WEIGHT="100.0" Z="6.284757986165876">
<NAME>X-ray defined pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:15:25 +1000" MODIFIED_BY="[Empty name]" ORDER="3084" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="4.327212957323991">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7260861576753392" CI_START="0.5473245073001173" EFFECT_SIZE="0.6304004667725829" ESTIMABLE="YES" ESTIMATE="-0.46140000000000003" LOG_CI_END="-0.13901184268436928" LOG_CI_START="-0.26175510521595147" LOG_EFFECT_SIZE="-0.20038347395016035" MODIFIED="2009-07-03 13:04:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3085" SE="0.0721" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="48.78960682439175">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9566932487621087" CI_START="0.5879416757645449" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.019227290776280433" LOG_CI_START="-0.23066575411085066" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2009-05-27 16:54:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3086" SE="0.1242" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="16.442000462346215"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 16:54:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3083" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="13.260304211086396"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 14:11:36 +1000" MODIFIED_BY="[Empty name]" ORDER="538" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="17.180875544851652"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.4104885083727905" CI_END="0.9760932595105632" CI_START="0.9052104893180535" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9399839663853904" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="-0.010508686271932936" LOG_CI_START="-0.04325042220896191" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02687955424044742" MODIFIED="2009-07-03 13:04:10 +1000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.49168537611556207" P_Q="1.0" P_Z="0.0012904644661638376" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="100.0" Z="3.2180919382583215">
<NAME>Clinical pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0100199508526517" CI_START="0.8199023067119334" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="0.004329952455553735" LOG_CI_START="-0.08623789174250697" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 16:54:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3090" SE="0.053200000000000004" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="13.069390746100702"/>
<IV_DATA CI_END="0.9767027067465047" CI_START="0.8793018534006116" EFFECT_SIZE="0.9267235295726528" ESTIMABLE="YES" ESTIMATE="-0.0761" LOG_CI_END="-0.010237608714679334" LOG_CI_START="-0.055862011430995576" LOG_EFFECT_SIZE="-0.03304981007283749" MODIFIED="2009-07-03 13:04:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3087" SE="0.0268" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="51.500212276180726">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 16:54:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3397" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="18.02528761664647"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 16:54:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3089" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="17.405109361072107"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.650487778898627" CI_END="0.9972282635804102" CI_START="0.8931912935930496" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9437773057003105" ESTIMABLE="YES" I2="84.96350894481897" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="-0.0012054211599775147" LOG_CI_START="-0.04905551887749632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02513047001873689" MODIFIED="2009-07-03 13:04:17 +1000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.009912907854337516" P_Q="1.0" P_Z="0.03952171192843528" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.058713294257491">
<NAME>All-cause admissions, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9456549629732606" CI_START="0.8024205026909985" EFFECT_SIZE="0.8710986917457983" ESTIMABLE="YES" ESTIMATE="-0.138" LOG_CI_END="-0.0242672938419463" LOG_CI_START="-0.09559798316335125" LOG_EFFECT_SIZE="-0.05993263850264875" MODIFIED="2009-07-03 13:04:17 +1000" MODIFIED_BY="[Empty name]" ORDER="3092" SE="0.04190000000000001" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.00003132812451">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 16:55:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3091" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="54.9999686718755"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.004599041390249462" CI_END="0.9989043381149315" CI_START="0.7396199751715565" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8595403432971169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="-4.7610078111165027E-4" LOG_CI_START="-0.13099136821373636" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06573373449742403" MODIFIED="2009-07-03 13:04:31 +1000" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.9459319218956488" P_Q="1.0" P_Z="0.048351810088496795" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="1.97426331368899">
<NAME>All-cause mortality, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0045916136575244" CI_START="0.7330208708144181" EFFECT_SIZE="0.8581297218113938" ESTIMABLE="YES" ESTIMATE="-0.153" LOG_CI_END="0.0019895483432768716" LOG_CI_START="-0.134883659805672" LOG_EFFECT_SIZE="-0.06644705573119752" MODIFIED="2009-07-03 13:04:31 +1000" MODIFIED_BY="[Empty name]" ORDER="1144" SE="0.08039999999999999" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="90.92550917456886">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:02:53 +1000" MODIFIED_BY="[Empty name]" ORDER="1143" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.074490825431132"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-03 13:09:16 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Children &lt; 24 months and/or HIV-1 negative and HIV-1 positive children</NAME>
<IV_OUTCOME CHI2="9.436323054025959" CI_END="0.424003876990443" CI_START="0.11968909238022293" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.22527458623351596" ESTIMABLE="YES" I2="36.415911519263524" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.3726301723038291" LOG_CI_START="-0.921945426326481" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.647287799315155" MODIFIED="2009-07-03 13:05:34 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15048559091669833" P_Q="1.0" P_Z="3.854775467414745E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.23106252864296095" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="4.619062605669345">
<NAME>IPD, vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:04:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3289" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="15.43944781425421"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:05:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3294" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.600707598783498">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:05:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3292" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.5958376884144467">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:04:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3291" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="12.72620383834771"/>
<IV_DATA CI_END="0.4843184202762225" CI_START="0.12162809344053996" EFFECT_SIZE="0.24270707875200323" ESTIMABLE="YES" ESTIMATE="-1.4159" LOG_CI_END="-0.31486901294357755" LOG_CI_START="-0.9149661009100509" LOG_EFFECT_SIZE="-0.6149175569268143" MODIFIED="2009-07-03 13:05:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3295" SE="0.3525" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="29.302209007799675">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.5706694780811643" CI_START="0.137373069987529" EFFECT_SIZE="0.2799903893925476" ESTIMABLE="YES" ESTIMATE="-1.273" LOG_CI_END="-0.24361535481288246" LOG_CI_START="-0.8620983961127966" LOG_EFFECT_SIZE="-0.5528568754628396" MODIFIED="2009-05-27 17:04:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3290" SE="0.36329999999999996" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="28.678258610383306"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:04:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3293" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.657335442017151"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.597881015278109" CI_END="0.6623878531512335" CI_START="0.2690468003427488" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.42215320971922254" ESTIMABLE="YES" I2="48.266411837678916" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.17888764022945758" LOG_CI_START="-0.5701721684632448" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.37452990434635125" MODIFIED="2009-07-03 13:05:50 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07156487037292203" P_Q="1.0" P_Z="1.753745616760896E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.14286849516455474" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.00000000000001" Z="3.7520784528106153">
<NAME>IPD, all serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:07:08 +1000" MODIFIED_BY="[Empty name]" ORDER="3283" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="14.484832764876066"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:05:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3287" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="2.9256345068953697">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:05:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3282" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="2.924798960539272">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:07:08 +1000" MODIFIED_BY="[Empty name]" ORDER="3285" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="17.091442298208175"/>
<IV_DATA CI_END="0.7756390044703381" CI_START="0.32234530490604235" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.11034035972701615" LOG_CI_START="-0.49167865108727155" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-27 17:07:08 +1000" MODIFIED_BY="[Empty name]" ORDER="3286" SE="0.22399999999999998" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="27.365484007807794"/>
<IV_DATA CI_END="0.8492180263380804" CI_START="0.38275480981497956" EFFECT_SIZE="0.5701247970071853" ESTIMABLE="YES" ESTIMATE="-0.5619" LOG_CI_END="-0.07098079564585699" LOG_CI_START="-0.41707934311701733" LOG_EFFECT_SIZE="-0.24403006938143712" MODIFIED="2009-07-03 13:05:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3284" SE="0.20329999999999998" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="28.679553085921512">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:07:08 +1000" MODIFIED_BY="[Empty name]" ORDER="3288" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.528254375751826"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.1852928010114787" CI_END="2.041642160951968" CI_START="0.551910744709724" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.0615103605155114" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.30997962553623487" LOG_CI_START="-0.2581311509198432" LOG_DATA="YES" LOG_EFFECT_SIZE="0.025924237308195843" MODIFIED="2009-07-03 13:06:01 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9462805201283591" P_Q="1.0" P_Z="0.8580354003376047" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48297" TOTAL_2="47311" WEIGHT="100.00000000000001" Z="0.17887557693481554">
<NAME>IPD, non-vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:07:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3299" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.1791512261700205"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:07:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3300" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="13.365647287362169"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:07:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3296" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="27.872099152434217"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:05:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3301" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.718329397403238">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:06:01 +1000" MODIFIED_BY="[Empty name]" ORDER="3297" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.716181750006782">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.7327398061044663" CI_START="0.5554689891982019" EFFECT_SIZE="1.4399379177717142" ESTIMABLE="YES" ESTIMATE="0.36460000000000004" LOG_CI_END="0.5720277181043456" LOG_CI_START="-0.25534018190049435" LOG_EFFECT_SIZE="0.15834376810192566" MODIFIED="2009-05-27 17:07:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3298" SE="0.486" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="47.14859118662359"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2884087887219784" CI_END="1.252964715939082" CI_START="0.2891992163917805" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.6019604754600857" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.0979388412346012" LOG_CI_START="-0.5388028881312646" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22043202344833163" MODIFIED="2009-07-02 18:40:24 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7318874599166489" P_Q="1.0" P_Z="0.17477166598755986" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46631" TOTAL_2="46479" WEIGHT="99.99999999999999" Z="1.3570300392540267">
<NAME>IPD, vaccine-related serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:08:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3302" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.2498713026596295"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:08:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3303" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.493943532662657"/>
<IV_DATA CI_END="1.3761647145928655" CI_START="0.2529659364846539" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="0.1386704181709836" LOG_CI_START="-0.5969379554752949" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-05-27 17:08:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3305" SE="0.4321" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="74.92612916637633"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:08:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3304" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="9.330055998301376"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="18.507596498618074" CI_END="0.990583136791399" CI_START="0.6707046100649103" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.815100408844549" ESTIMABLE="YES" I2="78.38725303796919" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.004109069510012314" LOG_CI_START="-0.17346870854100796" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08878888902551013" MODIFIED="2009-07-03 13:06:09 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="9.817775886605817E-4" P_Q="1.0" P_Z="0.039872166480261484" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03584325890811564" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="2.055070803327284">
<NAME>X-ray defined pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7361904731975046" CI_START="0.567035367095218" EFFECT_SIZE="0.6461006386171966" ESTIMABLE="YES" ESTIMATE="-0.4368" LOG_CI_END="-0.133009806917231" LOG_CI_START="-0.2463898524734498" LOG_EFFECT_SIZE="-0.18969982969534038" MODIFIED="2009-07-03 13:06:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3306" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="24.570744474905318">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:15:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3309" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="12.065557118147707">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9584492707762539" CI_START="0.7188077397979356" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.018430868706605385" LOG_CI_START="-0.14338725525054621" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-05-27 17:08:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3307" SE="0.07339999999999999" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="24.003417670355585"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:08:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3308" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="19.256977569445986"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:12:31 +1000" MODIFIED_BY="[Empty name]" ORDER="515" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="20.103303167145405"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.6785981631575484" CI_END="0.9733236290981255" CI_START="0.9059236697254848" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9390191232893506" ESTIMABLE="YES" I2="18.44719463935874" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.01174273325426962" LOG_CI_START="-0.04290839306660247" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02732556316043604" MODIFIED="2009-07-03 13:06:18 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2983267146611942" P_Q="1.0" P_Z="5.883442819936699E-4" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.549456888874964E-4" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.00000000000001" Z="3.4369315441565327">
<NAME>Clinical pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9721460644718857" CI_START="0.8518449210397556" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="-0.012268477637136009" LOG_CI_START="-0.06963946164981731" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:09:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3311" SE="0.0337" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="24.099858068520923"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:09:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3404" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="19.638458296697213"/>
<IV_DATA CI_END="0.9792572876694232" CI_START="0.891331260414753" EFFECT_SIZE="0.9342604735772135" ESTIMABLE="YES" ESTIMATE="-0.068" LOG_CI_END="-0.009103187732264605" LOG_CI_START="-0.04996086180657764" LOG_EFFECT_SIZE="-0.029532024769421125" MODIFIED="2009-07-03 13:06:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3312" SE="0.024" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="40.33250689594231">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:09:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3313" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="15.929176738839564"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.675281316602188" CI_END="1.0978345601285273" CI_START="0.8272269849315297" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9529734377876196" ESTIMABLE="YES" I2="86.97116159329656" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.040536898368407966" LOG_CI_START="-0.08237530691973292" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.020919204275662427" MODIFIED="2009-07-03 13:06:27 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.005598248499378178" P_Q="1.0" P_Z="0.5046716726265177" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.009067335000000001" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="0.6671572911643245">
<NAME>All-cause admissions, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9538953108787704" CI_START="0.823494301353758" EFFECT_SIZE="0.8862998096562691" ESTIMABLE="YES" ESTIMATE="-0.1207" LOG_CI_END="-0.02049928609516539" LOG_CI_START="-0.08433940183627958" LOG_EFFECT_SIZE="-0.052419343965722495" MODIFIED="2009-07-03 13:06:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3315" SE="0.0375" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="49.770254793931905">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:09:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3314" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="50.229745206068095"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5506370551371662" CI_END="1.0073758547045144" CI_START="0.8147374365643782" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9059507831658438" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.003191537255997339" LOG_CI_START="-0.0889823277303631" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04289539523718287" MODIFIED="2009-07-03 13:06:39 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9683879131072178" P_Q="1.0" P_Z="0.06811643935807145" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.0" Z="1.8242357479515559">
<NAME>All-cause mortality, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:10:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3320" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.671704242959978"/>
<IV_DATA CI_END="1.0135970971511672" CI_START="0.7709702548524879" EFFECT_SIZE="0.8839984232499385" ESTIMABLE="YES" ESTIMATE="-0.1233" LOG_CI_END="0.005865358097725951" LOG_CI_START="-0.11296237733506795" LOG_EFFECT_SIZE="-0.05354850961867098" MODIFIED="2009-07-03 13:06:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3318" SE="0.0698" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="60.169992276705315">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.1319396900082939" CI_START="0.7904659470596627" EFFECT_SIZE="0.94591742719797" ESTIMABLE="YES" ESTIMATE="-0.0556" LOG_CI_END="0.05382328816466002" LOG_CI_START="-0.10211683455230162" LOG_EFFECT_SIZE="-0.024146773193820824" MODIFIED="2009-05-27 17:10:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3316" SE="0.0916" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="34.93814586532953"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:06:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3319" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.1100788075025907">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:06:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3317" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.1100788075025907">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.43632305402596" CI_END="0.3547200856880565" CI_START="0.15105720168769646" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.23148007155359557" ESTIMABLE="YES" I2="36.41591151926354" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.4501142193191066" LOG_CI_START="-0.8208585648053318" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6354863920622192" MODIFIED="2009-07-03 13:06:53 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.15048559091669833" P_Q="1.0" P_Z="1.8287560927024863E-11" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="6.719079906525651">
<NAME>IPD, vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:10:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3254" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.698840039833756"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:06:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3253" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.7826377559151998">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:06:49 +1000" MODIFIED_BY="[Empty name]" ORDER="3256" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.7800176750552992">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:10:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3251" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="8.078672090954228"/>
<IV_DATA CI_END="0.4843184202762225" CI_START="0.12162809344053996" EFFECT_SIZE="0.24270707875200323" ESTIMABLE="YES" ESTIMATE="-1.4159" LOG_CI_END="-0.31486901294357755" LOG_CI_START="-0.9149661009100509" LOG_EFFECT_SIZE="-0.6149175569268143" MODIFIED="2009-07-03 13:06:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3250" SE="0.3525" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="38.168582664256256">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.5706694780811643" CI_START="0.137373069987529" EFFECT_SIZE="0.2799903893925476" ESTIMABLE="YES" ESTIMATE="-1.273" LOG_CI_END="-0.24361535481288246" LOG_CI_START="-0.8620983961127966" LOG_EFFECT_SIZE="-0.5528568754628396" MODIFIED="2009-05-27 17:10:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3255" SE="0.36329999999999996" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="35.93300023718638"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:10:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3252" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.558249536798867"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.597881015278105" CI_END="0.6103465684737149" CI_START="0.36373140478878574" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.47117110985178107" ESTIMABLE="YES" I2="48.2664118376789" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.21442349280008488" LOG_CI_START="-0.43921920007902066" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.32682134643955274" MODIFIED="2009-07-03 13:07:05 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.07156487037292181" P_Q="1.0" P_Z="1.2049524483817708E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="5.699024026340331">
<NAME>IPD, all serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:11:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3246" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="7.8597623912183785"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:06:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3247" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.0485968249415571">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:07:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3243" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.0482716282231084">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:11:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3245" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="10.489862810930527"/>
<IV_DATA CI_END="0.7756390044703381" CI_START="0.32234530490604235" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.11034035972701615" LOG_CI_START="-0.49167865108727155" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-27 17:11:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3244" SE="0.22399999999999998" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="34.750030863964376"/>
<IV_DATA CI_END="0.8492180263380804" CI_START="0.38275480981497956" EFFECT_SIZE="0.5701247970071853" ESTIMABLE="YES" ESTIMATE="-0.5619" LOG_CI_END="-0.07098079564585699" LOG_CI_START="-0.41707934311701733" LOG_EFFECT_SIZE="-0.24403006938143712" MODIFIED="2009-07-03 13:07:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3248" SE="0.20329999999999998" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="42.18678931497185">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:11:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3249" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="2.6166861657502083"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.185292801011479" CI_END="2.041642160951968" CI_START="0.551910744709724" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="1.0615103605155114" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.30997962553623487" LOG_CI_START="-0.2581311509198432" LOG_DATA="YES" LOG_EFFECT_SIZE="0.025924237308195843" MODIFIED="2009-07-03 13:07:14 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9462805201283591" P_Q="1.0" P_Z="0.8580354003376047" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48297" TOTAL_2="47311" WEIGHT="99.99999999999999" Z="0.1788755769348155">
<NAME>IPD, non-vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:11:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3260" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.179151226170019"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:11:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3262" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="13.365647287362163"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:11:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3258" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="27.872099152434206"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:07:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3261" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.7183293974032368">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:07:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3259" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.716181750006781">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 47,310.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.7327398061044663" CI_START="0.5554689891982019" EFFECT_SIZE="1.4399379177717142" ESTIMABLE="YES" ESTIMATE="0.36460000000000004" LOG_CI_END="0.5720277181043456" LOG_CI_START="-0.25534018190049435" LOG_EFFECT_SIZE="0.15834376810192566" MODIFIED="2009-05-27 17:11:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3257" SE="0.486" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="47.14859118662358"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2884087887219784" CI_END="1.252964715939082" CI_START="0.2891992163917805" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.6019604754600857" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.0979388412346012" LOG_CI_START="-0.5388028881312646" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22043202344833163" MODIFIED="2009-07-02 18:45:18 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7318874599166489" P_Q="1.0" P_Z="0.17477166598755986" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46631" TOTAL_2="46479" WEIGHT="99.99999999999999" Z="1.3570300392540267">
<NAME>IPD, vaccine-related serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:11:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3266" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.2498713026596295"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:11:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3265" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.493943532662657"/>
<IV_DATA CI_END="1.3761647145928655" CI_START="0.2529659364846539" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="0.1386704181709836" LOG_CI_START="-0.5969379554752949" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-05-27 17:11:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3264" SE="0.4321" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="74.92612916637633"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:11:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3263" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="9.330055998301376"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="18.507596498618074" CI_END="0.8443166463460107" CI_START="0.7166503798772912" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7778687841407373" ESTIMABLE="YES" I2="78.38725303796919" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.07349464819574908" LOG_CI_START="-0.14469266458516528" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10909365639045719" MODIFIED="2009-07-03 13:07:22 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="9.817775886605817E-4" P_Q="1.0" P_Z="1.897616488376844E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="6.0063369265121525">
<NAME>X-ray defined pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7361904731975046" CI_START="0.567035367095218" EFFECT_SIZE="0.6461006386171966" ESTIMABLE="YES" ESTIMATE="-0.4368" LOG_CI_END="-0.133009806917231" LOG_CI_START="-0.2463898524734498" LOG_EFFECT_SIZE="-0.18969982969534038" MODIFIED="2009-07-03 13:07:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3267" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="39.43324653824059">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:16:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3270" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="3.7873737200948696">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9584492707762539" CI_START="0.7188077397979356" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.018430868706605385" LOG_CI_START="-0.14338725525054621" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-05-27 17:12:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3268" SE="0.07339999999999999" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="32.46525904401222"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:12:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3269" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="11.24807194139445"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:12:51 +1000" MODIFIED_BY="[Empty name]" ORDER="516" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="13.066048756257873"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.678598163157547" CI_END="0.9681593224087369" CI_START="0.908860290594736" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9380413440282936" ESTIMABLE="YES" I2="18.44719463935871" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-0.014053168363731215" LOG_CI_START="-0.04150287110916514" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.027778019736448143" MODIFIED="2009-07-03 13:07:30 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.2983267146611943" P_Q="1.0" P_Z="7.284011135181925E-5" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.00000000000001" Z="3.9668129560592478">
<NAME>Clinical pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9721460644718857" CI_START="0.8518449210397556" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="-0.012268477637136009" LOG_CI_START="-0.06963946164981731" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:12:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3273" SE="0.0337" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="22.892366694425696"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:12:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3403" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="17.91020448411923"/>
<IV_DATA CI_END="0.9792572876694232" CI_START="0.891331260414753" EFFECT_SIZE="0.9342604735772135" ESTIMABLE="YES" ESTIMATE="-0.068" LOG_CI_END="-0.009103187732264605" LOG_CI_START="-0.04996086180657764" LOG_EFFECT_SIZE="-0.029532024769421125" MODIFIED="2009-07-03 13:07:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3272" SE="0.024" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="45.13651376943111">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:12:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3274" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="14.06091505202397"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.675281316602188" CI_END="1.005106007312859" CI_START="0.9075556115131225" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9550861726055585" ESTIMABLE="YES" I2="86.97116159329656" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.0022118686849893223" LOG_CI_START="-0.04212675358297887" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.019957442448994785" MODIFIED="2009-07-03 13:07:36 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.005598248499378178" P_Q="1.0" P_Z="0.07766210938107829" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="1.764415149715616">
<NAME>All-cause admissions, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9538953108787704" CI_START="0.823494301353758" EFFECT_SIZE="0.8862998096562691" ESTIMABLE="YES" ESTIMATE="-0.1207" LOG_CI_END="-0.02049928609516539" LOG_CI_START="-0.08433940183627958" LOG_EFFECT_SIZE="-0.052419343965722495" MODIFIED="2009-07-03 13:07:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3275" SE="0.0375" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="48.236640912286646">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:12:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3276" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="51.763359087713354"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5506370551371662" CI_END="1.0073758547045144" CI_START="0.8147374365643782" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9059507831658438" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.003191537255997339" LOG_CI_START="-0.0889823277303631" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04289539523718287" MODIFIED="2009-07-03 13:07:47 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9683879131072178" P_Q="1.0" P_Z="0.06811643935807145" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.0" Z="1.8242357479515559">
<NAME>All-cause mortality, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:13:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3279" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.671704242959978"/>
<IV_DATA CI_END="1.0135970971511672" CI_START="0.7709702548524879" EFFECT_SIZE="0.8839984232499385" ESTIMABLE="YES" ESTIMATE="-0.1233" LOG_CI_END="0.005865358097725951" LOG_CI_START="-0.11296237733506795" LOG_EFFECT_SIZE="-0.05354850961867098" MODIFIED="2009-07-03 13:07:40 +1000" MODIFIED_BY="[Empty name]" ORDER="3280" SE="0.0698" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="60.169992276705315">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.1319396900082939" CI_START="0.7904659470596627" EFFECT_SIZE="0.94591742719797" ESTIMABLE="YES" ESTIMATE="-0.0556" LOG_CI_END="0.05382328816466002" LOG_CI_START="-0.10211683455230162" LOG_EFFECT_SIZE="-0.024146773193820824" MODIFIED="2009-05-27 17:13:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3277" SE="0.0916" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="34.93814586532953"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:07:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3281" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.1100788075025907">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:07:47 +1000" MODIFIED_BY="[Empty name]" ORDER="3278" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.1100788075025907">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.010550032572709" CI_END="0.7077771647505964" CI_START="0.06556515238629981" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.21541939945700359" ESTIMABLE="YES" I2="50.08776262168634" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="-0.15010345325938054" LOG_CI_START="-1.1833269250677643" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6667151891635725" MODIFIED="2009-07-03 13:07:53 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.11109812318856638" P_Q="1.0" P_Z="0.011424510287110995" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.7094495973473249" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="2.5294387794332884">
<NAME>IPD, vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:13:47 +1000" MODIFIED_BY="[Empty name]" ORDER="3346" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="15.111140212240706"/>
<IV_DATA CI_END="0.43053616828498253" CI_START="0.07591992929760324" EFFECT_SIZE="0.18079346076740963" ESTIMABLE="YES" ESTIMATE="-1.7104" LOG_CI_END="-0.36599035866610513" LOG_CI_START="-1.1196442050285387" LOG_EFFECT_SIZE="-0.7428172818473219" MODIFIED="2009-07-03 13:07:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3349" SE="0.44270000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="40.68248435148146">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:14:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3348" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="27.54678835530626"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:14:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3347" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="16.65958708097157"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.88145013195652" CI_END="0.7861637321185019" CI_START="0.12470534689078916" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3131115151616038" ESTIMABLE="YES" I2="69.64008359159727" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="-0.10448699524515417" LOG_CI_START="-0.9041149252272921" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5043009602362231" MODIFIED="2009-07-03 13:08:00 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.01960123606390296" P_Q="1.0" P_Z="0.01342922268950649" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5750784528622507" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="2.472179078222149">
<NAME>IPD, all serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:14:18 +1000" MODIFIED_BY="[Empty name]" ORDER="1045" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="23.66986242185094"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:14:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3344" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="25.723339149121703"/>
<IV_DATA CI_END="0.8306784044596943" CI_START="0.3272969413134059" EFFECT_SIZE="0.521419697551558" ESTIMABLE="YES" ESTIMATE="-0.6512" LOG_CI_END="-0.0805670799475478" LOG_CI_START="-0.48505805328324736" LOG_EFFECT_SIZE="-0.2828125666153976" MODIFIED="2009-07-03 13:08:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3343" SE="0.2376" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="34.934586443769426">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:14:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3345" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="15.67221198525794"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.28795226665982154" CI_END="2.322357750826509" CI_START="0.2019643278037138" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.684860147815173" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.3659291220529434" LOG_CI_START="-0.694725331573632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16439810476034425" MODIFIED="2009-07-02 18:49:37 +1000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.8659084250996915" P_Q="1.0" P_Z="0.5434683888985625" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22034" TOTAL_2="21870" WEIGHT="100.0" Z="0.6075765077970616">
<NAME>IPD, non-vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:14:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3351" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="14.561638936598035"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:14:38 +1000" MODIFIED_BY="[Empty name]" ORDER="1046" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="46.59796412996252"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:14:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3350" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="38.84039693343944"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.22472616261143383" CI_END="4.865741064929072" CI_START="0.0737056216968501" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.5988593075226357" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.6871489938129258" LOG_CI_START="-1.1324993862412167" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22267519621414542" MODIFIED="2009-07-02 18:50:36 +1000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.635462195530701" P_Q="1.0" P_Z="0.6314464349583269" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8485" TOTAL_2="8301" WEIGHT="99.99999999999999" Z="0.47969197743261693">
<NAME>IPD, vaccine-related serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:14:49 +1000" MODIFIED_BY="[Empty name]" ORDER="3352" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="42.85853964080626"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:14:49 +1000" MODIFIED_BY="[Empty name]" ORDER="3353" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="57.14146035919372"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.443983763186267" CI_END="1.0079135905674237" CI_START="0.5698599097274751" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.7578717224793701" ESTIMABLE="YES" I2="80.57496015276135" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.0034233012083896355" LOG_CI_START="-0.2442318950468084" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12040429691920941" MODIFIED="2009-07-03 13:08:15 +1000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0014739912204604355" P_Q="1.0" P_Z="0.05667883282681938" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.06413815127222672" TOTALS="YES" TOTAL_1="22308" TOTAL_2="22046" WEIGHT="100.0" Z="1.905779399050782">
<NAME>X-ray defined pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:16:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3354" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="17.24037098220895">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7260861576753392" CI_START="0.5473245073001173" EFFECT_SIZE="0.6304004667725829" ESTIMABLE="YES" ESTIMATE="-0.46140000000000003" LOG_CI_END="-0.13901184268436928" LOG_CI_START="-0.26175510521595147" LOG_EFFECT_SIZE="-0.20038347395016035" MODIFIED="2009-07-03 13:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3356" SE="0.0721" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="30.521634989926238">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:15:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3355" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="25.41601111670193"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 14:14:57 +1000" MODIFIED_BY="[Empty name]" ORDER="539" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="26.821982911162888"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.375644591696946" CI_END="0.9740797783878186" CI_START="0.899143854925355" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9358620875665702" ESTIMABLE="YES" I2="11.128084769970064" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="-0.011405472387569062" LOG_CI_START="-0.04617081949896388" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02878814594326647" MODIFIED="2009-07-03 13:08:20 +1000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.3372524156624134" P_Q="1.0" P_Z="0.0011704898923444555" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.9830197060278538E-4" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="100.0" Z="3.2459753126981727">
<NAME>Clinical pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.974002258346723" CI_START="0.8132974710643074" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="-0.011440036153845453" LOG_CI_START="-0.0897505781296122" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-05-27 17:15:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3357" SE="0.046" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="18.019731631000024"/>
<IV_DATA CI_END="0.9767027067465047" CI_START="0.8793018534006116" EFFECT_SIZE="0.9267235295726528" ESTIMABLE="YES" ESTIMATE="-0.0761" LOG_CI_END="-0.010237608714679334" LOG_CI_START="-0.055862011430995576" LOG_EFFECT_SIZE="-0.03304981007283749" MODIFIED="2009-07-03 13:08:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3360" SE="0.0268" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.500480895522614">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:15:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3406" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="18.531482945251618"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:15:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3359" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="17.948304528225744"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.650487778898627" CI_END="1.0818933798552024" CI_START="0.8131645164294696" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9379537872721663" ESTIMABLE="YES" I2="84.96350894481897" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.03418446333791012" LOG_CI_START="-0.08982158066742262" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02781855866475625" MODIFIED="2009-07-03 13:08:25 +1000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.009912907854337516" P_Q="1.0" P_Z="0.3792026636340208" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.009018235000000001" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="0.8793663812449681">
<NAME>All-cause admissions, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9456549629732606" CI_START="0.8024205026909985" EFFECT_SIZE="0.8710986917457983" ESTIMABLE="YES" ESTIMATE="-0.138" LOG_CI_END="-0.0242672938419463" LOG_CI_START="-0.09559798316335125" LOG_EFFECT_SIZE="-0.05993263850264875" MODIFIED="2009-07-03 13:08:25 +1000" MODIFIED_BY="[Empty name]" ORDER="3361" SE="0.04190000000000001" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="49.24818015789159">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:16:09 +1000" MODIFIED_BY="[Empty name]" ORDER="3362" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="50.75181984210842"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.004599041390249462" CI_END="0.9989043381149315" CI_START="0.7396199751715565" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8595403432971169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="-4.7610078111165027E-4" LOG_CI_START="-0.13099136821373636" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06573373449742403" MODIFIED="2009-07-03 13:08:30 +1000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9459319218956488" P_Q="1.0" P_Z="0.048351810088496795" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="1.97426331368899">
<NAME>All-cause mortality, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0045916136575244" CI_START="0.7330208708144181" EFFECT_SIZE="0.8581297218113938" ESTIMABLE="YES" ESTIMATE="-0.153" LOG_CI_END="0.0019895483432768716" LOG_CI_START="-0.134883659805672" LOG_EFFECT_SIZE="-0.06644705573119752" MODIFIED="2009-07-03 13:08:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3363" SE="0.08039999999999999" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="90.92550917456886">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:16:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3364" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.074490825431132"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.010550032572709" CI_END="0.40455668950889945" CI_START="0.10065206726119191" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.2017906517245407" ESTIMABLE="YES" I2="50.08776262168634" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="-0.3930206131966999" LOG_CI_START="-0.9971773008457845" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6950989570212422" MODIFIED="2009-07-03 13:08:35 +1000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.11109812318856638" P_Q="1.0" P_Z="6.4832086389197976E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="4.509985403800749">
<NAME>IPD, vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:16:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3324" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="7.287643552119763"/>
<IV_DATA CI_END="0.43053616828498253" CI_START="0.07591992929760324" EFFECT_SIZE="0.18079346076740963" ESTIMABLE="YES" ESTIMATE="-1.7104" LOG_CI_END="-0.36599035866610513" LOG_CI_START="-1.1196442050285387" LOG_EFFECT_SIZE="-0.7428172818473219" MODIFIED="2009-07-03 13:08:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3327" SE="0.44270000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="64.26216228138856">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:16:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3326" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="20.062962741141206"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:16:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3325" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="8.38723142535048"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.881450131956521" CI_END="0.5991644207893847" CI_START="0.27465254799104893" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.40566246416865526" ESTIMABLE="YES" I2="69.64008359159729" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="-0.22245398354892348" LOG_CI_START="-0.5612163676117847" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.39183517558035413" MODIFIED="2009-07-03 13:08:41 +1000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.01960123606390296" P_Q="1.0" P_Z="5.786326014403518E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.00000000000001" Z="4.534050226018686">
<NAME>IPD, all serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:17:15 +1000" MODIFIED_BY="[Empty name]" ORDER="1047" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="11.091486270510755"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:17:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3323" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.011854555669112"/>
<IV_DATA CI_END="0.8306784044596943" CI_START="0.3272969413134059" EFFECT_SIZE="0.521419697551558" ESTIMABLE="YES" ESTIMATE="-0.6512" LOG_CI_END="-0.0805670799475478" LOG_CI_START="-0.48505805328324736" LOG_EFFECT_SIZE="-0.2828125666153976" MODIFIED="2009-07-03 13:08:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3322" SE="0.2376" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="70.14111939331464">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:17:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3321" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="4.755539780505496"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.28795226665982154" CI_END="2.322357750826509" CI_START="0.2019643278037138" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.684860147815173" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="0.3659291220529434" LOG_CI_START="-0.694725331573632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16439810476034425" MODIFIED="2009-07-02 18:49:47 +1000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.8659084250996915" P_Q="1.0" P_Z="0.5434683888985625" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22034" TOTAL_2="21870" WEIGHT="100.0" Z="0.6075765077970616">
<NAME>IPD, non-vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:17:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3328" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="14.561638936598035"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:17:42 +1000" MODIFIED_BY="[Empty name]" ORDER="1048" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="46.59796412996252"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:17:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3329" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="38.84039693343944"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.22472616261143383" CI_END="4.865741064929072" CI_START="0.0737056216968501" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.5988593075226357" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.28" LOG_CI_END="0.6871489938129258" LOG_CI_START="-1.1324993862412167" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22267519621414542" MODIFIED="2009-07-02 18:50:41 +1000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.635462195530701" P_Q="1.0" P_Z="0.6314464349583269" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8485" TOTAL_2="8301" WEIGHT="99.99999999999999" Z="0.47969197743261693">
<NAME>IPD, vaccine-related serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:18:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3330" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="42.85853964080626"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:18:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3331" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="57.14146035919372"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.443983763186267" CI_END="0.8071896115836229" CI_START="0.6504040520293352" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.7245684192193126" ESTIMABLE="YES" I2="80.57496015276135" I2_Q="0.0" ID="CMP-002.29" LOG_CI_END="-0.09302443604386665" LOG_CI_START="-0.18681676174286424" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.13992059889336544" MODIFIED="2009-07-03 13:08:53 +1000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.0014739912204604355" P_Q="1.0" P_Z="4.98119915809403E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22308" TOTAL_2="22046" WEIGHT="100.0" Z="5.847799006634552">
<NAME>X-ray defined pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:16:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3332" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="5.178693818985">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7260861576753392" CI_START="0.5473245073001173" EFFECT_SIZE="0.6304004667725829" ESTIMABLE="YES" ESTIMATE="-0.46140000000000003" LOG_CI_END="-0.13901184268436928" LOG_CI_START="-0.26175510521595147" LOG_EFFECT_SIZE="-0.20038347395016035" MODIFIED="2009-07-03 13:08:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3333" SE="0.0721" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="58.39010877995668">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:18:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3334" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="15.86958075164413"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 14:16:17 +1000" MODIFIED_BY="[Empty name]" ORDER="540" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="20.56161664941419"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.3756445916969464" CI_END="0.9703600392357434" CI_START="0.9013434672272653" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9352153132961041" ESTIMABLE="YES" I2="11.128084769970075" I2_Q="0.0" ID="CMP-002.30" LOG_CI_END="-0.01306709661876127" LOG_CI_START="-0.04510968460671301" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02908839061273717" MODIFIED="2009-07-03 13:08:58 +1000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.33725241566241315" P_Q="1.0" P_Z="3.7294128155327376E-4" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="99.99999999999999" Z="3.5585264205647076">
<NAME>Clinical pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.974002258346723" CI_START="0.8132974710643074" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="-0.011440036153845453" LOG_CI_START="-0.0897505781296122" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-05-27 17:19:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3337" SE="0.046" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="16.742284275869764"/>
<IV_DATA CI_END="0.9767027067465047" CI_START="0.8793018534006116" EFFECT_SIZE="0.9267235295726528" ESTIMABLE="YES" ESTIMATE="-0.0761" LOG_CI_END="-0.010237608714679334" LOG_CI_START="-0.055862011430995576" LOG_EFFECT_SIZE="-0.03304981007283749" MODIFIED="2009-07-03 13:08:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3338" SE="0.0268" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="49.32428370424985">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:19:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3405" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="17.263703603516618"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:19:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3336" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="16.669728416363757"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.650487778898627" CI_END="0.9972282635804102" CI_START="0.8931912935930496" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9437773057003105" ESTIMABLE="YES" I2="84.96350894481897" I2_Q="0.0" ID="CMP-002.31" LOG_CI_END="-0.0012054211599775147" LOG_CI_START="-0.04905551887749632" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02513047001873689" MODIFIED="2009-07-03 13:09:03 +1000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.009912907854337516" P_Q="1.0" P_Z="0.03952171192843528" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.058713294257491">
<NAME>All-cause admissions, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9456549629732606" CI_START="0.8024205026909985" EFFECT_SIZE="0.8710986917457983" ESTIMABLE="YES" ESTIMATE="-0.138" LOG_CI_END="-0.0242672938419463" LOG_CI_START="-0.09559798316335125" LOG_EFFECT_SIZE="-0.05993263850264875" MODIFIED="2009-07-03 13:09:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3339" SE="0.04190000000000001" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.00003132812451">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:19:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3340" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="54.9999686718755"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.004599041390249462" CI_END="0.9989043381149315" CI_START="0.7396199751715565" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8595403432971169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.32" LOG_CI_END="-4.7610078111165027E-4" LOG_CI_START="-0.13099136821373636" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06573373449742403" MODIFIED="2009-07-03 13:09:16 +1000" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.9459319218956488" P_Q="1.0" P_Z="0.048351810088496795" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="1.97426331368899">
<NAME>All-cause mortality, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0045916136575244" CI_START="0.7330208708144181" EFFECT_SIZE="0.8581297218113938" ESTIMABLE="YES" ESTIMATE="-0.153" LOG_CI_END="0.0019895483432768716" LOG_CI_START="-0.134883659805672" LOG_EFFECT_SIZE="-0.06644705573119752" MODIFIED="2009-07-03 13:09:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3342" SE="0.08039999999999999" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="90.92550917456886">
<FOOTNOTE>Treatment and control totals included children &lt; 29 months of age because investigators of the Gambian trial could not provide us with the actual numbers for children &lt; 24 months of age.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:19:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3341" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.074490825431132"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-07-03 13:12:57 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Pooled with Cutts 2005 children &lt; 29 months and/or HIV-1 negative children</NAME>
<IV_OUTCOME CHI2="9.720891635224696" CI_END="0.45720479264557795" CI_START="0.10028238009262457" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.21412516152067101" ESTIMABLE="YES" I2="38.27726688919815" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.33988922576446595" LOG_CI_START="-0.9987753670869088" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6693322964256874" MODIFIED="2009-07-03 13:09:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13690875023108762" P_Q="1.0" P_Z="6.831605705205737E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.36218077545037003" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="3.9820755435857285">
<NAME>IPD, vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3413" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="18.597148383244274"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:09:40 +1000" MODIFIED_BY="[Empty name]" ORDER="3416" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="4.9557056569056295">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:09:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3419" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="4.94929349739206">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7664669694602914" CI_START="0.03770221904235076" EFFECT_SIZE="0.16999266328673915" ESTIMABLE="YES" ESTIMATE="-1.7719999999999998" LOG_CI_END="-0.11550655612626679" LOG_CI_START="-1.4236330877388574" LOG_EFFECT_SIZE="-0.7695698219325622" MODIFIED="2009-05-27 17:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3418" SE="0.7684000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="15.724489601465102"/>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3414" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="15.780416009965283"/>
<IV_DATA CI_END="0.5695615619321245" CI_START="0.1476498633524408" EFFECT_SIZE="0.28999256333582235" ESTIMABLE="YES" ESTIMATE="-1.2379" LOG_CI_END="-0.24445932766483905" LOG_CI_START="-0.8307669506312318" LOG_EFFECT_SIZE="-0.5376131391480354" MODIFIED="2009-05-29 20:40:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3417" SE="0.3444" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="31.155777580289065"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:20:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3415" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="8.837169270738586"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.534778653608704" CI_END="0.7004495516008844" CI_START="0.24875911658062744" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.41742449816168264" ESTIMABLE="YES" I2="47.983397166248395" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.15462313839437955" LOG_CI_START="-0.6042209941677279" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.37942206628105374" MODIFIED="2009-07-03 13:09:54 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07318939179584216" P_Q="1.0" P_Z="9.39368556357482E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.19708664682061386" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="3.3080833251372357">
<NAME>IPD, all serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:21:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3408" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="16.648865485127104"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:09:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3407" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.7500304731084992">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:09:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3409" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.748990695385543">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:21:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3410" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="19.197787134871547"/>
<IV_DATA CI_END="0.8030558991369575" CI_START="0.37671398293763836" EFFECT_SIZE="0.5500203507920862" ESTIMABLE="YES" ESTIMATE="-0.5978" LOG_CI_END="-0.09525422328697526" LOG_CI_START="-0.4239882592765526" LOG_EFFECT_SIZE="-0.259621241281764" MODIFIED="2009-05-29 20:40:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3412" SE="0.1931" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="29.7586865320944"/>
<IV_DATA CI_END="1.3123520639622117" CI_START="0.25634758642305827" EFFECT_SIZE="0.5800157619703381" ESTIMABLE="YES" ESTIMATE="-0.5447" LOG_CI_END="0.11805035861060773" LOG_CI_START="-0.5911707671960101" LOG_EFFECT_SIZE="-0.23656020429270125" MODIFIED="2009-05-27 17:21:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3411" SE="0.41659999999999997" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.81779762684418"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:21:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3406" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="8.077842052568723"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.392140477314377" CI_END="1.5165379997569624" CI_START="0.5936123942311963" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.9488075426440916" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.18085329686099325" LOG_CI_START="-0.22649703985500388" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.022821871497005337" MODIFIED="2009-07-03 13:10:06 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9663347824928272" P_Q="1.0" P_Z="0.8261712987141119" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.00000000000001" Z="0.21961462732319909">
<NAME>IPD, non-vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:23:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3423" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="2.1486129605826143"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:23:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3425" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="6.871635275692198"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:23:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3420" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="14.329788571074673"/>
<IV_DATA CI_END="1.6831949430590951" CI_START="0.5509596300581605" EFFECT_SIZE="0.9630017980998817" ESTIMABLE="YES" ESTIMATE="-0.0377" LOG_CI_END="0.2261344176941599" LOG_CI_START="-0.258880221629665" LOG_EFFECT_SIZE="-0.016372901967752606" MODIFIED="2009-05-29 20:40:17 +1000" MODIFIED_BY="[Empty name]" ORDER="3424" SE="0.2849" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="70.53853973734479"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:10:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3426" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.9116921840365375">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:10:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3421" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.9105880213056243">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 17:23:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3422" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="2.289143249963571"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.5813456346296855" CI_END="1.4454767519976115" CI_START="0.33287330547697125" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6936574258433057" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.16001111118457745" LOG_CI_START="-0.47772103136449007" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1588549600899563" MODIFIED="2009-07-02 18:40:42 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6301313221042546" P_Q="1.0" P_Z="0.3288520508646845" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55349" TOTAL_2="55198" WEIGHT="100.0" Z="0.9764287536060852">
<NAME>IPD, vaccine-related serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:24:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3428" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.266215717653561"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:24:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3429" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.526614308407929"/>
<IV_DATA CI_END="1.4983669062418394" CI_START="0.2565643455878163" EFFECT_SIZE="0.620022196981994" ESTIMABLE="YES" ESTIMATE="-0.478" LOG_CI_END="0.17561817240557379" LOG_CI_START="-0.5908036971050825" LOG_EFFECT_SIZE="-0.20759276234975432" MODIFIED="2009-05-29 20:40:11 +1000" MODIFIED_BY="[Empty name]" ORDER="3427" SE="0.45020000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="69.23741353816192"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:24:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3431" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="9.35910324505495"/>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 17:24:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3430" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="5.6106531907216395"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="17.165391064664455" CI_END="0.9943915826663671" CI_START="0.659428665133904" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8097717665972756" ESTIMABLE="YES" I2="76.6972975743376" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.002442560570173778" LOG_CI_START="-0.18083217815298958" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09163736936158169" MODIFIED="2009-06-03 15:16:50 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0017950272135466294" P_Q="1.0" P_Z="0.04404768663021735" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03964457695172294" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="2.0136367353701385">
<NAME>X-ray defined pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7406208940078663" CI_START="0.5704478063783269" EFFECT_SIZE="0.6499888955549492" ESTIMABLE="YES" ESTIMATE="-0.43079999999999996" LOG_CI_END="-0.13040404002581146" LOG_CI_START="-0.2437840855820302" LOG_EFFECT_SIZE="-0.18709406280392085" MODIFIED="2009-05-29 20:40:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3433" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="24.90986752382058"/>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:16:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3432" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="12.793592415796795">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.982267336595287" CI_START="0.6516105384595232" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.007770297338020087" LOG_CI_START="-0.1860119004872109" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2009-05-27 17:24:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3435" SE="0.1047" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="21.69734618062815"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:24:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3434" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="19.893776564676067"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:13:18 +1000" MODIFIED_BY="[Empty name]" ORDER="517" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="20.70541731507841"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.5800739844857756" CI_END="0.9808780868522404" CI_START="0.914972860327077" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9473525366828051" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.008384967643032188" LOG_CI_START="-0.038591787665786664" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.023488377654409427" MODIFIED="2009-05-29 20:39:55 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4609935901659953" P_Q="1.0" P_Z="0.0023031001298244665" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.048078164019857">
<NAME>Clinical pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0077886986967415" CI_START="0.8581653148818031" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.0033694838856330425" LOG_CI_START="-0.06642904265798516" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-27 17:25:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3437" SE="0.040999999999999995" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.72912579256641"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:25:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3408" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="21.688787248161784"/>
<IV_DATA CI_END="0.9914478002889936" CI_START="0.8911780673295733" EFFECT_SIZE="0.9399768797793391" ESTIMABLE="YES" ESTIMATE="-0.061900000000000004" LOG_CI_END="-0.0037301464543672202" LOG_CI_START="-0.0500355104052554" LOG_EFFECT_SIZE="-0.026882828429811306" MODIFIED="2009-05-29 20:39:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3436" SE="0.027200000000000002" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="42.55468811811219"/>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:25:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3438" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="17.027398841159616"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.645880832401504" CI_END="1.1077652966007787" CI_START="0.8048290750724708" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9442254598667555" ESTIMABLE="YES" I2="89.63288042455494" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.04444775570969177" LOG_CI_START="-0.09429634278087944" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02492429353559384" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.001897787760677505" P_Q="1.0" P_Z="0.48131792465324486" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.011907280000000004" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="0.7041844402944211">
<NAME>All-cause admissions, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9372348680134331" CI_START="0.8075271263774072" EFFECT_SIZE="0.8699669992060597" ESTIMABLE="YES" ESTIMATE="-0.1393" LOG_CI_END="-0.028151562686958464" LOG_CI_START="-0.09284287997128751" LOG_EFFECT_SIZE="-0.06049722132912297" MODIFIED="2009-05-29 20:39:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3441" SE="0.038" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="49.74865444691182"/>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:25:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3440" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="50.251345553088186"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6023364943036507" CI_END="0.9809449967235168" CI_START="0.7734759475240669" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8710553144374442" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-0.008355343577401895" LOG_CI_START="-0.11155318683854713" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05995426520797451" MODIFIED="2009-07-03 13:10:27 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9628037299926189" P_Q="1.0" P_Z="0.022766031419009684" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.0" Z="2.277338301147145">
<NAME>All-cause mortality, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9766779259751815" CI_START="0.7572955624362241" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="-0.010248627716366213" LOG_CI_START="-0.12073458802565451" LOG_EFFECT_SIZE="-0.06549160787101034" MODIFIED="2009-05-29 20:39:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3445" SE="0.0649" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="87.24228914885624"/>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:26:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3443" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.855998889532296"/>
<IV_DATA CI_END="1.585930844210166" CI_START="0.630040284267446" EFFECT_SIZE="0.9996000799893344" ESTIMABLE="YES" ESTIMATE="-4.0E-4" LOG_CI_END="0.20028424563433728" LOG_CI_START="-0.20063168121985994" LOG_EFFECT_SIZE="-1.7371779276129093E-4" MODIFIED="2009-05-27 17:26:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3446" SE="0.23550000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="6.6257435608002835"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:10:23 +1000" MODIFIED_BY="[Empty name]" ORDER="3442" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.13798420040558482">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:10:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3444" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.13798420040558482">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.720891635224696" CI_END="0.36958176754350436" CI_START="0.13692542740697894" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.22495586563306383" ESTIMABLE="YES" I2="38.27726688919815" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.43228946183114825" LOG_CI_START="-0.8635158947650506" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6479026782980994" MODIFIED="2009-07-03 13:10:38 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.13690875023108762" P_Q="1.0" P_Z="3.872367241492013E-9" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="5.889555082751428">
<NAME>IPD, vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:27:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3374" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="14.474326683699541"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:10:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3375" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="2.411708291903257">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:10:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3376" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="2.408163617325199">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7664669694602914" CI_START="0.03770221904235076" EFFECT_SIZE="0.16999266328673915" ESTIMABLE="YES" ESTIMATE="-1.7719999999999998" LOG_CI_END="-0.11550655612626679" LOG_CI_START="-1.4236330877388574" LOG_EFFECT_SIZE="-0.7695698219325622" MODIFIED="2009-05-27 17:27:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3377" SE="0.7684000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="10.867039349292432"/>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:27:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3378" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="10.929534284052583"/>
<IV_DATA CI_END="0.5695615619321245" CI_START="0.1476498633524408" EFFECT_SIZE="0.28999256333582235" ESTIMABLE="YES" ESTIMATE="-1.2379" LOG_CI_END="-0.24445932766483905" LOG_CI_START="-0.8307669506312318" LOG_EFFECT_SIZE="-0.5376131391480354" MODIFIED="2009-05-29 20:39:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3373" SE="0.3444" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="54.095316543538175"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:27:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3372" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.813911230188806"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.534778653608704" CI_END="0.6232779199032203" CI_START="0.34926054829371567" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.46656873882072863" ESTIMABLE="YES" I2="47.983397166248395" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-0.20531825804951076" LOG_CI_START="-0.45685046854498934" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.3310843632972501" MODIFIED="2009-07-03 13:10:50 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.07318939179584216" P_Q="1.0" P_Z="2.4736630237051445E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="5.159684532082222">
<NAME>IPD, all serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:27:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3367" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="9.840577923602318"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:10:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3371" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.3128639585604325">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:10:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3366" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.312456805838873">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:27:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3369" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="13.13351565362758"/>
<IV_DATA CI_END="0.8030558991369575" CI_START="0.37671398293763836" EFFECT_SIZE="0.5500203507920862" ESTIMABLE="YES" ESTIMATE="-0.5978" LOG_CI_END="-0.09525422328697526" LOG_CI_START="-0.4239882592765526" LOG_EFFECT_SIZE="-0.259621241281764" MODIFIED="2009-05-29 20:39:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3368" SE="0.1931" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="58.546086679995376"/>
<IV_DATA CI_END="1.3123520639622117" CI_START="0.25634758642305827" EFFECT_SIZE="0.5800157619703381" ESTIMABLE="YES" ESTIMATE="-0.5447" LOG_CI_END="0.11805035861060773" LOG_CI_START="-0.5911707671960101" LOG_EFFECT_SIZE="-0.23656020429270125" MODIFIED="2009-05-27 17:27:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3370" SE="0.41659999999999997" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="12.578356159548346"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:27:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3365" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.276142818827061"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.3921404773143773" CI_END="1.5165379997569624" CI_START="0.5936123942311963" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.9488075426440916" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.18085329686099325" LOG_CI_START="-0.22649703985500388" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.022821871497005337" MODIFIED="2009-07-03 13:11:00 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9663347824928272" P_Q="1.0" P_Z="0.8261712987141119" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.00000000000001" Z="0.21961462732319906">
<NAME>IPD, non-vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:27:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3381" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="2.1486129605826143"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:27:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3383" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="6.871635275692198"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:27:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3380" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="14.329788571074673"/>
<IV_DATA CI_END="1.6831949430590951" CI_START="0.5509596300581605" EFFECT_SIZE="0.9630017980998817" ESTIMABLE="YES" ESTIMATE="-0.0377" LOG_CI_END="0.2261344176941599" LOG_CI_START="-0.258880221629665" LOG_EFFECT_SIZE="-0.016372901967752606" MODIFIED="2009-05-29 20:39:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3385" SE="0.2849" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="70.53853973734479"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:10:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3379" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.9116921840365375">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:11:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3384" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.9105880213056243">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 17:27:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3382" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="2.289143249963571"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.5813456346296855" CI_END="1.4454767519976115" CI_START="0.33287330547697125" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6936574258433057" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.16001111118457745" LOG_CI_START="-0.47772103136449007" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1588549600899563" MODIFIED="2009-07-02 18:45:29 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6301313221042546" P_Q="1.0" P_Z="0.3288520508646845" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55349" TOTAL_2="55198" WEIGHT="100.0" Z="0.976428753606085">
<NAME>IPD, vaccine-related serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3388" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.266215717653561"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3389" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.526614308407929"/>
<IV_DATA CI_END="1.4983669062418394" CI_START="0.2565643455878163" EFFECT_SIZE="0.620022196981994" ESTIMABLE="YES" ESTIMATE="-0.478" LOG_CI_END="0.17561817240557379" LOG_CI_START="-0.5908036971050825" LOG_EFFECT_SIZE="-0.20759276234975432" MODIFIED="2009-05-27 17:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3390" SE="0.45020000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="69.23741353816192"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3387" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="9.35910324505495"/>
<IV_DATA CI_END="88.7641668015923" CI_START="0.1802549499613394" EFFECT_SIZE="4.000022555584031" ESTIMABLE="YES" ESTIMATE="1.3862999999999999" LOG_CI_END="1.9482376808567727" LOG_CI_START="-0.7441128003318167" LOG_EFFECT_SIZE="0.6020624402624779" MODIFIED="2009-05-27 17:28:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3386" SE="1.5815000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="5.6106531907216395"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="17.165391064664455" CI_END="0.8365069406593358" CI_START="0.6991163778438447" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7647324384351633" ESTIMABLE="YES" I2="76.6972975743376" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="-0.07753045126160435" LOG_CI_START="-0.15545052375585472" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11649048750872956" MODIFIED="2009-06-03 15:17:02 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0017950272135466294" P_Q="1.0" P_Z="4.620560102185089E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.00000000000001" Z="5.860291263858109">
<NAME>X-ray defined pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7406208940078663" CI_START="0.5704478063783269" EFFECT_SIZE="0.6499888955549492" ESTIMABLE="YES" ESTIMATE="-0.43079999999999996" LOG_CI_END="-0.13040404002581146" LOG_CI_START="-0.2437840855820302" LOG_EFFECT_SIZE="-0.18709406280392085" MODIFIED="2009-05-29 20:39:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3394" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="47.23081520102008"/>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:17:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3392" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="4.536292696507507">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.982267336595287" CI_START="0.6516105384595232" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="-0.007770297338020087" LOG_CI_START="-0.1860119004872109" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2009-05-27 17:28:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3391" SE="0.1047" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="19.110873444118468"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:28:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3393" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="13.472276666761198"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:13:26 +1000" MODIFIED_BY="[Empty name]" ORDER="518" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="15.649741991592766"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.5800739844857756" CI_END="0.9808780868522404" CI_START="0.914972860327077" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9473525366828051" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="-0.008384967643032188" LOG_CI_START="-0.038591787665786664" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.023488377654409427" MODIFIED="2009-05-29 20:39:13 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4609935901659953" P_Q="1.0" P_Z="0.002303100129824471" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.0480781640198567">
<NAME>Clinical pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0077886986967415" CI_START="0.8581653148818031" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.0033694838856330425" LOG_CI_START="-0.06642904265798516" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-27 17:29:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3395" SE="0.040999999999999995" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="18.72912579256641"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:29:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3407" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="21.688787248161784"/>
<IV_DATA CI_END="0.9914478002889936" CI_START="0.8911780673295733" EFFECT_SIZE="0.9399768797793391" ESTIMABLE="YES" ESTIMATE="-0.061900000000000004" LOG_CI_END="-0.0037301464543672202" LOG_CI_START="-0.0500355104052554" LOG_EFFECT_SIZE="-0.026882828429811306" MODIFIED="2009-05-29 20:39:13 +1000" MODIFIED_BY="[Empty name]" ORDER="3396" SE="0.027200000000000002" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="42.55468811811219"/>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:29:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3398" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="17.027398841159616"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.645880832401504" CI_END="0.99752657628854" CI_START="0.9001266460192521" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9475759871533633" ESTIMABLE="YES" I2="89.63288042455494" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-0.0010755249327331184" LOG_CI_START="-0.045696381896428016" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.023385953414580597" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.001897787760677505" P_Q="1.0" P_Z="0.039932302557831784" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="2.054448504832748">
<NAME>All-cause admissions, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9372348680134331" CI_START="0.8075271263774072" EFFECT_SIZE="0.8699669992060597" ESTIMABLE="YES" ESTIMATE="-0.1393" LOG_CI_END="-0.028151562686958464" LOG_CI_START="-0.09284287997128751" LOG_EFFECT_SIZE="-0.06049722132912297" MODIFIED="2009-05-29 20:39:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3399" SE="0.038" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="47.57555074715732"/>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:29:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3400" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="52.42444925284268"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.6023364943036507" CI_END="0.9809449967235168" CI_START="0.7734759475240669" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8710553144374442" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="-0.008355343577401895" LOG_CI_START="-0.11155318683854713" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05995426520797451" MODIFIED="2009-07-03 13:11:25 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9628037299926189" P_Q="1.0" P_Z="0.022766031419009684" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.0" Z="2.277338301147145">
<NAME>All-cause mortality, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9766779259751815" CI_START="0.7572955624362241" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="-0.010248627716366213" LOG_CI_START="-0.12073458802565451" LOG_EFFECT_SIZE="-0.06549160787101034" MODIFIED="2009-05-29 20:39:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3402" SE="0.0649" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="87.24228914885624"/>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:29:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3404" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="5.855998889532296"/>
<IV_DATA CI_END="1.585930844210166" CI_START="0.630040284267446" EFFECT_SIZE="0.9996000799893344" ESTIMABLE="YES" ESTIMATE="-4.0E-4" LOG_CI_END="0.20028424563433728" LOG_CI_START="-0.20063168121985994" LOG_EFFECT_SIZE="-1.7371779276129093E-4" MODIFIED="2009-05-27 17:29:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3401" SE="0.23550000000000001" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="6.6257435608002835"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:11:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3403" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.13798420040558482">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:11:25 +1000" MODIFIED_BY="[Empty name]" ORDER="3405" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.13798420040558482">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.065251080395844" CI_END="0.5303586130765834" CI_START="0.09025121937310253" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.21878188118578085" ESTIMABLE="YES" I2="34.050545525990934" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="-0.27543037376949003" LOG_CI_START="-1.044546921683442" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.659988647726466" MODIFIED="2009-07-02 18:46:47 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.19432813307928476" P_Q="1.0" P_Z="7.689399614380863E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.34213118979877616" TOTALS="YES" TOTAL_1="47579" TOTAL_2="47371" WEIGHT="99.99999999999999" Z="3.36373982137721">
<NAME>IPD, vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:30:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3477" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="9.858828694717959"/>
<IV_DATA CI_END="0.8746631838195954" CI_START="0.025725216007809762" EFFECT_SIZE="0.15000299776283707" ESTIMABLE="YES" ESTIMATE="-1.8971" LOG_CI_END="-0.05815915334257466" LOG_CI_START="-1.5896409698947433" LOG_EFFECT_SIZE="-0.823900061618659" MODIFIED="2009-05-27 17:30:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3479" SE="0.8996" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="17.72674547125371"/>
<IV_DATA CI_END="0.5090899287812082" CI_START="0.1039059205511444" EFFECT_SIZE="0.22999447317996144" ESTIMABLE="YES" ESTIMATE="-1.4697" LOG_CI_END="-0.29320549443390664" LOG_CI_START="-0.9833597056725119" LOG_EFFECT_SIZE="-0.6382826000532091" MODIFIED="2009-05-29 20:38:56 +1000" MODIFIED_BY="[Empty name]" ORDER="3480" SE="0.4054" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="40.299245446945264"/>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:30:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3478" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="21.044847075694374"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:30:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3476" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="11.070333311388685"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.509621383381235" CI_END="0.7627393346612826" CI_START="0.12518181015929458" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3090001465899253" ESTIMABLE="YES" I2="68.45300271109929" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="-0.11762385635698924" LOG_CI_START="-0.9024587727339203" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5100413145454548" MODIFIED="2009-07-02 18:48:42 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.023229300671101738" P_Q="1.0" P_Z="0.010851439026696719" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5448420549993092" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="2.547446822960794">
<NAME>IPD, all serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:30:55 +1000" MODIFIED_BY="[Empty name]" ORDER="1049" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="23.56667663399049"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:30:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3474" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="25.685912670420333"/>
<IV_DATA CI_END="0.7981548974497817" CI_START="0.31325196674463957" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09791281719607922" LOG_CI_START="-0.5041061936182085" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-29 20:38:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3473" SE="0.2386" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="35.31830468529772"/>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:30:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3475" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="15.429106010291466"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.5600409498595291" CI_END="2.502034628924777" CI_START="0.5763162137965323" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="1.2008176897971394" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.3982933161675015" LOG_CI_START="-0.23933916201969924" LOG_DATA="YES" LOG_EFFECT_SIZE="0.07947707707390114" MODIFIED="2009-07-02 18:49:54 +1000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.668483855263472" P_Q="1.0" P_Z="0.6251280370497251" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="0.48859559068955577">
<NAME>IPD, non-vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:31:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3483" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="5.262635348726895"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:31:37 +1000" MODIFIED_BY="[Empty name]" ORDER="1050" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="16.840693158014815"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:31:37 +1000" MODIFIED_BY="[Empty name]" ORDER="3481" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.03707692179983"/>
<IV_DATA CI_END="4.134784121744075" CI_START="0.6584707884321952" EFFECT_SIZE="1.6500407754482138" ESTIMABLE="YES" ESTIMATE="0.5008" LOG_CI_END="0.6164528398419514" LOG_CI_START="-0.1814634867676544" LOG_EFFECT_SIZE="0.21749467653714846" MODIFIED="2009-05-29 20:38:47 +1000" MODIFIED_BY="[Empty name]" ORDER="3482" SE="0.46869999999999995" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="63.85959457145846"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.2319326810546541" CI_END="1.5136903941485902" CI_START="0.20206820641236722" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.55305397838659" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.180037054911124" LOG_CI_START="-0.6945020133816574" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.25723247923526676" MODIFIED="2009-07-02 18:51:18 +1000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.8905051997870491" P_Q="1.0" P_Z="0.24891545227651246" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16674" TOTAL_2="16452" WEIGHT="99.99999999999999" Z="1.1529877011424339">
<NAME>IPD, vaccine-related serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:32:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3486" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.899673000629653"/>
<IV_DATA CI_END="1.7022431855028182" CI_START="0.17129862472492663" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="0.23102160426647886" LOG_CI_START="-0.7662461237640463" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-05-29 20:38:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3485" SE="0.5858" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="76.9015158155225"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:32:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3484" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="13.19881118384784"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.530619698608064" CI_END="0.9407914416581638" CI_START="0.6095439107697165" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7572672543871131" ESTIMABLE="YES" I2="74.24442760414446" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="-0.02650664200936918" LOG_CI_START="-0.21499500289536003" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12075082245236463" MODIFIED="2009-06-03 15:17:14 +1000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.003718244225044187" P_Q="1.0" P_Z="0.012031688759336532" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04266269378702871" TOTALS="YES" TOTAL_1="39664" TOTAL_2="39396" WEIGHT="100.00000000000003" Z="2.5112135518370375">
<NAME>X-ray defined pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:17:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3488" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="12.10435305901932">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7257928755001224" CI_START="0.546889012312736" EFFECT_SIZE="0.6300223399419123" ESTIMABLE="YES" ESTIMATE="-0.462" LOG_CI_END="-0.1391872992191897" LOG_CI_START="-0.26210080205941494" LOG_EFFECT_SIZE="-0.20064405063930238" MODIFIED="2009-05-29 20:38:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3490" SE="0.0722" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="25.605346099747393"/>
<IV_DATA CI_END="0.9566932487621087" CI_START="0.5879416757645449" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.019227290776280433" LOG_CI_START="-0.23066575411085066" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2009-05-27 17:33:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3489" SE="0.1242" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="21.103542353641416"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:33:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3487" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="19.839421747073864"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 14:16:57 +1000" MODIFIED_BY="[Empty name]" ORDER="541" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="21.347336740518024"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.2311797332360297" CI_END="0.9813612279339565" CI_START="0.9062311337031553" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9430483010763075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="-0.008171104320216154" LOG_CI_START="-0.04276102165008218" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02546606298514918" MODIFIED="2009-05-29 20:38:27 +1000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5258331717529132" P_Q="1.0" P_Z="0.0039022122030705933" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="100.00000000000001" Z="2.885960426151398">
<NAME>Clinical pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0100199508526517" CI_START="0.8199023067119334" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="0.004329952455553735" LOG_CI_START="-0.08623789174250697" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:33:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3491" SE="0.053200000000000004" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="14.586496345512899"/>
<IV_DATA CI_END="0.9862937178397478" CI_START="0.8768679048728684" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="-0.005993733089730402" LOG_CI_START="-0.057065825682621765" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-29 20:38:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3492" SE="0.03" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.87031712991603"/>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:33:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3410" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="20.117677790410962"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:33:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3494" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="19.42550873416012"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.146925926042876" CI_END="1.0944461829333414" CI_START="0.7840204259652876" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9263196870084763" ESTIMABLE="YES" I2="89.06736527566243" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="0.03919441092019714" LOG_CI_START="-0.10567262255987905" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03323910581984094" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0024913711918134185" P_Q="1.0" P_Z="0.36843417033418846" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.012900535000000003" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="0.8994102898388378">
<NAME>All-cause admissions, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9222255092960167" CI_START="0.7834606030293128" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="-0.035162869111540394" LOG_CI_START="-0.10598283750701638" LOG_EFFECT_SIZE="-0.07057285330927841" MODIFIED="2009-05-29 20:38:19 +1000" MODIFIED_BY="[Empty name]" ORDER="3495" SE="0.0416" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="49.49228529096203"/>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:33:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3496" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="50.507714709037955"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.022116696493435162" CI_END="0.9719636902735483" CI_START="0.7305957255617559" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8426817415341838" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="-0.012349958744895934" LOG_CI_START="-0.13632287300881754" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07433641587685669" MODIFIED="2009-05-29 20:38:15 +1000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.8817770900543261" P_Q="1.0" P_Z="0.018750214855141223" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.3504601585514404">
<NAME>All-cause mortality, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9748782016473438" CI_START="0.7237152516207703" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="-0.011049640359598078" LOG_CI_START="-0.14043227492825616" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-29 20:38:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3497" SE="0.076" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="91.81246345482573"/>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:33:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3498" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="8.187536545174265"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.065251080395844" CI_END="0.4114425317531584" CI_START="0.12027140350048751" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.22245172679425587" ESTIMABLE="YES" I2="34.050545525990934" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="-0.3856908163093576" LOG_CI_START="-0.9198376210248221" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6527642186670899" MODIFIED="2009-07-02 18:47:18 +1000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.19432813307928476" P_Q="1.0" P_Z="1.664307357974246E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47579" TOTAL_2="47371" WEIGHT="100.00000000000001" Z="4.790422212355822">
<NAME>IPD, vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:34:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3450" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="5.696514637871286"/>
<IV_DATA CI_END="0.8746631838195954" CI_START="0.025725216007809762" EFFECT_SIZE="0.15000299776283707" ESTIMABLE="YES" ESTIMATE="-1.8971" LOG_CI_END="-0.05815915334257466" LOG_CI_START="-1.5896409698947433" LOG_EFFECT_SIZE="-0.823900061618659" MODIFIED="2009-05-27 17:34:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3451" SE="0.8996" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="12.164592917632229"/>
<IV_DATA CI_END="0.5090899287812082" CI_START="0.1039059205511444" EFFECT_SIZE="0.22999447317996144" ESTIMABLE="YES" ESTIMATE="-1.4697" LOG_CI_END="-0.29320549443390664" LOG_CI_START="-0.9833597056725119" LOG_EFFECT_SIZE="-0.6382826000532091" MODIFIED="2009-05-29 20:38:11 +1000" MODIFIED_BY="[Empty name]" ORDER="3454" SE="0.4054" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="59.90029825960945"/>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:34:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3452" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="15.682567364416961"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:34:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3453" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="6.556026820470086"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.509621383381235" CI_END="0.5816613551539359" CI_START="0.2660171652382894" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3933597651345545" ESTIMABLE="YES" I2="68.45300271109929" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="-0.235329789220226" LOG_CI_START="-0.575090338828526" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.40521006402437604" MODIFIED="2009-07-02 18:48:49 +1000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.023229300671101738" P_Q="1.0" P_Z="2.938958944072758E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="4.675040304570693">
<NAME>IPD, all serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:34:38 +1000" MODIFIED_BY="[Empty name]" ORDER="1051" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="11.156944837083442"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:34:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3448" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.094548244492191"/>
<IV_DATA CI_END="0.7981548974497817" CI_START="0.31325196674463957" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09791281719607922" LOG_CI_START="-0.5041061936182085" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-29 20:38:07 +1000" MODIFIED_BY="[Empty name]" ORDER="3449" SE="0.2386" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="69.96490139364265"/>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:34:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3447" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="4.78360552478171"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.5600409498595291" CI_END="2.502034628924777" CI_START="0.5763162137965323" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="1.2008176897971394" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.27" LOG_CI_END="0.3982933161675015" LOG_CI_START="-0.23933916201969924" LOG_DATA="YES" LOG_EFFECT_SIZE="0.07947707707390114" MODIFIED="2009-07-02 18:50:01 +1000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.668483855263472" P_Q="1.0" P_Z="0.6251280370497251" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="0.48859559068955577">
<NAME>IPD, non-vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3457" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="5.262635348726895"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="1052" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="16.840693158014815"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:34:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3455" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.03707692179983"/>
<IV_DATA CI_END="4.134784121744075" CI_START="0.6584707884321952" EFFECT_SIZE="1.6500407754482138" ESTIMABLE="YES" ESTIMATE="0.5008" LOG_CI_END="0.6164528398419514" LOG_CI_START="-0.1814634867676544" LOG_EFFECT_SIZE="0.21749467653714846" MODIFIED="2009-05-29 20:38:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3456" SE="0.46869999999999995" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="63.85959457145846"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.23193268105465406" CI_END="1.5136903941485902" CI_START="0.20206820641236722" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.55305397838659" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.180037054911124" LOG_CI_START="-0.6945020133816574" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.25723247923526676" MODIFIED="2009-07-02 18:51:24 +1000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.8905051997870491" P_Q="1.0" P_Z="0.24891545227651246" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16674" TOTAL_2="16452" WEIGHT="99.99999999999999" Z="1.1529877011424339">
<NAME>IPD, vaccine-related serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:35:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3460" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.899673000629653"/>
<IV_DATA CI_END="1.7022431855028182" CI_START="0.17129862472492663" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="0.23102160426647886" LOG_CI_START="-0.7662461237640463" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-05-29 20:37:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3459" SE="0.5858" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="76.9015158155225"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:35:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3458" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="13.19881118384784"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.530619698608064" CI_END="0.80425982523908" CI_START="0.6600894543053747" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.728617477941478" ESTIMABLE="YES" I2="74.24442760414446" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="-0.09460362483562697" LOG_CI_START="-0.1803972055510482" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.13750041519333764" MODIFIED="2009-07-03 13:12:57 +1000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.003718244225044187" P_Q="1.0" P_Z="3.333324190618011E-10" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39664" TOTAL_2="39396" WEIGHT="100.00000000000003" Z="6.282424847895515">
<NAME>X-ray defined pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:17:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3463" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="4.33306509409623">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7257928755001224" CI_START="0.546889012312736" EFFECT_SIZE="0.6300223399419123" ESTIMABLE="YES" ESTIMATE="-0.462" LOG_CI_END="-0.1391872992191897" LOG_CI_START="-0.26210080205941494" LOG_EFFECT_SIZE="-0.20064405063930238" MODIFIED="2009-07-03 13:12:57 +1000" MODIFIED_BY="[Empty name]" ORDER="3462" SE="0.0722" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="48.72034972334789"/>
<IV_DATA CI_END="0.9566932487621087" CI_START="0.5879416757645449" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.019227290776280433" LOG_CI_START="-0.23066575411085066" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2009-05-27 17:35:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3461" SE="0.1242" STUDY_ID="STD-Klugman-2003" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="16.46423667684821"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:35:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3464" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="13.278237489307294"/>
<IV_DATA CI_END="1.37044516377521" CI_START="0.8511766231967057" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.1368616626071554" LOG_CI_START="-0.06998031239405461" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2009-06-01 14:17:19 +1000" MODIFIED_BY="[Empty name]" ORDER="542" SE="0.1215" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="17.204111016400404"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.2311797332360297" CI_END="0.9813612279339565" CI_START="0.9062311337031553" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9430483010763075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="-0.008171104320216154" LOG_CI_START="-0.04276102165008218" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02546606298514918" MODIFIED="2009-05-29 20:37:38 +1000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.5258331717529132" P_Q="1.0" P_Z="0.0039022122030705933" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="100.00000000000001" Z="2.885960426151398">
<NAME>Clinical pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0100199508526517" CI_START="0.8199023067119334" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="0.004329952455553735" LOG_CI_START="-0.08623789174250697" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:36:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3465" SE="0.053200000000000004" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="14.586496345512899"/>
<IV_DATA CI_END="0.9862937178397478" CI_START="0.8768679048728684" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="-0.005993733089730402" LOG_CI_START="-0.057065825682621765" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-29 20:37:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3466" SE="0.03" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.87031712991603"/>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:36:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3409" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="20.117677790410962"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:36:00 +1000" MODIFIED_BY="[Empty name]" ORDER="3467" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="19.42550873416012"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.146925926042876" CI_END="0.985520894274657" CI_START="0.8830205771841544" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9328639927071104" ESTIMABLE="YES" I2="89.06736527566243" I2_Q="0.0" ID="CMP-003.31" LOG_CI_END="-0.006334163701135355" LOG_CI_START="-0.05402917586364833" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.030181669782391802" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0024913711918134185" P_Q="1.0" P_Z="0.013117902264446321" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.4805522877406077">
<NAME>All-cause admissions, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9222255092960167" CI_START="0.7834606030293128" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="-0.035162869111540394" LOG_CI_START="-0.10598283750701638" LOG_EFFECT_SIZE="-0.07057285330927841" MODIFIED="2009-05-29 20:37:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3470" SE="0.0416" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.35597116486737"/>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:36:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3469" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="54.64402883513264"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.022116696493435162" CI_END="0.9719636902735483" CI_START="0.7305957255617559" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8426817415341838" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="-0.012349958744895934" LOG_CI_START="-0.13632287300881754" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07433641587685669" MODIFIED="2009-05-29 20:37:28 +1000" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.8817770900543261" P_Q="1.0" P_Z="0.018750214855141223" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.3504601585514404">
<NAME>All-cause mortality, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9748782016473438" CI_START="0.7237152516207703" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="-0.011049640359598078" LOG_CI_START="-0.14043227492825616" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-29 20:37:28 +1000" MODIFIED_BY="[Empty name]" ORDER="3472" SE="0.076" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="91.81246345482573"/>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:36:33 +1000" MODIFIED_BY="[Empty name]" ORDER="3471" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="8.187536545174265"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-07-03 13:15:18 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Pooled with Cutts 2005 children &lt; 29 months and/or HIV-1 negative and HIV-1 positive children</NAME>
<IV_OUTCOME CHI2="9.73900162997477" CI_END="0.45114865194350506" CI_START="0.124948011669653" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.2374239394580616" ESTIMABLE="YES" I2="38.39204234720367" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.34568033598970876" LOG_CI_START="-0.9032706505240745" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6244754932568916" MODIFIED="2009-07-03 13:13:38 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13608235510056754" P_Q="1.0" P_Z="1.1327825902286216E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.24808100680029543" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.00000000000001" Z="4.39013893931602">
<NAME>IPD, vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:41:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3682" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="15.516533728957402"/>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:13:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3687" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="3.6883013086381564">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:13:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3683" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="3.683342077440035">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:41:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3685" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="12.845309391325616"/>
<IV_DATA CI_END="0.5706694780811643" CI_START="0.137373069987529" EFFECT_SIZE="0.2799903893925476" ESTIMABLE="YES" ESTIMATE="-1.273" LOG_CI_END="-0.24361535481288246" LOG_CI_START="-0.8620983961127966" LOG_EFFECT_SIZE="-0.5528568754628396" MODIFIED="2009-05-27 17:41:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3684" SE="0.36329999999999996" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="28.22568296507473"/>
<IV_DATA CI_END="0.5695615619321245" CI_START="0.1476498633524408" EFFECT_SIZE="0.28999256333582235" ESTIMABLE="YES" ESTIMATE="-1.2379" LOG_CI_END="-0.24445932766483905" LOG_CI_START="-0.8307669506312318" LOG_EFFECT_SIZE="-0.5376131391480354" MODIFIED="2009-05-29 20:36:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3686" SE="0.3444" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="29.25524753595508"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:41:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3681" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.785582992608981"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.35714112926071" CI_END="0.6516878868368065" CI_START="0.2705454149837857" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.4198942364264723" ESTIMABLE="YES" I2="47.16980328313866" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.18596035132114774" LOG_CI_START="-0.567759821790961" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.3768600865560543" MODIFIED="2009-07-03 13:13:48 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0779461508006315" P_Q="1.0" P_Z="1.091861464630037E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.13270458966219054" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="99.99999999999999" Z="3.8692154075101772">
<NAME>IPD, all serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:42:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3678" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="14.186450926570974"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:13:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3675" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="2.8012821157864316">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:13:48 +1000" MODIFIED_BY="[Empty name]" ORDER="3679" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="2.800477556386099">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:42:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3680" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="16.82616863751024"/>
<IV_DATA CI_END="0.7756390044703381" CI_START="0.32234530490604235" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.11034035972701615" LOG_CI_START="-0.49167865108727155" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-27 17:42:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3674" SE="0.22399999999999998" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="27.502883812139768"/>
<IV_DATA CI_END="0.8030558991369575" CI_START="0.37671398293763836" EFFECT_SIZE="0.5500203507920862" ESTIMABLE="YES" ESTIMATE="-0.5978" LOG_CI_END="-0.09525422328697526" LOG_CI_START="-0.4239882592765526" LOG_EFFECT_SIZE="-0.259621241281764" MODIFIED="2009-05-29 20:36:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3677" SE="0.1931" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="29.58808474135855"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:42:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3676" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="6.294652210247933"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2345593887892048" CI_END="1.5342446316499805" CI_START="0.6561802722027824" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="1.0033648688397168" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.18589461235429483" LOG_CI_START="-0.18297683064345213" LOG_DATA="YES" LOG_EFFECT_SIZE="0.0014588908554213913" MODIFIED="2009-07-03 13:13:58 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9751433391749957" P_Q="1.0" P_Z="0.9876306032874004" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="0.015503360795637064">
<NAME>IPD, non-vaccine serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:43:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3694" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="1.761862861589617"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:43:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3691" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="5.634741674158166"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:43:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3689" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="11.750428188314494"/>
<IV_DATA CI_END="1.6831949430590951" CI_START="0.5509596300581605" EFFECT_SIZE="0.9630017980998817" ESTIMABLE="YES" ESTIMATE="-0.0377" LOG_CI_END="0.2261344176941599" LOG_CI_START="-0.258880221629665" LOG_EFFECT_SIZE="-0.016372901967752606" MODIFIED="2009-05-29 20:36:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3688" SE="0.2849" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="57.84161026390339"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:13:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3693" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.5675877990291094">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:13:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3692" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.5666823854695544">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.7327398061044663" CI_START="0.5554689891982019" EFFECT_SIZE="1.4399379177717142" ESTIMABLE="YES" ESTIMATE="0.36460000000000004" LOG_CI_END="0.5720277181043456" LOG_CI_START="-0.25534018190049435" LOG_EFFECT_SIZE="0.15834376810192566" MODIFIED="2009-05-27 17:43:31 +1000" MODIFIED_BY="[Empty name]" ORDER="3690" SE="0.486" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="19.877086827535667"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.290960055478461" CI_END="1.0707680392998031" CI_START="0.3466783402873159" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6092717675201758" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.02969539971802883" LOG_CI_START="-0.46007329127566887" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21518894577882008" MODIFIED="2009-07-02 18:40:50 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8629074454456298" P_Q="1.0" P_Z="0.08501646285195708" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55349" TOTAL_2="55198" WEIGHT="99.99999999999999" Z="1.722292957281163">
<NAME>IPD, vaccine-related serotypes, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:44:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3698" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.1060187255175853"/>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:44:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3699" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="6.208606504403599"/>
<IV_DATA CI_END="1.3761647145928655" CI_START="0.2529659364846539" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="0.1386704181709836" LOG_CI_START="-0.5969379554752949" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-05-27 17:44:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3695" SE="0.4321" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="44.32907909636094"/>
<IV_DATA CI_END="1.4983669062418394" CI_START="0.2565643455878163" EFFECT_SIZE="0.620022196981994" ESTIMABLE="YES" ESTIMATE="-0.478" LOG_CI_END="0.17561817240557379" LOG_CI_START="-0.5908036971050825" LOG_EFFECT_SIZE="-0.20759276234975432" MODIFIED="2009-05-29 20:36:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3697" SE="0.45020000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="40.836288235407785"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:44:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3696" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="5.520007438310072"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="18.010381525668727" CI_END="0.989357953614675" CI_START="0.6733149566498708" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.816179825558847" ESTIMABLE="YES" I2="77.79058708834609" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.0046465505123154125" LOG_CI_START="-0.17178173824501852" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08821414437866691" MODIFIED="2009-06-03 15:17:53 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0012283482376946875" P_Q="1.0" P_Z="0.03855148352519052" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03461481248626261" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="2.0689424920587602">
<NAME>X-ray defined pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7406208940078663" CI_START="0.5704478063783269" EFFECT_SIZE="0.6499888955549492" ESTIMABLE="YES" ESTIMATE="-0.43079999999999996" LOG_CI_END="-0.13040404002581146" LOG_CI_START="-0.2437840855820302" LOG_EFFECT_SIZE="-0.18709406280392085" MODIFIED="2009-05-29 20:36:42 +1000" MODIFIED_BY="[Empty name]" ORDER="3700" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="24.682310436842002"/>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:17:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3703" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="11.929348045142808">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9584492707762539" CI_START="0.7188077397979356" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.018430868706605385" LOG_CI_START="-0.14338725525054621" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-05-27 17:45:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3701" SE="0.07339999999999999" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="24.094906288651966"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:45:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3702" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="19.213700587660732"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:13:42 +1000" MODIFIED_BY="[Empty name]" ORDER="519" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="20.07973464170249"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.628292878188491" CI_END="0.9770058798265359" CI_START="0.9071349870200871" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.941422442963303" ESTIMABLE="YES" I2="17.316487375246858" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-0.010102822597977104" LOG_CI_START="-0.04232808255850531" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.026215452578241174" MODIFIED="2009-05-29 20:36:34 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.30450035860686653" P_Q="1.0" P_Z="0.0014282210559278415" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.52465832013153E-4" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.1888861690925667">
<NAME>Clinical pneumonia, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9721460644718857" CI_START="0.8518449210397556" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="-0.012268477637136009" LOG_CI_START="-0.06963946164981731" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:45:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3704" SE="0.0337" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="25.81248644774206"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:45:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3416" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="21.027088658879027"/>
<IV_DATA CI_END="0.9914478002889936" CI_START="0.8911780673295733" EFFECT_SIZE="0.9399768797793391" ESTIMABLE="YES" ESTIMATE="-0.061900000000000004" LOG_CI_END="-0.0037301464543672202" LOG_CI_START="-0.0500355104052554" LOG_EFFECT_SIZE="-0.026882828429811306" MODIFIED="2009-05-29 20:36:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3705" SE="0.027200000000000002" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="36.10958682818531"/>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:45:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3706" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="17.050838065193602"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.645880832401504" CI_END="1.1077652966007787" CI_START="0.8048290750724708" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9442254598667555" ESTIMABLE="YES" I2="89.63288042455494" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.04444775570969177" LOG_CI_START="-0.09429634278087944" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02492429353559384" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.001897787760677505" P_Q="1.0" P_Z="0.48131792465324486" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.011907280000000004" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="0.7041844402944211">
<NAME>All-cause admissions, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9372348680134331" CI_START="0.8075271263774072" EFFECT_SIZE="0.8699669992060597" ESTIMABLE="YES" ESTIMATE="-0.1393" LOG_CI_END="-0.028151562686958464" LOG_CI_START="-0.09284287997128751" LOG_EFFECT_SIZE="-0.06049722132912297" MODIFIED="2009-05-29 20:36:29 +1000" MODIFIED_BY="[Empty name]" ORDER="3708" SE="0.038" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="49.74865444691182"/>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:46:03 +1000" MODIFIED_BY="[Empty name]" ORDER="3709" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="50.251345553088186"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.9263816146499498" CI_END="0.9832124581670215" CI_START="0.8026643040328165" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8883634073120228" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="-0.007352627193496197" LOG_CI_START="-0.09546605047318694" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05140933883334162" MODIFIED="2009-07-03 13:14:27 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9207458471278525" P_Q="1.0" P_Z="0.022192175951626925" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="100.0" Z="2.2870624890496156">
<NAME>All-cause mortality, ITT (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9766779259751815" CI_START="0.7572955624362241" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="-0.010248627716366213" LOG_CI_START="-0.12073458802565451" LOG_EFFECT_SIZE="-0.06549160787101034" MODIFIED="2009-05-29 20:36:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3712" SE="0.0649" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="63.60188086095632"/>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:46:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3710" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.2691743571564515"/>
<IV_DATA CI_END="1.1319396900082939" CI_START="0.7904659470596627" EFFECT_SIZE="0.94591742719797" ESTIMABLE="YES" ESTIMATE="-0.0556" LOG_CI_END="0.05382328816466002" LOG_CI_START="-0.10211683455230162" LOG_EFFECT_SIZE="-0.024146773193820824" MODIFIED="2009-05-27 17:46:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3713" SE="0.0916" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="31.927756693850778"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:14:24 +1000" MODIFIED_BY="[Empty name]" ORDER="3711" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.10059404401822006">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:14:27 +1000" MODIFIED_BY="[Empty name]" ORDER="3714" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.10059404401822006">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.73900162997477" CI_END="0.37927172690153665" CI_START="0.16275270535542086" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.2484501954477948" ESTIMABLE="YES" I2="38.39204234720367" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="-0.42104953090202274" LOG_CI_START="-0.7884717836435446" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6047606572727837" MODIFIED="2009-07-03 13:14:38 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.13608235510056754" P_Q="1.0" P_Z="1.1036406832153949E-10" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="6.452026782140934">
<NAME>IPD, vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22493226217752849" CI_START="0.016542143201498972" EFFECT_SIZE="0.060998866313873294" ESTIMABLE="YES" ESTIMATE="-2.7969" LOG_CI_END="-0.6479482489627539" LOG_CI_START="-1.7814082239076559" LOG_EFFECT_SIZE="-1.2146782364352051" MODIFIED="2009-05-27 17:47:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3642" SE="0.6658" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="10.50796296769059"/>
<IV_DATA CI_END="0.5695615619321245" CI_START="0.1476498633524408" EFFECT_SIZE="0.28999256333582235" ESTIMABLE="YES" ESTIMATE="-1.2379" LOG_CI_END="-0.24445932766483905" LOG_CI_START="-0.8307669506312318" LOG_EFFECT_SIZE="-0.5376131391480354" MODIFIED="2009-05-29 20:36:19 +1000" MODIFIED_BY="[Empty name]" ORDER="3645" SE="0.3444" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="39.27171158884691"/>
<IV_DATA CI_END="4.091244538722802" CI_START="0.006808052256681595" EFFECT_SIZE="0.16689339895420674" ESTIMABLE="YES" ESTIMATE="-1.7904" LOG_CI_END="0.6118554385900273" LOG_CI_START="-2.166977119389191" LOG_EFFECT_SIZE="-0.7775608403995821" MODIFIED="2009-07-03 13:14:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3640" SE="1.6323" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.7482605349436016">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.062088520170427" CI_START="0.006791406233927823" EFFECT_SIZE="0.16609423017869124" ESTIMABLE="YES" ESTIMATE="-1.7952" LOG_CI_END="0.6087493832250338" LOG_CI_START="-2.168040291050469" LOG_EFFECT_SIZE="-0.7796454539127177" MODIFIED="2009-07-03 13:14:38 +1000" MODIFIED_BY="[Empty name]" ORDER="3644" SE="1.6311" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.7508338711693685">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.5706694780811643" CI_START="0.137373069987529" EFFECT_SIZE="0.2799903893925476" ESTIMABLE="YES" ESTIMATE="-1.273" LOG_CI_END="-0.24361535481288246" LOG_CI_START="-0.8620983961127966" LOG_EFFECT_SIZE="-0.5528568754628396" MODIFIED="2009-05-27 17:47:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3646" SE="0.36329999999999996" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="35.29192271354294"/>
<IV_DATA CI_END="28.7339232677647" CI_START="0.31115054383324237" EFFECT_SIZE="2.9900795727250546" ESTIMABLE="YES" ESTIMATE="1.0953" LOG_CI_END="1.4583949276701829" LOG_CI_START="-0.5070294356129196" LOG_EFFECT_SIZE="0.4756827460286317" MODIFIED="2009-05-27 17:47:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3643" SE="1.1545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.494767117115032"/>
<IV_DATA CI_END="0.7811597574671563" CI_START="0.03875775535731072" EFFECT_SIZE="0.17399999647956382" ESTIMABLE="YES" ESTIMATE="-1.7487000000000001" LOG_CI_END="-0.10726013809299395" LOG_CI_START="-1.411641382915439" LOG_EFFECT_SIZE="-0.7594507605042164" MODIFIED="2009-05-27 17:47:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3641" SE="0.7662" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="7.934541206691562"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.35714112926071" CI_END="0.6021997394584482" CI_START="0.3630083225675984" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.467550550498506" ESTIMABLE="YES" I2="47.16980328313866" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="-0.22025943672060713" LOG_CI_START="-0.44008341792876526" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.33017142732468624" MODIFIED="2009-07-03 13:14:48 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0779461508006315" P_Q="1.0" P_Z="3.9170888668607796E-9" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="5.887657049280595">
<NAME>IPD, all serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.2743756946830035" CI_START="0.0433025810710802" EFFECT_SIZE="0.10900080624905811" ESTIMABLE="YES" ESTIMATE="-2.2163999999999997" LOG_CI_END="-0.56165436283617" LOG_CI_START="-1.3634862165445645" LOG_EFFECT_SIZE="-0.9625702896903673" MODIFIED="2009-05-27 17:47:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3633" SE="0.47100000000000003" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="7.515943866916017"/>
<IV_DATA CI_END="4.1531768942229865" CI_START="0.026493031096520413" EFFECT_SIZE="0.3317080713639625" ESTIMABLE="YES" ESTIMATE="-1.1035" LOG_CI_END="0.6183804291953183" LOG_CI_START="-1.576868350755795" LOG_EFFECT_SIZE="-0.47924396078023834" MODIFIED="2009-07-03 13:14:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3639" SE="1.2894999999999999" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.0027268615769698">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="4.1747962339043845" CI_START="0.02661007033381501" EFFECT_SIZE="0.3333040975048787" ESTIMABLE="YES" ESTIMATE="-1.0987" LOG_CI_END="0.620635283017097" LOG_CI_START="-1.5749539775513026" LOG_EFFECT_SIZE="-0.47715934726710274" MODIFIED="2009-07-03 13:14:48 +1000" MODIFIED_BY="[Empty name]" ORDER="3634" SE="1.2897" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.0024158903083857">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0647897017282202" CI_START="0.21537441151813647" EFFECT_SIZE="0.4788825068848177" ESTIMABLE="YES" ESTIMATE="-0.7363" LOG_CI_END="0.02726384214333247" LOG_CI_START="-0.666805896194061" LOG_EFFECT_SIZE="-0.3197710270253643" MODIFIED="2009-05-27 17:47:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3636" SE="0.4077" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="10.030992813051459"/>
<IV_DATA CI_END="0.7756390044703381" CI_START="0.32234530490604235" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.11034035972701615" LOG_CI_START="-0.49167865108727155" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-27 17:47:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3635" SE="0.22399999999999998" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="33.22992074658236"/>
<IV_DATA CI_END="0.8030558991369575" CI_START="0.37671398293763836" EFFECT_SIZE="0.5500203507920862" ESTIMABLE="YES" ESTIMATE="-0.5978" LOG_CI_END="-0.09525422328697526" LOG_CI_START="-0.4239882592765526" LOG_EFFECT_SIZE="-0.259621241281764" MODIFIED="2009-05-29 20:36:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3638" SE="0.1931" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="44.715778334425735"/>
<IV_DATA CI_END="4.9328583180289" CI_START="0.20110691426334387" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.6930986417986738" LOG_CI_START="-0.6965729976538998" LOG_EFFECT_SIZE="-0.001737177927613002" MODIFIED="2009-05-27 17:47:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3637" SE="0.8162999999999999" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="2.5022214871390807"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.2345593887892046" CI_END="1.5342446316499805" CI_START="0.6561802722027824" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="1.0033648688397168" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.18589461235429483" LOG_CI_START="-0.18297683064345213" LOG_DATA="YES" LOG_EFFECT_SIZE="0.0014588908554213913" MODIFIED="2009-07-03 13:14:56 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9751433391749957" P_Q="1.0" P_Z="0.9876306032874004" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57015" TOTAL_2="56030" WEIGHT="100.0" Z="0.015503360795637123">
<NAME>IPD, non-vaccine serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:48:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3653" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="1.761862861589617"/>
<IV_DATA CI_END="3.9922505722863724" CI_START="0.11149727530710074" EFFECT_SIZE="0.66717693391869" ESTIMABLE="YES" ESTIMATE="-0.4047" LOG_CI_END="0.6012177918202745" LOG_CI_START="-0.9527357454727665" LOG_EFFECT_SIZE="-0.175758976826246" MODIFIED="2009-05-27 17:48:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3651" SE="0.9128000000000001" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="5.634741674158166"/>
<IV_DATA CI_END="3.3061793065291836" CI_START="0.2774836588302475" EFFECT_SIZE="0.9578156037174212" ESTIMABLE="YES" ESTIMATE="-0.0431" LOG_CI_END="0.5193264032960803" LOG_CI_START="-0.5567625876361406" LOG_EFFECT_SIZE="-0.018718092170030162" MODIFIED="2009-05-27 17:48:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3648" SE="0.6321" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="11.750428188314494"/>
<IV_DATA CI_END="1.6831949430590951" CI_START="0.5509596300581605" EFFECT_SIZE="0.9630017980998817" ESTIMABLE="YES" ESTIMATE="-0.0377" LOG_CI_END="0.2261344176941599" LOG_CI_START="-0.258880221629665" LOG_EFFECT_SIZE="-0.016372901967752606" MODIFIED="2009-05-29 20:36:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3649" SE="0.2849" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="57.84161026390339"/>
<IV_DATA CI_END="29.580450044262285" CI_START="0.033483125896163736" EFFECT_SIZE="0.9952115015900972" ESTIMABLE="YES" ESTIMATE="-0.0048" LOG_CI_END="1.471004777174494" LOG_CI_START="-1.475174004200765" LOG_EFFECT_SIZE="-0.002084613513135605" MODIFIED="2009-07-03 13:14:53 +1000" MODIFIED_BY="[Empty name]" ORDER="3647" SE="1.7306" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="1.5675877990291094">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="29.751919580884664" CI_START="0.033611276653305114" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="1.4735149914592371" LOG_CI_START="-1.4735149914592371" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-03 13:14:56 +1000" MODIFIED_BY="[Empty name]" ORDER="3652" SE="1.7311" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="1.5666823854695544">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 56,029.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.7327398061044663" CI_START="0.5554689891982019" EFFECT_SIZE="1.4399379177717142" ESTIMABLE="YES" ESTIMATE="0.36460000000000004" LOG_CI_END="0.5720277181043456" LOG_CI_START="-0.25534018190049435" LOG_EFFECT_SIZE="0.15834376810192566" MODIFIED="2009-05-27 17:48:12 +1000" MODIFIED_BY="[Empty name]" ORDER="3650" SE="0.486" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="19.877086827535667"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.290960055478461" CI_END="1.070768039299803" CI_START="0.3466783402873159" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6092717675201758" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="0.02969539971802874" LOG_CI_START="-0.46007329127566887" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21518894577882008" MODIFIED="2009-07-02 18:45:38 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8629074454456298" P_Q="1.0" P_Z="0.08501646285195702" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55349" TOTAL_2="55198" WEIGHT="99.99999999999999" Z="1.7222929572811632">
<NAME>IPD, vaccine-related serotypes, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.2064820979782347" CI_START="0.03470836979838888" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.5060288195624826" LOG_CI_START="-1.4595657840292624" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:48:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3656" SE="1.1545999999999998" STUDY_ID="STD-Black-2000" TOTAL_1="18927" TOTAL_2="18941" WEIGHT="6.208606504403599"/>
<IV_DATA CI_END="1.4983669062418394" CI_START="0.2565643455878163" EFFECT_SIZE="0.620022196981994" ESTIMABLE="YES" ESTIMATE="-0.478" LOG_CI_END="0.17561817240557379" LOG_CI_START="-0.5908036971050825" LOG_EFFECT_SIZE="-0.20759276234975432" MODIFIED="2009-05-29 20:36:06 +1000" MODIFIED_BY="[Empty name]" ORDER="3654" SE="0.45020000000000004" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="40.836288235407785"/>
<IV_DATA CI_END="1.3761647145928655" CI_START="0.2529659364846539" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="0.1386704181709836" LOG_CI_START="-0.5969379554752949" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-05-27 17:48:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3655" SE="0.4321" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="44.32907909636094"/>
<IV_DATA CI_END="8.16980636913829" CI_START="0.013589671702941125" EFFECT_SIZE="0.33320412127281185" ESTIMABLE="YES" ESTIMATE="-1.099" LOG_CI_END="0.9122117635322573" LOG_CI_START="-1.8667910347556045" LOG_EFFECT_SIZE="-0.4772896356116738" MODIFIED="2009-05-27 17:48:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3658" SE="1.6324" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="3.1060187255175853"/>
<IV_DATA CI_END="21.114835529220322" CI_START="0.17377813161468345" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="1.3245877029037048" LOG_CI_START="-0.7600048764294773" LOG_EFFECT_SIZE="0.28229141323711376" MODIFIED="2009-05-27 17:48:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3657" SE="1.2245" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="5.520007438310072"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="18.01038152566873" CI_END="0.8463166602125143" CI_START="0.7183479784066967" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7797113965792516" ESTIMABLE="YES" I2="77.7905870883461" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="-0.07246710971324374" LOG_CI_START="-0.14366512610265997" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10806611790795184" MODIFIED="2009-06-03 15:18:04 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0012283482376945765" P_Q="1.0" P_Z="2.685293152466346E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44818" TOTAL_2="44639" WEIGHT="100.0" Z="5.949764046519985">
<NAME>X-ray defined pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7406208940078663" CI_START="0.5704478063783269" EFFECT_SIZE="0.6499888955549492" ESTIMABLE="YES" ESTIMATE="-0.43079999999999996" LOG_CI_END="-0.13040404002581146" LOG_CI_START="-0.2437840855820302" LOG_EFFECT_SIZE="-0.18709406280392085" MODIFIED="2009-05-29 20:35:58 +1000" MODIFIED_BY="[Empty name]" ORDER="3659" SE="0.0666" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="39.43324653824059"/>
<IV_DATA CI_END="1.0955935380287836" CI_START="0.4718489997909534" EFFECT_SIZE="0.7189956294000078" ESTIMABLE="YES" ESTIMATE="-0.3299" LOG_CI_END="0.039649462056989694" LOG_CI_START="-0.3261969612167553" LOG_EFFECT_SIZE="-0.1432737495798828" MODIFIED="2009-06-03 15:18:04 +1000" MODIFIED_BY="[Empty name]" ORDER="3662" SE="0.21489999999999998" STUDY_ID="STD-Hansen-2006" TOTAL_1="8396" TOTAL_2="8382" WEIGHT="3.7873737200948696">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9584492707762539" CI_START="0.7188077397979356" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.018430868706605385" LOG_CI_START="-0.14338725525054621" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2009-05-27 17:49:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3660" SE="0.07339999999999999" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="32.46525904401222"/>
<IV_DATA CI_END="1.0725162346112596" CI_START="0.6578308096758433" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="0.030403874794965435" LOG_CI_START="-0.18188579008281966" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-27 17:49:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3661" SE="0.1247" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="11.24807194139445"/>
<IV_DATA CI_END="1.392593495855965" CI_START="0.8848228415862507" EFFECT_SIZE="1.110044383877422" ESTIMABLE="YES" ESTIMATE="0.1044" LOG_CI_END="0.1438243624606583" LOG_CI_START="-0.05314367463925935" LOG_EFFECT_SIZE="0.04534034391069949" MODIFIED="2009-06-01 14:13:48 +1000" MODIFIED_BY="[Empty name]" ORDER="520" SE="0.1157" STUDY_ID="STD-O_x0027_Brien-2002" TOTAL_1="2974" TOTAL_2="2818" WEIGHT="13.066048756257873"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.628292878188491" CI_END="0.9725636357540283" CI_START="0.9098801750857489" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9406999368459146" ESTIMABLE="YES" I2="17.316487375246858" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="-0.012081972775868767" LOG_CI_START="-0.041015797487160145" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.026548885131514485" MODIFIED="2009-05-29 20:35:47 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.30450035860686653" P_Q="1.0" P_Z="3.2213302920459523E-4" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52374" TOTAL_2="52381" WEIGHT="100.0" Z="3.596818547611697">
<NAME>Clinical pneumonia, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9721460644718857" CI_START="0.8518449210397556" EFFECT_SIZE="0.9100097183707231" ESTIMABLE="YES" ESTIMATE="-0.0943" LOG_CI_END="-0.012268477637136009" LOG_CI_START="-0.06963946164981731" LOG_EFFECT_SIZE="-0.040953969643476626" MODIFIED="2009-05-27 17:49:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3664" SE="0.0337" STUDY_ID="STD-Madhi-2005a" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="25.434727811885402"/>
<IV_DATA CI_END="1.003179672278535" CI_START="0.86400681039202" EFFECT_SIZE="0.9309962775948618" ESTIMABLE="YES" ESTIMATE="-0.07150000000000001" LOG_CI_END="0.0013787233404035483" LOG_CI_START="-0.06348283425256852" LOG_EFFECT_SIZE="-0.031052055456082497" MODIFIED="2009-05-27 17:49:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3415" SE="0.0381" STUDY_ID="STD-Black-2002a" TOTAL_1="18926" TOTAL_2="18942" WEIGHT="19.899260840501327"/>
<IV_DATA CI_END="0.9914478002889936" CI_START="0.8911780673295733" EFFECT_SIZE="0.9399768797793391" ESTIMABLE="YES" ESTIMATE="-0.061900000000000004" LOG_CI_END="-0.0037301464543672202" LOG_CI_START="-0.0500355104052554" LOG_EFFECT_SIZE="-0.026882828429811306" MODIFIED="2009-05-29 20:35:47 +1000" MODIFIED_BY="[Empty name]" ORDER="3663" SE="0.027200000000000002" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="39.04353107250233"/>
<IV_DATA CI_END="1.0966701488367647" CI_START="0.9265581692762404" EFFECT_SIZE="1.0080320855042735" ESTIMABLE="YES" ESTIMATE="0.0080" LOG_CI_END="0.04007602221346478" LOG_CI_START="-0.033127310503012784" LOG_EFFECT_SIZE="0.003474355855226035" MODIFIED="2009-05-27 17:49:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3665" SE="0.043" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="15.622480275110943"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.645880832401504" CI_END="0.99752657628854" CI_START="0.9001266460192521" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9475759871533633" ESTIMABLE="YES" I2="89.63288042455494" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="-0.0010755249327331184" LOG_CI_START="-0.045696381896428016" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.023385953414580597" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.001897787760677505" P_Q="1.0" P_Z="0.039932302557831784" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14815" TOTAL_2="14813" WEIGHT="100.0" Z="2.054448504832748">
<NAME>All-cause admissions, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9372348680134331" CI_START="0.8075271263774072" EFFECT_SIZE="0.8699669992060597" ESTIMABLE="YES" ESTIMATE="-0.1393" LOG_CI_END="-0.028151562686958464" LOG_CI_START="-0.09284287997128751" LOG_EFFECT_SIZE="-0.06049722132912297" MODIFIED="2009-05-29 20:35:43 +1000" MODIFIED_BY="[Empty name]" ORDER="3667" SE="0.038" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="47.57555074715732"/>
<IV_DATA CI_END="1.0992748072322664" CI_START="0.9538482414458557" EFFECT_SIZE="1.0239830768837097" ESTIMABLE="YES" ESTIMATE="0.023700000000000002" LOG_CI_END="0.04110627508548485" LOG_CI_START="-0.020520716643270705" LOG_EFFECT_SIZE="0.010292779221107076" MODIFIED="2009-05-27 17:49:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3668" SE="0.0362" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="52.42444925284268"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.9263816146499497" CI_END="0.9832124581670214" CI_START="0.8026643040328165" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8883634073120228" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="-0.007352627193496246" LOG_CI_START="-0.09546605047318694" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05140933883334162" MODIFIED="2009-07-03 13:15:18 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9207458471278525" P_Q="1.0" P_Z="0.022192175951626893" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35114" TOTAL_2="34271" WEIGHT="99.99999999999999" Z="2.287062489049616">
<NAME>All-cause mortality, ITT (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9766779259751815" CI_START="0.7572955624362241" EFFECT_SIZE="0.8600196853970379" ESTIMABLE="YES" ESTIMATE="-0.1508" LOG_CI_END="-0.010248627716366213" LOG_CI_START="-0.12073458802565451" LOG_EFFECT_SIZE="-0.06549160787101034" MODIFIED="2009-05-29 20:35:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3673" SE="0.0649" STUDY_ID="STD-Cutts-2005" TOTAL_1="8718" TOTAL_2="8719" WEIGHT="63.60188086095632"/>
<IV_DATA CI_END="1.4355829133550004" CI_START="0.5377449089872959" EFFECT_SIZE="0.8786224462679074" ESTIMABLE="YES" ESTIMATE="-0.1294" LOG_CI_END="0.15702828061704058" LOG_CI_START="-0.2694236925336022" LOG_EFFECT_SIZE="-0.05619770595828078" MODIFIED="2009-05-27 17:50:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3670" SE="0.2505" STUDY_ID="STD-Lucero-2009" TOTAL_1="6097" TOTAL_2="6094" WEIGHT="4.2691743571564515"/>
<IV_DATA CI_END="1.1319396900082939" CI_START="0.7904659470596627" EFFECT_SIZE="0.94591742719797" ESTIMABLE="YES" ESTIMATE="-0.0556" LOG_CI_END="0.05382328816466002" LOG_CI_START="-0.10211683455230162" LOG_EFFECT_SIZE="-0.024146773193820824" MODIFIED="2009-05-27 17:50:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3671" SE="0.0916" STUDY_ID="STD-Klugman-2003" TOTAL_1="18633" TOTAL_2="18626" WEIGHT="31.927756693850778"/>
<IV_DATA CI_END="36.611603525247695" CI_START="0.0610192905442754" EFFECT_SIZE="1.4946618590165826" ESTIMABLE="YES" ESTIMATE="0.4019" LOG_CI_END="1.5636187506492403" LOG_CI_START="-1.2145328460954066" LOG_EFFECT_SIZE="0.17454295227691688" MODIFIED="2009-07-03 13:15:15 +1000" MODIFIED_BY="[Empty name]" ORDER="3672" SE="1.6319" STUDY_ID="STD-Kilpi-2003" TOTAL_1="835" TOTAL_2="416" WEIGHT="0.10059404401822006">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="36.787761663477134" CI_START="0.06131288720717349" EFFECT_SIZE="1.5018534820271767" ESTIMABLE="YES" ESTIMATE="0.4067" LOG_CI_END="1.5657033641623759" LOG_CI_START="-1.212448232582271" LOG_EFFECT_SIZE="0.17662756579005248" MODIFIED="2009-07-03 13:15:18 +1000" MODIFIED_BY="[Empty name]" ORDER="3669" SE="1.6319" STUDY_ID="STD-Eskola-2001" TOTAL_1="831" TOTAL_2="416" WEIGHT="0.10059404401822006">
<FOOTNOTE>The software could not accept entry of 415.5 so we had to enter a whole number of 416. Actual number of controls in Finnish studies is 831 giving a total control population of all studies to 34,270.</FOOTNOTE>
</IV_DATA>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.846804715475878" CI_END="0.75020904734892" CI_START="0.07518952334159604" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.23750339087414762" ESTIMABLE="YES" I2="48.68992302651541" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="-0.12481770266194359" LOG_CI_START="-1.1238426683432874" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6243301855026154" MODIFIED="2009-07-02 18:46:59 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.11930630708855439" P_Q="1.0" P_Z="0.014296816973142798" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.6468390894220903" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.00000000000001" Z="2.4497179151309543">
<NAME>IPD, vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:50:44 +1000" MODIFIED_BY="[Empty name]" ORDER="3742" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="14.499800701586224"/>
<IV_DATA CI_END="0.5090899287812082" CI_START="0.1039059205511444" EFFECT_SIZE="0.22999447317996144" ESTIMABLE="YES" ESTIMATE="-1.4697" LOG_CI_END="-0.29320549443390664" LOG_CI_START="-0.9833597056725119" LOG_EFFECT_SIZE="-0.6382826000532091" MODIFIED="2009-05-29 20:35:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3745" SE="0.4054" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="42.452789848694394"/>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:50:56 +1000" MODIFIED_BY="[Empty name]" ORDER="3744" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="27.018506540225914"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:50:56 +1000" MODIFIED_BY="[Empty name]" ORDER="3743" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="16.028902909493485"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.509621383381235" CI_END="0.7627393346612826" CI_START="0.12518181015929458" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3090001465899253" ESTIMABLE="YES" I2="68.45300271109929" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="-0.11762385635698924" LOG_CI_START="-0.9024587727339203" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5100413145454548" MODIFIED="2009-07-02 18:48:56 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.023229300671101738" P_Q="1.0" P_Z="0.010851439026696719" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5448420549993092" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.00000000000001" Z="2.547446822960794">
<NAME>IPD, all serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:51:16 +1000" MODIFIED_BY="[Empty name]" ORDER="1053" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="23.56667663399049"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:51:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3739" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="25.685912670420333"/>
<IV_DATA CI_END="0.7981548974497817" CI_START="0.31325196674463957" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09791281719607922" LOG_CI_START="-0.5041061936182085" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-29 20:35:30 +1000" MODIFIED_BY="[Empty name]" ORDER="3741" SE="0.2386" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="35.31830468529772"/>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:51:16 +1000" MODIFIED_BY="[Empty name]" ORDER="3740" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="15.429106010291466"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.5600409498595291" CI_END="2.502034628924777" CI_START="0.5763162137965323" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="1.2008176897971394" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.19" LOG_CI_END="0.3982933161675015" LOG_CI_START="-0.23933916201969924" LOG_DATA="YES" LOG_EFFECT_SIZE="0.07947707707390114" MODIFIED="2009-07-02 18:50:09 +1000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.668483855263472" P_Q="1.0" P_Z="0.6251280370497251" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="0.48859559068955577">
<NAME>IPD, non-vaccine serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:51:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3746" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="5.262635348726895"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:51:41 +1000" MODIFIED_BY="[Empty name]" ORDER="1054" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="16.840693158014815"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:51:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3748" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.03707692179983"/>
<IV_DATA CI_END="4.134784121744075" CI_START="0.6584707884321952" EFFECT_SIZE="1.6500407754482138" ESTIMABLE="YES" ESTIMATE="0.5008" LOG_CI_END="0.6164528398419514" LOG_CI_START="-0.1814634867676544" LOG_EFFECT_SIZE="0.21749467653714846" MODIFIED="2009-05-29 20:35:25 +1000" MODIFIED_BY="[Empty name]" ORDER="3747" SE="0.46869999999999995" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="63.85959457145846"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.23193268105465406" CI_END="1.5136903941485902" CI_START="0.20206820641236722" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.55305397838659" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="0.180037054911124" LOG_CI_START="-0.6945020133816574" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.25723247923526676" MODIFIED="2009-07-02 18:51:32 +1000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.8905051997870491" P_Q="1.0" P_Z="0.24891545227651246" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16674" TOTAL_2="16452" WEIGHT="99.99999999999999" Z="1.1529877011424339">
<NAME>IPD, vaccine-related serotypes, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:52:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3751" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.899673000629653"/>
<IV_DATA CI_END="1.7022431855028182" CI_START="0.17129862472492663" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="0.23102160426647886" LOG_CI_START="-0.7662461237640463" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-05-29 20:35:21 +1000" MODIFIED_BY="[Empty name]" ORDER="3749" SE="0.5858" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="76.9015158155225"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:52:54 +1000" MODIFIED_BY="[Empty name]" ORDER="3750" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="13.19881118384784"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.8636869742809823" CI_END="0.7374244979874816" CI_START="0.5785984969504561" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.6532018877422212" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.21" LOG_CI_END="-0.132282438788413" LOG_CI_START="-0.23762269887153192" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.18495256882997252" MODIFIED="2009-06-03 15:18:11 +1000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.3938270841973588" P_Q="1.0" P_Z="5.882525125119014E-12" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19836" TOTAL_2="19763" WEIGHT="100.0" Z="6.882465896113788">
<NAME>X-ray defined pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:18:11 +1000" MODIFIED_BY="[Empty name]" ORDER="3754" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="6.532424481238498">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7257928755001224" CI_START="0.546889012312736" EFFECT_SIZE="0.6300223399419123" ESTIMABLE="YES" ESTIMATE="-0.462" LOG_CI_END="-0.1391872992191897" LOG_CI_START="-0.26210080205941494" LOG_EFFECT_SIZE="-0.20064405063930238" MODIFIED="2009-05-29 20:35:05 +1000" MODIFIED_BY="[Empty name]" ORDER="3753" SE="0.0722" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="73.44962477044915"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:53:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3752" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="20.017950748312355"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.278528215887546" CI_END="0.9771988949827632" CI_START="0.9001588381832274" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9378881713624593" ESTIMABLE="YES" I2="8.495525966127591" I2_Q="0.0" ID="CMP-004.22" LOG_CI_END="-0.010017032798846142" LOG_CI_START="-0.04568085004961907" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.027848941424232613" MODIFIED="2009-05-29 20:34:59 +1000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.3506423775446247" P_Q="1.0" P_Z="0.002206218243369178" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.558312866481698E-4" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="100.0" Z="3.060969150624424">
<NAME>Clinical pneumonia, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.974002258346723" CI_START="0.8132974710643074" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="-0.011440036153845453" LOG_CI_START="-0.0897505781296122" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-05-27 17:54:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3758" SE="0.046" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="19.31767162300376"/>
<IV_DATA CI_END="0.9862937178397478" CI_START="0.8768679048728684" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="-0.005993733089730402" LOG_CI_START="-0.057065825682621765" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-29 20:34:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3755" SE="0.03" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="41.56581769579592"/>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:54:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3418" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="19.876836662487754"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:54:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3756" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="19.239674018712563"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.146925926042876" CI_END="1.0944461829333414" CI_START="0.7840204259652876" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9263196870084763" ESTIMABLE="YES" I2="89.06736527566243" I2_Q="0.0" ID="CMP-004.23" LOG_CI_END="0.03919441092019714" LOG_CI_START="-0.10567262255987905" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.03323910581984094" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0024913711918134185" P_Q="1.0" P_Z="0.36843417033418846" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.012900535000000003" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="99.99999999999999" Z="0.8994102898388378">
<NAME>All-cause admissions, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9222255092960167" CI_START="0.7834606030293128" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="-0.035162869111540394" LOG_CI_START="-0.10598283750701638" LOG_EFFECT_SIZE="-0.07057285330927841" MODIFIED="2009-05-29 20:34:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3759" SE="0.0416" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="49.49228529096203"/>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:54:39 +1000" MODIFIED_BY="[Empty name]" ORDER="3760" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="50.507714709037955"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.022116696493435162" CI_END="0.9719636902735483" CI_START="0.7305957255617559" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8426817415341838" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="-0.012349958744895934" LOG_CI_START="-0.13632287300881754" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07433641587685669" MODIFIED="2009-05-29 20:34:50 +1000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.8817770900543261" P_Q="1.0" P_Z="0.018750214855141223" Q="0.0" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.3504601585514404">
<NAME>All-cause mortality, PP (Random)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9748782016473438" CI_START="0.7237152516207703" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="-0.011049640359598078" LOG_CI_START="-0.14043227492825616" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-29 20:34:50 +1000" MODIFIED_BY="[Empty name]" ORDER="3761" SE="0.076" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="91.81246345482573"/>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:54:59 +1000" MODIFIED_BY="[Empty name]" ORDER="3762" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="8.187536545174265"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.846804715475878" CI_END="0.4527982416152282" CI_START="0.12189028113869643" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.23492914882914712" ESTIMABLE="YES" I2="48.68992302651541" I2_Q="0.0" ID="CMP-004.25" LOG_CI_END="-0.34409526834426873" LOG_CI_START="-0.9140309212569557" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6290630948006122" MODIFIED="2009-07-02 18:47:28 +1000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.11930630708855439" P_Q="1.0" P_Z="1.5143048927906262E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.00000000000001" Z="4.3265972343070445">
<NAME>IPD, vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.3419361189973926" CI_START="0.0019768143302972257" EFFECT_SIZE="0.02599892728710673" ESTIMABLE="YES" ESTIMATE="-3.6497" LOG_CI_END="-0.4660550218920487" LOG_CI_START="-2.7040341193125474" LOG_EFFECT_SIZE="-1.5850445706022982" MODIFIED="2009-05-27 17:55:20 +1000" MODIFIED_BY="[Empty name]" ORDER="3720" SE="1.3146" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="6.485442291545789"/>
<IV_DATA CI_END="0.5090899287812082" CI_START="0.1039059205511444" EFFECT_SIZE="0.22999447317996144" ESTIMABLE="YES" ESTIMATE="-1.4697" LOG_CI_END="-0.29320549443390664" LOG_CI_START="-0.9833597056725119" LOG_EFFECT_SIZE="-0.6382826000532091" MODIFIED="2009-05-29 20:34:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3718" SE="0.4054" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="68.19607291560436"/>
<IV_DATA CI_END="1.0962326796574158" CI_START="0.04910082386713325" EFFECT_SIZE="0.2320041545344701" ESTIMABLE="YES" ESTIMATE="-1.4609999999999999" LOG_CI_END="0.03990274462847955" LOG_CI_START="-1.3089112207497813" LOG_EFFECT_SIZE="-0.6345042380606508" MODIFIED="2009-05-27 17:55:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3719" SE="0.7923" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="17.85449385998816"/>
<IV_DATA CI_END="21.973558994522882" CI_START="0.18020866190905852" EFFECT_SIZE="1.9899310701083912" ESTIMABLE="YES" ESTIMATE="0.6881" LOG_CI_END="1.3419004040531122" LOG_CI_START="-0.744224338057857" LOG_EFFECT_SIZE="0.29883803299762757" MODIFIED="2009-05-27 17:55:32 +1000" MODIFIED_BY="[Empty name]" ORDER="3721" SE="1.2254" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="7.46399093286169"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.509621383381235" CI_END="0.5816613551539359" CI_START="0.26601716523828933" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.3933597651345545" ESTIMABLE="YES" I2="68.45300271109929" I2_Q="0.0" ID="CMP-004.26" LOG_CI_END="-0.235329789220226" LOG_CI_START="-0.575090338828526" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.40521006402437604" MODIFIED="2009-07-02 18:49:06 +1000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.023229300671101738" P_Q="1.0" P_Z="2.938958944072758E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="99.99999999999999" Z="4.675040304570693">
<NAME>IPD, all serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.22996652612508017" CI_START="0.02210440253073085" EFFECT_SIZE="0.07129707330643105" ESTIMABLE="YES" ESTIMATE="-2.6409" LOG_CI_END="-0.6383353751874212" LOG_CI_START="-1.655521219329174" LOG_EFFECT_SIZE="-1.1469282972582977" MODIFIED="2009-05-27 17:55:55 +1000" MODIFIED_BY="[Empty name]" ORDER="1055" SE="0.5975" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="11.156944837083444"/>
<IV_DATA CI_END="1.0970413279370408" CI_START="0.13652918820923035" EFFECT_SIZE="0.38701183694458263" ESTIMABLE="YES" ESTIMATE="-0.9493" LOG_CI_END="0.04022298870226041" LOG_CI_START="-0.8647744920437743" LOG_EFFECT_SIZE="-0.41227575167075703" MODIFIED="2009-05-27 17:55:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3717" SE="0.5316" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.094548244492193"/>
<IV_DATA CI_END="0.7981548974497817" CI_START="0.31325196674463957" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09791281719607922" LOG_CI_START="-0.5041061936182085" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-29 20:34:41 +1000" MODIFIED_BY="[Empty name]" ORDER="3716" SE="0.2386" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="69.96490139364265"/>
<IV_DATA CI_END="3.9648464813678213" CI_START="0.11086221712213883" EFFECT_SIZE="0.6629869316007273" ESTIMABLE="YES" ESTIMATE="-0.41100000000000003" LOG_CI_END="0.5982263761213196" LOG_CI_START="-0.9552164402457926" LOG_EFFECT_SIZE="-0.17849503206223655" MODIFIED="2009-05-27 17:55:55 +1000" MODIFIED_BY="[Empty name]" ORDER="3715" SE="0.9125" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="4.78360552478171"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.5600409498595291" CI_END="2.502034628924777" CI_START="0.5763162137965323" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="1.2008176897971394" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.27" LOG_CI_END="0.3982933161675015" LOG_CI_START="-0.23933916201969924" LOG_DATA="YES" LOG_EFFECT_SIZE="0.07947707707390114" MODIFIED="2009-07-02 18:50:19 +1000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.668483855263472" P_Q="1.0" P_Z="0.6251280370497251" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30223" TOTAL_2="30021" WEIGHT="100.0" Z="0.48859559068955577">
<NAME>IPD, non-vaccine serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:56:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3724" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="5.262635348726895"/>
<IV_DATA CI_END="3.979511721339793" CI_START="0.11118507445628702" EFFECT_SIZE="0.6651784024130908" ESTIMABLE="YES" ESTIMATE="-0.4077" LOG_CI_END="0.5998297882202432" LOG_CI_START="-0.9539535087641547" LOG_EFFECT_SIZE="-0.17706186027195578" MODIFIED="2009-05-27 17:56:14 +1000" MODIFIED_BY="[Empty name]" ORDER="1056" SE="0.9127" STUDY_ID="STD-Black-2000" TOTAL_1="13549" TOTAL_2="13569" WEIGHT="16.840693158014815"/>
<IV_DATA CI_END="6.589490262326688" CI_START="0.1309059705796164" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="0.8188518205392412" LOG_CI_START="-0.8830405449645418" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:56:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3723" SE="0.9997" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="14.03707692179983"/>
<IV_DATA CI_END="4.134784121744075" CI_START="0.6584707884321952" EFFECT_SIZE="1.6500407754482138" ESTIMABLE="YES" ESTIMATE="0.5008" LOG_CI_END="0.6164528398419514" LOG_CI_START="-0.1814634867676544" LOG_EFFECT_SIZE="0.21749467653714846" MODIFIED="2009-05-29 20:34:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3722" SE="0.46869999999999995" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="63.85959457145846"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.23193268105465406" CI_END="1.51369039414859" CI_START="0.20206820641236717" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.55305397838659" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.28" LOG_CI_END="0.18003705491112396" LOG_CI_START="-0.6945020133816575" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.25723247923526676" MODIFIED="2009-07-02 18:51:39 +1000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.8905051997870491" P_Q="1.0" P_Z="0.24891545227651235" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16674" TOTAL_2="16452" WEIGHT="100.0" Z="1.152987701142434">
<NAME>IPD, vaccine-related serotypes, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="8.184426961490026" CI_START="0.013597991274428942" EFFECT_SIZE="0.3336042062212981" ESTIMABLE="YES" ESTIMATE="-1.0978" LOG_CI_END="0.9129882773735053" LOG_CI_START="-1.8665252418402853" LOG_EFFECT_SIZE="-0.4767684822333899" MODIFIED="2009-05-27 17:56:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3725" SE="1.6327" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="9.899673000629653"/>
<IV_DATA CI_END="1.7022431855028182" CI_START="0.17129862472492663" EFFECT_SIZE="0.5399925153407321" ESTIMABLE="YES" ESTIMATE="-0.6162" LOG_CI_END="0.23102160426647886" LOG_CI_START="-0.7662461237640463" LOG_EFFECT_SIZE="-0.26761225974878383" MODIFIED="2009-05-29 20:34:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3726" SE="0.5858" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="76.9015158155225"/>
<IV_DATA CI_END="14.8424166889391" CI_START="0.058117464055408" EFFECT_SIZE="0.9287645656541845" ESTIMABLE="YES" ESTIMATE="-0.0739" LOG_CI_END="1.171504619893156" LOG_CI_START="-1.2356933443184568" LOG_EFFECT_SIZE="-0.03209436221265033" MODIFIED="2009-05-27 17:56:36 +1000" MODIFIED_BY="[Empty name]" ORDER="3727" SE="1.4140000000000001" STUDY_ID="STD-O_x0027_Brien-2003" TOTAL_1="2472" TOTAL_2="2283" WEIGHT="13.19881118384784"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.8636869742809823" CI_END="0.7374244979874816" CI_START="0.5785984969504561" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_SIZE="0.6532018877422213" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.29" LOG_CI_END="-0.132282438788413" LOG_CI_START="-0.23762269887153192" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.18495256882997244" MODIFIED="2009-06-03 15:18:22 +1000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.3938270841973588" P_Q="1.0" P_Z="5.882525125119058E-12" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19836" TOTAL_2="19763" WEIGHT="100.0" Z="6.8824658961137875">
<NAME>X-ray defined pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9482920833871931" CI_START="0.3671050321760201" EFFECT_SIZE="0.5900193181448559" ESTIMABLE="YES" ESTIMATE="-0.5276" LOG_CI_END="-0.023057875039839006" LOG_CI_START="-0.43520966226447233" LOG_EFFECT_SIZE="-0.22913376865215565" MODIFIED="2009-06-03 15:18:22 +1000" MODIFIED_BY="[Empty name]" ORDER="3728" SE="0.2421" STUDY_ID="STD-Hansen-2006" TOTAL_1="5634" TOTAL_2="5594" WEIGHT="6.532424481238498">
<FOOTNOTE>Treatment and control totals are in person-years as provide by Hansen. No actual counts were available.</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.7257928755001224" CI_START="0.546889012312736" EFFECT_SIZE="0.6300223399419123" ESTIMABLE="YES" ESTIMATE="-0.462" LOG_CI_END="-0.1391872992191897" LOG_CI_START="-0.26210080205941494" LOG_EFFECT_SIZE="-0.20064405063930238" MODIFIED="2009-05-29 20:33:52 +1000" MODIFIED_BY="[Empty name]" ORDER="3730" SE="0.0722" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="73.44962477044915"/>
<IV_DATA CI_END="1.0110233331620666" CI_START="0.5879208088018839" EFFECT_SIZE="0.7709744845001154" ESTIMABLE="YES" ESTIMATE="-0.2601" LOG_CI_END="0.004761178683578818" LOG_CI_START="-0.2306811681696503" LOG_EFFECT_SIZE="-0.11295999474303577" MODIFIED="2009-05-27 17:57:10 +1000" MODIFIED_BY="[Empty name]" ORDER="3729" SE="0.1383" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="20.017950748312355"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.2785282158875457" CI_END="0.9747622431226742" CI_START="0.9018412631871064" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.9375930954549793" ESTIMABLE="YES" I2="8.49552596612758" I2_Q="0.0" ID="CMP-004.30" LOG_CI_END="-0.011101301318507843" LOG_CI_START="-0.04486989770044842" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.02798559950947814" MODIFIED="2009-05-29 20:33:46 +1000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.3506423775446248" P_Q="1.0" P_Z="0.0011596390922549245" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48459" TOTAL_2="48384" WEIGHT="99.99999999999999" Z="3.248625824061379">
<NAME>Clinical pneumonia, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.974002258346723" CI_START="0.8132974710643074" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="-0.011440036153845453" LOG_CI_START="-0.0897505781296122" LOG_EFFECT_SIZE="-0.050595307141728815" MODIFIED="2009-05-27 17:57:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3734" SE="0.046" STUDY_ID="STD-Madhi-2005a" TOTAL_1="17356" TOTAL_2="17350" WEIGHT="18.594545140121216"/>
<IV_DATA CI_END="0.9862937178397478" CI_START="0.8768679048728684" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="-0.005993733089730402" LOG_CI_START="-0.057065825682621765" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-29 20:33:46 +1000" MODIFIED_BY="[Empty name]" ORDER="3731" SE="0.03" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="43.7178416849961"/>
<IV_DATA CI_END="1.032709951975901" CI_START="0.8646881403023923" EFFECT_SIZE="0.9449719825718722" ESTIMABLE="YES" ESTIMATE="-0.056600000000000004" LOG_CI_END="0.013978362231908941" LOG_CI_START="-0.06314049758335703" LOG_EFFECT_SIZE="-0.024581067675724044" MODIFIED="2009-05-27 17:57:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3417" SE="0.0453" STUDY_ID="STD-Black-2002a" TOTAL_1="16901" TOTAL_2="16865" WEIGHT="19.173651017497523"/>
<IV_DATA CI_END="1.0934680468141416" CI_START="0.9126942498000263" EFFECT_SIZE="0.999000499833375" ESTIMABLE="YES" ESTIMATE="-0.0010" LOG_CI_END="0.03880609666030159" LOG_CI_START="-0.03967468562410812" LOG_EFFECT_SIZE="-4.3429448190323867E-4" MODIFIED="2009-05-27 17:57:35 +1000" MODIFIED_BY="[Empty name]" ORDER="3732" SE="0.0461" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="18.513962157385148"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.146925926042876" CI_END="0.985520894274657" CI_START="0.8830205771841544" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.9328639927071104" ESTIMABLE="YES" I2="89.06736527566243" I2_Q="0.0" ID="CMP-004.31" LOG_CI_END="-0.006334163701135355" LOG_CI_START="-0.05402917586364833" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.030181669782391802" MODIFIED="2009-07-02 18:03:08 +1000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0024913711918134185" P_Q="1.0" P_Z="0.013117902264446321" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.4805522877406077">
<NAME>All-cause admissions, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9222255092960167" CI_START="0.7834606030293128" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="-0.035162869111540394" LOG_CI_START="-0.10598283750701638" LOG_EFFECT_SIZE="-0.07057285330927841" MODIFIED="2009-05-29 20:33:34 +1000" MODIFIED_BY="[Empty name]" ORDER="3735" SE="0.0416" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="45.35597116486737"/>
<IV_DATA CI_END="1.0854369610683363" CI_START="0.9355856005326364" EFFECT_SIZE="1.0077297212355303" ESTIMABLE="YES" ESTIMATE="0.0077" LOG_CI_END="0.035604605998498066" LOG_CI_START="-0.028916470977188028" LOG_EFFECT_SIZE="0.0033440675106550786" MODIFIED="2009-05-27 17:57:51 +1000" MODIFIED_BY="[Empty name]" ORDER="3736" SE="0.0379" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="54.64402883513264"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.022116696493435162" CI_END="0.9719636902735483" CI_START="0.7305957255617559" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.8426817415341838" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.32" LOG_CI_END="-0.012349958744895934" LOG_CI_START="-0.13632287300881754" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07433641587685669" MODIFIED="2009-05-29 20:33:14 +1000" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.8817770900543261" P_Q="1.0" P_Z="0.018750214855141223" Q="0.0" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14202" TOTAL_2="14169" WEIGHT="100.0" Z="2.3504601585514404">
<NAME>All-cause mortality, PP (Fixed)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PCV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9748782016473438" CI_START="0.7237152516207703" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="-0.011049640359598078" LOG_CI_START="-0.14043227492825616" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2009-05-29 20:33:14 +1000" MODIFIED_BY="[Empty name]" ORDER="3738" SE="0.076" STUDY_ID="STD-Cutts-2005" TOTAL_1="8189" TOTAL_2="8151" WEIGHT="91.81246345482573"/>
<IV_DATA CI_END="1.4389459034814007" CI_START="0.5306191036487408" EFFECT_SIZE="0.8738032876479285" ESTIMABLE="YES" ESTIMATE="-0.1349" LOG_CI_END="0.15804446713943213" LOG_CI_START="-0.2752171183569295" LOG_EFFECT_SIZE="-0.05858632560874864" MODIFIED="2009-05-27 17:58:02 +1000" MODIFIED_BY="[Empty name]" ORDER="3737" SE="0.2545" STUDY_ID="STD-Lucero-2009" TOTAL_1="6013" TOTAL_2="6018" WEIGHT="8.187536545174265"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-07-28 14:53:42 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-07-28 14:53:42 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary_January 29, 2009.JPG" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2009-06-01 22:16:01 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each of the six included trials.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-07-03 12:30:37 +1000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HIV-1 negative and &lt;24 months children, outcome: 1.1 IPD, vaccine serotypes, ITT (Random-effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAAEgCAMAAAA9h0TZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-07-03 12:31:01 +1000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HIV-1 negative and &lt;24 months children, outcome: 1.2 IPD, all serotypes, ITT (Random-effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAAEgCAMAAAA9h0TZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-07-03 12:31:24 +1000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HIV-1 negative and &lt;24 months children, outcome: 1.3 IPD, non-vaccine serotypes, ITT (Random-effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAAEACAMAAAA6K0HvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-07-08 18:15:21 +1000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: HIV-1 negative and &lt;24 months children, outcome: X-ray defined pneumonia ITT (Random-effects model) with five studies included in the model (includes the PCV X-ray pneumonia effect among American Indian children as provided in <LINK REF="REF-O_x0027_Brien-2009c" TYPE="REFERENCE">O'Brien 2009c</LINK>)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAADwCAMAAACJzlNCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 7 updated Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-07-08 18:11:42 +1000" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest plot of comparison: HIV-1 negative and &lt;24 months children, outcome: X-ray defined pneumonia ITT (Random-effects model); excludes the outlier result of the PCV effect against X-ray defined pneumonia among American Indian children</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAADgCAMAAACKGFHZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-07-03 12:31:56 +1000" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.06" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HIV-1 negative and &lt;24 months children, outcome: 1.6 Clinical pneumonia, ITT (Random-effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAADQCAMAAACOYlZ0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-07-03 12:32:31 +1000" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.08" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HIV-1 negative and &lt;24 months children, outcome: 1.8 All-cause mortality, ITT (Random-effects model).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAAEACAMAAAA6K0HvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-06-23 11:21:10 +1000" MODIFIED_BY="Clare Dooley">
<APPENDIX ID="APP-01" MODIFIED="2009-06-23 11:21:10 +1000" MODIFIED_BY="Clare Dooley" NO="1">
<TITLE MODIFIED="2009-05-29 12:54:10 +1000" MODIFIED_BY="[Empty name]">Embase AND Medline Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-06-23 11:21:10 +1000" MODIFIED_BY="Clare Dooley">
<P>
<B>EMBASE (WebSPIRS)</B>
<BR/>#1 explode 'pneumonia-' / all subheadings<BR/>#2 (pneumonia in ti) or (pneumonia in ab)<BR/>#3 explode 'Streptococcus-infection' /<BR/>#4 (pneumococc* in ti) or (pneumococc* in ab)<BR/>#5 #1 or #2 or #3 or #4<BR/>#6 explode 'Pneumococcus-vaccine' / all subheadings<BR/>#7 (pneumococcal vaccine$ in ti) or (pneumococcal vaccine$ in ab)<BR/>#8 #6 or #7<BR/>#9 explode 'infant-' / all subheadings<BR/>#10 explode 'child-' / all subheadings<BR/>#11 (infant$ or child$) in ti<BR/>#12 (infant$ or child$) in ab<BR/>#13 #9 or #10 or #11 or #12<BR/>#14 #5 and #8 and #13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-06-01 18:01:31 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-06-01 18:01:10 +1000" MODIFIED_BY="[Empty name]">Books of Abstracts of International Symposia</TITLE>
<APPENDIX_BODY MODIFIED="2009-06-01 18:01:31 +1000" MODIFIED_BY="[Empty name]">
<P>1. Books of Abstracts of the International Symposium for Pneumococci and Pneumococcal Disease (ISPPD) of the following meetings:<BR/>a. 13 to 17 June 1998 in Copenhagen, Denmark;<BR/>b. 19 to 23 March 2000 in Sun City, South Africa;<BR/>c. 5 to 8 May 2002 in Anchorage, Alaska;<BR/>d. 9 to13 May 2004 in Helsinki, Finland;<BR/>e. 2 to 6 April 2006 in Alice Springs, Central Australia;<BR/>f. 8 to 12 June 2008 in Reykjavik, Iceland.</P>
<P>2. Books of Abstracts of the World Congress of Paediatric Infectious Diseases (WSPID) of the following triennial meetings:<BR/>a. 19 to 23 November 2002 in Santiago, Chile;<BR/>b. 1 to 4 September 2005 in Warsaw, Poland;<BR/>c. 15 to 18 November 2007 in Bangkok, Thailand.<BR/>
</P>
<P>3. Books of Abstracts of the Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) of the following meetings:<BR/>a. 17th Annual Meeting, 19 to 21 May 1999 in Heraklion, Crete, Greece;<BR/>b. 19th Annual Meeting, 26 to 28 March 2001 in Istanbul, Turkey;<BR/>c. 21st Annual Meeting, 9 to 11 April 2003 in Giardini Naxos, Taormina, Sicily;<BR/>d. 22nd Annual Meeting, 26 to 28 May 2004 in Tampere, Finland;<BR/>e. 23rd Annual Meeting, 18 to 20 May 2005 in Valencia, Spain;<BR/>f. 24th Annual Meeting, 3 to 5 May 2006 in Basel, Switzerland;<BR/>g. 25th Annual Meeting, 2 to 4 May 2007 in Porto, Portugal;<BR/>h. 26th Annual Meeting, 13 to 17 May 2008 in Graz, Austria.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>